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Abstract 
Background 
Multidisciplinary teams (MDTs) are the established model for managing cancer care 
in England. Weekly MDT meetings bring together different healthcare professionals 
with diverse knowledge and expertise in order to facilitate patient-centred decision 
making. However, little consideration has been given to the role of status 
hierarchies in the decision making process in these teams.  
 
Aim 
The aim of this PhD is to explore the way that status hierarchies between 
healthcare professionals unfold during the decision making process in cancer MDT 
meetings, and to identify factors that inhibit or facilitate multidisciplinary 
discussion. It also considers approaches used by lower status groups to contribute 
during meetings.  
 
Methods  
A qualitative study was undertaken of four MDTs: one gynaecology, one skin and 
two haematology cancer MDTs. This involved thematic analysis of data from non-
participant observation of 122 MDT meetings and 26 semi-structured interviews 
with professionals and patients. 
 
Findings 
Higher status professionals (medical and surgical consultants) played a dominant 
role in all four cancer MDTs. Although lower status professionals (specialist nurses 
and junior doctors) contributed much less frequently, they were more likely to 
participate in complex cases, for example when patients had limited treatment 
options. Multidisciplinary discussion was influenced by team size, seating 
arrangements, the approach to presenting cases for discussion, and the behaviours 
of both higher and lower status individuals. Higher status individuals provided 
support for lower status contributions when they demonstrated inclusive leadership 
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behaviours. In turn, lower status individuals contributed successfully by sharing 
information, asking questions, providing practical suggestions, framing 
contributions in medical or surgical terms, and using humour. These approaches 
prompted discussion, influenced treatment plans and facilitated teamwork.  
 
Conclusion 
This study enhances understanding of the approaches that can be used by MDTs to 
capitalise on the relevant knowledge and skills of all team members when making 
decisions in the MDT meeting.
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Chapter 1. Introduction  
 
In recent years, cancer care has become increasing complex, reflecting scientific 
advances in diagnosis and treatment, and increased specialisation (Mukherjee, 
2011). In response, there has been a growing emphasis on teamwork as a 
mechanism for bringing together the different professional groups necessary to 
deliver quality patient care (West and Lyubovnikova, 2013). A key example of this is 
the multidisciplinary team (MDT). This is a model endorsed as the ‘gold standard’ of 
care for patients with cancer in the UK (Independent Cancer Taskforce, 2015), and 
internationally (Harrison et al., 2008, American College of Surgeons and Commission 
on Cancer, 2012, Ministry of Health, 2012, Prades et al., 2014).  
 
Cancer MDTs bring together professionals involved in the delivery of care for 
patients with a particular type of cancer (Commission for Health Improvement, 
2001). This usually includes medical, surgical and diagnostic specialists, as well as 
specialist nurses (NHS England, 2013, NHS England, 2014, NHS Improving Quality, 
2014). These teams typically meet weekly, in order to discuss and agree treatment 
plans for all newly diagnosed cancer patients (Harris et al., 2014). The aim of these 
meetings is to ensure a uniform standard of quality care and to facilitate patient 
centred decision making (Department of Health, 1995, Department of Health, 
2000). It is assumed that bringing together different professional groups in this way 
will ensure that each patient’s treatment is considered from a range of perspectives 
(National Institute for Health and Clinical Excellence, 2003).  
 
However, the literature on group dynamics suggests that teams are not always 
successful in using the knowledge and information held by different members 
(Mesmer-Magnus and DeChurch, 2009, Bunderson and Reagans, 2011). This is 
particularly salient in healthcare contexts, where there are well-established status 
differences between professional groups (Freidson, 1988, Larkin, 1988, Price et al., 
2014). Status hierarchies have been shown to impact on levels of participation 
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between professional groups in healthcare teams, and specifically in the MDT 
setting (Atwal and Caldwell, 2005, Nembhard and Edmondson, 2006). Surgical, 
medical, and diagnostic professionals have been shown to dominate MDT meetings, 
while nursing or psychosocial professionals have more limited input (Lanceley et al., 
2008, Lamb et al., 2011b, Raine et al., 2014a). These patterns of participation are 
potentially problematic for MDTs because information sharing and discussion 
amongst team members are key to the decision making process, and have been 
shown to improve the accuracy of medical diagnoses (Larson et al., 1998), and to 
increase the likelihood of reaching a decision during MDT meetings (Lamb et al., 
2013b, Soukup et al., 2016a).  
 
The specific role of specialist nurses in the MDT meeting is also important. The 
literature suggests that when specialist nurses are actively involved in MDT 
discussion, and medical and psychosocial information are integrated, this improves 
discussion and leads to greater satisfaction amongst MDT members (Lanceley et al., 
2008, Kidger et al., 2009). In addition, nurses can act as the patient’s advocate and 
can ensure that patient related factors are taken into account when treatment 
decisions are made (Amir et al., 2004, Lamb et al., 2011a, Lamb et al., 2013c).   
 
At the same time, MDTs are under increasing pressure as demand on services 
continues to grow (NHS England, 2015). In practice, the number of cases to be 
discussed at the weekly MDT meeting means that there is little time for in-depth 
review of each. A recent study shows that individual discussions in MDT meetings 
across a range of cancer specialties last an average of 2 minutes 49 seconds (Jalil et 
al., 2014). In this context, achieving genuine multidisciplinary discussion, and 
facilitating and incorporating contributions from the full range of professional 
groups who attend the meeting, is challenging. This is acknowledged in the most 
recent national cancer strategy Achieving world-class cancer outcomes: a strategy 
for England 2015 – 2020. This strategy suggests that MDT processes should be 
streamlined, with less time spent on cases that can be managed according to 
evidence based treatment guidelines, in order to free up time for multidisciplinary 
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discussion of more complex cases (Independent Cancer Taskforce, 2015). However, 
there is little evidence to guide MDTs in making decisions about which patients to 
discuss in depth, or about how to facilitate multidisciplinary discussion within the 
team during these cases.  
 
In this fast-paced and pressurised environment, a better understanding of the role 
of status hierarchies in the decision making process is crucial to ensuring that MDTs 
can benefit from their diverse membership when making decisions. My aim is to 
explore the way that status hierarchies unfold in MDT meetings, and to identify the 
factors that facilitate or inhibit multidisciplinary discussion. I will also explore the 
approaches used by lower status groups to contribute, when they do participate in 
discussion. In doing so, this thesis will contribute knowledge that can be used to 
help MDTs appropriately capitalise on the skills and knowledge of all team members 
when making decisions in MDT meetings. 
 
1.1 Background to the thesis 
The research I carried out for this PhD was part of a larger study of chronic disease 
MDT meetings. In this section I describe how this broader programme of research 
informed the work I went on to carry out independently for my doctoral research. 
 
1.1.1 The NIHR-funded ‘MDT Study’  
Between November 2010 and November 2014 I was employed in the Department 
of Applied Health Research at UCL. During this time I was one of three full time 
Research Associates working on a mixed methods study of chronic disease MDT 
meetings. This study was funded by the National Institute for Health Research (NIHR 
project reference HS&DR 09/2001/04). An overview of the ‘MDT Study’ is provided 
in Box 1. 
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Box 1: Overview of the NIHR-funded MDT Study 
Improving the effectiveness of MDT meetings for patients with chronic 
diseases 
The MDT Study was led by my primary supervisor, Professor Rosalind Raine, 
and was guided by a project steering group composed of clinicians, academics 
and patient representatives. 
Aims: 
 to identify the characteristics of MDT meetings associated with decision 
implementation (whether or not treatment decisions recommended by the 
team were carried out), and  
 to derive recommendations for improving MDT decision making for 
patients with chronic diseases. 
 
Methods: 
We studied 12 MDTs in cancer, heart failure, mental health and memory clinic 
teams in the London and North Thames area. Data were collected by non-
participant observation of 370 MDT meetings. Then, medical records of 2,654 
patients were reviewed to determine whether the decisions agreed during the 
MDT meeting had been implemented. A questionnaire on team climate was 
completed by 161 MDT members across the 12 teams, and semi-structured 
interviews were conducted with 53 MDT members and 20 patients. 
 
The quantitative analysis investigated the influence of MDT and patient-
related factors on the implementation of decisions agreed in MDT meetings. 
The qualitative data were used to explore possible reasons for the 
quantitative results, and to highlight differences between teams and disease 
types. The final stage of the study used these findings to generate a series of 
potential recommendations for improving decision making in MDT meetings.  
Introduction 
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We recruited a panel of healthcare professionals, policy makers and patient 
representatives with experience of MDTs in each of the disease types under 
study to discuss and rate these recommendations using a formal consensus 
development technique.  
Results: 
 The MDT Study found no evidence of a relationship between decision 
implementation and patient age or gender, or with discussion of patient 
preferences or comorbidities. However, decisions were less likely to be 
implemented for patients living in more deprived areas of England.  
 
 The team factors associated with decision implementation were disease 
type (implementation was highest in gynaecological cancer and lowest 
in mental health) and team climate (implementation was more likely in 
teams with a good team climate). In mental health and memory clinic 
teams, an increase in the number of professional groups in attendance 
was associated with a reduced odds of decision implementation.  
 
 The qualitative results were structured around 16 meta-themes, which 
highlighted variation in the processes, structures and the content of 
discussion during weekly meetings across the 12 teams studied. 
 
 The consensus development process generated 21 recommendations 
for improved practice in MDT meetings, including good practice in 
meeting processes and functions, the content of discussions, and the 
role of the patient.   
 
The full results of the MDT Study are available in the peer reviewed 
publications listed in Appendix 1. 
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As described in Box 1, the NIHR-funded MDT Study demonstrated that decision 
implementation was relatively high in the four cancer teams (ranging from 78 per 
cent to 84 per cent), particularly in comparison with the four mental health teams 
(65 per cent to 77 per cent) (Raine et al., 2014a). However, the existence of 
inequalities in the participation of different professional groups when making 
decisions in MDT meetings was a key theme to emerge from the qualitative 
component of the research. While participants emphasised the value of disciplinary 
diversity, they also highlighted challenges inherent in working across disciplinary 
boundaries. These challenges reflected status differences and contrasting 
professional perspectives. Cancer and heart failure teams in particular were 
characterised by a strong medical dominance, which was manifest both in the 
degree of participation and in the seating arrangements. Overall then, while the 
principle of multidisciplinary input was highly valued, there was some dissatisfaction 
with how this worked in practice (Raine et al., 2014a).  I took this finding as a 
starting point for my PhD, exploring and extending the meta-theme generated in 
the original analysis by focusing specifically on decision making processes in the four 
cancer teams. 
 
1.1.2 Making an independent contribution for my doctoral research 
Study design and data collection 
My PhD draws on data from the four cancer teams recruited to the MDT Study. I 
was responsible for the data collection and qualitative analysis in these teams. The 
exception to this was cover for the observation of meetings when I was on annual 
leave, which was provided by the research team. I describe my role in study design 
and data collection, as well as my independent analysis, in more detail in Chapter 5. 
 
Developing research questions and a theoretical framework 
Taking one of 16 meta-themes generated in the original analysis as my starting 
point, the process of developing research questions for my doctoral research was 
very iterative. Although the MDT Study did not focus on the issue of hierarchy in 
depth, it provided a rich dataset for further exploration. I spent a considerable 
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period of time working back and forth between existing literature and theory, the 
data collected, and the initial mixed methods analysis from the MDT Study. In this 
way, I was able to develop research questions that built on the earlier work of the 
study, while also ensuring that the new questions I wanted to pose could be 
appropriately answered by the data I had.  
 
While doing this, I also spent time exploring the micro organisational behaviour 
literature to identify theoretical perspectives that could enhance my understanding 
of the group dynamics I had observed during data collection. There were a number 
of possible theoretical perspectives that could be applied in the context of cancer 
MDT meetings, including diversity, power, and status amongst others. However, 
status characteristics theory held the most resonance for me when I reflected on 
my observations and interviews with MDT members, particularly in relation to the 
lower rates of participation from specialist nurses and junior doctors. Adopting this 
theoretical framework for my doctoral research enabled me to explore the role of 
status hierarchies in the decision making process in cancer MDT meetings in much 
more depth than had been possible within the MDT Study.  
 
Although this non-linear approach to my doctoral research has limitations (which I 
discuss in Chapter 10) it nonetheless reflects the journey that Edmondson and 
McManus (2007) describe as characteristic of field research.  As Figure 1 shows, this 
is best viewed as an iterative process, which can involve almost as many steps 
backwards as it does forwards.  
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Figure 1: Field research as an iterative journey  
(Edmondson and McManus, 2007)  
 
1.2 Overview of the thesis 
Following on from this introductory chapter, Chapter 2 presents a review of cancer 
policy and analyses the literature on cancer MDTs. Chapter 3 sets out the 
theoretical framework for the study. It draws on the literature on status hierarchies 
in teams, before the research questions that this thesis seeks to answer are 
presented in Chapter 4. Chapter 5 provides an overview of the methodological 
approach underpinning the study, and the methods used to collect and analyse the 
data. Following this, Chapters 6, 7 and 8 present the findings of the qualitative 
analysis, with each chapter addressing one of the research questions posed. These 
findings are then integrated in Chapter 9. Finally, Chapter 10 sets the findings in 
context and discusses the implications for policy, practice and research. 
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Chapter 2. Review of policy and practice in cancer 
multidisciplinary teams 
 
This chapter begins by reviewing the key national policies and guidance that have 
shaped the development of cancer MDTs in England. The aim is to establish the 
context within which MDT meetings operate, to clarify the goals of policy in regards 
to MDT meetings, and to understand the role of different professional groups in 
these meetings. The analysis is based on a review of policy and guidance documents 
identified in a search of the grey literature.  
 
The second part of the chapter reviews the research literature on cancer MDTs. 
Given that the first cancer MDTs were introduced in England almost 20 years ago, a 
vast body of literature seeking to measure and improve the effectiveness of MDT 
working already exists. This literature has been systematically reviewed by others 
(Coory et al., 2008, Lamb et al., 2011b, Ke et al., 2013, Prades et al., 2014, Pillay et 
al., 2016). However, my aim is to focus on those aspects that have most relevance 
to the issues of participation and information sharing in MDT meetings, and to 
establish why this remains an important field for further study.  
 
An overview of the search and review strategies underpinning these chapters is 
provided in Appendix 2.  
 
2.1 Cancer MDTs: the policy vision 
2.1.1 The emergence of a national cancer policy 
Improving the delivery of cancer care has been on the policy agenda in England 
since the mid-1990s, when a growing awareness emerged that cancer survival rates 
were worse in England than in many other European countries (Haward, 2006, 
Richards, 2010). At this time, cancer care was largely delivered by general surgeons 
and physicians, who were supported by specialists (Haward, 2006). However, there 
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were often long waits for diagnosis and treatment, and there were inequalities in 
both prevalence and delivery of services (Griffith and Turner, 2004, Haward, 2006). 
It was against this backdrop that changes were proposed at a national level to 
improve cancer services  (Griffith and Turner, 2004). 
 
2.1.2 Establishing MDTs as a model of care  
One of the central catalysts for change was the publication of the Calman-Hine 
Report: A Policy Framework for Commissioning Cancer Services (Department of 
Health, 1995). The report, which was written by an Expert Advisory Group on 
Cancer to the Chief Medical Officers of England and Wales, set out key principles for 
the organisation of cancer services (Haward, 2006). Specifically, it introduced the 
concept of specialist multidisciplinary teams, moving away from a model of care 
where clinicians had worked predominantly as individuals. These multidisciplinary 
teams were tasked with making joint decisions about diagnosis and treatment for 
individual patients (Haward, 2006). The changes proposed in the Calman-Hine 
Report were underpinned by a desire to ensure a uniform standard of high quality 
care for all patients, a commitment to the principle of patient centred care, and 
acknowledgement of the importance of the psychosocial aspects of cancer care 
(Department of Health, 1995).  
 
Crucially, however, although the Calman-Hine report provided a framework for 
change, it was not accompanied by additional funding or central guidance about 
how the proposed changes should be implemented (Commission for Health 
Improvement, 2001, Richards, 2010). Initial progress was therefore inconsistent 
(Richards, 2010). This changed in 1999, when cancer became a key priority under 
the then Prime Minister, Tony Blair, in advance of the publication of the NHS Cancer 
Plan: A Plan for Investment A Plan for Reform in 2000 (Griffith and Turner, 2004).   
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2.1.3 Embedding MDTs as the cornerstone of cancer treatment 
The NHS Cancer Plan was published as a comprehensive strategy for the reform of 
cancer services (Department of Health, 2000). It was accompanied by dedicated 
funding, which was allocated to improve standards in cancer care (Department of 
Health, 2000). The role of MDTs was extended, reflecting the policy view that they 
facilitated high quality diagnosis and treatment, and improved the coordination and 
continuity of care for patients (National Institute for Health and Clinical Excellence, 
2003). To build on progress made in establishing specialist teams for the most 
common cancers (breast, colorectal and lung) the Plan committed to putting in 
place multidisciplinary teams in all cancer specialties from 2001 (Department of 
Health, 2000). By 2004, discussion of individual patients at team meetings was seen 
as a central component of the cancer pathway (Griffith and Turner, 2004), and by 
2007, around 1,500 cancer MDTs had been established (Department of Health, 
2007).  
 
2.1.4 Recent policy developments affecting MDTs  
2011 heralded a significant shift in NHS policy under the Coalition Government 
elected in 2010 (Thomas and Miller, 2013). This included considerable changes to 
the structure of the NHS, and a focus on reducing costs as part of a commitment to 
make extensive efficiency savings (Department of Health, 2010, Department of 
Health, 2013a). In spite of these changes, commitments to embedding MDTs in 
cancer services echoed those of earlier policy documents. Improving Outcomes: A 
Strategy for Cancer was published in 2011, retaining MDTs as a core feature of the 
Government’s plans alongside a clear mandate to focus on outcomes and survival 
rates (Department of Health, 2011).  
 
However, four years after the publication of Improving Outcomes, the Public 
Accounts Committee concluded that there had been a loss of momentum in the 
process of improving cancer services in England (House of Commons: Committee of 
Public Accounts, 2015). This was a view echoed in the most recent strategy for 
cancer services, which was published in July 2015: Achieving World-Class Cancer 
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Outcomes: a Strategy for England 2015 - 2020 (Independent Cancer Taskforce, 
2015). This latest iteration of the national cancer strategy was developed by an 
Independent Cancer Taskforce, chaired by the Chief Executive of Cancer Research 
UK. The aim was to develop a five year strategy to reduce the burden of cancer 
overall, and to improve care for patients with cancer, with patient experience at its 
core (Cancer Strategy Taskforce, 2015). The strategy continues to promote the MDT 
model of care as the ‘gold standard’ in service delivery. However, it also notes that 
many MDTs are not operating as effectively as they should be as a result of 
pressures on the system.  
 
This is also evident in the findings from the most recent National Cancer Peer 
Review Programme report, published in March 2015 (NHS England, 2015). The Peer 
Review process is a national quality assurance programme for NHS cancer services, 
which benchmarks MDTs across England (National Peer Review Programme, 2013). 
The most recent report concluded that although some teams and services achieved 
very high levels of adherence to the measures, there remained a group of MDTs 
that were significant outliers (NHS England, 2015). Of the 1,449 MDTs reviewed, 
only 8 per cent achieved 100 per cent compliance, with 40 per cent achieving 
compliance with over 90 per cent of the measures. A key issue raised in the report 
was the general trend of increasing workload without a commensurate increase in 
capacity (NHS England, 2015).  
 
The response proposed by the Independent Cancer Task Force in relation to these 
challenges has been to recommend that MDT processes should be streamlined 
(Independent Cancer Taskforce, 2015). While guidelines for individual cancer 
specialties stipulate that MDTs must discuss all new cancer patients to develop an 
initial treatment plan, the new national strategy recommends that MDT discussions 
should focus more on difficult cases, where the treatment options are high risk 
(NHS England, 2014). The strategy does not go as far as to recommend that some 
cases are not discussed at all, but instead, that ‘less time’ is spent discussing 
patients who follow standard treatment pathways (Independent Cancer Taskforce, 
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2015). However, there is little in the way of guidance for cancer MDTs about how to 
manage the potentially competing demands of patient centred care and the greater 
efficiency envisaged by the recommendation to streamline MDT meeting processes 
(NHS England, 2013, NHS England, 2014). 
 
2.1.5 The role of different professional groups in the MDT meeting 
In addition to the national policy documents described above, MDTs are shaped by 
tumour specific guidelines. These guidelines document the clinical outcomes and 
indicators that MDTs are required to meet, as well as setting out their structure and 
key functions (NHS England, 2013, NHS England, 2014, NHS Improving Quality, 
2014). This includes a description of the core members required to attend the MDT 
meeting in each specialty. For example, surgeons are requisite members of 
gynaecology and skin but not haematology MDTs, reflecting differences in the way 
that underlying conditions are treated. All MDTs however must have a quorum of 
physicians, radiologists, pathologists, clinical nurse specialists and an MDT 
coordinator (NHS England, 2013, NHS England, 2014, NHS Improving Quality, 2014). 
In practice, attendees include both senior (e.g. consultant doctors) and junior staff 
(e.g. doctors in training), who vary in terms of status and experience (Kane and Luz, 
2011). At the heart of the MDT model is an assumption that each of these 
professional groups brings specific skills and knowledge that can enhance decision 
making (NHS Improving Quality, 2014). 
 
Consultant surgeons and physicians 
Consultant medical and surgical doctors use expert knowledge and skill to diagnose 
and treat patients (British Medical Association, 2008a), and have ultimate 
responsibility for the care of all patients referred to them. This is the case even if a 
patient’s treatment is being carried out by other doctors within their team (British 
Medical Association, 2008b). As a result, they are often regarded as the ‘key 
decision makers’ within the healthcare environment (Price et al., 2014). However, 
other professionals within the MDT also have specific responsibilities and are 
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expected to participate actively in the decision making process (National Institute 
for Health and Clinical Excellence, 2003). 
 
Radiologists 
The radiology role in the MDT meeting is primarily concerned with the diagnosis, 
staging and management of patients, and radiologists are responsible for 
presenting the relevant features in any images that have been undertaken by 
means of a ‘primary report’ (The Royal College of Radiologists, 2014). This enables 
the team to determine the stage of the disease, or to review the extent of a 
patient’s disease following treatment.  
 
Pathologists 
Guidelines for pathologists state that their role is to illustrate features of 
importance for prognosis and further management, for example by presenting 
slides of cells in tissue samples (The Royal College of Pathologists, 2009).  
 
Clinical Nurse Specialists 
Another key member of the MDT is the Clinical Nurse Specialist (CNS). In cancer 
care, these are registered nurses, with clinical expertise in a specialised area of 
nursing (National Cancer Action Team, 2010b). This can be a tumour type (e.g. skin 
cancer), treatment type (e.g. chemotherapy) or patient type (e.g. paediatrics) 
(National Cancer Action Team, 2010b). The role itself is relatively new, developing 
alongside the model of MDT working. As a result there is still variation across 
different specialities in the way this role is carried out (Pollard et al., 2010, Lamb et 
al., 2011a).  
 
As a core member of the MDT, Clinical Nurse Specialists are expected to contribute 
to multidisciplinary discussion, to lead on patient and carer communication issues 
and to ensure that decision making incorporates holistic needs assessments (NHS 
Improving Quality, 2014). The contribution of clinical nurse specialists (CNS) is 
therefore a key mechanism for ensuring that clinical decision making is focused on 
Policy Review 
30 
 
the needs, values and priorities of individual patients (National Institute for Health 
and Clinical Excellence, 2003, Dempsey et al., 2016).  
 
Junior doctors 
In addition, Specialty Registrars (StRs) play an active role in many MDT meetings 
(Raine et al., 2014a). StRs are junior doctors who have successfully completed their 
two year foundation programme following medical school, and who are continuing 
their training in a specialist area of medicine (British Medical Association, 2016). 
Given their status as doctors in training, they are not listed as core members of the 
MDT in national guidelines. This may be one reason why the junior doctor role in 
the MDT meeting has as yet received very little attention in the literature. In part, 
involving junior doctors in MDT meetings is an opportunity to deliver learning and 
training opportunities. However, it is also another way to ensure that patients’ 
perspectives are included in discussions, particularly when junior doctors have had 
extended contact with patients either on the ward or in clinic (Sharma et al., 2009). 
 
2.1.6 Summary: the development of cancer multidisciplinary teams 
To summarise, this review of national policy and supporting guidance has 
demonstrated that MDT meetings are a fundamental aspect of cancer care. They 
are widely established and deeply embedded in the English NHS, and there are 
systematic processes in place to assess their performance. However, despite a huge 
national commitment, extensive guidelines and additional funding, there is 
variation in how well MDTs perform, and there is still scope for improvement. In 
particular, MDTs are under increasing pressure and it has been suggested that 
meeting processes should be streamlined in order to accommodate the increasing 
number of cancer cases being referred for discussion. 
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Table 1: Timeline of key policies and guidance relating to MDTs 
 1995 1999 2000 2001 2003 2004 2006 2007 2008 
National 
policy 
The Calman-Hine 
Report 
 The NHS 
Cancer Plan 
    The Cancer 
Reform Strategy 
 
 Introduction of 
MDTs 
 
 Committed to 
full roll out of 
MDTs in all 
tumour types 
 
 
 
    MDT working to 
remain the core 
model for cancer 
service delivery 
 
Guidelines 
and 
measures 
 First Improving 
Outcomes 
Guidance (IOG) 
published by 
NICE 
   First Manual for 
Cancer Services 
published  
  Revised 
Manual for 
Cancer 
Services 
published 
  Gynaecology 
IOG published 
  Haematology 
IOG published 
 Skin  
IOG published 
  
Peer 
review 
process  
 National Cancer 
Action Team 
established 
 First round of 
peer review 
(regional) - 
breast, 
colorectal and 
gynaecology 
cancers 
 National Cancer 
Peer Review 
programme 
formally 
established 
  No. of 
measures in 
National 
Cancer Peer 
Review 
programme 
reduced 
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 2010 2011 2012 2013 2014 2015 
National 
policy 
Review of the Cancer 
Reform Strategy 
Improving Outcomes: 
a Strategy for Cancer 
   Achieving World-
Class Cancer 
Outcomes: a Strategy 
for England 2015 - 
2020 
 Focus shifts to cancer 
outcomes and 
improvement in survival 
rates 
MDTs to remain the 
cornerstone of cancer 
care 
 Cancer networks 
become Strategic 
Clinical Networks 
 
Independent Cancer 
Taskforce set up by 
NHS England 
MDTs to remain but 
recognition of 
pressures on MDTs 
leads to calls for 
improved efficiency 
Guidelines 
and 
measures 
   Revised Manual for 
Cancer Services 
Published 
  
 Skin  
IOG updated 
  Gynaecology, 
haematology and 
skin Manuals revised  
Gynaecology Manual 
revised and reissued 
by NHS Improving 
Quality 
 
Peer 
review 
process  
 Introduction of ‘Clinical 
Lines of Enquiry’, which 
identify key aspects 
that reflect the quality 
of a service 
 Introduction of 
‘Service Profiles’, to 
facilitate 
benchmarking of 
MDTs across England 
Peer Review 
Programme moves to 
a biennial self-
assessment cycle 
managed by NHS 
England 
Results of the 2013-
14  National Peer 
Review Programme 
published 
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2.2 The functioning of MDT meetings in practice 
2.2.1 Are MDTs effective? 
Although the proposed benefits of MDT working feature prominently in the policy 
documents described above, when MDTs were initially rolled out at a national level 
there was no real evidence of their effectiveness (Taylor et al., 2010). Since then, 
‘effectiveness’ has been measured in a number of different ways, and there is now 
a vast body of literature that addresses the issue. Studies have looked at the impact 
of MDTs on patient outcomes, cost effectiveness, and the quality of decision 
making.  
 
Patient outcomes 
Evidence of the effectiveness of MDTs in terms of patient outcomes is currently 
limited (Coory et al., 2008, Croke and El-Sayed, 2012), although it is growing (Kesson 
et al., 2012, Prades et al., 2014). One of the reasons for the ongoing debate is the 
challenge of evaluating effectiveness against outcomes such as survival. In part, this 
is because patient outcomes are affected by a much wider range of factors than 
MDT decision making alone (Sevdalis and Green, 2014). It also reflects the fact that 
there is no longer scope in the UK to conduct a randomised control study with a 
separate ‘non-MDT’ control group, because MDTs are mandatory within cancer 
services (Taylor et al., 2010, Sevdalis and Green, 2014). 
 
Cost effectiveness 
Given the number of healthcare professionals involved, MDT meetings are by 
nature an expensive resource. It has been estimated that they cost the NHS around 
£50 million per year, based on preparation time alone (Taylor et al., 2010). A more 
recent study of 52 MDT meetings across 14 different tumour types at an NHS Trust 
in London assessed the overall cost of MDT meetings, based on attendance of key 
professionals and overhead costs (e.g. heating, lighting and information technology 
support) (De Ieso et al., 2013). Costs were shown to range from £3,912 per MDT 
meeting for a melanoma MDT, to £8,490 per meeting for a Gynaecology MDT. 
These costs did not include the time required for core members to prepare for the 
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MDT (particularly pathologists and radiologists who are required to review material 
in advance).  
 
A crucial question however is whether this investment is cost effective. Even if MDT 
meetings are an expensive resource, if they improve decision making and save 
healthcare professionals time in the long run by bringing together all the individuals 
necessary for making a treatment plan, these costs may well be justified. At 
present, however, the findings from existing studies are inconsistent and a 
systematic review of the literature has concluded that concrete evidence of cost 
effectiveness is lacking (Ke et al., 2013).  
 
Quality of decision making 
Despite the challenges relating to measuring patient outcomes and gaps in the 
evidence base relating to cost effectiveness, there is a strong and growing body of 
evidence that MDT meetings can positively influence clinical decision making and 
treatment recommendations (Croke and El-Sayed, 2012, van Hagen et al., 2013, Rao 
et al., 2014, Ung et al., 2014, Leff et al., 2015, Schmidt et al., 2015). Benefits that 
have been documented include better team performance after case discussion (Kee 
et al., 2007), improved adherence to clinical guidelines, more accurate diagnoses 
(Lamb et al., 2011b, Pillay et al., 2016), and increased screening rates for clinical 
trials (McNair et al., 2008).  
 
Nonetheless, echoing the findings of the National Cancer Peer Review Programme 
(NHS England, 2015), studies of decision making in MDT meetings have shown that 
there is wide variation between teams against measures of effectiveness. An 
extensive number of studies have used proxy measures of decision quality to assess 
the effectiveness of MDT meetings. This includes the ability of teams to reach a 
decision the first time a patient is discussed in an MDT meeting. This is used as a 
measure of decision quality on the basis that delays to treatment as a result of a 
failure to make a diagnosis or treatment decision can have a negative impact on 
patient outcomes (Stalfors et al., 2007). Reported rates of effectiveness against this 
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measure in different cancer specialities range from 48 per cent to 74 per cent (Lamb 
et al., 2011b).  
 
Similarly, implementation rates of decisions made in MDT meetings have been used 
as a proxy for effective team decision making (Raine et al., 2014a, Raine et al., 
2014b). This measure is used on the basis that decisions are more likely to be 
implemented if all relevant clinical and non-clinical information has been taken into 
account when the decision is made. There is also considerable variation between 
teams in different cancer specialities in decision implementation rates. These 
differences are apparent across hospital trusts in England, and internationally, with 
implementation rates ranging from 72 per cent to 97 per cent of decisions made 
(Blazeby et al., 2006, Goolam-Hossen et al., 2011, English et al., 2012, Rajan et al., 
2013, Raine et al., 2014b, Ung et al., 2014, Schmidt et al., 2015). Common reasons 
cited for non-implementation of decisions relate to a lack of information about 
patient centred factors such as patient treatment preference and comorbidities 
(Blazeby et al., 2006, Raine et al., 2014b, Ung et al., 2014, Schmidt et al., 2015, 
Stairmand et al., 2015). It has been suggested that this may reflect time pressures 
or limited multidisciplinary input, particularly from nurse specialists (Taylor et al., 
2013). However, some of the variation is also likely to reflect differences in 
measurement, reflecting more or less stringent definitions of implementation (Ung 
et al., 2014). 
 
To summarise, the variety of outcome measures that have been used to determine 
whether or not MDTs are effective means that the literature is heterogeneous. As a 
result, published reviews, including four systematic reviews, have been unable to 
make a definitive judgement about whether or not MDTs are genuinely effective 
(Coory et al., 2008, Lamb et al., 2011b, Croke and El-Sayed, 2012, Ke et al., 2013, 
Prades et al., 2014). Nonetheless, there is a strong body of evidence that suggests 
that MDTs do positively influence clinical decision making, even if this does not 
extend to certainty about improvements in patient outcomes. What is also clear 
however, is that there is still a considerable degree of variation between MDTs.  
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2.2.2 Decision making in MDT meetings 
Understanding this variation is key to supporting improvements in MDT meetings 
(Lamb et al., 2014a). As a result, a number of researchers have explored the 
decision making process in cancer MDTs in order to understand why some are more 
effective than others. A series of standardised tools and checklists have been 
developed to assess the component parts of the MDT decision making process. 
These have been used to score a range of teamwork behaviours including 
leadership, multidisciplinary participation, and the presentation of different types of 
information during the meeting (Lamb et al., 2011d, Lamb et al., 2011e, Lamb et al., 
2012b, Taylor et al., 2012a, Taylor et al., 2012b, Lamb et al., 2013b, Harris et al., 
2014, Jalil et al., 2014, Harris et al., 2016). This reflects a growing consensus about 
the features of an effective MDT meeting (Taylor and Ramirez, 2009, Lamb et al., 
2012a, Lamb et al., 2014a, Raine et al., 2015). A number of these tools have already 
been validated (Lamb et al., 2011d, Lamb et al., 2012b, Lamb et al., 2013a, Jalil et 
al., 2014, Shah et al., 2014), although some require further testing to confirm 
validity and reliability (Taylor et al., 2012a, Harris et al., 2014, Harris et al., 2016). 
 
Application of these tools has deepened our understanding of decision making 
processes in cancer MDT meetings in a number of important ways. First, they have 
demonstrated that participation in MDT meetings varies by professional group. 
CNSs have been shown to participate less frequently in MDT meetings than medical 
or surgical team members, despite having an important contribution to make (Lamb 
et al., 2011b, Lamb et al., 2011d, Lamb et al., 2011e, Taylor et al., 2012a, Jalil et al., 
2014).  
 
Secondly, evaluation of MDT meetings using these tools has also raised issues about 
the extent to which patient centred information is shared during decision making. A 
study of decision making in a colorectal cancer MDT (using the cMDT-MODe 
checklist1) found that presentation of information relating to patient preferences or 
                                                     
1
 cMDT-MODe: the Colorectal Multidisciplinary Team Metric for Observation of Decision-Making is a 
validated assessment tool for measuring the quality of contributions made by professional groups 
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psychosocial factors was poor in comparison to information on biomedical factors 
(Shah et al., 2014). In addition, an observational study of ten bowel cancer teams 
(using a tool called ‘MDT OARS’2) found that none of the teams under study took 
patient centred factors (including demography, comorbidities, psychosocial needs 
or preferences) into account in all patient discussions. Instead, the majority of 
teams took these factors into account in less than half of the cases they discussed 
(Taylor et al., 2012a). Furthermore, there is some evidence that although teams 
generally have good insight into their performance, they can over-estimate how 
patient centred they are (Lamb et al., 2011d). 
 
Data collected using these checklists have also more recently been used to 
investigate the influence of key factors in the decision making process on the ability 
of MDTs to reach a decision (Soukup et al., 2016a). Analysis of data collected from 
four cancer MDTs using the MDT-MODe checklist suggests that patient centred 
information can influence the MDT decision making process in different ways. 
Notably, while teams were more likely to make decisions in cases where 
psychosocial factors were mentioned, they were less likely to do so when 
information about comorbidities was shared. Similarly, nursing input during MDT 
discussion was associated with reducing the ability of the team to reach a decision 
(Soukup et al., 2016a). One of the most likely explanations for these findings is that 
mention of comorbidities and nursing input reflect greater case complexity, which 
makes it more difficult for a decision to be reached (Soukup et al., 2016a). 
 
However, these tools have been designed to capture data on numerical scales 
(typically ranging from 1 to 5 or 1 to 10). As a result, they do not provide rich detail 
about the way in which different professional groups interact and participate in 
discussions. In addition, by focusing attention on decision making processes at the 
                                                                                                                                                      
and the quality of information shared during the MDT. It is based on a modified surgical observation 
tool. 
2
 MDT-OARS: the Multidisciplinary Team Observational Assessment Rating Scale measures 15 
observable elements of teamwork, based on characteristics of effective MDTs identified in a UK 
national survey of over 2000 MDT members. 
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level of the MDT meeting, there has as yet been little consideration of what is 
different about those cases where CNSs do contribute to discussion and when 
patient centred information is shared. There is scope therefore to further explore 
the complexity of the decision making process in the MDT meeting.  
 
2.2.3 The participation of different professional groups in MDT meetings 
A small number of qualitative studies, based on interviews and focus groups with 
MDT members, as well as observation of MDT meetings, explore these teamwork 
and decision making processes in more detail. Reflecting the findings described 
above, a common theme which emerges from these studies relates to inequalities 
in participation between professional groups. It has been shown that medical, 
surgical and diagnostic professionals tend to dominate discussion in MDT meetings. 
In contrast, nursing or psychosocial professionals have been shown to have more 
limited input (Lanceley et al., 2008, Lamb et al., 2011c, Raine et al., 2014a). Two 
qualitative studies of gynaecology cancer MDT meetings in the UK also suggest that 
even when nurses do speak up during the MDT meeting, their contributions can be 
overlooked by other members of the team. Observation data from these studies 
provide examples of nurses being ‘talked over’, (Lanceley et al., 2008) ignored, or 
contributing only when asked specific questions (Kidger et al., 2009). 
 
These findings are not unique to cancer MDT meetings in England. A similar picture 
emerges from the study of MDT meetings in other countries. For example an 
Australian study of a lung cancer team concluded that despite the rhetoric of 
multidisciplinarity, MDT meetings were predominantly a “decision making forum for 
doctors”, (p. 26) with little opportunity for genuine multidisciplinary engagement  
(Rowlands and Callen, 2013). This has also been found in other types of healthcare 
team. In the UK, nurses have been shown to be less confident about speaking up 
during ward round discussions, tending only to contribute in response to direct 
questions from medical staff (Busby and Gilchrist, 1992). Similarly, nurses have been 
shown to be reluctant to contribute to discussion in hospital based older people’s 
teams (Atwal and Caldwell, 2005).  
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These findings are important because CNSs have a key role to play within the MDT. 
A study examining 72 breast cancer MDTs in England found that a higher proportion 
of CNSs in the team was associated with improved clinical performance across a 
range of measures, as determined by existing evidence and expert advice (e.g. the 
percentage of patients under 70 receiving chemotherapy as first line treatment, and 
the number of clinical trials entered). This finding suggests that CNSs made an 
important contribution to the overall functioning of the team (Haward et al., 2003). 
This is also a view expressed by MDT members themselves. An interview study of 19 
MDT members in the UK found that there was a desire among most participants for 
more open discussion in their MDT meetings, with greater involvement from nurses 
to counteract the dominance of surgeons in particular. These views were expressed 
by participants from different professional groups, including nurses and surgeons 
themselves (Lamb et al., 2011c).  
 
The finding that discussion in MDT meetings tends to be dominated by surgical, 
medical and diagnostic professionals raises questions about the factors that may 
inhibit multidisciplinary participation. However, only a very small number of studies 
which have highlighted imbalances in participation go on to give any kind of insight 
into why these inequalities exist and specifically how they are enacted. Devitt et al 
(2010) use focus group data from cancer MDT members in Australia to explore the 
reasons allied health professionals gave for feeling inhibited in MDT meetings. This 
was attributed to a perceived lack of time and respect for the information they 
wanted to share in the meeting, and a sense that they were “interrupting the 
process between medical staff members” (p.19) (Devitt et al., 2010).  
 
The impact of time pressures has also been noted in two gynaecology MDTs, with 
the fast paced, highly pressurised nature of meetings restricting holistic discussion 
and leaving some team members reluctant to speak up (Lanceley et al., 2008, Kidger 
et al., 2009). It has also been suggested that the way that discussion within the MDT 
meeting is framed can limit multidisciplinary discussion. This was shown to be the 
case for nurses when patients were introduced for discussion with a rigidly 
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biomedical focus. In these cases it was difficult for those with patient centred 
information to share to participate (Lanceley et al., 2008). 
 
However, observation studies have also highlighted that there are specific examples 
of multidisciplinary discussion, even in teams where, overall, CNS participation is 
lower. These have shown that nurses can play an important role in leading case 
discussions, and challenging decisions (Kidger et al., 2009). In addition, a more 
recent study of a colorectal cancer MDT (based on the MDT-MODe checklist) scored 
cancer nurse participation as positive, in contrast with previous studies that have 
assessed CNS participation less favourably (Taylor et al., 2012a, Jalil et al., 2014, 
Shah et al., 2014). This suggests that genuine multidisciplinary discussion can be 
achieved, even if this does not happen consistently. To date however, there has 
been very limited discussion in the literature of how and when this happens, in 
terms of the nature of the discussion and the behaviours adopted by different 
professional groups in the MDT. 
  
2.2.4 The role of patient centred information in MDT meetings 
Defining patient centred care 
Patient centred care is underpinned by two key components. First, it relates to 
treatment decisions that reflect a patient’s preferences, as well as their physical and 
psychosocial needs (Ouwens et al., 2010). In this way it can be contrasted with 
disease centred care, which focuses primarily on the illness or disease rather than 
the individual experiencing it. The second component relates to the involvement of 
patients in decisions about their care (Ouwens et al., 2010). Given that patients did 
not attend the cancer MDT meetings I observed, the first component of patient 
centred care has most relevance for the purposes of this study. Although patients 
may have been involved in decisions about their care outside of the MDT meeting, 
my observation did not include the wider cancer care pathway. As a result, I define 
patient centredness in the context of the MDT meeting as decisions that took into 
account a patient’s physical, social and emotional needs and preferences.  
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The importance of patient centred information for MDT treatment plans 
Patient centred information is important in the MDT context for a number of 
reasons. While survival rates for cancer in England are improving (House of 
Commons: Committee of Public Accounts, 2015), the impact of cancer, and 
treatment, can have lasting effects which are social and psychological, as well as 
physical (Ouwens et al., 2010, Macmillan Cancer Support, 2014, Macmillan Cancer 
Support, accessed 4.4.2014). In this context, making appropriate treatment 
decisions is arguably not “a matter of science alone” (Mulley et al., 2012) (p.1). 
Policy makers, healthcare professionals and patients themselves therefore regard 
patient centred information as central to the decision making process (Barry and 
Edgman-Levitan, 2012, Lamb et al., 2014b).  
 
The importance of treating each patient as an individual, and as a person with 
distinct treatment and support needs, is a key theme in current policy documents, 
ranging from the NHS Constitution, to cancer specific policy and practice guidelines 
(National Institute for Health and Clinical Excellence, 2003, Department of Health, 
2013b, Independent Cancer Taskforce, 2015). A national survey of 2,054 MDT 
members also indicates that there is agreement amongst healthcare professionals 
about the importance of this information to the MDT decision making process. Over 
90 per cent of respondents to this survey agreed that patient preferences, 
demography, comorbidities, psychosocial and supportive issues should always be 
considered by the MDT (Taylor and Ramirez, 2009). In addition, focus groups with 
cancer patients suggest that information about physical and psychosocial needs is 
perceived as critical to making appropriate decisions in the MDT meeting (Lamb et 
al., 2014b). This does not negate the importance of biomedical information (e.g. 
pathology), because patients themselves recognise that without this teams would 
be unable to make a decision (Lamb et al., 2014b). Nonetheless, there is broad 
agreement that it is important for clinicians to take patient centred information into 
consideration alongside the biomedical information necessary to diagnose and treat 
cancer.  
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One of the reasons so much emphasis is placed on the role of patient centred 
information is that it can be fundamental to making decisions that reflect the needs 
and specific circumstances of each patient (Jalil et al., 2013). For example, if 
decisions about treatment are based solely on a patient’s chronological age, 
without knowledge of their fitness for treatment, frailty, or existing comorbidities, 
there is a risk that patients will be under, or over, treated. Either outcome is 
undesirable: while more intensive treatment can prolong survival, it can also impact 
significantly on quality of life due to the burden of side-effects (National Cancer 
Intelligence Network, 2015).  
 
There may also be social circumstances that potentially impact on the treatment 
that patients are willing, or able, to accept. For example, a patient with cancer who 
has caring responsibilities may refuse treatment with a specific chemotherapy drug 
if the side effects will impact on their ability to continue providing care to a loved 
one. Alternatively, a patient who is afraid of hospitals may not attend scheduled 
treatment appointments if supportive psychosocial care is not provided alongside 
the cancer treatment. If treatment plans do not accommodate patient centred 
information of this nature when it is relevant therefore, it may not be possible to 
implement the decisions agreed by the MDT (Blazeby et al., 2006, Wood et al., 
2008, Raine et al., 2014b). 
 
Mechanisms for incorporating patient centred information into MDT treatment 
plans 
In practice, patient centred decision making in the MDT meeting requires someone 
in the team to hold information about patients’ views, comorbidities, personal 
circumstances, and support needs. It also requires that this information is shared, 
and incorporated into the decision making process. As noted previously, the 
contribution of CNSs is seen as a key mechanism for integrating this type of 
information during multidisciplinary discussion (National Institute for Health and 
Clinical Excellence, 2003). This is because CNSs are responsible for assessing 
patients’ holistic needs and identifying high risk patients who are likely to need 
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ongoing monitoring and complex care plans (National Cancer Action Team, 2010b, 
Macmillan Cancer Support, 2014).  
 
In addition, CNSs often spend longer periods of time with patients than other 
members of the MDT, for example during extended consultations or regular visits 
on inpatient wards (Sweeney and Tapper, 2006, Kelly and Masterman, 2011). In a 
series of focus groups, cancer patients themselves described the CNS as the “easiest 
person to talk to” in the MDT (Lamb et al., 2014b) (p. 4). The role of CNSs in 
discussing and sharing information on psychosocial concerns, including social and 
emotional wellbeing is also well recognised by other professionals, including 
surgeons, radiologists and oncologists (Catt et al., 2005). As a result CNSs may be 
more likely to hold patient centred information, and may be better placed to 
identify patients’ concerns than other members of the MDT (Amir et al., 2004, Lamb 
et al., 2013c). 
 
Of course, CNSs are not the only members of the team with patient centred 
information. Consultant doctors may also be aware of patients’ comorbidities and 
preferences, or of psychosocial concerns (Lamb et al., 2013c). Junior doctors may 
also have spent time consulting patients explicitly either on the ward or in clinic and 
be able to act as their advocate in the MDT meeting (Sharma et al., 2009). The 
participation of CNSs in the MDT meeting is not therefore the only way to ensure 
that decision making is patient centred. Nonetheless, given the findings about lower 
rates of participation among CNSs, it is perhaps unsurprising that patient centred 
factors have also been shown to play a less central role than disease centred 
information in MDT meetings (Kidger et al., 2009, Taylor et al., 2012a, Shah et al., 
2014). 
 
Barriers to incorporating patient centred information into MDT treatment plans 
The literature suggests that there are a number of potential explanations for limited 
discussion of patient centred information in MDT meetings. First, it is possible that 
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this reflects a lack of time in the MDT meeting, which can create barriers to raising 
psychosocial or other patient centred information (Schofield et al., 2006). 
 
Secondly, it may also be the case  that at the point at which a patient is initially 
discussed, none of the members of the MDT have extensive knowledge of the 
patient (Raine et al., 2014a). Although it is regarded as best practice for at least one 
member of the team to have met the patient before an MDT discussion (Lamb et 
al., 2014b, Sarkar et al., 2014), in reality there are practical barriers to achieving this 
(Raine et al., 2014a). The pressure to diagnose and treat patients within waiting 
time targets means that many MDT discussions take place at a very early stage of a 
patient’s treatment pathway. In this context, patients may not yet know their 
diagnosis, or be in a position to articulate the factors that they think may impact on 
their treatment (Taylor et al., 2014). This situation is further exacerbated for MDTs 
that receive referrals for a specialist opinion from surrounding teams. In these 
cases, the receiving MDT is reliant on relevant information being included in the 
referral, which may not include patient centred information (Taylor et al., 2014). 
 
While this is problematic if it impacts on the extent to which teams are able to 
make patient centred decisions, it is also possible that differences in the frequency 
with which patient centred information is raised in MDT meetings reflect 
appropriate judgements by MDT professionals about when this type of information 
is most relevant to the decision (Raine et al., 2014b). It may be that patient centred 
factors are only brought into discussion in those cases where it is likely to influence 
a decision. If this is the case however, it raises important questions about the 
factors that trigger the sharing of this type of information, and the approaches used 
by MDT members to ensure the information is integrated into a treatment plan. 
 
2.3 Chapter Summary 
Based on review of both policy and literature on MDT meetings, it is clear that at 
the heart of the MDT model in England is a desire for an equal standard of high 
quality care for all patients. Diversity of input is seen as fundamental to a patient 
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centred decision making process, and specific professional groups are expected to 
bring unique knowledge and skills to MDT discussion. However, this is dependent 
not only on team members holding information, but also on exchanging and 
integrating this information during the decision making process in an environment 
that can be hectic and time pressured. MDT meetings are reliant therefore on 
collaboration between people with different skills, expertise and professional 
backgrounds. This makes the role of “human factors” on MDT decision making 
particularly salient (Sevdalis and Green, 2014) (p. 2).  
 
A theme that has emerged consistently from the literature on MDTs relates to 
medical and surgical dominance in MDT meetings. This is reflected both in the 
limited contributions from CNSs in particular, and in the content of discussions, 
which have been shown to emphasise disease centred information. The evidence 
suggests that this has the potential to be problematic, given the central role of CNSs 
in providing patient centred information and the importance of this information to 
the decision making process. However less is known about the factors that underpin 
these patterns of participation, and there has been little consideration of the 
specific mechanisms that inhibit or facilitate multidisciplinary discussion in MDT 
meetings. There is therefore a need to explore the participation of different 
professional groups, specifically those who have been shown to contribute least 
frequently (notably CNSs and StRs) in the decision making process, and to better 
understand the role of patient centred information during MDT discussions.
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Chapter 3. Status hierarchies in team settings  
 
This chapter presents the theoretical framework underpinning this study. It begins 
by outlining definitions for the key terms used, before drawing on theoretical and 
empirical literature on status hierarchies predominantly from the field of micro 
organisational behaviour. In doing so, it considers the impact of status hierarchies 
on individuals and teams, reviews the key principles of status characteristics theory, 
and considers the potential implications of this for cancer MDTs. 
 
Micro organisational behaviour is a sub-discipline of organisational behaviour, 
which has been heavily influenced by social psychology (Thompson, 2003). Research 
on micro organisational behaviour focuses on individual or small group dynamics 
within an organisational context (Thompson, 2003). This includes the study of 
decision making and the impact of status on small groups or teams (Thompson, 
2003, Piazza and Castellucci, 2013). These theoretical perspectives on status have 
not yet been applied in the context of cancer MDTs. In fact, a striking feature of the 
literature on cancer MDTs is that there has been very little explicit use of any theory 
to underpin the research that has so far been conducted (Lamb et al., 2013c). The 
purpose of drawing on the theoretical and empirical literature on status is to 
facilitate a deeper understanding of the decision making process in MDT meetings.  
 
3.1 Definitions: status, hierarchies and teams 
3.1.1 Status and hierarchy  
The concept of status spans a number of disciplines. While it has traditionally been 
of interest to social scientists, more recently it has emerged as a key concept in 
management and organisation theory (Piazza and Castellucci, 2013). In this context, 
the focus has shifted from the role of status in a wide range of social situations, 
towards the impact of status on markets, organisations and, most importantly for 
this study, small groups or teams (Piazza and Castellucci, 2013).  
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Although status appears to be a relatively intuitive concept there has been a great 
deal of debate in the literature about the most appropriate way to define and 
operationalise the term in the context of empirical research (Piazza and Castellucci, 
2013). In part this is because status is often correlated with other concepts, 
including power, or position in a hierarchy of authority. However, status can be 
distinguished from these concepts because it is conferred on the basis of 
contributions to the common good and implies the granting of respect and esteem. 
Thus, deference to those with higher status is not an obligation, as it might be in a 
relationship based on power or authority (Pearce, 2011). 
 
For the purposes of this study, I define status as having characteristics that are 
deemed to be more or less desirable within the context of a specific group (Berger 
et al., 1983). This makes status a relative concept,  where characteristics that are 
desirable in one context may not necessarily be in another (Cohen and Zhou, 1991). 
A hierarchy emerges when different evaluations of status within a group lead to the 
“rank ordering of individuals” (Anderson and Brown, 2010) (p. 57).  
 
Status within teams can be measured in a number of different ways (Piazza and 
Castellucci, 2013). This includes ‘peer rating’ of status, most often used in 
experimental settings (Bendersky and Hays, 2012), measuring indicators of award or 
recognition (Marr and Thau, 2014), or the assessment of core individual 
characteristics such as age, gender or professional group (Bloom, 1980). For this 
study, I adopt the latter measure, and use healthcare profession as an indicator of 
status within MDTs. This is an approach that is well established in the study of 
healthcare teams (Bloom, 1980, Lichtenstein et al., 2004, Nembhard and 
Edmondson, 2006, Satterstrom et al., 2014). It is particularly appropriate in the 
context of MDT meetings because of the historical and clearly defined differences 
between the healthcare professions which make up these teams. These separate 
professional identities have arisen over decades, and are consolidated by variations 
in the nature and length of training, the process of socialisation into a specific 
profession, and differences in legal registration and levels of autonomy in practice 
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(Hudson, 2002). The strength of these professional identities means that status 
differences between professional groups in healthcare are distinctive and well 
recognised (Nembhard and Edmondson, 2006).  
 
3.1.2 The status hierarchy in healthcare teams 
Modern medicine sits at the apex of the professional status hierarchy in healthcare, 
as an archetypal profession with a special status even amongst other professions 
(Freidson, 1988, Filc, 2004). As rated by members of the public, patients and 
medical professionals themselves, surgeons are accorded the highest rank, followed 
by medical, then diagnostic doctors including pathologists and radiologists (Shortell, 
1974, Hinze, 1999, Norredam and Album, 2007). Nurses have been ranked below all 
of these groups, at the lower end of the healthcare professional status hierarchy 
(Shortell, 1974, Stein et al., 1990, Nembhard and Edmondson, 2006). Greater 
patient involvement and the emergence of stronger roles for nurses have led to 
recent changes within the healthcare setting (Kenny and Duckett, 2004, Stein et al., 
1990). Nonetheless, in practice, doctors are still the key decision makers in the 
healthcare arena (Battilana, 2011, Price et al., 2014). 
 
This hierarchy is particularly stable because it has legitimacy, reflected in the nature 
and levels of expertise held by doctors, based on scientifically established 
knowledge and their ability to cure disease and to relieve pain (Radcliffe, 2000, Filc, 
2004). It also reflects the lengthy education and training pathways required to 
qualify (Hudson, 2002), as well as the legal responsibility doctors hold of a duty of 
care to their patients (Sidhom and Poulsen, 2006). In contrast, nurses have less 
autonomy (Price et al., 2014), and nursing knowledge is often grounded in ‘patient 
knowledge’ (Stein-Parbury and Liaschenko, 2007). This emphasises the importance 
of understanding the experience of disease from the perspective of an individual. It 
has been argued that this type of knowledge is less privileged in the healthcare 
setting than the objective measures that underpin the biomedical approach to 
diagnosis and treatment adopted by doctors (Coombs and Ersser, 2004, Stein-
Parbury and Liaschenko, 2007). 
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I use the clear distinctions between professional groups to determine status within 
the MDT meeting. Accordingly, surgeons, medical and diagnostic doctors will be 
classed as high status within the MDT, and Clinical Nurse Specialists (CNSs) will be 
classed as lower status. The role of junior doctors in MDT meetings has been given 
little consideration in the literature to date. However, reflecting their position as 
doctors in training, and the literature from other types of healthcare team - for 
example teams in intensive care units (Reader et al., 2008) - I have also classified 
junior doctors (namely Specialty Registrars) as lower status on the basis that they 
have yet to gain the knowledge and expertise held by consultant doctors within the 
team.  
 
This dichotomous distinction between high status (consultant surgeon, medical or 
diagnostic doctor), and lower status (CNS or StR) is consistent with the application 
of status used in other studies of healthcare teams (Nembhard and Edmondson, 
2006, Battilana, 2011, Weiss et al., 2016). Although there may also be differences in 
status within professions, according to their specialty (for example depending on 
the type of cancer they treat) (Album and Westin, 2008), the advantage of this 
approach was that it enabled me to accommodate the differences in composition 
between teams. 
 
3.1.3 Cancer MDTs as ‘teams’ 
The label of ‘team’ has been applied extensively, both in the academic literature 
and in practice. As a result it has been argued that there are risks to the 
indiscriminate application of the term (West and Lyubovnikova, 2012). Traditional 
definitions emphasise the importance of clear membership, interdependence in the 
team task, and the presence of shared goals, embedded within a wider 
organisational context (Cohen and Bailey, 1997, Lemieux-Charles and McGuire, 
2006, Bosch et al., 2009).  
 
Cancer MDTs share many of these features. They are defined in national guidelines 
as the group of different healthcare professionals who contribute to the decision 
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making process for patients discussed at the weekly meeting. A prescribed list of 
core members must demonstrate their commitment to the MDT by attending at 
least two thirds of weekly meetings over the course of each year (NHS England, 
2014, NHS Improving Quality, 2014). MDTs also have a shared goal of making 
treatment plans for patients with cancer, and they operate within the 
organisational context of NHS Trusts.  
 
In other respects however, MDTs are more dynamic than the type of teams 
described in traditional definitions. For example, although the shared team task of 
treatment planning is a key feature of the weekly team meeting, outside of this 
levels of interdependence between professional groups are in practice often limited 
(Opie, 1997, Mickan and Rodger, 2000). Attendance of core members at MDT 
meetings can also be variable (Lamb et al., 2011c), and guidelines specifically allow 
for members to attend only part of each meeting (NHS England, 2013). Other 
‘extended’ members (including StRs) may attend meetings regularly, but only on a 
short-terms basis, or they may attend more sporadically but over a longer period of 
time (e.g. consultants from another specialty who attend to provide expert input in 
certain cases) (NHS Improving Quality, 2014). Nonetheless, there is a growing 
recognition of the value in studying these more dynamic types of team as they 
become more common, not just in healthcare, but also in other fields such as 
aviation and emergency response teams (Wageman et al., 2012, Bienefeld and 
Grote, 2013). 
 
3.2 The impact of status hierarchies on individuals and teams 
The existence of status hierarchies within healthcare teams is important because a 
number of studies have demonstrated that the relative status of group members 
affects a variety of outcomes, both at the level of the individual and at the level of 
the team.  
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3.2.1 Individual level outcomes 
For individuals, high status has been associated with a range of benefits, from 
financial rewards to greater social influence and higher self-esteem as well as 
subjective wellbeing  (Levine and Moreland, 1990, Pearce, 2011). In contrast, the 
performance of low status team members is often undervalued. For example, low 
status members may be evaluated less favourably than higher status members of a 
team even if they have given equal input (Weisband et al., 1995).   
 
3.2.2 Team level outcomes 
Efficiency 
At the level of the team, functionalist perspectives of hierarchy suggest that status 
hierarchies can help groups to make better quality decisions, by ceding control to 
the most competent team members (Anderson and Brown, 2010). It has also been 
argued that clearly defined and stable hierarchies also mean that interaction within 
teams becomes more predictable and less uncertain, supporting efficient decision 
making within the group (Halevy et al., 2011).  
 
Information sharing  
However, status hierarchies can also negatively affect the ability of teams to share 
knowledge and information, particularly information held by lower status members 
(Bunderson and Reagans, 2011, Bendersky and Hays, 2012). For example, lower 
professional status has been found to negatively influence beliefs about how safe it 
is to speak up or contribute to improvement efforts in neonatal intensive care 
teams (Nembhard and Edmondson, 2006).  
 
This is problematic because information sharing is a key feature of effective 
teamwork, in part because it increases the likelihood that relevant information will 
be taken into account when making decisions (Lemieux-Charles and McGuire, 2006, 
Mesmer-Magnus and DeChurch, 2009, Schippers et al., 2014, Hewitt et al., 2015). 
Specifically, sharing information held by only a minority of team members has been 
shown to improve the overall accuracy of medical diagnoses made by clinical teams 
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(Larson et al., 1998). Better presentation of information and better contributions 
from all professionals during MDT meetings also increases the likelihood that a 
team will reach a decision (Lamb et al., 2013b).  
 
3.3 Status characteristics theory 
An important strand of theory which has explored issues relating to status in a team 
context is status characteristics theory. This body of work considers the way in 
which status differences affect participants’ expectations of one another and how 
this translates into inequalities in interaction amongst team members (Berger et al., 
1972, Berger et al., 1980, Ridgeway, 2001). This may be particularly salient in the 
context of multidisciplinary teams where, as has been shown, inequalities in 
participation between groups in MDT meetings are well documented.  
 
3.3.1 Overview of status characteristics theory 
Status characteristics theory was developed in order to explain the behaviour of 
teams working on a specific task, with a shared goal (Nijstad and van Knippenberg, 
2012). The theory proposes that in this environment individuals will rely on status 
characteristics to assess the relative competence of other group members. In turn, 
these evaluations will determine a status hierarchy which is reflected in the way the 
group interact (Berger et al., 1972, Berger et al., 1980).  
 
Status characteristics can be specific characteristics that are directly relevant to the 
task the team is working on, for example educational background. They can also be 
diffuse characteristics which provide information about an individual’s general 
aptitude, which is presumed to affect competence on a range of tasks. Examples of 
diffuse status characteristics can include gender, age, ethnicity or professional 
occupation (Berger et al., 1972, Lichtenstein et al., 2004). Status characteristics and 
the corresponding expectations of competence are relative, both to the task and to 
team members. For example, gender may be a status characteristic in one team, 
and influence the way members of the group interact. However, individuals in 
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another team may not have different expectations of team members based on their 
gender (for example because they do not think it is relevant to the task) in which 
case it would not have an impact (Cohen and Zhou, 1991). 
 
A key premise of the theory, and the part which is most relevant to my thesis, is 
that the effect of these expectations is reflected in the way the group interact: the 
‘power and prestige order’. This order relates to who initiates participation, who 
has opportunities to participate, who has influence, and how members of the group 
are evaluated by others (Ridgeway, 2001). In practice, this means that individuals 
with higher status are more likely to be listened to and have greater influence than 
individuals with lower status, even if those with lower status have an important 
contribution to make to the team’s task. It also means that individuals in lower 
status positions will be more likely to defer to those with high status, and have 
fewer opportunities to participate or influence the rest of the group (Berger et al., 
1972, Berger et al., 1980, Bunderson and Reagans, 2011).  
 
If status and expertise are aligned, this may be beneficial for the decision making 
process. However, crucially, this order will operate regardless of whether group 
members’ expectations are correct or not. In the context of MDT meetings, this 
means that if the dominance of medical professionals is explained not only by their 
expertise and training, but also by more general expectations about competence 
that are grounded in a broader social context which prizes the medical profession 
above others, decision making could be impaired (Lichtenstein et al., 2004). This can 
be illustrated by a practical example. A nurse may hold information about a 
patient’s social circumstances, which is likely to impact on the treatment that the 
patients is willing, or able, to undertake. If the nurse defers to higher status 
members or is given limited opportunity to participate because of general 
expectations about the value of lower status contributions, then the decision made 
by the team may not be accepted by the patient. In this case, status hierarchies are 
likely to be detrimental to the functioning of the team.   
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3.3.2 Empirical evidence relating to status characteristics theory 
Most early research based on status characteristics theory was conducted in 
experimental laboratory settings, as opposed to naturalistic settings (Berger et al., 
1972, Berger et al., 1980)). This includes an experimental study by Bloom (1980) to 
determine the effects of status hierarchy on decision making in nursing teams in the 
USA. The results of this study showed that status hierarchies based on occupation 
did affect interaction within the groups, with lower status individuals having less 
influence. However, the effects of this varied according to the level of consensus 
amongst groups on the hierarchy within the team. These findings reflect the 
functionalist view of hierarchies, because where the groups developed a stable 
status hierarchy, more information was brought into the discussion, and decisions 
were judged to be higher quality (using predetermined criteria of good nursing care 
and as evaluated by three nursing experts). These findings led the author to 
conclude that some status distinctions between members of professional work 
teams could be beneficial for the quality of problem solving. However, this was 
caveated by the need for genuine differences in expertise and clarity about the role 
of different members, for example around information sharing.  
 
More recently, the idea that hierarchies within healthcare teams can be beneficial 
for certain types of task has also been demonstrated in an experimental study of 
multidisciplinary teams in Sweden. The results are based on observation of 54 
teams in occupational health, psychiatric care, rehabilitation and school healthcare. 
These results showed that tasks involving simple ‘convergent’ problems, which had 
only one possible correct solution, benefitted from the effects of hierarchy even 
when this led to unequal participation amongst team members (Thylefors, 2012). 
The dominance of certain team members was also shown to be beneficial for 
dealing with more complex problems, where dominance was aligned with the 
relevant expertise necessary to complete the task (Thylefors, 2012). Similarly to 
Bloom’s study however, this research involved simulated team tasks, and was not 
based on observation of the teams in their natural environment. This suggests that 
some caution is required in generalising the findings to a naturalistic setting.  
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A relatively small number of studies have applied status characteristics theory in a 
naturalistic setting. In contrast to the studies described above, these suggest that 
status hierarchies can lead teams to overlook legitimate indicators of knowledge 
and expertise, and negatively impact on levels of participation and information 
sharing. The first attempt to test the theory of status characteristics in well-
established teams was made by Cohen and Zhou (1991) using data from 244 
Research and Development Teams from 29 large corporations in the USA. The 
authors examined the effects of status characteristics on self-reported team 
interaction, finding that beliefs associated with diffuse status characteristics (such 
as age and gender) affected levels of participation within the group. This indicates 
that competence and performance were not the only basis for determining the 
status of an individual within a team.  
 
Similarly, Bunderson (2003) examined the association between status and 
performance expectations in manufacturing production teams. The results showed 
that in teams with unequal participation and influence, the knowledge and 
expertise of team members had little bearing on influence and involvement in 
decision making, even when their experience was directly relevant to the task of the 
group. Instead, influence was related not to task expertise, but to other factors such 
as gender and ethnicity. These factors were weaker cues in teams where influence 
was more evenly distributed (Bunderson, 2003, Bunderson and Reagans, 2011).  
 
Status characteristics theory has also been applied in a naturalistic healthcare 
setting. A survey study of 1,025 healthcare professionals in psychiatric treatment 
units in the USA examined the effects of status on participation and job satisfaction 
within teams. The results suggested that status influenced levels of participation 
within the team, with higher status professionals participating more actively and 
being more satisfied with their levels of autonomy and with their co-workers than 
those with lower status (Lichtenstein et al., 2004).  
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Importantly however, these studies have been carried out in America, where there 
are many contextual differences in the healthcare system in comparison with the 
UK NHS. Nonetheless, it is possible to conclude from the findings of both the 
experimental and real-world studies, that while in some circumstances status 
hierarchies can lead to more efficient decision making, in others, they can lead 
teams to overlook legitimate indicators of knowledge and expertise.  
 
3.3.3 Moderating status hierarchies 
A number of researchers have considered possible moderators of status hierarchies 
in order to explain the mixed results in the literature. Although much of this 
research has been carried out in non-healthcare settings, it provides a starting point 
for understanding the factors that have the potential to moderate some of the 
negative effects of status that have been documented. Factors that have been 
identified include the length of time that a team has been working together, the 
task of the group, and the role of the leader. I discuss these below and consider the 
potential implications for MDTs.  
 
The length of time that a team has been operating  
The average length of time a team has been operating has been shown to moderate 
the impact of status in manufacturing production teams (Bunderson, 2003). The 
results from this study suggest that as group members interacted over time, they 
were better able to determine which members were (or were not) competent, and 
could adjust their expectations accordingly (Bunderson, 2003).  
 
However, this may be less influential in the MDT setting, given the more limited 
collaboration outside of the weekly meeting that is a feature of these teams 
(Mickan and Rodger, 2000). Even if MDTs are well-established, if different 
professional groups essentially work in parallel outside of the meeting, this may act 
to reinforce boundaries and potentially undermine the ability of members to “learn 
about, compare and verify one another’s task relevant background” (Bunderson, 
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2003) (p. 563). It is possible therefore that status hierarchies may be more durable 
in the MDT setting than in other non-healthcare teams.   
 
Team task 
It has also been argued that the effects of status hierarchies will vary depending on 
the type of task a team is working on (Anderson and Brown, 2010, Cantimur et al., 
2016). For example, if teams are making routine decisions it may be more efficient 
to give disproportionate control to a small number of the most competent 
members. In contrast, tasks that are likely to benefit from diverse sources of 
knowledge and information may benefit from a flatter structure that provides 
opportunities for all members to contribute (Anderson and Brown, 2010).  
 
In the case of MDT decision making, teams are faced with the challenge of 
managing both of these scenarios. This is because MDTs must make decisions about 
patients whose treatment can be managed according to agreed evidence-based 
protocols, as well as decisions about cases which are more complex and therefore 
likely to benefit from wider input. As yet, there is little evidence to show how teams 
can manage status hierarchies in the context of these potentially competing 
demands.   
 
Leadership  
There is a considerable body of evidence to suggest that leadership behaviours can 
have an important influence on the willingness of team members to speak up in 
hierarchical settings (Anderson and Brown, 2010, Morrison, 2011). For example, 
subtle body language signals and a lack of willingness to listen can discourage 
contributions from team members. However, other behaviours can foster 
opportunities for contributions and create an environment that supports speaking 
up (Morrison, 2011).  
 
A key mechanism that has recently been explored in the context of healthcare 
teams is the concept of ‘leader inclusiveness’ (Mitchell et al., 2015). This is 
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described as behaviour that creates psychological safety for speaking up in teams, 
and is concerned with encouraging participation, specifically from those whose 
voice might otherwise not be heard (Nembhard and Edmondson, 2006). Through 
this mechanism it is argued that teams can overcome the negative effects of status, 
by reducing perceived status differences (Nembhard and Edmondson, 2006, 
Mitchell et al., 2015). Lichtenstein et al (2004) also emphasise this point by arguing 
that effective team leaders should be able to foster open and supportive 
communication among members that “prevents the hierarchical relationships that 
exist outside the team from being replicated within the team context” (p.333).  
 
More recently however, Bienfeld and Grote (2013) have argued that in teams where 
status hierarchies are well established and deeply entrenched, it may not be 
possible to completely overcome the effects of the hierarchy. Studying the effects 
of hierarchy on speaking up within and between aviation teams, they concluded 
that while leader inclusiveness mitigated or weakened some of the effects of status 
hierarchies, it did not overcome them completely. This has relevance to the MDT 
setting, where despite teams being operational in the UK since 1995, with clear 
‘collective’ goals dictated at a national level, inequalities in participation are still a 
key feature of some teams. This raises questions about whether in this context the 
status hierarchy can in fact be ‘overcome’ or ‘flattened’.  
 
Nonetheless, if leader inclusiveness can mitigate some of the effects of hierarchy 
this could provide a mechanism for enabling MDTs to improve participation and 
information sharing amongst lower status groups. To date however, leader 
inclusiveness has been measured using items adapted from previously validated 
scales, which gather the views of team members about how inclusive their leaders 
are (Nembhard and Edmondson, 2006, Bienefeld and Grote, 2013, Mitchell et al., 
2015). These measures only capture general perceptions of inclusiveness without 
linking them to specific behaviours. For example, leaders are assessed by team 
members against statements such as “our leadership encourages the input of 
members from all professionals” (Mitchell et al., 2015) (p. 225). At present 
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therefore, little is known about what leaders actually do to encourage and 
incorporate contributions from those who are less likely to speak up. A better 
understanding of leadership behaviours which invite and integrate contributions 
from lower status individuals is crucial if MDTs are to utilise the knowledge and 
skills of all team members within a context where status hierarchies are well-
established and are unlikely to be easily overcome. 
 
3.3.4 The participation of lower status groups  
Although consideration has been given to the role of leaders in moderating status 
hierarchies, less is known about the role of lower status individuals themselves. 
Specifically, this includes the approaches that can be adopted by lower status 
groups in order to participate within a hierarchical setting.  
 
Two approaches that have previously been identified are the use of questioning and 
humour. A study of communication between different professional groups within a 
specialist palliative care setting showed that questions were used by nurses as a 
way to make tentative suggestions to higher status individuals in a diplomatic 
manner. Questions were also employed as a strategic tactic to gain control of a 
discussion by framing them in a way that shaped the response (Arber, 2008). 
Similarly, it has been shown that humour can be used by those with lower status as 
a means of resisting professional dominance in community mental health MDT 
meetings, for example by signalling dissent or resisting a course of action proposed 
by a higher status member of the team (Griffiths, 1998).  
 
This existing research provides a valuable insight into possible mechanisms for 
increasing the influence of lower status groups in a healthcare setting. However, in 
practice, individuals within the MDT meeting are likely to use a wide range of 
approaches to participate, depending on the specific contribution to be made, and 
taking into account the impact of their contribution on their future credibility 
(Morrison, 2011). It is also conceivable that certain approaches may be less 
effective in particular circumstances, and when used by certain individuals or 
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groups. For example, the use of humour by junior doctors with less knowledge or 
experience than other team members may break implicit group norms, which 
dictate when and in what circumstances humour is an appropriate form of 
communication (Rowe and Regehr, 2010). To date there has been little 
consideration of these issues in the MDT context. 
 
3.3.5 Applying existing solutions to MDT meetings 
The research described above is useful in identifying tentative explanations for the 
patterns of participation and information sharing previously observed in MDT 
meetings. In particular, it challenges a key assumption underpinning the policy 
vision of MDTs – that teams will optimally share and integrate the knowledge and 
skills of all professional groups in the decision making process. The theoretical and 
empirical literature instead suggests that while status hierarchies may improve 
efficiency, they are also likely to complicate the decision making process by 
disrupting information sharing and integration. As noted above, this is likely to be 
problematic in the MDT setting because sharing information and engaging in robust 
discussion is central to the decision making process in healthcare teams (Larson et 
al., 1998, Lemieux-Charles and McGuire, 2006, Lanceley et al., 2008, Lamb et al., 
2013b).  
 
However, the nature of status hierarchies within MDTs - and healthcare teams more 
generally – means that the moderating factors identified in existing literature are 
unlikely to be sufficient to ‘cancel out’ the effects of status in these teams 
(Bienefeld and Grote, 2013). As described previously, status hierarchies in 
healthcare teams are well-established and have proved to be remarkably stable 
over time (Filc, 2004). These hierarchies are bound up in the way that professional 
groups within the MDT are educated and trained. Doctors in particular have been 
socialised to make decisions and to act decisively (Hall, 2005, Bartunek, 2011). As a 
result, although they may recognise the value of contributions from other 
professional groups in principle, in practice they may not necessarily seek or use 
this information when making decisions (Coombs and Ersser, 2004). In this context 
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there are likely to be specific challenges in overcoming the effects of the status 
hierarchy, and existing solutions identified in the empirical and theoretical literature 
to encourage lower status contributions will not necessarily transfer to the MDT 
setting. 
 
It is also worth considering, in the context of medical decision making, whether 
attempting to cancel out the effects of status hierarchies entirely is even a desirable 
goal. Certain types of information may not be necessary for every single decision 
made in the MDT meeting - for example, psychosocial information may be relevant 
in some cases but may not have a bearing on the clinical decision in others (Stein-
Parbury and Liaschenko, 2007). Encouraging all team members to speak up equally 
may therefore be an overly simplistic solution (Morrison, 2011). Bloom (1980) and 
Thylefors’ (2012) findings are illustrative here. Unequal participation amongst those 
of different status in clinical teams did not negatively impact on the quality of 
decisions made in cases where real differences in expertise existed, and where 
team members had clear expectations about their respective roles. In the MDT 
setting, where those with the highest status are likely to be the most experienced in 
the treatment of disease, it is essential that these individuals have, and maintain, a 
key role in decision making. This is particularly true given the time pressures and 
calls for improved efficiency facing MDTs noted in the previous chapter.  
 
The specific challenge in this context however, is that while some decisions may not 
require full participation of all members, others will benefit considerably from 
multidisciplinary discussion. To date, there has been little consideration in the 
literature of situations in which teams must simultaneously capitalise on existing 
status hierarchies, whilst also finding ways to minimise their effects in a subset of 
cases. In practice however, MDTs must be able to identify and integrate the unique 
knowledge and information held by lower status groups in cases that are complex 
with respect to the interplay between clinical and patient centred factors. They 
must also be able to do this even if it does not necessarily entail consistent equal 
participation of all professional groups. Given that opportunities to integrate the 
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information contributed by low status individuals may in fact be relatively rare in 
MDT meetings, lower status members must continually offer information or 
opinions, even if this does not necessarily equate to influence over decisions. In this 
context encouraging multidisciplinary participation is likely to be particularly 
challenging.  
 
3.4 Chapter Summary 
My thesis will use status characteristics theory as a framework to explore the role of 
status hierarchies in the decision making process in cancer MDT meetings. Status 
characteristics theory has not yet been applied in this particular setting. There is 
therefore scope to add real value to an important aspect of cancer care by 
enhancing our understanding of the decision making process, with a focus on the 
interaction between different professional groups and the contribution of lower 
status groups in particular.  
 
MDT meetings also provide an opportunity to extend the theoretical literature on 
status by studying the decision making process of cancer MDTs in a naturalistic 
setting. The distinctive characteristics of MDT meetings, including the well-
established hierarchies amongst professional groups, and the changing membership 
of the teams, offer new opportunities to explore the way teams function in 
situations where it is not possible – or even desirable – to moderate or flatten the 
hierarchy. In this context there is also scope to extend the literature in relation to 
the way in which teams manage the conflicting effects of hierarchy where these 
occur within a single meeting or encounter. This will include consideration of the 
role of both higher and lower status individuals, adding nuance to our 
understanding of what approaches are employed, how and when they are used, 
and the effect that they have on the decision making process.
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Chapter 4: Research Questions 
 
In response to gaps identified in the empirical and theoretical literature, my thesis 
will explore the role of status hierarchies in the decision making process in cancer 
MDT meetings. The aim is to contribute knowledge that can be used to help MDTs 
appropriately utilise the skills and knowledge of all team members when making 
decisions in MDT meetings. To do this I will address the following questions: 
 
1. How do status hierarchies unfold during the decision making process in 
cancer MDT meetings? 
 
2. What factors facilitate or inhibit multidisciplinary discussion in MDT 
meetings? 
 
3. What approaches are used by lower status groups in order to contribute 
during MDT meetings?
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Chapter 5. Research design and methods 
 
The preceding chapters have outlined the policy context within which MDT 
meetings operate, and reviewed the research and theoretical literature. Together 
these reviews informed my research questions about the role of status hierarchies 
in the decision making process in cancer MDT meetings. In answering these 
research questions, my aim is to explore the complex social interactions and the 
processes that underpin decision making in MDT meetings. In order to achieve this, 
I have used a generic qualitative approach, focused on naturally occurring events in 
the setting of four cancer MDTs in England.  
 
This chapter describes the rationale for my methodological approach and gives an 
overview of the research design and setting. It also outlines the specific methods of 
non-participant observation and semi-structured interviews used to generate data 
to answer the research questions posed. It then goes on to describe my analytic 
strategy, and the steps I took to ensure the quality and ethical conduct of my 
research.   
 
5.1 Methodological approach  
I adopted a qualitative approach to address the research questions posed in this 
thesis. A key strength of qualitative approaches is that they can provide rich and 
vivid accounts of an issue of interest, set within a clearly defined real-world context 
(Miles and Huberman, 1994, Snape and Spencer, 2009). It is therefore well suited to 
exploring complex processes such as decision making (Maxwell, 2005, Ritchie, 2009, 
Snape and Spencer, 2009). In the context of this research, adopting a qualitative 
approach also enabled me to explore the taken for granted knowledge and 
assumptions that underpinned the decision making processes in the four MDTs 
under study (Tracy, 2010). This is in contrast to quantitative methods where the 
focus is often on causation or the correlation between factors of interest (Maxwell, 
2005). 
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There are many different methodological approaches within the framework of 
qualitative research (Murphy, 2001, Carter and Little, 2007, Snape and Spencer, 
2009).  The approaches used by health services researchers are often influenced by 
methodologies well-established in the social sciences, for example from sociology, 
anthropology and psychology (e.g. grounded theory, ethnography and 
phenomenology) (Thorne, 2011). These methodological approaches incorporate a 
range of beliefs about the nature of reality and what we can know about the social 
world, as well as the nature of knowledge and how we can acquire it (Ritchie, 2009, 
Snape and Spencer, 2009). They also shape the way in which research should be 
conducted, from the development of research questions to data collection, analysis 
and dissemination of the findings (Thorne, 1991).  
 
However, there can be tensions between the applied nature of health services 
research, and these traditional qualitative methodologies. While many of the latter 
prioritise the development of theory, in the field of health services research, 
findings must add practical value in the context of complex clinical settings (Thorne, 
1991, Thorne, 2008, Thorne, 2011).  
 
As a result a number of researchers in applied fields have advocated the use of 
generic qualitative research (Neergaard et al., 2009, Ritchie, 2009, Kahlke, 2014). 
This is research that “has not been guided by an explicit or established set of 
philosophic assumptions in the form of one of the known qualitative methodologies” 
(Caelli et al., 2003) (p.4). Instead, generic qualitative research modifies aspects of a 
single established methodological approach, or integrates a series of tools and 
techniques from more than one (Kahlke, 2014). As described below, I adopted the 
latter approach, using tools and techniques that best helped me to address the 
research questions posed in this study.  
 
5.1.1 Rationale for adopting a generic qualitative approach 
Moving away from a reliance on a single traditional methodology is not an entirely 
new approach in qualitative research (Caelli et al., 2003), and has been used by 
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other health service researchers, for example in a study exploring collaboration in 
unscheduled emergency care (Cooper et al., 2007). The key benefit relates to the 
ability to prioritise real-world clinical issues, and to make decisions about methods 
on the basis of what works. This can help to avoid a preoccupation with 
methodology at the expense of the substance of the research, or ‘methodolatry’ 
(Chamberlain, 2000, Ritchie, 2009, Thorne, 2011).  
 
In addition to these benefits, a generic approach was particularly suitable for this 
study because my research questions were developed after data collection 
(reflecting the timescales of the NIHR-funded MDT Study). Using data collected for 
one purpose to address a different set of research questions can result in poor 
methodological fit (Edmondson and McManus, 2007). This would have been 
particularly problematic if I had tried to apply a traditional qualitative methodology 
‘post hoc’ to data collected as part of a mixed methods study. Instead, adopting a 
generic approach enabled me to develop research questions that capitalised on the 
data that had already been collected, and to build on the earlier mixed methods 
analysis (Raine et al., 2014a). To ensure congruence between methodology and 
methods I made a series of iterative decisions about which data to use from the 
MDT Study dataset, and how to analyse these. I also constantly reviewed whether 
the new questions I wanted to pose could be appropriately answered by the data I 
had. 
 
5.1.2 Rationale for data collection methods 
Within this framework, I used qualitative data collected from non-participant 
observation and semi-structured interviews with MDT professionals and patients to 
address the research questions posed in this thesis. Non-participant observation 
was an appropriate method in this context because it generated data that enabled 
me to explore the decision making process in detail in a naturalistic setting (Savage, 
2000). Importantly, it also allowed me to consider the largely unarticulated and 
taken for granted dimensions of behaviour in these four teams by reflecting on who 
did or did not participate, as well as reflecting on what was and was not being said 
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(Tracy, 2010). In turn, the semi-structured approach used during the interviews 
provided me with rich data about participants’ perspectives of the meetings, and 
the views of patients (Bloomberg and Volpe, 2012). Combining these approaches 
enabled me to contrast and compare what happened in practice with what was said 
in interviews (Savage, 2000).   
 
Observation and interview methods have been used by other health service 
researchers who have studied MDT meetings (Lanceley et al., 2008, Kidger et al., 
2009, Frykholm and Groth, 2011), as well as by organisational behaviour scholars to 
study status in real-world settings (Nembhard and Edmondson, 2006, Rivera, 2010). 
Although the patient perspective has less frequently been included in studies of 
MDT meetings, a small number of researchers have recently begun to consider this 
too (Lamb et al., 2014b, Taylor et al., 2014).  
 
One of the benefits of combining these different methods within my study is that it 
enabled me to gain an understanding of MDT meetings from different perspectives 
(Barbour, 2001). The purpose of this was not to establish a more ‘accurate’ 
representation of MDT meetings, but to explore complementary perspectives in 
order to broaden and deepen understanding of the decision making process 
(Barbour, 2001). 
 
5.1.3 Philosophical approach  
This approach to combining methods reflects the critical realist philosophy that 
underpinned my methodological approach. Critical realism acknowledges the 
existence of a social world independent of individual understanding. However, it 
also recognises that different actors will create different interpretations of this 
reality (combining a realist ontology with a constructivist epistemology) (Maxwell, 
2012). Research conducted from this philosophical position is therefore less 
concerned with determining whether participants’ perspectives are valid than with 
a desire to understand meaning from their perspective (Thorne, 2000).  
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5.2 Research design 
As described in Chapter 1 this research was conducted as part of a larger mixed 
methods study, the NIHR-funded MDT Study. I drew on a selection of data from the 
MDT Study in order to explore the role of status hierarchies in the decision making 
process in cancer MDT meetings. This included data collected from 122 meetings of 
four cancer teams, 19 semi-structured interviews with healthcare professionals, and 
seven patient interviews. Table 2 illustrates the link between each of the methods 
and the three research questions posed in this thesis.  
 
Table 2: Linking research questions and methods 
Research Question Data collection methods Data analysis 
methods 
1. How do status hierarchies 
unfold during the decision-
making process in cancer 
MDT meetings? 
 Non-participant observation  
 Interviews with MDT professionals 
 Interviews with patients Thematic 
analysis I 
2. What factors facilitate or 
inhibit multidisciplinary 
discussion in MDT meetings? 
 Non-participant observation  
 Interviews with MDT professionals 
 
3. What approaches are 
used by lower status groups 
to contribute during MDT 
meetings? 
 Non-participant observation  
 Thematic 
analysis II 
 
The MDTs were initially recruited to the MDT Study in late 2010, and I collected 
data between December 2010 and May 2012. Following data collection, and while 
conducting the analysis for the MDT Study, I began to develop additional research 
questions to address by means of further independent analysis as part of my PhD. I 
undertook this additional analysis following completion of the MDT Study in 
December 2013.  
 
There were a number of decisions made as part of the MDT Study which shaped 
certain aspects of the research design and data collection processes that underpin 
my thesis. These include: 
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 the selection of teams 
 the choice of methods  
 the number of meetings observed (which was driven by the need to collect a 
pre-defined quantitative sample of patients discussed in each MDT meeting) 
 the number of qualitative interviews conducted with cancer MDT 
professionals and patients (these teams made up only one quarter of the 
teams in the MDT Study) 
 the design of the data collection tools, including the observation coding 
framework and the interview topic guides. 
 
As a key member of the core research team on the MDT Study, I was involved in 
making many of these decisions, and in influencing the design of the data collection 
tools. Nonetheless, there were limitations to using these data to address different 
research questions – for example, some data collected during the semi-structured 
interviews were not relevant to the specific research questions posed in this study. 
However, there were also benefits, particularly in terms of having established a 
deep familiarity with the teams and the data. It was also useful to have worked 
through a previous analysis as part of a dynamic and diverse research team, as this 
sensitised me to a number of different issues and perspectives. I discuss the 
strengths and limitations of this approach in more detail in Chapter 10. 
 
5.3 Research setting 
The four cancer MDTs that provide the setting for this research were purposively 
recruited as part of the MDT Study alongside heart failure, mental health and 
memory clinics. The aim was to incorporate a diverse range of teams and chronic 
conditions, to enable issues relating to MDT decision making and the 
implementation of decisions to be explored. However, consideration was also given 
to issues of feasibility, because the data collection phase involved extended periods 
of observation at multiple sites.   
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Although the four teams were initially recruited to address the aims of the MDT 
Study, they also offer a useful setting for this research. A key advantage was the 
range of different cancer types, which provided an opportunity to explore the 
decision making process in MDT meetings in a number of different contexts. The 
four cancer teams were recruited from three hospital trusts in a single cancer 
network in a large metropolitan area of England. They included two haematology 
cancer teams, one skin cancer team and one gynaecology cancer team. These teams 
varied in size, the number of patients discussed each week, and the length of MDT 
meetings. Three of the four teams were based in teaching hospitals, while the 
fourth (Haematology 1) was a district general hospital (Table 3).  
 
Table 3: Overview of the four cancer MDTs  
Specialty  Trust Type of 
hospital 
No.  team 
members 
MDT lead Patients 
discussed1 
Meeting 
duration2  
Gynae A Teaching  28 Consultant 
Surgeon 
35 2.5 
Haem 1 B District 
General  
17 Consultant 
Haematologist 
15 1 
Haem 2 C Teaching  40 Consultant 
Haematologist 
14 1 
Skin C Teaching  21 Consultant  
Oncologist 
47 1.5 
1 
average number of patients discussed per meeting 
2
 approximate duration of the weekly meeting in hours 
 
The four cancer MDTs included in the study are described below to provide context 
for the findings presented in the following chapters.  
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5.3.1 The Gynaecology Cancer MDT 
Context 
The Gynaecology team I observed was a specialist MDT1 based at a large inner city 
teaching hospital. This meant that the team was responsible for managing all 
gynaecological cancers within their local area, as well as receiving referrals for 
patients who needed specialist treatment (e.g. for ovarian cancer) from the 
surrounding local MDTs. 
 
Team composition 
The team was large, with around 28 members. This included five surgical 
consultants in gynaecological oncology, four medical and clinical oncologists, two 
psychologists, three clinical nurse specialists, four pathologists, two radiologists, 
two research nurses, a clinical trials manager and an MDT co-ordinator. Between 
four and six StRs or Clinical Fellows attended each week. 
 
The MDT Lead in Gynaecology was a consultant gynaecologist. This position rotated 
every three years, but only amongst the consultant gynaecologists (and not for 
example among the consultant oncologists). The MDT Lead chaired the meeting, 
although the role of Chair in this team was slightly different to the other MDTs I 
observed. It involved both steering the meeting and documenting decisions.  These 
tasks were usually conducted by different individuals in other teams. 
 
The decision making process  
An average of 35 patients were discussed by the team each week. Meetings lasted 
around two and a half hours, making these the longest MDT meetings that I 
                                                     
1 The organisation of cancer MDTs varies according to specialty. For example, while there are three 
levels of MDT provision in gynaecology (primary care, and local and specialist MDTs in secondary 
care), there are 6 levels of specialisation for skin cancer (ranging from primary care through to 
specialist MDT management). The rationale for these different levels of care relates to the extent to 
which services for relatively infrequent procedures need to be consolidated to maintain appropriate 
levels of clinical skills and expertise (NHS Improving Quality, 2014).   
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observed. Patients who required review of both radiology and pathology were 
discussed first and in most detail, there was then briefer discussion of new patients 
who had been referred to the centre, and an opportunity to discuss a small number 
(generally only one or two) of complex cases. The final part of the meeting was 
dedicated to the review of pathology results. During the meeting, the decisions 
made for each of these patients were documented by the MDT Lead, although they 
were not always summarised verbally. They were typed up and projected on a 
screen at the front of the room. 
 
5.3.2 The Haematology Cancer 1 MDT meeting  
 
Context 
Haematology 1 was the only team of the four observed that was not based at an 
inner city teaching hospital. The team was based across two District General 
Hospital sites in a suburban area. Video-conferencing facilities were used to link the 
two sites, to enable all members of the team to participate in the weekly MDT 
meeting.  
 
This MDT did not provide transplantation services, which meant that a small 
number of patients had to be referred on to another more specialist centre for 
treatment (e.g. patients requiring a stem cell transplant).  
 
Team composition 
In comparison with the other three teams I observed, this was a relatively small 
team. The 17 members included four consultant haematologists, a staff grade 
haematology doctor, a pathologist and a radiologist, two clinical nurse specialists in 
haematology and chemotherapy, two clinical trials practitioners and an MDT co-
ordinator. In addition two or three StRs and one or two chemotherapy nurses 
attended each week. A consultant clinical oncologist from a neighbouring specialist 
MDT also attended the meeting intermittently to provide specialist oncology input. 
The MDT Lead, who chaired the meeting, was a consultant haematologist. 
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The decision making process   
The weekly meeting in Haematology 1 usually lasted for around an hour, with an 
average of 15 patients discussed each week.  
 
The patient list was not organised on the basis of disease sub-types, and the team 
discussed each case in turn, following the order in which the MDT coordinator had 
added patients to the list. The decisions made for each patient were initially 
recorded on paper by the MDT coordinator, before being reviewed by the MDT 
Lead and uploaded into patients’ electronic records.  
 
5.3.3 The Haematology Cancer 2 MDT meeting 
 
Context 
In contrast to Haematology 1, this team was based at an inner city teaching 
hospital. It had a dedicated transplant team, and received referrals from other 
hospitals that did not provide this level of specialised care. 
 
Team composition 
This was the largest team of the four I observed, with approximately 40 people 
attending the meetings. The importance of diagnosis was apparent in the number 
of diagnostic specialists who attended each week (around six individuals, including 
one or two pathologists, a radiologist, a specialist in nuclear medicine, a 
cytogeneticist, and a molecular biologist). In addition, there were 13 consultant 
haematologists, two clinical oncologists, five clinical nurse specialists, two research 
nurses, a clinical trials practitioner, a pharmacist, and an MDT coordinator. In 
addition up to ten haematology specialty registrars or clinical fellows attended the 
weekly meetings. Within this team, both consultants and clinical nurse specialists 
were sub-specialists with dedicated responsibility for haematological cancer sub-
types, for example lymphoma, leukaemia or myeloma. 
 
The meeting was chaired by the MDT Lead who was a consultant haematologist.  
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The decision making process  
In Haematology 2 the average number of patients discussed each week was 14, and 
meetings were scheduled to run for an hour. The patient list grouped patients 
according to their disease sub-type. Decisions were recorded for each patient 
directly into an electronic patient record by one of the haematology specialty 
registrars. This information was also projected onto a screen at the front of the 
room for other team members to see. These notes were intermittently checked by 
the MDT Lead or other members of the team who would point out any errors or 
omissions as they were being typed up. 
 
5.3.4 The Skin Cancer MDT meeting 
 
Context 
The Skin Cancer Team I observed for this study was a specialist skin cancer team, 
based in an inner city teaching hospital with a large plastic surgery unit. This meant 
that the team managed all skin cancer cases in their catchment area, as well as a 
subset of patients referred from surrounding local MDTs (e.g. those who required 
plastic or reconstructive surgery, or those with advanced metastatic melanoma).  
 
Team composition 
The team was composed of a consultant medical oncologist, two consultant plastic 
surgeons, around seven dermatologists in any one week, a dermatopathologist, a 
clinical oncologist, a radiologist, and occasionally a nuclear medicine specialist. 
There were also two or three specialty registrars in plastic surgery, one StR in 
oncology and one in radiology, a skin cancer CNS, a research nurse and an MDT co-
ordinator. Although there was a wide range of disciplines, the team was smaller 
than the Gynaecology and Haematology 2 teams, with 21 members. 
 
The MDT Lead was a consultant medical oncologist, who chaired the first part of the 
meeting covering melanoma patients. After these cases had been discussed, some 
of the oncology team left the meeting, although the MDT Lead and the skin cancer 
CNS remained. Although there was no formal chair during the second stage of the 
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meeting (for discussion of Squamous Cell Carcinoma and Basal Cell Carcinoma 
cases) the position was often filled by the consultant dermatopathologist or 
pathologist – a role which was periodically rotated amongst 4 different individuals 
who each brought their own approach. 
 
The decision making process   
The team discussed an average of 47 patients, at weekly meetings lasting for 
around an hour and a half. The MDT coordinator pointed out on a number of 
occasions that this made it one of the busiest MDT meetings in the Trust.  
 
The patient list divided patients into three distinct groups: melanoma cases, 
squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs). The melanoma 
cases were generally discussed first, and in greater depth because “they’re more 
complex. And their disease is life threatening” (CNS, Skin, interview). Following this, 
there was a distinct change in the pace of the meeting when the less complex SCC 
and BCC cases were discussed towards the end. A long list of patients was reviewed 
fairly quickly with much less in the way of discussion, providing an ‘audit’ function.  
This was in line with the Peer Review measures for skin cancer, which set out that 
SCC and BCCs (with the exception of recurrent SCCs/BCC, or those that have been 
positively excised) did not require mandatory, formal discussion of the case by the 
MDT (NHS England, 2014). 
 
The role of capturing the decisions made for each patient was delegated to 
whichever member of the team presented the patient, and therefore varied 
throughout the meeting. The decision was recorded on a paper proforma which was 
subsequently filed in the patient’s medical records by the MDT coordinator. 
 
5.4 Methods  
5.4.1 MDT Recruitment   
Teams were initially identified by the MDT Study’s clinical co-applicants, and invited 
to take part by Professor Raine, the Principal Investigator (PI). This was followed by 
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a discussion with the lead clinician from each MDT to clarify any issues or concerns. 
The four cancer teams invited all agreed to participate.  
 
Following this initial recruitment phase, I was one of three researchers who visited 
the teams to introduce the study at a weekly MDT meeting. I visited three of the 
cancer teams, while for logistical reasons another researcher introduced the study 
to the fourth team. After presenting the study to the teams, I provided participant 
information sheets at each of the meetings I attended (Appendix 3). Participants 
were given one week to review these. I was then responsible for gaining signed 
consent from all members to observe, record data from, and audiotape their MDT 
meetings (Appendix 4). This included the fourth cancer team, which I attended from 
this point forward.  
 
Since other professionals occasionally attended MDT meetings on an ‘ad hoc’ basis, 
I displayed a printed notice at the entrance to the meeting room during every 
meeting that was recorded. This explained the nature of the observation and 
provided my contact details. It also made clear that if individuals did not wish to 
take part in the study their contributions would be deleted from any transcripts. 
Nobody requested this.  
 
5.4.2 Data collection  
I collected data from each of the four teams by non-participant observation at 
weekly MDT meetings, semi-structured interviews with MDT professionals, and 
semi-structured interviews with patients under the care of the four cancer teams I 
observed. A summary of the data collected is provided in Table 4. 
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Table 4: Summary of data collected   
Team Meetings 
observed 
Observation period 
(Month/Year) 
No. patients 
discussed  
Professional 
interviews  
Patient 
interviews  
Gynae  18  Dec 10 – Apr 11 324 7  1 
Haem 1 38  Dec 10 –Jan 12 390 5  3 
Haem 2 35  Jun 11 – May 12 371 4  3 
Skin 31  Dec 10 – Oct 11 384 3  0 
Total 122 Dec 10 – Jan 12 1469 19 7 
 
Non-participant observation at weekly MDT meetings 
Before I began data collection I attended two MDT meetings at each site. This was 
to enable the team to get used to my presence and to pilot the quantitative data 
collection tools used for the MDT Study. Following on from these ‘pilot’ meetings, I 
collected non-participant observation data at 122 weekly MDT meetings (these 
were consecutive with the exception of weeks where I was unable to attend, for 
example due to annual leave). On four occasions out of 122 meetings the 
observation data were collected by another Research Associate, Caoimhe Nic a 
Bháird, on my behalf.   
 
During observation I made free-form field notes, audiotaped the meetings and 
collected data on who attended the meeting and their profession. I also collected 
quantitative data on each of the patients who were discussed during the 
observation period using an observation proforma.   
 
Field notes 
My field notes were initially free-form, and recorded significant events and 
interactions that I observed. Within 24 hours of each meeting, I organised these 
according to a qualitative observation coding sheet (Appendix 5). This was designed 
in collaboration with clinical co-applicants and patient advisors for the MDT Study 
prior to the start of data collection. It was based on an adaptation of an Inputs-
Process-Outcome model (McGrath, 1964, Cohen and Bailey, 1997, Lemieux-Charles 
and McGuire, 2006). It included sections on the meeting environment (e.g. the size 
of room and seating arrangements), mention of national or local policies, features 
of the team and task, levels of participation, and mediators of team processes and 
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outcomes. This provided a framework to map out features of the meeting context 
and decision making processes.  
 
Audio recordings 
Following each meeting, I re-listened to the audio recordings within 24 hours, 
adding further information to my field notes and documenting the timing of key 
events on the recording for future reference. 
 
Attendance data  
MDT co-ordinators in each of the teams provided me with ‘sign in sheets’ that were 
used to record attendance at each meeting. I used this to augment my observation 
field notes on meeting attendance and profession (e.g. at the beginning of the 
observation period when I was not familiar with all the team members, or when a 
new member attended a meeting).   
  
Quantitative data 
I used a standard proforma to collect quantitative data on each of the 1469 patients 
discussed during the observation period (Appendix 6). This proforma was initially 
developed by the clinical co-applicants for the MDT Study, but was subsequently 
amended based on feedback from me and another Research Associate following the 
pilot phase. Quantitative data collection included information on patient features 
such as diagnosis, comorbidities and whether patient preferences were mentioned 
during the discussion. I also used the proforma to record discussion features (e.g. 
whether the presenter was questioned), and decision features (e.g. the decision 
made by the team).  
  
These quantitative data will not be described in detail in my PhD analysis, but they 
will be used to provide background information on patient and team characteristics 
as an additional source of context.  
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Interviews 
Interviews were carried out at the end of the observation period to avoid sensitising 
teams to the primary outcome measure for the MDT Study. This was decision 
implementation (whether or not teams implemented the decisions made during the 
MDT meeting) and the aim was to minimise the impact of the observation on the 
behaviour of MDT members. Participants were informed that the study was related 
to the decision making process, but they were not given specific details of which 
aspects. 
 
Interview topic guides  
In collaboration with the other research associates and under the supervision of the 
Principal Investigator on the MDT Study, I drafted topic guides for the MDT 
professional and patient interviews. These were based on reviews of the literature 
and the research aims of the MDT Study. We revised these based on emerging 
issues identified during non-participant observation and suggestions from the MDT 
Study steering group.  
 
The MDT professional interview topic guide included open-ended prompts about 
how different professional groups interacted in the team, and the information 
needed to make a decision, in addition to questions about things that did not get 
discussed enough in the meeting (Appendix 7). I piloted the interview topic guide 
with a clinical co-applicant from the MDT Study and amended it on the basis of their 
feedback.  
 
The patient topic guide covered issues such as whether patients were aware of the 
MDT meeting, and what issues they believed should be considered when the MDT 
was making decisions about their care (Appendix 8). This topic guide was piloted by 
another researcher with two patient representatives and amended on the basis of 
their comments. 
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Sampling and recruitment of MDT professionals  
I used purposive sampling to select participants for interview. This is an approach 
commonly adopted by qualitative researchers when the emphasis is on exploring 
different accounts of the issue of interest (O’Reilly and Parker, 2013). For this study, 
my aim was not to generate a representative sample, but to intentionally 
incorporate the views of a diverse group of MDT professionals and patients and to 
explore these in depth (Barbour, 2001). I therefore selected MDT professionals on 
the basis of professional group, seniority, and level of participation in the MDT 
meeting as these issues were most salient to the decision making process, and to 
understanding interaction between team members. A summary of the number of 
interviewees from each professional group and team is presented in Table 5. 
 
Table 5: Number of interviews by professional group and team 
Profession  Gynae Haem 1 Haem 2 Skin Total 
Surgeon1  3 - - 0 3 
Medical doctor2  - 2 1 2 5 
Diagnostic doctor3 1 1 1 0 3 
Psychologist 1 - - - 1 
CNS 1 1 1 1 4 
StR 1 1 1 0 3 
Total 7 5 4 3 19 
1
 includes Consultant Gynaecologists and Plastic Surgeons 
2
 includes Consultant Haematologists, Dermatologists, and Oncologists 
3 
includes Consultant Radiologists, Pathologists, and Nuclear Medicine 
 
I approached interviewees after observation for each team was complete. This was 
done either in person or by email, and individuals were provided with an 
information sheet and consent form. While I recommended we arrange a one hour 
appointment, the interviews lasted on average around 38 minutes, ranging from 20 
minutes (when a clinician was called away) to 64 minutes.   
 
The interviews were all conducted at the place of work of the participants and were 
audiotaped. Information sheets were provided in advance, and written consent 
obtained on the day of the interview (Appendix 3 and Appendix 4). I wrote 
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reflective field notes following each interview, including comments on setting, the 
main issues discussed, and areas to follow up in subsequent interviews.  
 
Sampling and recruitment of patients  
I also used purposive sampling to select patients under the care of the four cancer 
teams for interview. To increase the likelihood that interviewees would still be 
under the care of the team at the point of interview, I initially selected the thirty 
patients who had been most recently discussed by each team at the end of the 
observation period. I purposively sampled from this group in terms of disease type, 
gender and age.  
 
There were five exclusion criteria for the patient interviews, which are detailed in 
Box 2. I used medical records to assess patients against criteria 1 to 3, and asked a 
clinician in each team to highlight any cases where they thought the interview 
would present a risk to the patient or to the interviewer (criteria 4 and 5). These 
patients were not approached for interview.  
 
Box 2: Exclusion criteria for recruiting patients to interview 
Exclusion criteria: 
1. Non-English speaker 
2. Not living in England 
3. No longer under the care of a participating team  
4. Clinician deems a risk to interviewer 
5. Clinician deems too vulnerable for interview 
 
Following this, I asked the lead clinician or a Clinical Nurse Specialist in each team to 
contact the selected patients in the first instance, as this was a condition of our 
ethics approval. These clinicians were asked to provide patients with a study 
information sheet and consent form, and to seek permission for a researcher to 
contact them directly to discuss the study further. Patients who agreed to be 
contacted were telephoned, either by me or by another member of the research 
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team, to confirm participation, address any questions they had, and arrange the 
interview.  
 
Patient interviews took place in the hospital or at the patient’s home and were 
audiotaped. The length of the interviews ranged from 21 minutes to 67 minutes, 
with an average time of 34 minutes. As with the professional interviews, 
information sheets were provided in advance (Appendix 9), and written consent 
obtained on the day of the interview (Appendix 10). I wrote reflective field notes 
directly after each interview I conducted (I recruited and interviewed 4 of the 7 
cancer patients included in this sample). We also trained and supervised two 
Masters students and a medical student to conduct the remaining patient 
interviews. 
 
There were some specific recruitment challenges for the patient interviews. Initially, 
the plan had been to conduct 24 interviews with patients under the care of the four 
cancer MDTs. However, strict time constraints and deadlines imposed by the MDT 
Study meant that this figure was revised, and it was agreed with the funders that a 
total of 20 patient interviews would be conducted across the 12 teams recruited 
(i.e. including mental health, memory clinic and heart failure MDTs). In addition to 
this, the need for clinicians in each team to generate the initial contact with each 
patient meant I had less control over the process, and was reliant on busy clinicians 
taking time out of their schedule to introduce the study to patients on my behalf. As 
a result of these factors, only seven cancer patients were recruited and interviewed 
from three of the four teams I observed (there were no patient interviews 
conducted with patients under the care of the Skin team due to time constraints).  
 
However, despite the small numbers these interviews provide an opportunity to 
explore an alternative perspective - both to the views of MDT clinicians, and to the 
data I captured during observation (O’Reilly and Parker, 2013). For example, the 
patient interviews gave an insight into patients’ views about what information they 
shared with different team members, and who they felt should best represent their 
views in the MDT meeting. For this reason I have decided to include it in my 
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analysis, whilst being mindful of the limitations inherent in such a small number of 
cases. 
 
5.4.3 Data management  
A key challenge in qualitative research is to manage and make sense of the large 
volumes of data collected (Bloomberg and Volpe, 2012). In the section below I set 
out how I managed, organised and analysed the data described above in order to 
generate and interpret my findings. I followed the same key principles of data 
management, coding, and thematic analysis to generate findings to answer all three 
of the research questions posed in this study. However, I initially addressed 
research questions one and two separately from research question three.  
 
Observation data 
As noted above, the period of observation was determined by the need to continue 
collecting quantitative data for the MDT Study until we reached a predefined 
sample size of 330 patient discussions per team. I collected qualitative data for the 
duration of this period, which meant that I had full audio recordings and field notes 
from 122 cancer MDT meetings. This equated to around 175 hours of audio, and 
nearly 1,500 individual patient discussions.  
 
Given this volume of data, it was not practical to transcribe all the meetings 
verbatim. As other researchers have described, quiet talk and background noise can 
obscure dialogue (Bucholtz, 2000). I also had to contend with overlapping speech, 
when members of the MDT either talked over each other, or in some instances, 
conducted entirely separate conversations between different groups at the same 
time.   
 
Another challenge in this context related to the fact that a key area of interest for 
my research was to explore the contributions and participation of low status 
individuals. By their very nature, these interactions were at times difficult to 
capture in a written transcript because they tended to be less vocal than higher 
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status members of the team. For example, when CNSs or junior doctors whispered 
to other colleagues rather than voicing their opinions out loud, or where they would 
get the attention of another team member immediately before the meeting started 
to share information or get a key point across. This information was not always 
picked up by the recording and it was therefore not possible to transcribe these 
sorts of interactions.  
 
To deal with these challenges, I used a combination of approaches to manage and 
analyse the qualitative observation data. This included using my field notes, 
transcribing a selection of audio data, and working directly from the audio files. 
Each of these approaches has advantages and disadvantages. By using all three I 
aimed to overcome the disadvantages that any one approach might pose when 
used on its own (Tessier, 2012).  
 
 
Figure 2: Advantages and disadvantages of qualitative data recording methods 
(adapted from (Tessier, 2012)) 
 
Observation field notes 
I used my field notes to capture interactions that were not easily recorded or 
transcribed, for example, non-verbal cues. My field notes were also useful because 
they captured my initial thoughts while they were still fresh (Tessier, 2012). They 
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also gave me a manageable overview of the entire dataset, which I was able to use 
to identify specific instances of interest to return to on the audio or transcripts.   
 
Observation transcripts 
As mentioned above, it was not feasible to transcribe all 122 meetings verbatim. 
Instead, I used a process of selective transcription (Emerson et al., 1995, Frykholm 
and Groth, 2011). This meant I had to decide how many and which meetings (or 
parts of meetings) to transcribe. When considering how much transcription to 
undertake, I took as my starting point my existing levels of familiarity with the 
observation data I had collected. As part of the MDT Study I had previously: 
 
 attended 118 out of 122 meetings in person 
 written up field notes for each meeting within 24 hours of attending  
 re-listened to the audio recording of all meetings at least once 
 selectively transcribed, coded and analysed a subset of meetings for the 
MDT Study (64 of the 122) 
 participated in analytic conferences with five other researchers. This 
involved listening to audio files from a selection of meetings and discussing 
the coding and analysis process. 
 
My main concern therefore was to capitalise on my familiarity with this extensive 
dataset, while at the same time, giving myself the opportunity to look at these data 
in a new light, and with different questions in mind. When I began analysis for my 
PhD therefore, I started by transcribing verbatim one meeting from each of the four 
teams. This had two purposes. First, it was an opportunity for me to re-immerse 
myself in the data, which I had collected 18 months previously. Secondly, by having 
a full transcript from each team I was better able to consider differences in 
participation and influence throughout each discussion and for the duration of an 
entire meeting. For example, the detailed review of each full transcript enabled me 
to follow through cases from initial presentation to subsequent discussion and the 
final decision. This provided me with opportunities in my analysis that review of my 
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field notes alone could not – for example, to explore the features of case 
presentations that led to input from lower status members versus those that did 
not.  
 
I chose to transcribe meetings from the first month in which I had observed each 
team, when my field notes were the richest. This enabled me to produce a more 
detailed transcript as I could refer to my field notes throughout the process (for 
example, where it was not clear from the audio who said what). I also chose 
meetings that I felt best reflected the ‘norm’ for each team, for example, where key 
members were in attendance and processes were followed as usual.  
 
In addition to the verbatim transcript of four meetings, I also used a process of 
selective transcription (Emerson et al., 1995, Frykholm and Groth, 2011). Selective 
transcription was an approach we had used as part of the MDT Study, to enable us 
to manage the large volume of qualitative data collected (Raine et al., 2014a). I 
utilised the same approach for my PhD, although for the purposes of this study I 
used different criteria to select sections for transcription.  
 
In order to address research question three, I theoretically sampled cases from the 
full dataset where a CNS or StR had contributed to discussion. This was possible 
because these individuals in all four MDTs spoke up much less frequently than 
others. To identify these cases I coded my field notes for any reference to these 
contributions during the MDT meetings. I then re-listened to the relevant section of 
audio file and transcribed those sections of audio that illustrated the lower status 
contribution, with the following exceptions. I did not transcribe references from my 
field notes that were:  
 
 general observations only (e.g. ‘the CNS is the most likely to mention patient 
preferences, although she often does this very quietly’) 
 about a lack of participation (e.g. ‘StR did not present any cases today’) 
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 related to processes other than decision making (e.g. those that focused on 
teaching and learning) 
 there were also a small number of cases that could not be transcribed 
because the audio quality was poor (e.g. when someone was talking very 
quietly) – in these cases I relied on my field notes as it was easier to hear 
during the meeting itself than when listening back to the audio. 
 
This generated a total of 88 selective transcripts across the four teams, with 43 
discussions involving CNSs and 30 selective transcripts with discussions involving 
StRs. 15 selective transcripts contained input from a combination of lower status 
groups (Table 6). These selective transcriptions enabled me to undertake a closer 
analysis of discussions that were most pertinent to research question three across 
the full observation dataset (Frykholm and Groth, 2011).  
 
Table 6: Selective transcripts by team and lower status group 
Team CNS only StR only Both CNS and StR Total 
Gynae 10  5 2 17 
Haem 1 4 10 6 20 
Haem 2 5 13 2 20 
Skin  24 2 5 31 
Total 43 30 15 88 
 
Working directly from the audio file 
I used a software package called ExpressScribe to listen to the audio files from the 
meetings. This software allowed me to move back and forth through the files 
quickly and easily. Using my field notes as reference, I was able to return to specific 
dialogues of interest and to listen to these sections repeatedly. I could then 
transcribe these sections, add more detail to my field notes, or write analytic 
memos. This approach enabled me to retain much of the contextual data, such as 
tone of voice, which can get lost in the process of transcription (Crichton and Childs, 
2005). I also found that listening to the audio files helped me to remember specific 
events more vividly (Crichton and Childs, 2005).  
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Interview data 
I also used field notes, transcripts and the original audio files to analyse data from 
the professional and patient interviews. However, the professional and patient 
interviews were ‘easier’ to transcribe because they involved only two individuals 
(the participant and me). In addition, they were conducted in quiet rooms which 
provided ideal conditions for audio recording (in contrast to the large and often 
noisy rooms where MDT meetings took place). As a result, I used professional 
transcription agencies with experience of health research and medical terminology 
to transcribe all 26 interviews verbatim. I reviewed each of the completed 
transcripts against the audio file in order to check the quality of the transcription, 
and to ensure that all identifying information had been removed to protect the 
anonymity of participants (McLellan et al., 2003, MacLean et al., 2004). Re-listening 
to the audio files in this way also gave me an opportunity to further familiarise 
myself with the data (Patton, 2002). 
 
Organising the observation and interview data  
I imported all my field notes and transcripts into Nvivo V.10. This software enabled 
me to manage the large volume of data more easily. 
 
5.4.4 Data analysis  
In order to analyse the data to answer my research questions, I used the principles 
of thematic analysis described by Braun and Clarke (2006) (Figure 3). This approach 
fitted well in the context of the generic qualitative methodology I adopted for this 
study because of its theoretical flexibility (Braun and Clarke, 2006).     
 
In the sections below I describe in more detail the data I drew on for the analysis 
and the process I followed. In reporting this process it is important to point out that 
although it is presented as a series of stages, in reality it was much more iterative. 
During the analysis I moved back and forth between strategies to explore the data, 
developing and refining codes, and abstracting higher level themes. This continued 
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as I wrote up my findings, reflecting the messy and complex nature of qualitative 
analysis (Barbour, 2014).  
 
 
 
Figure 3: Phases of thematic analysis (adapted from (Braun and Clarke, 2006)) 
Exploring the data 
In the first phase of analysis I explored the data by reading through my entire 
dataset, and adopting a number of different strategies to familiarise myself with the 
data (Table 7). Using these approaches while coding prevented the process from 
becoming too mechanical (Bazeley, 2013).  
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Table 7: Strategies used to explore the data 
Technique Description Examples 
 
Shifting sequence Reading through 
transcripts in a non-
linear way (Dey, 2005) 
 Reading observation transcripts 
‘backwards’ – starting at the 
bottom and working up, rather 
than always starting with the 
cases discussed first by the 
team 
Writing as you 
read 
Recording analytic 
thoughts as they arise 
(Bazeley, 2013) 
 Writing memos: scribbling in the 
margins of paper copy 
transcripts and field notes to 
record thoughts and reflections 
Questioning Asking questions of the 
data (Dey, 2005, Bazeley, 
2013) 
 Asking: what’s interesting? Why 
is it interesting?  
Making contrasts 
and comparisons 
Exploring similarities and 
contrasts between data 
sources (Bazeley, 2013) 
 Looking for deviant cases  
 
Counting Simple counting in order 
to avoid the risk of 
anecdotalism  (Barbour, 
2014) 
 Carrying out simple counts of 
who said what and exploring the 
context using the Nvivo matrix 
coding query function  
Reflexive coding Interrogating and 
challenging each code 
created (Bazeley, 2013, 
Barbour, 2014)  
 Using memos to record 
definitions of codes and how 
used  
 Conducting a trial run to see if I 
could answer my research 
questions from the codes 
created. Are there any gaps that 
need filling? 
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Following this, I conducted two separate thematic analyses of the data I had 
collected. The first thematic analysis (Thematic Analysis I) addressed research 
questions one and two by exploring the role of status hierarchies and the factors 
that facilitated or inhibited multidisciplinary discussion. This analysis was based on 
the observation and interview data. The second thematic analysis (Thematic 
Analysis II) addressed research question three, and was initially based only on the 
selective transcripts from the observation audio files. Conducting this analysis 
separately enabled me to focus solely on the approaches used by lower status 
groups to contribute to the MDT meeting using relevant extracts from across the 
whole dataset.  
 
Thematic Analysis I  
 
Generating initial codes  
The first phase of coding I undertook for Thematic Analysis I was both inductive and 
deductive (Langley, 1999, Dey, 2005). This meant that some codes were grounded 
in the data, while others were drawn from relevant literature and my theoretical 
framework. Using this inductive and deductive approach I continually expanded and 
refined the coding framework (Dey, 2005, Barbour, 2014).  
 
My coding framework covered the four full meeting transcripts, observations from 
all 122 sets of field notes, the observation audio files, the professional interview 
data, and the patient interview data (i.e. all data, except for the selective transcripts 
of lower status contributions). Having a single coding framework for these different 
datasets meant that I was able to consider key issues from different perspectives 
throughout the analysis process. This enabled me to undertake a process of 
complementary triangulation, using different types of data to gain a more nuanced 
understanding (Moran-Ellis et al., 2006). For example, I could explore features of 
the initial case presentation based on my observations and the views of 
professionals within the team, as illustrated in Table 8. 
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Table 8: Integration of datasets during the analysis process 
Code Illustrative quotations    
Initial case 
presentation 
Observation transcript: 
Consultant Haematologist: So the next one is [name of 
patient] who is an elderly gentleman that I saw with an 
isolated significant large sub mandibular lymph node, no 
other systemic symptoms and actually, remarkably fit and 
well for his age past history of prostatic carcinoma which 
he had major surgery on er in 1993 and he now has 
zoladex but his PSA is normal (Haematology 1) 
 
Observation field note: 
Consultant Haematologist 1 presented most of the 
patients, although StR1 presented a couple, as did the 
Consultant Pathologist towards the end (Haematology 1) 
 
Interview transcript: 
Chemotherapy CNS:  it is usually the doctor who has seen 
them in the clinic that presents that patient to the rest of 
the team (Haematology 1) 
 
During this phase of the analysis, I reviewed my initial coding framework alongside 
excerpts of data and my research questions with my supervisors. This provided an 
opportunity for me to reflect, and to be challenged on, my approach to coding.  
I reached a stage where no new codes were generated by review of the additional 
material following analysis of the four full meeting transcripts, and a selection of 
interview transcripts from both patients and professionals. The field notes and 
audio files therefore provided me with a wider pool of examples to draw on for my 
analysis, but the key codes emerged from the meeting and interview transcripts.  
 
Developing and reviewing themes 
Building on my coding framework, I grouped my codes into broader categories to 
develop an initial set of themes. For example, codes such as ‘provides information’, 
‘interruption’ and ‘introduces new topic’ all seemed to represent attempts to 
participate in the meeting, so I grouped them under a theme titled ‘initiating 
participation’.   
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Defining and naming themes and producing a written report 
Braun and Clarke (2006) describe these as two separate stages. The first (defining 
and naming themes) is presented as the stage at which the essence of each theme 
is defined. The second is described as beginning once a set of themes are “fully 
worked out” (Braun and Clarke, 2006) (p. 23). Instead, I found that these stages 
were heavily intertwined. It was through the process of writing that I was able to 
achieve clarity within each theme and to determine the most appropriate names for 
these. In practice, this meant that my themes continued to develop as I wrote, and 
my writing developed as my themes became clearer and more well-defined.  
 
The final overarching themes from Thematic Analysis I are presented in Box 3 
below. A full list of the sub-themes and codes is presented in Appendix 11. Themes I 
and II are discussed in detail in Chapter 6, and Theme III is discussed in detail in 
Chapter 7. 
 
Box 3: Themes from Thematic Analysis I 
 
I. The decision making process in MDT meetings 
 
II. The effects of status hierarchies  
 
III. Multidisciplinary discussion 
 
 
Thematic Analysis II 
 
Generating initial codes 
I created a second thematic framework based only on the 88 selective transcripts 
from discussions that involved lower status contributions in the 122 MDT meetings 
observed. This formed the basis of the analysis for research question three. I used a 
hybrid inductive and deductive approach to generate two sets of codes: ‘outcome 
codes’ and ‘strategy codes’.  
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Outcome codes 
I initially reviewed each of the 88 discussions to deductively identify successful 
contributions. I made a decision about whether a contribution was successful or not 
based on the content of the selective transcripts themselves. My focus was on the 
effect of a contribution on the decision making process, rather than the quality of 
the decision itself. For example, contributions made by a lower status individual 
that prompted further discussion or influenced the clinical decision made by the 
team were deemed to be ‘successful’. Where the outcome of a contribution was 
unclear I used the quantitative dataset from the MDT Study to ascertain what 
decision had ultimately been implemented as a way of determining if a contribution 
had been incorporated into the final treatment plan or not.  
 
Following this I generated inductive codes to explore the way in which a 
contribution was successful. I grouped these codes into three themes linked to the 
decision making process, as illustrated in Table 9.  
 
Table 9: Final themes and codes for successful contributions (outcomes) 
Theme Codes 
Prompts discussion  Prompts others to share expertise 
 Raises awareness of an issue with the team  
 Determines logistics of treatment   
 
Influences decision  Acts as patient’s advocate  
 Ensures a decision is made 
 Influences a clinical decision 
 Influences practicalities of treatment delivery 
 
Facilitates team work  Promotes social cohesion  
 Supports higher status decision 
 
Strategy codes 
I then generated another series of inductive codes based on the approaches being 
used by lower status groups to contribute in successful cases (Table 10). 
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Table 10: Final themes and codes for successful contributions (strategies) 
Theme Codes  
Asking questions  Asks questions 
 
Framing  Psychosocial frames from medical perspective 
 StR provides clinical rationale for discussion 
 
Providing a practical 
alternative or solution 
 Proposes an alternative solution (specifically 
challenging another suggestion) 
 Proposes solution to a problem facing the team 
 
Sharing information  Provides clinical information 
 Provides information about patient as a person 
 
Using humour  Uses humour 
 
I discussed the development of this coding framework with my Departmental 
Qualitative Research Group. I presented a selection of data extracts to the group, 
before facilitating a discussion about different interpretations of the data. I found 
this process helpful in stimulating my thoughts at an early stage of coding.   
 
Developing and reviewing themes 
At the end of this stage my coding framework was composed of a series of ‘strategy’ 
and ‘outcome’ codes, which I explored in Nvivo using the ‘Matrix coding query’. This 
enabled me to explore each of the approaches used by lower status groups to 
contribute in relation to the different outcomes, as illustrated in Figure 4. 
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Figure 4: Matrix coding query: strategy and outcome codes Thematic Analysis II 
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Defining and naming themes and producing a written report 
In line with my approach for Thematic Analysis One, I continued to develop themes 
through the process of writing. I discussed these themes with my PhD supervisors 
as my analysis progressed to further clarify and refine them. The final thematic 
framework incorporating the three outcome and five strategy themes is provided in 
Appendix 12. 
 
5.4.5 Analytic Integration 
As noted above, I used a form of complementary triangulation when conducting the 
first thematic analysis, actively drawing on different sources of data throughout the 
process to gain alternative perspectives for individual codes and themes. However, I 
also undertook an additional level of integration at a later stage in the analysis 
(Moran-Ellis et al., 2006). As I moved from description of my results to 
interpretation and explanation I reviewed the findings from Thematic Analysis I in 
light of Thematic Analysis II.  
 
This involved considering how the key team and decision making characteristics 
identified in Thematic Analysis I could further shape my interpretation of the 
strategies used by lower status individuals to contribute (as identified in Thematic 
Analysis II). To do this, I summarised the data relating to each team from Thematic 
Analysis I, (specifically, data on specialty, team structure – including size and seating 
arrangements – decision making processes and leadership). I used these summaries 
to group teams according to their shared characteristics. This resulted in a series of 
different groupings for each of the key characteristics. I then compared and 
contrasted each grouping with the patterns of lower status contributions identified 
in Thematic Analysis II. For example, I grouped the two Haematology teams 
together and compared them to Skin and Gynaecology in order to consider the role 
of specialty on patterns of lower status contributions. In turn, I grouped the two 
largest teams (Gynaecology and Haematology 2) and compared them with the two 
smaller teams (Skin and Haematology 1) in order to explore the role of team size on 
patterns of lower status contributions.  
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This process of analytical integration provided a means of furthering my 
interpretation across all three findings chapters. The results of this analytic 
integration are presented in Chapter 9. 
 
5.5 Reflections on the role of the researcher  
Reflexivity is an important concept in qualitative research because of the role of the 
researcher in the data collection and analysis process (Miles and Huberman, 1994). 
It is therefore important to explicitly consider the motives and biases that may have 
had a bearing on the assumptions I made during data collection and analysis 
(Bloomberg and Volpe, 2012). These reflections provide important contextual 
information for a qualitative research study (Caelli et al., 2003).  
 
5.5.1 Reflections on the non-participant observation process 
My interest in health services research stems from my experience of working as a 
service improvement manager in the NHS. I was therefore familiar with the ‘world 
of the hospital’ and with working alongside clinicians in a busy environment. 
However, I am not a clinician, and had little experience of working directly with 
patients, or with complex medical terminology.  
 
Observing a clinical decision making forum as a non-clinician brought challenges and 
advantages. It meant that I was able to observe with a fresh pair of eyes, and was 
not limited by prior experience of ‘normal’ behaviour in these meetings. Ferlie 
(2001) argues that from this position researchers are better placed to resist capture 
by vested interests in the field. However, the first few weeks of observation in 
particular were challenging. Nevertheless, the rapid pace of meetings, complex 
medical terminology, seemingly endless new faces, and new images in the form of 
pathology and radiology presentations, did eventually become familiar as the 
observation period continued. I used my field notes to record this transition and to 
remind myself of my earlier thoughts and questions to keep myself stimulated and 
engaged.  
Methods 
99 
 
5.5.2 Reflections on the interview process  
The ability to set the agenda in qualitative interviews can place a researcher in a 
position of power relative to the interviewee (Allmark et al., 2009). However, in the 
context of this research I was conducting interviews as a junior researcher without a 
clinical background, with clinicians who were exceptionally busy, with many being 
senior and influential in their field.  In light of this, I turned to the literature on 
conducting elite interviews, in order to gain insight into the different dynamics likely 
to be generated by these interviews. Issues that were particularly salient ranged 
from strategies to gain access, negotiating the power dynamics during the 
interview, and reflecting on and adapting my interview style as I gained more 
experience (Morris, 2009, Harvey, 2011, Mikecz, 2012). I used field notes and 
listening back to the audio recordings of the interviews to reflect on this process. 
This also gave me the opportunity to work on strategies to develop my interview 
technique, for example reminding myself to use silence or non-verbal cues more 
effectively to encourage interviewees to open up and expand on relevant issues.  
 
My experience of conducting the professional interviews contrasted quite sharply 
with my experience of conducting the patient interviews. I had anticipated the 
challenges of interviewing some of the more senior clinicians in particular, and had 
a body of literature on elite interviewing to draw on to provide me with strategies 
to manage this. However, this was the first time I had interviewed people who had 
been so acutely unwell and it was difficult on a far more personal level. The focus of 
my questions related to quite practical matters around the way decisions had been 
made about treatment and care. I found some of these questions incongruous in 
light of the very honest descriptions provided of the way that cancer had impacted 
directly on these individuals and their families.  The insight I gained was even 
starker when contrasted with the very clinically focused meetings in which decisions 
about these patients were made.  
 
As detailed above, there were practical reasons that meant that I was not able to 
conduct as many patient interviews as initially planned. However I feel strongly that 
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the insight that I was able to gain from these interviews has an important role to 
play in the overall narrative of MDT meetings. It provides a reminder that each and 
every ‘case’ presented and discussed is much more than just a disease to be 
treated. It provides an opportunity to consider the views of a small number of 
patients on what is now a critical part of the cancer pathway, even if there remains 
scope for further exploration of these perspectives. Given that the aim of 
conducting semi-structured interviews was to explore in depth a range of views – 
and not to be representative of a larger population - the small number of interviews 
does not in itself invalidate the views expressed in these (O’Reilly and Parker, 2013). 
 
5.6 Strategies to establish rigour 
While generic qualitative research provides a useful, pragmatic approach to 
addressing real-world clinical problems, its value can be undermined unless careful 
consideration is given to rigour (Cooper and Endacott, 2007).  
 
Although there is widespread consensus amongst quantitative researchers about 
the fundament role of the concepts of validity, reliability, and generalisability, there 
is much debate about how best to establish quality, or rigour, in qualitative research 
studies (Caelli et al., 2003, Tracy, 2010, Reynolds et al., 2011, O’Reilly and Parker, 
2013). Some approaches advocate the measurement of quality in terms of the 
outputs of research, for example the use of checklists to document the application 
of specific techniques such as triangulation, or multiple coding. In contrast, other 
approaches emphasise the need for quality to be embedded at each stage of the 
research process, through reflexivity and ‘methodological awareness’ (Reynolds et 
al., 2011).  
 
For the purposes of this research, I worked within the framework proposed by Caelli 
(2003). This framework focuses on ensuring quality throughout the research 
process, and has been developed for researchers who adopt a generic qualitative 
approach. It is based on four key elements: the need to articulate beliefs about 
epistemology and ontology, the assumptions and motives of the researcher that 
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underpin a study, to ensure congruence between methodology and methods, and 
to record the criteria used to establish rigour. These are described in Table 11 
alongside details of where I have addressed each of the key elements within this 
chapter. Following this I discuss the specific quality criteria I used to establish 
rigour. 
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Table 11: Caelli’s (2003) framework for credible generic qualitative research  
Element of Caelli’s 
framework 
Description Approach adopted 
The ‘analytic lens’ 
used to explore data 
The beliefs about 
epistemology and ontology 
which have shaped a study   
I adopted a ‘critical realist 
philosophy’ for this study, 
incorporating a realist 
ontology with a 
constructivist epistemology 
(see p.  67) 
The researcher’s 
theoretical 
positioning 
The motives, assumptions 
and personal history that 
lead a researcher to a 
particular area of interest, 
and which subsequently 
shape the approach taken to 
a study 
There were a number of 
factors that shaped the 
approach taken to this study, 
primarily my prior 
experience of working as a 
manager in the NHS, my role 
in the MDT Study, and my 
choice of theoretical 
framework (described in 
Chapter 3). I provide a 
reflective account of the way 
in which my background 
influenced some of the key 
aspects of the research on 
pp. 98-100. 
Congruence 
between 
methodology and 
methods 
The tools used to collect and 
analyse the data must fit with 
the broader methodological 
approach underpinning a 
study 
I used a generic qualitative 
approach, which required 
me to make a series of 
iterative decisions about 
which methods were most 
suitable to address the 
research questions posed in 
this thesis. I describe this 
process in the section on 
‘Rationale for the 
methodological approach’ on 
pp. 65-66. 
Strategies used to 
establish rigour 
The approach taken within a 
study to demonstrate its 
quality and credibility  
In this thesis I use the 
concepts of credibility, 
dependability, and 
transferability. I discuss 
these quality criteria in the 
section below on pp.  103-
105. 
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5.6.1 Quality Criteria 
In this thesis I use the concepts of credibility, dependability, and transferability in 
place of validity, reliability and generalisability (Bloomberg and Volpe, 2012). The 
approaches I used throughout the duration of the study to enhance its credibility, 
reliability and generalisability have already been described in this chapter, at the 
point at which they were most relevant. However, they are briefly summarised 
below to illustrate the overarching approach I adopted to establish rigour.  
 
Credibility 
Credibility is closely related to the concept of validity, which is used in quantitative 
studies to demonstrate that findings accurately represent the world being studied 
(Bloomberg and Volpe, 2012). Given the interpretative nature of this research, the 
concept of credibility is more meaningful. In this context, credibility relates to 
whether my analysis of the MDT decision making process matches with the 
perceptions of those being studied (Bloomberg and Volpe, 2012).  
 
A key aspect of establishing credibility in qualitative research is founded on 
recognising the biases or pre-conceptions you bring as a researcher to your study 
(Bloomberg and Volpe, 2012). I have already described my theoretical positioning, 
and the process of using reflective field notes during data collection to record my 
thoughts, actions and decisions relating to data collection and ideas for analysis. In 
addition, strategies such as re-listening to the audios of my interviews enabled me 
to reflect on my approach to data collection to track emerging thoughts and 
perspectives.  
 
I also engaged in analytic meetings, initially during data collection as part of the 
MDT Study, and subsequently with my supervisors and departmental qualitative 
methods group when conducting the analysis. These meetings challenged me to 
think about the data from a range of different perspectives, and provided an 
opportunity to review and discuss my emerging ideas with other experienced 
researchers and clinicians. This encouraged me to reflect on my existing 
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preconceptions and expectations during the data collection and analysis processes 
(Maxwell, 2005). 
 
Another way in which I have endeavoured to establish credibility is through my 
deep immersion in the field. As described previously, I collected data over a period 
of a year, attending a total of 126 meetings (including 8 meetings where I piloted 
the data collection forms, and excluding those attended by Caoimhe Nic a Bháird) 
across the four sites. This extended period of time in the field gave me a solid 
grounding from which to conduct my analysis. 
 
In addition, I collected data from a number of sources, including observation and in-
depth interviews with professionals and patients. I used these different sources of 
data to consider issues from more than one perspective, adopting a 
‘complementary’ approach to triangulation (Moran-Ellis et al., 2006). Although I did 
not undertake a formal process of member checking, the interviews were carried 
out following the observation period in each team. This meant that they provided 
me with an informal opportunity to reflect on my interpretation of the observation 
data.  
 
Dependability 
While reliability is a key concept in quantitative research, the premise that research 
findings can be replicated is less central to a good qualitative study (Maxwell, 2005). 
However, it is important that qualitative research is dependable, in the sense that it 
can be demonstrated that the findings are consistent with the data collected 
(Bloomberg and Volpe, 2012). 
 
In order to ensure the dependability of my findings, I have endeavoured to create a 
clear audit trail of data collection and analysis through detailed description of my 
methods. I have included my coding frameworks in Appendix 11 and Appendix 12 as 
well as detailing the steps I took to analyse the data and produce my findings. In 
writing up my results I have extensively used quotes and sections of transcript to 
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illustrate key points (Tracy, 2010). Although I did not assess inter-coder agreement, 
the analytical meetings I attended to discuss my coding framework provided 
scrutiny of the processes I was following during the analysis.  
 
Transferability 
While the concept of generalisability is central to quantitative research, this 
research is based on observation of a small number of purposively selected teams, 
and interviews with a relatively small number of professionals and patients within 
these teams. The approach I took to selecting cases, which is characteristic of 
qualitative research, means that the empirical findings produced are not 
generalisable to a wider population (Small, 2009). However, this does not mean that 
learning cannot be transferrable (Small, 2009). My goal is therefore to address the 
extent to which my findings, in the context of the four MDT meetings I have 
observed, can transfer to another setting or context (Bloomberg and Volpe, 2012).  
 
One approach I have adopted to address the transferability of my findings is to 
present my findings using rich description (Bloomberg and Volpe, 2012). In this way 
I hope to encourage the reader to identify a sense of shared experience that 
enables them to apply these ideas in a different context (Tracy, 2010). To aid this 
process, I have also provided detailed information about each of the four teams 
recruited to the study in the Research Setting section on pages 71 to 75. This 
background information provides important contextual information to enable 
readers to determine whether they can transfer findings to their own setting 
(Bloomberg and Volpe, 2012). I consider this issue further in Chapter 10.  
 
5.7 Ethics and research governance  
The ethics and research governance permissions for this thesis were gained as part 
of the MDT Study. The initial application for ethics approval was therefore 
completed by the Principal Investigator for the MDT Study, although I was 
responsible for gaining approval for minor and substantial amendments from the 
East London Research Ethics Committee during the study (10/H0704/68).  
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The Principal Investigator also gained approval from the National Information 
Governance Board (NIGB) Ethics and Confidentiality Committee (ECC) (NIGB; ECC 6-
05 (h)/2010), under Section 251 of the NHS Act 2006, to process patient identifiable 
information without consent.  
 
Authorisation to process patient identifiable data without consent was granted 
because it was not feasible to gain consent from every patient in advance of being 
discussed in an MDT meeting. In total, 2654 patients were discussed across the 12 
teams during the MDT Study, including 1469 patients from the four cancer teams. 
Although the cancer MDTs generally compiled lists of patients to be discussed each 
week, these changed right up until the start of the meeting and some patients were 
discussed who were not on the list at all. It was therefore not possible to contact all 
individual patients in advance of the meeting, or to give them a reasonable length 
of time to make an informed decision about participating in the MDT observation 
component of the study.    
 
Given that I had access to an extensive body of sensitive, identifiable patient data, I 
had to be particularly aware of issues relating to data protection, confidentiality and 
ethics for the duration of the MDT Study and my PhD. This placed particular 
obligations on me as a researcher to safeguard the data. I completed training in 
research governance and information governance, and established contacts at each 
of the Research and Development Departments for the NHS Trusts recruited to the 
study. This initial contact was made when I submitted my Research Passport in 
order to gain access at each site. The Letters of Access that were subsequently 
issued set out the local information governance processes I was required to follow 
when collecting data from each of the teams.   
 
Other practical steps I used to safeguard the data included using a password 
protected dictaphone to record the meetings, and transferring all data collected on 
to a secure and encrypted server at UCL immediately on my return from each 
meeting or interview. Paper notes (e.g. fieldnotes) were stored in a locked filing 
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cabinet at UCL, with restricted swipe card access to the room. Electronic and paper 
files were only accessible to researchers working on the MDT Study. 
 
As data were collected, patients, MDT professionals and teams were assigned 
unique identifiers. In addition, before analysing the data, I reviewed my fieldnotes 
and meeting transcripts, as well as the interview transcripts to ensure that these 
were fully pseudonymised. It was not possible however to pseudonymise or 
anonymise the audio files.  
 
At the end of the MDT Study, all identifiable data were transferred to a secure 
online data portal: the UCL ‘data safe haven’. This is a technical environment for 
storing and handling sensitive data securely, which meets the ISO27001 standard 
for information security management and conforms to the requirements of the NHS 
Information Governance Toolkit. Access to the data safe haven meant that I could 
complete analysis for my PhD remotely, in a secure and safe manner. All analysis 
that involved identifiable data (e.g. listening to audio files) conducted outside of 
UCL premises was carried out within the data safe haven. 
 
Informed consent was gained from all MDT professionals involved in the 
observation and interviews, and from patients who took part in an interview. 
Participants were given plain English information sheets detailing the purpose of 
the study, and clarifying that they were under no obligation to participate, and that 
they could withdraw at any time. For the patient interviews it was made clear that 
although a healthcare professional involved in their care would be aware that they 
had been invited to participate, they would not see any information collected as 
part of the interview. The steps I would follow in ensuring that information 
collected would remain confidential were also outlined. In addition to presenting 
this in the information sheet, I also explained the key points verbally at the 
beginning of each interview before discussing any questions participants had, in 
advance of signing a consent form.  
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Participants were also reminded at the end of the interview of the purpose of the 
study and what would happen to the information they had shared. They were also 
given my contact details, the contact details of the Principal Investigator, and for a 
local complaints manager. Participants were encouraged to use these if they had 
any questions or concerns following the interview, although none did.    
 
5.8 Chapter Summary 
This chapter has articulated the rationale for the use of a generic qualitative 
research methodology to answer the questions posed in this thesis. It also 
described the research setting and introduced the four MDTs under study as a 
means of setting the context for the findings chapters. It documented the collection 
of data from four cancer MDTs, which included observation of 122 MDT meetings, 
interviews with 19 healthcare professionals and seven patients. It has also 
described how these data were managed and thematically analysed to generate the 
findings that are presented in the chapters that follow. Consideration was also given 
to strategies used to establish rigour in the research process. Finally, it concluded by 
summarising the ethics and research governance processes that underpinned the 
study. 
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Chapter 6. The role of status hierarchies in the decision 
making process in MDT meetings  
 
This chapter presents the first two overarching themes from Thematic Analysis I, 
using the observation and interview data from the four cancer MDTs described in 
the previous chapter.  Theme I sets the scene by describing the decision making 
process in the four teams. It explores patterns of participation and influence using 
Berger’s power and prestige order from status characteristics theory as a 
framework (Berger et al., 1972, Berger et al., 1980). Theme II then explores the 
effects of status hierarchies on the decision making process in terms of efficiency, 
information sharing and multidisciplinary discussion. Taken together these themes 
address research question one: how do status hierarchies unfold during the decision 
making process in cancer MDT meetings? 
 
Box 4: Summary of approach to defining status in MDT meetings 
The status hierarchy in MDT meetings 
Chapter 3 established that there are clearly defined status hierarchies within 
healthcare teams. As described in that chapter, I have defined status on the basis 
of professional group, with consultant surgeons, medical and diagnostic doctors 
classed as high status, and Clinical Nurse Specialists (CNSs) and Specialty 
Registrars (StRs) as lower status. 
 
Theme I: The decision making process 
Across all four teams there was agreement amongst MDT members that the main 
purpose of the weekly MDT meeting was to make decisions about patient 
management. Although the meeting was also regarded as an opportunity for 
teaching and peer to peer learning, these were seen as secondary functions. 
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The pattern of decision making was largely similar across all four teams. This was 
the case even though the nature of decisions being made varied by specialty as a 
result of the different treatment modalities available. A list of patients to be 
discussed each week was circulated by the MDT coordinator, and used as an agenda 
to structure the meeting. Broadly speaking discussion of each patient involved an 
initial case presentation and a clinical history. This was followed by a radiology 
presentation describing the results of imaging. For example, a presentation 
highlighting the relevant features on a CT scan, MRI or x-ray. A pathologist then 
presented slides of cells in tissue samples, in order to help with the diagnosis. 
Following any subsequent questions, comments or discussion, a decision was made 
and recorded for the patient’s notes.  
 
6.1 The power and prestige order in MDT meetings 
Status characteristics theory proposes that within teams, those with higher status 
are more likely to initiate participation (1) and to have more opportunity to 
contribute (2). They are also more likely to be evaluated favourably by other 
members of the team (3), and to influence group decisions (4) (Ridgeway, 2001).  
 
Applying this in the context of MDT meetings, we would expect the effects of status 
hierarchies to be evident in the dominance of surgical, medical and diagnostic 
consultants at each stage of the decision making process. In turn, CNSs and StRs 
would be expected to participate much less frequently, be evaluated less 
favourably, and to have less influence over group decisions. In Figure 5 I have 
mapped the four key elements of the power and prestige order against the decision 
making process in the MDTs I observed.  
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Figure 5: Key components of status characteristics theory mapped against the basic decision making process in MDT meetings 
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In the section below, I use this model to explore the four components of the power 
and prestige order. This helps to illustrate the way that status hierarchies unfolded 
at each stage of the decision making process. 
 
6.1.1 Initiating participation  
The first component of Berger’s power and prestige order relates to the initiation of 
participation within a team (Ridgeway, 2001). In the context of cancer MDT 
meetings, a key opportunity to initiate participation was the initial case 
presentation of a patient. This was the point at which a verbal summary of the 
patient to be discussed was presented to the rest of the team, based on a patient’s 
medical history and current disease status.  
 
The initial case presentation  
The initial case presentation for each patient was usually given by the patient’s lead 
consultant – a haematologist, gynaecologist, oncologist or dermatologist, 
depending on the team in question. For new patients, this was generally the 
individual who had seen the patient during their initial clinic appointment. For 
patients already under the care of the team, presentations tended to be given by 
the individual who knew the patient best, given their stage of treatment:  
 
All the discussions start with the patient history and that’s given by the 
person who knows them best at that time.  So maybe two people who 
know the patient very well but temporarily, you know, the surgeon may 
know them from a year ago and the medical oncologist has seen them 
now. (Consultant Gynaecologist, Gynaecology, interview) 
 
In the Skin and the two Haematology teams it was also relatively common for StRs 
to deliver the case presentation to the team. However, in Gynaecology, this was less 
common:  
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If I put a patient on the MDT sheet then normally it’s one of the 
oncologists who leads. (Oncology StR, Gynaecology, interview) 
 
In keeping with the observation that presentations were usually given by the doctor 
who had seen the patient during their initial clinic appointment, CNSs were the least 
likely to deliver the initial case presentation in all teams. I did not observe CNSs 
presenting in either of the Haematology teams, although there were a small 
number of examples in the Skin and Gynaecology teams. In these cases, CNSs were 
presenting in the absence of a consultant. Alternatively, they had added a patient to 
the MDT list in order to bring them to the attention of the rest of the team. This 
provided a formal opportunity to contribute to the meeting, although this only 
tended to happen when a patient was being re-discussed by the team (for example 
where an issue had arisen following the patient’s first MDT discussion): 
 
Consultant Gynaecologist: complex cases [221016] does anyone 
want to talk about her? 
CNS: oh yes I put her on because she phoned today she’s 2 months 
out of her chemo for cervical cancer…she’s had her post treatment 
MRI…but she’s got a CT scan on the system and I can’t see any 
reason why she needs it…do we want it for a specific reason?  
(Gynaecology, observation transcript)4 
 
6.1.2 Opportunities for participation 
The second component of Berger’s power and prestige order relates to 
opportunities to participate and patterns of participation within a team (Ridgeway, 
2001). In the MDT, members had the opportunity to contribute during review of 
imaging or pathology, or during any subsequent multidisciplinary discussion. 
Importantly however, each team had a finite period of time for the weekly meeting. 
                                                     
4
 Interview data are presented in italics and indented, observation data are indented only 
Findings I: The role of status hierarchies 
114 
 
 
This meant that opportunities to contribute certain types of information had the 
potential to impact on the time available for others.  
 
Review of imaging and pathology  
Following the initial case presentation it was common for diagnostic material to be 
reviewed. This provided formal opportunities for consultant radiologists and 
pathologists to participate by presenting their findings to the team. In all four teams 
there was dedicated time allocated for these contributions, reflecting the 
importance of diagnosis to determining the appropriate treatment plan. However, 
given the very technical nature of these presentations, not all members of the team 
were able to contribute during this stage of the MDT meeting. This was particularly 
the case for non-medical members: 
  
Now I’m not a radiologist I don’t have a full appreciation of how they 
review scans, but it seems like we have a separate radiology meeting 
before we can talk about anything else…There has to be a more concise 
way to present patients. (CNS, Gynaecology, interview) 
 
This quote highlights the impact of time spent reviewing scans on the time available 
to discuss other types of information. There were however differences between the 
four teams in the proportion of time allocated for review of imaging and pathology 
during the meeting. As illustrated in the quote above, in Gynaecology some of the 
radiology presentations were extremely long and detailed. In part, this was 
attributed to the fact that the consultant gynaecologists often used the scans to 
visualise the surgery they planned to undertake:  
 
Part of our MDM is actually surgery preparation time...they [consultant 
gynaecologists] are actually visualising what they’re going to do…but it’s 
not one of the key goals, necessarily, of what an MDM thinks it’s doing, 
or what government thinks an MDM’s doing. (Psychologist, 
Gynaecology, interview) 
Findings I: The role of status hierarchies 
115 
 
 
However, the view that radiology presentations went on for too long was also 
echoed by two of the consultant gynaecologists themselves: 
 
All these images come on, these endless, endless scans…and you think ‘if 
I see one more of these I’ll scream’. (Consultant Gynaecologist 5, 
Gynaecology, interview) 
 
In contrast, although there was dedicated time for consultant diagnostic 
professionals to participate in the MDT meeting in the other three teams, 
proportionately less time was spent reviewing images: 
 
I try and be concise…I tend to spend more time when I think something is 
difficult or mature and when it is straightforward I tend to spend little 
time. (Imaging Consultant, Haematology 2, interview)  
 
The presentation of imaging and pathology also provided opportunities for other 
members of the team to participate as well. On occasion, the pathologist or 
radiologist required further information to help them reach a diagnosis. In these 
cases it was usually the medical or surgical consultants who used their clinical 
expertise or knowledge of the patient to provide this information. For example, in 
the Gynaecology team, the consultant gynaecologists were the most likely to 
provide information to help with interpretation of imaging or pathology. Often, this 
was because they were able to explain what had happened during the surgical 
procedure where the tissue sample was acquired, or because they had information 
about the patient’s clinical history that could support the radiologist’s 
interpretation of a scan: 
 
Consultant Radiologist: …at some stage she must have been 
obstructed 
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Consultant Gynaecologist: yeh she had hydronephrosis [where a 
kidney becomes swollen as a result of urine build up] 
(Gynaecology, observation meeting transcript) 
 
‘Multidisciplinary’ discussion 
Following the initial case presentation, and review of imaging and pathology, any 
subsequent discussion was in theory an opportunity for all professionals within the 
MDT to participate in the meeting. However, there were obvious differences 
between professional groups in terms of the frequency with which they initiated 
participation or made contributions. This led some interviewees to argue that there 
was very little genuine multidisciplinary discussion during the decision making 
process: 
 
It’s rarely a multidisciplinary meeting…it often consists of a surgeon 
talking to the radiologist or a surgeon to an oncologist. (Oncology StR, 
Gynaecology, interview) 
 
Overall, in all teams, surgical or medical consultants were the most likely to initiate 
participation and to contribute to discussion: “it is very doctor driven in general” 
(Consultant in Nuclear Medicine, Haematology 2, interview) and “most 
communication is doctor to doctor” (CNS, Haematology 1, interview). In contrast 
CNSs and StRs were much less likely to participate or contribute: “it tends to be the 
junior doctors [who don’t speak up]” (Consultant Gynaecologist, Gynaecology, 
interview), or, as one CNSs described: “an hour of my time… without any 
opportunity to really contribute” (CNS, Haematology 2, interview). In view of their 
specific diagnostic expertise, levels of contribution from consultant diagnostic 
specialists were somewhere in the middle.  
 
These patterns of participation were apparent when it came to asking questions, to 
answering questions, and to giving advice in relation to a treatment decision. 
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Detailed coding summaries from Nvivo and a series of illustrative quotes evidencing 
this are provided in Appendices 13-15. For clarity, Table 12 summarises the specific 
patterns of high and low participation by professional group in each team. 
 
Table 12: Patterns of high and low participation by professional group and MDT 
Team High participation* Low participation 
Gynae Consultant Gynaecologists (highest) 
Consultant Medical and Clinical Oncologists 
CNS 
StR (lowest) 
Haem 1 Consultant Haematologists CNS and StR 
Haem 2 Consultant Haematologists StR 
CNS (lowest) 
Skin Consultant Medical Oncologist (highest) 
Consultant Plastic Surgeons 
Consultant Dermatologists 
CNS 
StR (lowest) 
*’High’ and ‘low’ rates are based on coding frequencies from Nvivo, in addition to observation data 
from field notes. See Appendices 13-15 for more detail. 
 
Further consideration will be given to the role of CNSs and StRs in the MDT meeting 
in Chapter 8, where a more detailed analysis of the nature of their contributions 
and approaches used to participate will be presented.   
 
6.1.3 Evaluations of contributions 
The third key component of the power and prestige order proposes that individuals 
with lower status are less likely to receive positive evaluations of the contributions 
they make (Ridgeway, 2001). In the context of these MDT meetings, this was 
apparent when lower status contributions were not taken on board by a higher 
status member of the team or were on occasion ignored. 
 
The observation data highlighted 23 occasions across the four teams where a 
contribution made by a lower status individual was not taken on board by a higher 
status member of the team. On some occasions this seemed to reflect a lack of 
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knowledge or a certain type of expertise on the part of a CNS or StR. This could be a 
lack of knowledge about a local treatment protocol, or a lack of medical expertise. 
This is illustrated in the example below when an StR suggested treating a patient 
using radiotherapy. In response, a consultant haematologist explained that it would 
be better to wait until the patient had started chemotherapy before proceeding to 
radiotherapy because the cancer might respond quickly without the need for both: 
 
Consultant Haematologist 1: so what would you like to do with him?  
StR: …radiotherapy? 
Consultant Haematologist 1: to what? 
StR: to his rib lesions 
Consultant Haematologist 1: no 
StR: they’re causing a lot of pain 
Consultant Haematologist 1:  well there’s no need to irradiate them 
yet because sometimes they respond very rapidly to chemo 
StR: because they are saying he’s in a lot of pain 
Consultant Haematologist 1: yeh, if they continue to be painful once 
he’s started on his chemo you can always just do spot radiation to 
those but you might get away without it once he starts on chemo  
(Haematology 1, observation transcript) 
 
However, on other occasions it appeared that lower status contributions were not 
taken on board not because they lacked expertise, but because a higher status 
member of the team prioritised other types of information. An example from the 
observation data below illustrates a lower status contribution being ignored: 
 
CNS: just to let you know her daughter’s getting married in [another 
country] in January and when I saw her a couple of weeks ago she 
was quite upset so  
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Consultant Gynaecologist: [interrupts] and what sort of tumour did 
you say that was sorry? 
Pathologist: it looks like a serous 
Consultant Gynaecologist: oh right ok  
(Gynaecology, observation transcript) 
 
In this case, when the CNS attempted to introduce information about the patient’s 
psychosocial circumstances the Consultant Gynaecologist returned the discussion 
back to the disease itself. Overall, the number of instances in the observation data 
where CNS or StR contributions were directly ignored was relatively low, with ten 
examples coded across the Gynaecology and Skin teams. Nonetheless, these 
examples were particularly noticeable during the observation given that lower 
status members of the team participated much less frequently than others. In 
addition, the interviews with MDT professionals suggested that being ignored could 
have an impact in the longer term on the willingness of lower status groups to 
contribute during MDT meetings:  
 
Interviewer:  do you feel able to speak freely [during the meetings]? 
Oncology StR: no 
Interviewer: and is there anything in particular that you could identify 
that attributes to that? 
Oncology StR: …it’s general sort of atmosphere and, and the fact that 
you know, in the past I have been talked over and ignored 
(Oncology StR, Gynaecology, interview) 
 
The view that contributions from CNSs or StRs were ignored was raised more 
frequently by members of the Gynaecology team during interviews than it was in 
the other three teams. Three of the seven interviewees in the Gynaecology team 
raised this as an issue: 
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Quite often when CNSs say things, they’re talked over, so they’ll begin to 
say something, particularly if they raise something and then, say one of 
the oncologists would start to speak over them, which then makes them 
feel very upset and angry. (Psychologist, Gynaecology, interview)  
  
This appeared to relate to differences of opinion about the value of specific types of 
information in the MDT meeting.  The MDT Lead in Gynaecology expressed the view 
that the MDT meeting was a forum for making clinical decisions, with a limited role 
for patient centred information. This was attributed to time pressures: 
 
I think it should be a clinically focused meeting. I know some of my 
colleagues disagree with me and think that we should give more time to 
psychosocial issues. In an ideal world you probably would but then the 
meeting would never end. (Consultant Gynaecologist, Gynaecology, 
interview)  
 
This view contrasted directly with that of the CNS interviewed in this team: 
 
I truly feel it’s not just about what treatment they’re going to have…I 
think trying to get the team to think about the, for it to be patient 
centred…important [psychosocial] work happens about patients that 
we’re discussing in the MDT that I think that, in its current state there 
isn’t the time or the capacity to do that but I truly believe that that is a 
very important function of the MDT. (CNS, Gynaecology, interview) 
 
These differences of opinion are important, because they appear to have created an 
impression amongst the lower status individuals interviewed in the Gynaecology 
team that their contributions were less likely to be taken into consideration by 
other members of the team. This view was less apparent in the other three teams, 
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although the CNS in Haematology 2 attributed her reluctance to participate to the 
view that some contributions were seen to be less relevant than others: 
 
I don’t feel unable to [contribute]… I could go to one of the doctors after 
the [meeting], if I really had something I felt strongly about…I’m not 
frightened of doing that; I don’t feel intimidated.  I just think you 
wouldn’t get very far in that meeting because I think it would be, “We 
haven’t got time to discuss this now; we’ll do it somewhere else.”  (CNS, 
Haematology 2, interview) 
 
6.1.4 Influence 
The fourth key premise of status characteristics theory is that individuals within a 
group who have higher status will have more influence than individuals with lower 
status (Ridgeway, 2001). In the context of MDT meetings, the most obvious sources 
of influence related to leadership and to control over the final treatment decision 
for each patient. 
 
Leadership in the MDT meeting 
Influence in MDT meetings extended to the way in which different professional 
groups took responsibility for steering discussion, and to assigning tasks to other 
members in the team. In this regard, the MDT Lead played a crucial role and their 
influence could be seen in a number of ways. First, they managed the overall timing 
of the meeting: “is everything set up and ready to go?...we’ll start in one minute” 
(MDT Lead, Haematology 2, observation field note). Although each meeting had a 
fixed time, some MDT Leads were themselves late for the meeting or delayed the 
start time to wait for specific individuals to arrive. This was not the case in all teams, 
however. Haematology 2 was the exception. In this team, meetings started and 
ended on time almost every week. 
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Secondly, the MDT Leads also decided on the order in which patients would be 
discussed, and controlled the length of time spent on each case: “can we move on?” 
(MDT Lead, Haematology 2, observation field note). The MDT Lead also made 
decisions about which cases (if any) to defer: “put her back on for next week” (MDT 
Lead, Skin, observation field note). In this way they exerted considerable influence 
over the decision making process. In all four teams, the MDT Lead was a surgical or 
medical consultant.  
 
The MDT Leads were also most likely to issue directives or requests to 
other members of the team, although not exclusively. Other consultants 
also gave instructions or asked lower status team members to follow up an 
action on their behalf: 
 
One of the surgeons had added a patient to the list this week, and 
had told the pathologist that it was urgent. However he didn't turn 
up to the meeting to present the patient. The pathologist was 
frustrated because she said she had spent ages chasing this. There 
was then a humorous discussion which ended with one of the 
plastic surgery registrars being 'sent down to theatre' to find the 
surgeon in question and pass on the message that the pathologist 
was not happy. (Skin, observation field note)  
 
Less frequently, directives or requests within the MDT meeting were also 
made from one consultant to another:  
 
Consultant Gynaecologist 1: did you speak to the pathologist?  
Consultant Gynaecologist 2: eh she didn’t pick up the phone shall I 
try her again? 
Consultant Gynaecologist 1: try again 
(Gynaecology, observation transcript) 
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In contrast, I did not observe CNS or StR members making requests of the 
consultants in any of the teams.  
 
Treatment plan decision making 
Reflecting the patterns of participation described above, medical or surgical 
consultants were also those most likely to make the final treatment decisions in all 
four teams:  
 
Consultant Haematologist 1: I think she needs a biopsy…the reason 
I’m saying that is if she’s got transformed disease in that shoulder 
that’s progressive then a transplant would be futile  
Consultant Haematologist 2: ok…biopsy  
Consultant Haematologist 3: yep biopsy  
(Haematology 2, observation transcript) 
 
This reflected the specialist knowledge and expertise held by these professionals, as 
well as their legal duty of care and professional accountability to patients (Sidhom 
and Poulsen, 2006). These are key factors in understanding the influence of these 
groups on the treatment plan. 
 
In contrast, the input into treatment plan decision making provided by radiologists 
and pathologists was largely restricted to information provision. Reflecting their 
areas of expertise, this information related to diagnosis, or to suggestions about the 
need for further investigations. While the information they provided was prioritised 
because it was seen as essential to decision making, they were very rarely involved 
in the final decision about patient treatment: 
 
At the meeting I tend to just give input on the scans I review… I don’t 
know enough about patient management to interact…I would say 
maybe repeat MRI or repeat this PET…but I wouldn’t give any 
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recommendation for treatment decisions. (Imaging Consultant, 
Haematology 2, interview) 
 
This was true also of the CNSs and StRs who were generally not involved in making 
the final treatment decision. This was the case even when they had initiated 
participation by presenting a case during the meeting. This is perhaps illustrated 
most clearly by an example from Haematology 2, where a junior doctor presented a 
patient for discussion and asked for a review of the patient’s PET scan. When the 
imaging consultant presented the PET report however, he turned and spoke directly 
to the consultant in charge of the patient, rather than responding to the junior 
doctor who had presented the case.  
 
6.2 Explanations for higher participation and influence  
In a clinical decision making forum, there are clearly obvious potential explanations 
for the predominant influence of consultant medical or surgical doctors. Some of 
these have already been noted above - in particular, the fact that medical and 
surgical consultants have a legal responsibility of a duty of care to their patients 
(Sidhom and Poulsen, 2006). They also have the clinical training and expertise to 
make decisions about treatment in the healthcare arena:  
 
The clinicians are very strong, very knowledgeable, very skilled experts in 
their field whether it be surgery or oncology. (CNS, Gynaecology, 
interview) 
 
The importance of the knowledge and expertise of these individuals was also 
illustrated in a small number of examples when key individuals were missing from 
the meeting, and decisions made by lower status members of the team (for 
example StRs) were subsequently overturned: 
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When we hit that summer period, and we had lots of consultant away at 
the same time. I think we had sub-optimal meetings and um, un-robust 
decisions were made. We just brought them back…because I felt…the 
patients weren’t discussed properly. It was obvious...there was nobody 
senior enough there to make proper decisions. (CNS, Skin, interview)   
 
However, the MDT Lead in Haematology 1 challenged what he saw as the 
expectation from other team members that he should take the lead in making all 
the decisions. This was particularly an issue when he did not know the patient. He 
argued that his medical expertise was not the only important source of information. 
Instead, he argued that there was a role for CNSs and StRs who had met the patient 
to contribute more actively:  
 
I think sometimes there is too much emphasis on what do those that are 
particularly involved in haemoto-oncology think the decision should be, 
rather than a more generalised input…actually I think if I sat there and 
said nothing there would be, I may be wrong, but I have a feeling there 
would be an unearthly silence until I say well, this is lymphoma so we 
should be thinking along these lines. Rather than the person who saw 
the patient actually saying “I think the patient would be able to cope 
with x chemotherapy, I would be interested to know what other 
members of the group think”. (Consultant Haematologist 1, 
Haematology 1, interview) 
 
Overall then, the influence of higher status members of the team on the decision 
making process reflected their specialist knowledge and expertise. However, the 
point made by the MDT Lead in Haematology 1 was a reminder that this did not 
necessarily need to be at the exclusion of other members of the team.  
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6.3 Explanations for lower participation and influence  
There are also potential explanations for the lower rates of participation and 
influence observed amongst lower status groups. First, for StRs this was because, as 
doctors in training, they did not always have the requisite knowledge or familiarity 
with local protocols to make decisions. During one interview, an StR pointed out 
that he simply did not have the experience or evidence base to contribute to the 
decision making process. He described attending the MDT meeting in order “to get 
an opinion” (StR, Haematology 2, interview). This was attributed to a natural order 
in which consultants were the experts and should therefore make the decisions. The 
view that StRs were not necessarily in a position to make decisions in the MDT 
meeting was also echoed by the CNS in Skin: 
 
I think sometimes it’s quite daunting for a new reg [StR] to come in and 
be in charge of making decisions…because they don’t always know 
[what patients should be offered], which is a bit tricky. (CNS, Skin, 
interview) 
 
Secondly, for CNSs, who unlike junior doctors have completed their specialist 
training, and are in many cases vastly experienced, lower rates of participation at 
times reflected the stage at which a patient was being discussed. New patients were 
not always known to all members of the team. As a result, CNSs were at times 
limited in the amount of information they could share. This is illustrated in the 
example below from the Gynaecology team, during discussion of a patient with a 
new diagnosis of cancer who had previously been undergoing IVF treatment. The 
patient had been so upset by her diagnosis that she had left the hospital before her 
appointment with the CNS: 
 
Consultant Gynaecologist: they’ve had two IVF and, you saw her 
[CNS]? 
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CNS: I tried to see her but she was really upset and she didn’t want 
to talk…she just went, I literally said hello my name is [CNS]  
Consultant Gynaecologist: but you can you can touch base later  
CNS: I can, I can try  
(Gynaecology, observation transcript) 
 
In this case the CNS was provided with an opportunity to contribute. The fact that 
she had not been able to meet with the patient before the MDT meeting however 
meant that she was not in a position to provide further information.  
 
Nonetheless, a lack of knowledge or a lack of information were not necessarily the 
only reasons for lower levels of participation amongst CNSs and StRs. A third 
potential explanation was that some individuals were reluctant to speak up, even 
when they had a contribution to make. This may in part reflect individual 
differences in confidence or personality. However, it is worth pointing out that for 
junior doctors, not only were they less experienced than other clinicians within the 
team, but they were often also the newest members. This meant that they had to 
develop their clinical expertise as well as to learn how the meetings worked and to 
develop confidence to contribute according to the group norms. A consultant 
gynaecologist argued that the MDT meeting could be intimidating for this group in 
particular: 
 
A lot of the junior staff feel inhibited about putting their views forward. 
And when they do sometimes they have very good ideas. But they don’t 
always speak. (Consultant Gynaecologist 1, Gynaecology, interview) 
 
The potential implications of this were illustrated in an example provided by an StR 
in Haematology 1, who referred to a situation where one of her StR colleagues had 
not spoken up at the MDT meeting. This was despite having reservations about a 
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decision made by a consultant haematologist to refer a patient for palliative care 
after their second line of chemotherapy (instead of trying an alternative treatment): 
 
My colleague who put him forward was quite surprised but didn’t 
question it there…she was quite surprised at that [decision not to 
continue chemotherapy] because you wouldn’t necessarily do that with 
a patient in that situation. You’d normally try third line or something else 
or get a second opinion so that was quite strange. But then it [the 
decision] was changed.  So after a few weeks this particular consultant 
who said that then contacted me to start investigating him [the patient] 
and then doing all sorts.  (Haematology StR, Haematology 1, interview) 
 
In this example, the StR had not challenged the decision made by a consultant, even 
though she believed that the patient would tolerate a third line of chemotherapy. 
This case was described as a one off. However it suggests that a failure to speak up 
by those with knowledge about a patient’s ability to cope with treatment can 
impact on the appropriateness of a treatment decision. In this case, even though 
the decision was subsequently changed, it potentially delayed the start of 
treatment by a number of weeks.  
 
A reluctance to speak up during the meeting was sometimes hinted at in the 
observation data as well, although of course it is particularly challenging to identify 
and interpret the absence of a behaviour using observation data alone (Dyne et al., 
2003, Schwappach and Gehring, 2014). However, this could be inferred from certain 
behaviours, for example in the Skin team the CNS often whispered relevant 
information directly to a consultant who would then share it with the rest of the 
team, rather than speaking to the whole room. Similarly, I observed StRs in 
Haematology 2 and Skin, who were responsible for recording decisions made during 
the meeting, on occasion leaving the form blank rather than interrupting to 
seek clarification on the decision.  
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Theme II: Exploring the effects of status hierarchies  
In the section above, the power and prestige order described in status 
characteristics theory provided me with a framework for exploring the decision 
making process in MDT meetings. This demonstrated the central role of higher 
status surgical, medical and diagnostic consultant members of the team at each 
stage of the decision making process. In the next section I go on to explore the 
effects of these patterns of participation and influence on two key elements 
identified in my theoretical framework: efficiency and information sharing. 
Following on from this, I consider the circumstances in which the four teams 
engaged in multidisciplinary discussion, which included contributions from lower 
status members of the team.  
 
6.4 Efficiency 
As described in my theoretical framework, functionalist perspectives of hierarchy 
suggest that status hierarchies can improve decision making by giving 
disproportionate control to the most competent team members (Anderson and 
Brown, 2010). In the context of MDT meetings, this suggests that the dominant role 
of higher status members could be beneficial if it enables teams to capitalise on 
medical, surgical and diagnostic expertise to make treatment decisions quickly and 
efficiently. It is not possible using the qualitative data I collected for this study to 
determine if limiting discussion to higher status groups impacted on the quality of 
decisions made. However, it is possible to consider the impact of limiting discussion 
to a subset of team members on perceptions of efficiency of the decision making 
process during the MDT meeting. 
 
6.4.1 The importance of efficiency for MDT decision making 
Table 13 illustrates differences between teams in the duration of meetings, and the 
number of patients discussed each week.   
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Table 13: Summary of structural features of MDT meetings by week  
Team No. pts 
discussed  
(average)  
No. pts 
discussed 
(range)  
Meeting 
duration 
(average) 
Meeting 
duration 
(range) 
Gynae 35 24-45 140 mins 105 – 160mins 
Haem 1 15 7-27 61 mins 10 – 90 mins 
Haem 2 14 5-41 57 mins 14-82 mins 
Skin 47 23-64 87 mins 58 – 130 mins 
 
In spite of these differences, efficiency was an important issue in all teams due to 
time pressures during MDT meetings. In part, this reflected the number of cases to 
be discussed in the time allocated. This often created a sense of urgency: 
 
We try to get through quite a large number of cases in quite a short 
period of time, and compressing that into 90 or so minutes is always a 
problem. (Consultant Oncologist, Skin, interview) 
 
This was accentuated by a pervading sense of pressure from factors external to the 
meeting. This included reference to national pressures such as waiting time targets. 
It also included local pressures related to bed shortages, insufficient theatre lists, or 
other clinical commitments such as a busy clinic following the meeting. This could 
add pressure to finish the meeting on time: 
 
[The clinic following the MDT meeting] is going to be awful as well I 
can warn you in advance that [the clinic this morning] was 
heaving…I mean I was stuck with a man trying to usher him out 
standing up trying to push him out the clinic room. 
(Consultant Haematologist, Haematology 1, observation transcript) 
 
Efficiency was a practical way to manage the often lengthy list of patients. If cases 
presented in the earlier stages of the meeting took a long time to discuss, this 
impacted on those patients presented at the end. As it was, there was often less 
time to discuss patients presented towards the end of the meeting. In all teams, 
Findings I: The role of status hierarchies 
131 
 
 
with the exception of Haematology 1, I observed some discussions being curtailed 
at the end of a meeting as time ran out: 
 
We’re at time now, can we just breeze through the last five 
[patients]. (Consultant Haematologist, Haematology 2, observation 
field note) 
 
Haematology 1 appeared to be an exception to this because there were fewer 
patients to discuss than in Gynaecology or Skin. Although both Haematology teams 
discussed similar numbers of patients, the MDT Lead in Haematology 1 let the 
meeting run on as long as necessary and often went over time. This did not happen 
in Haematology 2.  
 
Efficiency however, was not just important in terms of controlling the amount of 
time spent on each case. It was also a mechanism for maintaining focus and 
concentration amongst the team when meetings ran on for a long time: 
 
You can’t go on for three hours…to grind on you know and I’m sure you 
have to say the discussion at a quarter to six is less robust than at 
quarter past three…so what happens to the poor patient at quarter to 
six you know? (Consultant Gynaecologist 5, Gynaecology, interview) 
 
Given these pressures, patterns of participation that reflected the status hierarchy 
were a way of capitalising on medical, surgical and diagnostic expertise. This 
enabled teams to make a considerable number of treatment decisions quickly and 
efficiently. 
 
6.4.2 Minimising ‘unnecessary’ discussion  
Patients with a new diagnosis of cancer formed the largest group of cases in all four 
teams. This reflects the National Peer Review programme requirement for MDTs to 
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review all of these patients in the weekly meeting (NHS England, 2013, NHS 
England, 2014, NHS Improving Quality, 2014). In practice, decision making in these 
cases was largely characterised by a series of information exchanges between 
higher status members of the team. There was often little in the way of discussion 
or interaction with the full range of professionals who attended the meeting: “often 
it is, at times just rubber stamping things rather than a proper discussion” (MDT 
Lead, Consultant Haematologist, Haematology 1, interview). 
 
The influence of medical and surgical consultants in these cases could be 
instrumental in actively curtailing or limiting discussion in a bid to save time and 
ensure that all cases could be discussed: 
 
[StR] was presenting a patient for discussion in the meeting today 
when he was interrupted by one of the Consultant Haematologists: 
“we just need to discuss him very briefly”. (Haematology 2, 
observation field note) 
 
Although it was not explicitly articulated in this instance, a key rationale for 
curtailing discussion, and allowing higher status groups to dominate in these cases, 
was the view that discussion would be unlikely to change the treatment plan. In 
some cases this was for practical reasons – for example if treatment had already 
been initiated, or if the information needed to make a decision was missing:  
 
Consultant Haematologist 2: it’s a very unremarkable CT scan so I 
just thought as we don’t either have any clinical information and 
[Consultant Haematologist 1] isn’t here…it seemed pointless to 
discuss. (Haematology 2, observation field note) 
 
In other cases it was argued that for most patients the decision agreed during the 
meeting was likely to be the same decision that most people would have reached 
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“through their own knowledge base or an informal chat in clinic” (Consultant 
Haematologist, Haematology 1, interview). From this perspective there could be 
“too much information” (Consultant Haematologist, Haematology 1, interview) for 
cases that were straightforward to manage.  
 
Overall, the proportion of patients that MDT members believed benefited from an 
in depth discussion was small, with these discussions happening “occasionally” 
(Consultant Dermatologist, Skin, interview) for the “minority of patients” 
(Consultant Medical Oncologist, Skin, interview). In the Gynaecology team a 
consultant gynaecologist estimated that: 
 
There will maybe be 5% of patients who actually end up having a long 
discussion that branches off into other things but most people are fairly 
snappy, you know, the decision has already been made, we’re just 
confirming that it’s the right thing to do. (Consultant Gynaecologist 2, 
Gynaecology, interview) 
 
This was largely because many patients could be managed according to 
standardised evidence-based protocols. These protocols set out clear processes for 
the treatment and management of a specific disease type: 
 
[To] work up someone with suspected ovarian cancer isn’t that difficult 
and so…in that sense you can argue that much of the approach is really 
about logging patients and rubber stamping decisions and stuff. 
(Oncology StR, Gynaecology, interview) 
 
In both Skin and Gynaecology, medical and surgical consultants within the team had 
been involved in developing treatment protocols for their cancer specialty, 
providing a clear example of status aligning with expertise: 
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During the period I’ve been working here, protocols have been written 
for treatment of various cancers but they’ve been written by the medical 
members of the team; medical and surgical members of the teams 
themselves. (Psychologist, Gynaecology, interview) 
 
In cases where patients could follow an agreed treatment protocol therefore, many 
clinicians did not think that there was a need to debate the treatment plan. Limiting 
discussion in these cases to higher status members of the team was a way to 
streamline discussion to free up time for cases that were more challenging or 
complex. Some argued that there was scope to triage patients in this way even 
more explicitly. One suggestion was to reserve the meeting only for those cases that 
required genuine multidisciplinary discussion: 
 
In order to really think about one or two cases in depth, you can’t review 
every single case. And that’s the conundrum, that, as a circle that can’t 
be squared. (Psychologist, Gynaecology, interview) 
 
However, as noted above, the National Peer Review Programme still requires all 
new patients to be reviewed in the MDT meeting for discussion of an initial 
treatment plan (NHS England, 2013, NHS England, 2014). This was acknowledged by 
the MDT Lead in Skin: 
 
Peer review demands that these patients need to be discussed…the fact 
is by law you have, well by peer review, you have to do it. (Consultant 
Oncologist, Skin, interview) 
 
To summarise, prioritising medical, surgical and diagnostic expertise meant that 
MDTs were able to review a considerable number of cases in a relatively short 
period of time. Underpinning these decisions with evidence based protocols was a 
way of ensuring consistency and promoting equality of treatment for patients. 
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Reflecting functionalist views of hierarchy, this appeared to be a way of maximising 
efficiency in the decision making process by capitalising on the status hierarchy 
(Anderson and Brown, 2010).  
 
6.5 Information sharing  
However, curtailing discussion also had the potential to undermine the benefits that 
could be gained from a multidisciplinary approach to decision making, and not 
everyone agreed that their team achieved the right balance between efficiency and 
patient centred discussion. The need to review all cases could mean that there was 
less time for patient centred information to be shared and discussed: 
 
You have nothing about the woman herself actually, that’s all been 
bleached out. And part of that is definitely efficiency, just to get 
through…in the old days [in the MDT meeting], you would actually talk a 
lot more about the women themselves. (Psychologist, Gynaecology, 
interview) 
 
A second key effect of status hierarchies identified in my theoretical framework 
related to a team’s ability to share and integrate information, which has 
implications for the quality of decisions made in healthcare teams (Cohen and Zhou, 
1991, Larson et al., 1998, Lanceley et al., 2008, Bunderson and Reagans, 2011, 
Bendersky and Hays, 2012). Taking this as a starting point, the following section 
explores the nature of information sharing in the four MDTs under study. It begins 
by presenting the views of members themselves about the levels of information 
shared in MDT meetings, before exploring the types of information held by different 
team members, with a particular emphasis on lower status groups. It then considers 
the potential implications of lower rates of participation and influence amongst 
lower status groups on the sharing of patient centred information about 
preferences and psychosocial factors.  
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6.5.1 Reflections on levels of information shared in the MDT meeting 
In all four teams, and across professional groups, interviewees outlined the 
advantages of having access to the range of opinions that MDT meetings facilitated. 
This was particularly important because the weekly meeting was often the only 
opportunity that different professionals had to come together: 
 
It’s quite clear that the MDM’s [multidisciplinary team meeting] very 
precious… the fact that you’ve got all these people together and all these 
minds.  And they don’t come together at any other point. (Psychologist, 
Gynaecology, interview) 
 
This dedicated time to share information and opinions with those from other 
professions was seen as highly valuable. However, the dominance of higher status 
members in the MDT meeting meant that in some cases the information held by 
lower status members risked being overlooked:  
 
What worries me about the MDT is not that it has bad decision making 
but that it’s sub-optimal because it doesn’t make an effort to structure 
and include all the bits of information. (Oncology StR, Gynaecology, 
interview) 
 
Of the 19 healthcare professionals interviewed, 12 suggested that there were issues 
that were not discussed enough during the MDT meeting. Of these, ten individuals 
(across the four teams) cited issues that were not directly related to the disease 
itself, including social factors, patient preferences and psychosocial issues: 
 
It is mainly psychosocial things because of the real focus on decision 
making, so I think probably that’s the side of things that has slipped over 
the years. (Consultant Gynaecologist 2, Gynaecology, interview) 
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This also included comorbidities: 
 
I think sometimes there are cases where people haven’t actually 
necessarily found out that much about the patient’s comorbidities.  
There have been a couple of occasions where I’ve noticed them actually 
so I suppose with that other example [I mentioned earlier] of the rather 
frail man I don’t think that was quite taken into account. (StR, 
Haematology 1, interview) 
 
Sharing a wide range of information, both disease focused and person centred 
information, was described as being essential to good MDT decision making: 
 
That’s why the best MDTs have pathologists, radiologists, oncologists, 
surgeons and also specialist nurses…because all of those people bring 
different things into the mix so the good MDTs work very well because 
they will, pathologically they have this disease and radiologically they 
have this stage and clinically they have these symptoms and 
psychosocially this is their context and all of those things matter in then 
thinking about treatment. (Oncology StR, Gynaecology, interview)  
 
The view that there was scope for a wider range of information to be incorporated 
during some discussions in the MDT meeting was articulated by interviewees in the 
two Haematology teams and the Gynaecology team: “I think some people need 
more of an opportunity to speak” (Consultant Gynaecologist, Gynaecology, 
interview). Importantly, however, it was not seen as necessary for every 
professional group to share information during every single discussion in the MDT: 
 
I don’t think that everyone’s sitting in a circle and saying, “Has nursing 
got anything to say?  Has the dietician got anything to say?”  I don’t 
think it needs that; we do do lots of those things as well in other 
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meetings, but I do think that sometimes there could be perhaps more 
inclusion of other professions. (CNS, Haematology 2, interview) 
 
6.5.2 Patient perspectives on the role of MDT members in their care 
In order to better understand the effects of status hierarchies on information 
sharing in the MDT meeting, it is useful first to explore the different types of 
knowledge held by different professionals within the MDT.  
 
The patient interviews gave some insight into the relationship that patients had 
with professionals involved in their care within three of the four teams (with the 
exception of Skin cancer, where as described in Chapter 5 no patients were 
interviewed). Exploring these relationships provides one way of identifying the 
types of information that different professionals potentially held and could share in 
MDT meetings.  
 
Medical or Surgical Consultants 
As would be expected, and in keeping with the patterns of participation already 
described, all seven patients interviewed identified a consultant as the main person 
responsible for their care. The patients from both Haematology teams named 
consultant haematologists from the MDT as their main point of contact, the team 
member they saw on a regular basis, and the individual that coordinated their care:  
 
[I asked] who do I go to that’s ultimately responsible for getting me 
better and you know, so they said well that’s [Consultant 
Haematologist], and that played out…she’s the person that I would go 
to…she’s the person sort of directing, the deal for…my overall care. 
(Patient 111308, Haematology 2, interview) 
 
One patient who had been an inpatient during treatment under Haematology 2 
described seeing her consultant haematologist regularly on the ward “they always 
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came around every day” (Patient 111368, Haematology 2, interview). In contrast 
however, a patient from Haematology 1 said the consultants only tended to see 
patients when they were first diagnosed, when a decision needed to be made, or 
“when things have become serious” (Patient 161212, Haematology 1, interview). In 
Gynaecology the one patient interviewed had not seen a consultant oncologist at 
her clinic appointments for 18 months, following the decision to start her on 
chemotherapy: 
 
Patient’s husband: that’s the only thing I thought, you know, after sort 
of 18 months maybe the next few months [I’d like to] try and see 
[Medical Oncologist]…it's so comforting to know that the top man’s…still 
involved 
Patient: yeah but you are seeing you are seeing people that are working 
with him…and he really while I'm while I'm keeping reasonably well…you 
know, that’s how I feel about it. (Patient 221333, Gynaecology, 
interview) 
 
These differences in levels of contact between consultants and patients were also 
evident in the professional interviews and the observation data. Some consultants 
had detailed knowledge of specific patients and their circumstances or preferences 
for treatment. For example a consultant haematologist in Haematology 2 reported 
that he insisted on seeing all his patients in clinic. He contrasted this with other 
consultants who only saw a patient once before delegating this task to StRs. 
Consultants in the Gynaecology and Skin cancer teams were quite open about 
knowing very little about a patient’s circumstances, or their preferences for 
treatment for example: 
 
Sometimes we won’t know what the patient’s underlying issues are but 
[CNS] will. (Consultant Gynaecologist 2, Gynaecology, interview) 
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The patient interviews also highlighted that doctors were not always aware of the 
factors that were of concern to patients, or likely to influence their decisions about 
treatment. A patient from Haematology 1 illustrated the potential for doctors to be 
unaware of a patient’s views. In this example, the patient noted how it had been 
difficult on at least one occasion to raise issues about her treatment with the 
consultant, because of a lack of time and privacy:  
 
I didn’t see Dr [Consultant Haematologist] every single time I was in 
there, and that’s fair enough but…I [saw] another doctor one day and 
she just came over and sort of knelt down and just said oh how you 
doing der de der and that was it and I felt like there was things that I 
probably would have said to her, had I been into a private room, rather 
than being in like the day-care room where everybody is in the room. It’s 
a sort of open forum, I thought that that was a bit, you didn’t get your 
chance to sort of say right I’m experiencing this, is that normal or, you 
know I kind of felt, urgh, I didn’t really want to talk about things in front 
of everybody. (Patient 161379, Haematology 1, interview) 
 
This patient also suggested that while some doctors did get to know their patients 
well, other doctors were not necessarily of the same mind set:  
 
Some doctors might just think oh well, that doesn’t matter, first and 
foremost it’s the treatment that we need to do. (Patient 161379, 
Haematology 1, interview)  
 
Some of these differences in levels of contact with consultants seemed to be a 
reflection of the nature of the disease and the treatment that patients received. For 
example some patients were treated during long inpatient admissions, while others 
received outpatient chemotherapy, radiotherapy, or one-off surgery. Regardless of 
this however, all patients were aware that there were professionals other than the 
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consultants involved in their care, and all knew that decisions were made by a 
multidisciplinary team: 
 
I know Dr [Consultant Haematologist] did mention that to me early 
on…that people get together on a, I don’t know, it was like a Monday or 
something…and discuss the case…she said…”we’ll all get together and 
have a discussion and make sure that this is the right route for you”. 
(Patient 161379, Haematology 1, interview) 
 
StRs 
When patients did not see their lead consultant, the other groups mentioned most 
frequently were StRs and CNSs. In the teams where patients were interviewed, 
interviewees described seeing registrars on a regular basis during their treatment: 
 
From a doctor’s standpoint…it was largely, it was really almost always 
[StR], you know, I had other doctors, but I would see him you know, two 
thirds of the time…so for me, say we built up a rapport and a trust. 
(Patient 111308, Haematology 2, interview) 
 
This view was reiterated by an StR in Haematology 1, who explained that in their 
team StRs were responsible for reviewing patients in advance of every cycle of 
treatment. This was to make sure that patients were well enough to undergo 
treatment, and to flag up any issues that had arisen previously: “we then bring it 
forward at the MDT” (Haematology StR, Haematology 1, interview).  
 
CNSs 
All patients interviewed mentioned that a CNS had also been involved in their care. 
For patients under the Haematology 1 team, this involvement extended to detailed 
discussions about treatment and potential side-effects:   
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She [chemotherapy CNS] was the one I sort of interacted with quite a bit 
with regards to my care and she would give me like sort of advice on all, 
guidance as to what was going to happen and you know, sort of any side 
effects and things like that, what I might experience. (Patient 161379, 
Haematology 1, interview) 
 
The supportive role of the CNS was acknowledged by all three of the patients 
interviewed in this team. In addition, the more regular interaction with a CNS was 
also mentioned by patients in Haematology 2. They described contacting their 
named CNS for day to day issues relating to their treatment, or in between 
appointments with their lead consultant:  
 
The Clinical Nurse gave me her email address so if I have a non-urgent 
problem or if I, or if I even if I have an urgent problem I don’t know, erm, 
but if I have a non-urgent problem I just send her a note saying, you 
know, what is happening about this or when…is this going to happen 
and she will get back to me on that. (Patient 111359, Haematology 2, 
interview) 
 
The importance of the CNS as a key link between the patient and the MDT was 
reiterated in the professional interviews. An StR in the Haematology 1 team noted 
that the involvement of CNSs in the process of administering treatment meant that 
they had a key role to play in the MDT meeting. The reason given for this was that 
CNSs had a more up to date and detailed insight into the patients being discussed 
by the team, and how well they were coping with treatment. CNSs themselves also 
described having a different rapport with patients: 
 
We can tend to present a side of a patient that maybe others haven’t 
heard or, or been aware about…there’s a group of people that don’t feel 
confident and will disclose information to you that they haven’t felt, for 
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whatever reason, they’ve been able to talk to their doctors about…and 
maybe if we weren’t there and nobody else had known about these 
discussions then their voice wouldn’t be heard. (CNS, Gynaecology, 
interview) 
 
This view was reflected by other professionals as well: 
 
That’s where I think that to a degree the clinical nurse specialist role is 
crucial to that meeting…because often they [CNSs] have a more personal 
discussion with the patient and maybe a wider understanding of the 
patient’s life. And the impact that decisions may have on that patient’s 
life. (Consultant Gynaecologist 1, Gynaecology, interview)  
 
6.5.3 The role of patient centred information in the MDT meeting 
As illustrated in the previous section, although lower status individuals were not the 
only members of the team to hold patient centred information, StRs and CNSs often 
had more regular and frequent contact with patients than others. As a result, they 
were more likely to have detailed knowledge of patients being discussed in the MDT 
meeting. Given the lower rates of participation and influence of these groups 
described previously, this had potential implications for the nature of discussions in 
the MDT.   
 
To consider this further, the next section goes on to explore the role of patient 
centred information in MDT meetings, focusing specifically on information about 
patients’ treatment preferences, and their psychosocial wellbeing.  
 
Information about patient preferences  
The most common patient preferences that were shared in the four teams related 
to whether or not a patient wanted any further tests or treatment, as well as 
specific preferences for one modality of treatment over another (for example a 
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preference for surgery instead of radiotherapy). When shared, this information 
could have an important influence on decisions made by the MDT: 
 
Sometimes it’s quite apparent the patient has stated that they don’t 
want treatment X or whatever. They don’t want surgery or they don’t 
want chemotherapy. And that obviously strongly influences what the 
MDM is there to decide. So yes the short answer is if a patient 
preference is known beforehand, or we have some idea, then that is 
useful information. (Consultant Medical Oncologist, Skin, interview) 
 
However, overall, information about patients’ treatment preferences was rarely 
mentioned in any of the four MDTs. The frequency ranged from between 5 to 8 per 
cent of the 2,356 cases presented across the teams during the observation period 
(Table 14). 
 
Table 14: Discussions where patient preferences and psychosocial factors were 
mentioned in the MDT meeting 
Team No. cases 
presented during 
observation*  
Cases where patient 
preferences 
mentioned** 
Cases where 
psychosocial factors 
mentioned*** 
Gynae 621 50 (8%) 60 (10%) 
Haem 1 550 31 (6%) 65 (12%) 
Haem 2 511 35 (7%) 58 (11%) 
Skin 674 32 (5%) 29 (4%) 
Total 2356 148 (6%) 212 (9%) 
* Includes cases where the same patient was discussed at multiple meetings 
** There was very little overlap between mention of patient preferences and psychosocial factors – 
both were mentioned in the same discussion in less than 2% of cases in all four teams (ranging from 
8 cases in Skin to 15 cases in Gynaecology)  
***Variables included mention of a patient’s: caring role; disability; English proficiency; marital 
status; relationship with service; whether in residential care; difficult social or economic 
circumstances; social support; and a free text variable on social support 
 
In light of the findings that CNSs and StRs were most likely to hold information 
about patient preferences, but least likely to participate, these figures are perhaps 
unsurprising. It is likely therefore that to some extent the figures reflect the effects 
Findings I: The role of status hierarchies 
145 
 
 
of the power and prestige order, which prioritised contributions from higher status 
medical and surgical consultants.  
 
However, the influence of status is not the only potential explanation for the fact 
that preferences were only mentioned in around one in twenty cases. First, 
although information about patient preferences was most likely to be presented by 
a CNS, lower status members of the team were not necessarily the only individuals 
in the group who had access to this information. There were occasions in all four 
teams where information about a patient’s preferences was raised by a medical or 
surgical consultant who also knew the patient:  
 
[Consultant Haematologist] certainly mentions her patients’ wishes 
when she knows them. And I would hope we [the CNSs] would if we 
knew them, and they would affect a treatment decision. (CNS, 
Haematology 2, interview) 
 
In addition, patients with a new diagnosis of cancer formed the largest group of 
cases in all four MDTs. This meant that in practice patient preferences were not 
always known at the time of the weekly meeting. In fact, there were occasions 
when no one in the team had met a patient being discussed. In these cases there 
was little scope for patient centred information to be shared, regardless of the 
status hierarchy: 
 
They’re [patient preferences] not really discussed that often. So 
sometimes that’s perhaps because…a lot of the reviews are before the 
patient’s known well or has been met, so perhaps the patient’s views are 
not known. (CNS, Haematology 2, interview)  
 
Furthermore, there were also a range of views about the extent to which patient 
preferences should influence decision making in the MDT meeting. These 
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differences were apparent both within teams and professional groups, as well as 
amongst patients. This is illustrated in an example from the observation data from 
Haematology 2. During discussion of a patient, the team were informed by the StR 
presenting the case that the patient had refused a bone marrow test and did not 
want any further investigations or treatment. One consultant haematologist 
emphasised that the patient’s wishes should be respected. However, another 
consultant haematologist argued that the team had a responsibility to make the 
best clinical decision. In this case he proposed that this would be to recommend 
further assessment and treatment, in spite of the patient’s stated wishes. It was this 
latter view that was documented in the MDT record, although the MDT Lead 
suggested that the issue was discussed further outside of the meeting.  
 
The view that patient preferences should be considered outside of the meeting, was 
also expressed by both patients and professionals. During the interviews, a range of 
professionals across all four teams articulated the view that the MDT meeting was 
not the final decision making arena. Instead, the patient was seen as the individual 
responsible for making the final decision about treatment outside of the meeting, 
particularly if there was more than one option. Again, this reflected the fact that in 
some cases, teams were discussing management options before they had had 
conversations with the patient about possible treatment. At this stage, patients’ 
views and preferences were not necessarily known by anyone in the team. It was 
argued that in these cases discussions involving patient centred factors should 
happen after the MDT meeting instead: 
 
I think…patient input in terms of what they would like, comes up 
subsequent to the MDT and is between that person and the clinician 
seeing them…and actually I am not sure that is a decision for the MDT to 
be involved in. (Consultant Haematologist, Haematology 1, interview) 
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However, as noted previously, the MDT meeting was often the only point in time at 
which all professional groups came together. Given that certain members of the 
team are more likely to hold patient centred information than others, if this is not 
shared during the meeting there is a risk that it will not be shared at all. This is 
further complicated by the fact that the extent to which it is desirable to discuss 
patient centred factors in the MDT meeting is in itself a patient preference. Some 
patients themselves emphasised the importance of making the best clinical 
decision, almost irrespective of their preferences. This was particularly the case for 
patients who had been very sick: 
 
When she [Consultant Haematologist] says something to us we just say 
to her well you’re the boss…and she laughs but that’s how we 
feel…there’s no point in going and seeking an expert opinion and then 
just going and turning your back on it…we accept their advice so 
therefore really we don’t need to say anything [about our 
preferences]…because we, perhaps it’s a bit glib to say we follow blindly 
but we sort of do. (Patient 161212, Haematology 1, interview) 
 
However, other patients saw information about patient preferences as an essential 
part of decision making: 
 
What’s the saying, a happy patient is a healthy patient…you have to 
take their preferences into consideration because, you know, a lot of it 
obviously is your mental outlook and if you’re…more comfortable with 
what’s going on, you know, chances are you’ll do better right, and so you 
definitely have to try…I mean, it has to be part of the equation there’s no 
doubt about that. (Patient 111308, Haematology 2, interview) 
 
Overall then, information about patient preferences was shared relatively 
infrequently, reflecting the lower rates of participation amongst CNSs and StRs 
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across the four teams. However, although consideration of patient preferences was 
sometimes seen as a way to make the best decision in the context of a specific 
patient, this was not necessarily seen as desirable, or feasible, in every case 
presented in the MDT meeting. This was because patient preferences were not 
always known at the time of the initial discussion, and because some patients and 
professionals wanted the MDT to focus on making the best clinical decision. In 
addition, there were potentially other points outside of the MDT meeting where 
this information could be discussed. 
 
Information about psychosocial factors   
Similarly, psychosocial information about a patient’s social circumstances or 
wellbeing, information that gave a sense of the patient as a person, was also 
relatively rarely mentioned in any of the MDT meetings. The frequency of this 
ranged from between 4 to 12 per cent of the 2,356 cases presented across the 
teams during the observation period (Table 14, p. 144). As with information about 
patient preferences, this information was not always known at the time of an MDT 
discussion. Again, when it was known, it tended to be shared by a CNS.  
 
The quantitative data show that psychosocial information was least likely to be 
mentioned in the Skin team (in only 4 per cent of cases presented). However, this 
was not raised as an issue of concern in the professional interviews, either by higher 
or lower status individuals. Although the MDT Lead and the CNS acknowledged the 
limited time to discuss psychosocial factors, they also argued that they were taken 
into account when this was necessary: 
 
My personal feeling is that I think we don’t have a time limit on a specific 
case. If a case is complicated and needs a lot of discussion, we take that 
time. So I don’t actually think much is missing from the MDM. If 
anything probably, we already discuss things in sometimes in too great a 
detail. (Consultant Medical Oncologist, Skin, interview) 
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In contrast, the frequency of psychosocial factors being mentioned in the MDT 
meeting (in 10 per cent of cases) was more of a concern amongst some of the 
interviewees in the Gynaecology team. In this team, a range of professionals 
(including a CNS, an oncology StR, a consultant gynaecologist and a psychologist) 
expressed the view that the meeting no longer gave a sense of the patient as a 
whole. It was argued that this made it more difficult for the team to make decisions 
centred around individual patients, and in the words of one consultant 
gynaecologist, risked the team making poor decisions: 
 
Because they’re not sitting with a patient really really really battling to 
see whether what would be the best treatment in this particular, in this 
particular patient’s context, sometimes decisions are bad actually. 
(Consultant Gynaecologist 5, Gynaecology, interview) 
 
The consultant gynaecologist caveated this with the conclusion that bad decisions 
were relatively rare. It is also important to acknowledge that the MDT meeting was 
not the only forum for discussing patients holistically “I think there’s other places to 
discuss these things as well” (CNS, Skin, interview).  Nonetheless, it again highlights 
the different views about the extent to which this type of information should be 
shared in the MDT meeting. 
 
6.6 Multidisciplinary discussion 
The analysis above suggests that there are certain circumstances in which the input 
of lower status members of the team can be instrumental in the decision making 
process. This was particularly the case when lower status members held 
information about a patient’s treatment preferences or their psychosocial 
circumstances. However, based on the views of both professional members of the 
MDT and some patients, it did not appear that this type of input was essential in 
each and every case. What then, were the circumstances in which the information 
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held by lower status members of the team was incorporated during the decision 
making process?   
 
During MDT meetings there were two overarching scenarios that were likely to 
prompt multidisciplinary discussion that included contributions from lower status 
members of the team. These were cases where patients had limited treatment 
options, and cases where there were concerns about a patient’s ability to cope with 
treatment. These scenarios are discussed below, alongside the views from MDT 
professionals about the extent to which they believed multidisciplinary involvement 
was appropriately encouraged (or not).  
 
6.6.1 Patients with limited treatment options  
There were cases in all teams where multidisciplinary discussion was triggered 
when a patient had limited options for further treatment because of the extent of 
their disease: “it’s pretty grim” (Consultant Haematologist, Haematology 2, 
observation transcript), or because their disease had recurred: 
 
For relapse patients it [multidisciplinary discussion] is quite useful 
because when you get to relapse there is not necessarily one definite 
way of doing it. (Consultant Haematologist, Haematology 1, interview) 
 
Almost by default, if a patient needed to be re-discussed at the MDT meeting 
because they had not responded to treatment or because their disease had 
recurred, the case was likely to be complex:  
 
You know, it’s not like you have a new patient, you treat them, they’re 
gone, it is very much an on-going care package for them and that gets 
more complex as time goes by…the ones who stay, stay because they’re 
complicated. (Consultant Gynaecologist, Gynaecology, interview) 
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In these cases, there was often no “right or a wrong, there isn’t a best way of 
treating them” (Consultant Gynaecologist, Gynaecology, interview). Knowledge of 
the patient and their preferences therefore became increasingly important. It was 
also more likely that at this stage this information was known by a member of the 
team: 
 
There are instances where sometimes there are relapses, so the patient 
is already relatively well known. (Consultant Haematologist, 
Haematology 1, interview) 
 
An example from the observation data illustrates how in these circumstances, the 
contribution of lower status members of the team could be instrumental in 
ensuring that the clinical decision reflected a patient’s circumstances:    
 
Consultant Medical Oncologist: against my better judgement I think 
that if they want to go to [another Trust] for a second opinion I will 
[refer them]  
CNS: I think that’s a good idea…they’ll [his family] take him off 
privately anyway 
Consultant Medical Oncologist: ok so I might as well facilitate it and 
just offer it (Skin, observation transcript) 
 
In this case, the CNS was able to use her knowledge of the patient’s family in order 
to persuade the consultant that referring a patient for a second opinion was indeed 
the best course of action, even if he did not think it would change the end result. In 
another example from Haematology 2, a CNS reminded the team about a patient’s 
previous reaction to a chemotherapy drug. In doing so, she altered the practicalities 
of the way treatment was to be delivered. The MDT Lead explicitly acknowledged 
the value of this contribution, and asked the team to ensure that treatment was not 
initiated on a Friday:  
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Consultant Haematologist 1: I’d propose consideration of an 
autologous stem cell transplant  
CNS: [Consultant Haematologist 1] I think she’s a lady who reacted 
to ritux [chemotherapy treatment] although she didn’t actually get 
admitted 
Consultant Haematologist 1: …that’s a very important point to 
document thank you  
Consultant Haematologist 2: so not on a Friday afternoon but  
Consultant Haematologist 1: not on a Friday and early in the day 
(Haematology 2, observation transcript) 
 
6.6.2 Concerns about a patient’s ability to cope with treatment 
Other factors that made a decision more complex, and more likely to benefit from 
multidisciplinary discussion, included situations where patient factors were likely to 
impact on the team’s ability to deliver treatment. This included elderly or ‘frail’ 
patients, and vulnerable patients. 
 
Elderly or frail patients  
Lower status contributions took on particular importance during discussion of 
patients described as ‘elderly’. In reality, these were often discussions about the 
physical frailty of a patient, because there did not seem to be a specific age at which 
the term elderly was consistently invoked. For example, in Haematology 2, the term 
elderly was ascribed to a 72 year old. In the Haematology 1 team, chemotherapy 
treatment was ruled out for an ‘elderly patient’, aged 87, as it was felt to be too 
much for them to cope with given their physical frailty. However, during the same 
meeting a decision was made to start a 97 year old patient on chemotherapy.  
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Regardless of these differences, the age or frailty of a patient was often a key 
consideration in making a treatment decision: 
 
It may be difficult because maybe the person is older or they have a 
comorbidity...So yes, ideal treatment would be x and I will try to 
facilitate…by saying “do you think they are fit enough for this?” Often 
we see that with the review of patients, so where they have had a 
response to treatment. We try to decide how much more treatment to 
give them. There is often a lot more input there from the nursing staff, 
you know how have they been coping, what do you think or we’ve had 
these problems... (Consultant Haematologist, Haematology 1, interview) 
 
However, it was an area where there could be disagreement between professionals. 
For example, in Haematology 2 a decision was made to follow recommended 
evidence based protocols by requesting a PET scan for an 81 year old patient [this is 
a type of scan used to diagnose and stage cancer]. This decision was challenged by a 
consultant haematologist in the team. He argued that even if the scan highlighted 
disease, they would not treat the patient with further chemotherapy given her age: 
“to spend all this money!” (Consultant Haematologist, Haematology 2, observation 
field note).  However, the patient’s lead consultant responded by saying they were 
following international guidelines “that are not ageist” and refused to back down 
(Haematology 2, observation field note). 
 
In this example, there was no input from other professional groups within the team. 
However, it is in these cases where decisions are not clear cut that there is perhaps 
greatest benefit to be gained from including input from lower status members of 
the team. Where there is a lack of certainty about a patient’s ability to cope with 
treatment, knowledge of the patient in question and their physical wellbeing could 
be instrumental to making an appropriate decision. This is particularly true where 
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an over-reliance on evidence based protocols could run the risk of over-treating or 
over-investigating. As one consultant dermatologist noted: 
  
In this MDT like setting, I think you know protocol driven 
medicine…sometimes it can be quite black and white. So patient has X, 
we need to do Y, whereas actually if you did nothing it would probably 
be fine. And a lot of the cases here I think there is a tendency to over-
treat and over-investigate sometimes. (Consultant Dermatologist, Skin, 
interview) 
 
This view was echoed by a CNS in Haematology 1, who highlighted the need for 
careful consideration to be given in these cases: “I do sometimes worry 
about…where we draw the line” (CNS, Haematology 1, interview). An StR in the 
same team also described the need “to be a bit careful…with what you’re exposing 
elderly and delicate patients to” (Haematology StR, Haematology 1, interview). For 
these reasons, lower status input could be instrumental in the decision making 
process, whether the decision was to deliver intensive treatment or to provide only 
supportive care. This is illustrated in the example below from Skin, where the CNS 
played an instrumental role in shaping the decision for a 97 year old patient: 
 
Consultant Medical Oncologist (MDT Lead): well first of all how fit is 
this lady? 
Surgical StR: she is 97 
CNS: she is 97 
Consultant Medical Oncologist (MDT Lead): well let’s not be let’s not 
be ageist [laughing] 
CNS: that’s pushing it a bit 
Consultant Medical Oncologist (MDT Lead): how fit is she?... 
CNS: she’s 97 she is her age…leave her alone 
(Skin, observation transcript) 
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Subsequent review of this patient’s medical records indicated that the patient had 
indeed been ‘left alone’, and had not undergone the tests and investigations that 
had initially been proposed by the Consultant Medical Oncologist.  
 
Vulnerable patients  
Lower status contributions were also important during discussions where concerns 
had been raised about a patient’s vulnerability. Vulnerability could relate to a 
patient’s ability to cope with news about their prognosis, or to mental health issues 
that impacted on their ability to understand what was happening. Vulnerability was 
also an issue where there were concerns about patients who did not have family or 
carers readily available to support them through treatment. In all of these cases, 
there were examples where the contribution of lower status members was 
instrumental in helping the team to reach a decision. In one example, a consultant 
gynaecologist was visibly affected when the pathologist reported that a very young 
patient, who was described as not doing well psychologically, had metastatic 
disease. When given the news about the patient’s poor prognosis the consultant 
responded by hitting the table and exclaiming, “fuck you are joking” (Consultant 
Gynaecologist, Gynaecology, observation transcript). In this case, contributions 
from both the CNS and the clinical psychologist ensured that the appropriate 
psychosocial support would be in place for the patient at their next clinic 
appointment: 
 
Psychologist: so can I just check when she’ll know [about the spread 
of her disease]  
CNS: she’s coming back on the 4th…will you be around?  
Psychologist: yeh perhaps. She’s your [patient] isn’t she [to 
CNS]?...Are you around on Tuesday [the 4th]? 
CNS1: yeh I think she’ll need it from what I can gather 
Psychologist: yeh I’m happy to be around 
(Gynaecology, observation transcript) 
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Multidisciplinary discussion also occurred in a small number of cases where a 
member of the team wanted to make others aware of a vulnerable patient. During 
one meeting of the Haematology 1 team, a young patient was described by a 
consultant clinical oncologist as being completely and utterly shell-shocked after 
being told he only had three to six months to live. The oncologist reported finding 
the patient staring at the ceiling with his mouth open after being told that they had 
exhausted all chemotherapy options. The CNS, consultant haematologists and the 
oncologist were all actively involved in this discussion, and it served to raise 
awareness amongst the team of the specific psychosocial needs of this patient. 
 
In other cases (specific to the two Haematology teams), lower status contributions 
were also important when there was disagreement or uncertainty about whether a 
patient was able to cope with the treatment involved in a stem cell transplant. Due 
to the very intensive nature of this treatment, discussion often included reference 
to a patient’s social or psychological circumstances. This was particularly the case if 
a patient was deemed to be vulnerable. There were a number of examples where 
CNSs were able to contribute information that was used to help the team reach a 
final decision in these cases. In one discussion in Haematology 2, a consultant 
queried whether a patient with alcohol dependence would be able to comply with 
therapy: “is he able to do that?” (Consultant Haematologist 7, Haematology 2, 
observation transcript). It was the CNS who responded:  
 
He messes around but he understands…I don’t think he drinks that 
excessively when he goes [to the pub from the ward] he does go but. 
(CNS, Haematology 2, observation transcript)  
 
These examples illustrate that in cases where a patient’s vulnerability was a 
concern, lower status contributions could be instrumental in helping the team to 
reach a decision. They were also important in ensuring that patients were provided 
with the support they needed following this. 
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6.7 Chapter Summary 
This chapter began by using status characteristics theory as a framework to explore 
the patterns of participation and influence in the decision making process.  This 
illustrated that medical and surgical consultants were more likely to initiate 
participation, had more opportunities to participate, were evaluated more 
favourably, and had more influence than lower status members of the team. In 
contrast, some lower status groups reported being reluctant to contribute, and in a 
small number of cases their contributions were not taken on board or were ignored 
by higher status members of the team.  
 
Potential explanations for these patterns of participation reflected the legal 
responsibilities of consultant doctors with a duty of care to their patients (Sidhom 
and Poulsen, 2006), as well as their extensive clinical training and expertise. In 
contrast, StRs - as doctors in training - did not necessarily have the knowledge or 
expertise to make clinical decisions in the MDT setting. In addition, for CNSs, if they 
had not met the patient being discussed they were unlikely to hold information that 
they could share with the MDT. These explanations suggested that lower rates of 
participation from lower status groups were not necessarily in and of themselves 
problematic, even if they had the potential to be in certain circumstances. 
 
Building on this analysis, Theme II explored the effects of these patterns of 
participation and influence on efficiency and information sharing, and considered 
the circumstances in which multidisciplinary discussion took place. Reflecting the 
literature on functionalist perspectives of hierarchies, teams appeared to capitalise 
on the expertise of higher status individuals in order to make a considerable 
number of decisions quickly and efficiently. Limiting discussion in this way to a 
subset of higher status members could minimise the amount of time spent on 
discussion that was unlikely to impact on the treatment plan. Using evidence based 
protocols to make these decisions was a way of ensuring consistency and promoting 
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equality of treatment for patients. This freed up time to spend on cases that were 
more challenging or complex.  
 
However, in other cases, it was shown that medical and surgical expertise was not 
the only important source of information for decision making. Team members 
valued the MDT meeting as an opportunity to bring together a diverse range of 
professional groups. Nonetheless, multidisciplinary discussion which included the 
full spectrum of professionals was potentially challenging for MDTs to achieve. This 
was because of the finite period of time in the MDT meeting. This meant that 
opportunities to share certain types of information could impact on the time 
available for other contributions. This was compounded by the fact that there was 
some disagreement amongst MDT professionals about the appropriate balance 
between efficiency and more holistic multidisciplinary discussion in the MDT 
meeting context. 
 
In spite of these different opinions, it was possible to identify a subset of cases 
where the knowledge held by lower status groups was incorporated into the 
decision making process. In all four teams this reflected the nature of the 
relationship between lower status groups and patients. These relationships meant 
that CNSs and StRs were often more likely than other members of the MDT to hold 
patient centred information. Specifically, this included information about patient 
preferences and psychosocial factors.  
 
Information about patient preferences was important because doctors were not 
always aware of patients’ views. Discussing patient preferences during the meeting 
could therefore enable the team to more fully consider the benefits and drawbacks 
of different treatment options. Information about psychosocial factors was 
important because it enabled the team to consider whether the recommended 
treatment was appropriate given a specific patient’s context. It was argued that 
without this information there was a risk that poor decisions would be made.  
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Overall, however, multidisciplinary discussion, which involved lower status groups, 
was not seen to be necessary or desirable for every case. Instead, it occurred in 
certain circumstances.  This included cases where patients had limited treatment 
options as a result of the extent of their disease or the fact that it had recurred. It 
also included cases where there were concerns about a patient’s ability to cope 
with treatment.  This was more likely for patients who were elderly or frail, for 
patients deemed to be vulnerable in some way, as well as for haematology patients 
being considered for a transplant. In these cases the knowledge held by lower 
status members of the team could be instrumental in making sure that the clinical 
decision agreed by the MDT reflected the context of a specific patient’s 
circumstances. Lower status contributions were also a way to counteract the risk of 
over-treating or over-investigating a patient if evidence based protocols were rigidly 
followed.
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Chapter 7. Factors that influence multidisciplinary 
discussion in MDT meetings  
 
This chapter presents the third overarching theme (‘multidisciplinary discussion’) 
from Thematic Analysis I, which was described in Chapter 5. It explores the factors 
that reinforced the effects of the status hierarchy, and therefore limited the 
contributions of lower status members of the team. It also explores the factors 
which moderated the effects of the status hierarchy, and facilitated contributions 
from lower status members of the team. In doing so it addresses research question 
two: what factors facilitate or inhibit multidisciplinary discussion in MDT meetings? 
It considers the three factors identified in the analysis that played a role in all four 
teams in either inhibiting or facilitating contributions from lower status groups. 
These are: the impact of the physical layout of the meetings, the leadership style of 
the MDT Lead, and the way that a case was presented to the team. 
 
In light of the findings from the previous chapter, it is evident that factors that limit 
contributions will not necessarily be problematic. However, understanding the 
processes that facilitate or inhibit multidisciplinary discussion is important if teams 
are to appropriately use the knowledge and information held by members in a time 
pressured environment. This is particularly relevant in cases where lower status 
groups hold unique information. If MDTs are to incorporate this information during 
the decision making process then they must be cognisant of the range of factors 
that can influence multidisciplinary participation.  
 
7.1 Seating arrangements in the MDT meeting 
Although there were some differences in the layout of the meeting rooms between 
teams, all four had the same essential components. These were designed to support 
the decision making process. The MDT meetings were held in slightly darkened 
rooms, either windowless or with closed blinds, to facilitate viewing of imaging. 
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Chairs were ordered in rows, facing forwards towards large screens. These screens 
were used to present radiology images, pathology slides and in some teams an 
electronic proforma for each patient discussed. The lecture style set up prompted 
one CNS to comment: “I suppose it’s like being at school” (CNS, Skin, interview).  
 
In all teams, people generally sat in the same place each week, almost to the point 
where this became a ritual: 
 
When [Consultant Surgeon 1] arrived at the meeting this morning, 
one of the plastic surgery registrars was sitting on the right hand 
side of the room. This prompted [Consultant Surgeon 1] to make a 
joke about how the plastic surgeons always sat on the left hand 
side: ‘it’s the rule!’ The registrar then moved further along the row 
to the left, which made everyone laugh. (Skin, observation field 
note) 
 
In all teams, diagnostic consultants sat at desks at the very front of the room 
surrounded by the specialist equipment needed to display their findings. In 
Haematology 2 and Gynaecology, the MDT Lead sat alongside them, separating 
themselves from the remainder of the group but achieving a direct view of the 
room and other team members. In Skin and Haematology 1 the MDT Lead sat with 
the rest of the team facing the front of the room.  
  
It also became apparent that these seating arrangements were highly symbolic. 
Higher status groups generally sat towards the front of the room and lower status 
groups further back. In Gynaecology and Haematology 2, the front two rows of 
seats facing the screens seemed to have particular significance and medical and 
surgical consultants appeared markedly reluctant to sit further back if the front 
rows were already full: “I’m not sitting at the back!” (Consultant Oncologist, 
Gynaecology, observation transcript). This was also evidenced in specific 
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behaviours, for example a consultant gynaecologist pulling up an additional chair 
from the row behind to sit at the front, even though this made space in the front 
row very tight. The opposite was also true however, with some appearing equally 
reluctant to sit in the front row. During one meeting of Haematology 2 the room 
was completely full, with the exception of two seats in the front row. Although 
these were empty, two StRs had chosen to remain standing at the back of the room.  
 
The interviews highlighted that there were a number of practical reasons for these 
seating arrangements. At the front of the room it was easier to see the radiology 
imaging and pathology slides being presented, and this clinical information was 
more relevant to some members of the team than others. For example, as noted 
previously, consultant gynaecologists often used radiology imaging to visualise the 
surgery they were planning. In addition, it was suggested that some individuals 
wanted to sit at the back, where they could be inconspicuous and “drop off to 
sleep” (Consultant Radiologist, Gynaecology, interview field note). Although this did 
not appear to be the case for most, one of the CNSs in Haematology 2 pointed out 
that there was no need for her to sit right at the front. This was because she only 
needed to pay attention to a small group of patients in her particular sub-specialty.  
 
7.1.1 The importance of being ‘visible’ 
Overall, discussion in all teams was much more likely between individuals sitting at 
the front of the room, with “maybe a bit of infiltration from the back” (CNS, 
Gynaecology, interview). As a result, the seating arrangement of the MDT could at 
times inhibit contributions from certain professional groups. In part, this was 
because those sitting towards the back of the room were not directly visible to 
those in the front rows. This could exclude them from discussion:  
 
If you’re the last one in and you’re sat right at the back…you really don’t 
feel that you’re a part of the discussion. So I think it does have an effect. 
(CNS, Gynaecology, interview) 
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This was accentuated by the fact that in all teams it could be difficult at times to 
hear everything that was being said, particularly because some members of the 
team spoke very quietly, and the rooms were large: 
 
You can’t hear what people are saying in the front two rows sometimes 
because they talk quite quietly and they’re talking forward and you’re 
sort of excluded a bit straight away. (CNS, Haematology 2, interview) 
 
Although these views were articulated by lower status members, they were 
acknowledged by higher status members too. One consultant gynaecologist 
described the impact of the physical environment on the ability of the team to 
engage all its members: 
 
If you just bang on, you’re whispering to each other about this and that 
and the other and [consultant oncologist] says ‘well if it’s 3A let’s do 
protocol B5’ and then somebody else mumbles, you think okay well 
that’s showbiz. But I mean, we haven’t really used the MDT to kind of 
open up to a discussion. (Consultant Gynaecologist, Gynaecology, 
interview) 
 
The impact of seating arrangements on contributions was most pronounced in the 
two largest teams, Haematology 2 and Gynaecology, where the room was often full. 
Competition for physical space and the opportunity to contribute during the 
meeting was therefore more apparent. In both these teams it was relatively 
common for other professionals who were not formal members of the team to 
attend the weekly meeting. This largely happened on an ad hoc basis, for example 
to give or seek advice about a specific patient, or to agree on treatment across 
specialty boundaries. As a result, in Haematology 2 and in Gynaecology, attendance 
at meetings could be very high (with up to 40 people present), and it was difficult at 
times to know who everyone was:  
Findings II: Multidisciplinary discussion 
164 
 
 
I don’t know, some people speak up I don’t know who they are 
sometimes. I am not sure if they are registrars or specialist nurses 
sometimes or technicians. (Imaging Consultant, Haematology 2, 
interview)  
 
It was also relatively common for medical students, visiting academics or other 
interested parties to attend meetings in Haematology 2 and Gynaecology as 
observers without participating in the discussion. This further accentuated 
inequalities in participation, because while there was wide input from a core group 
of members, around a third to half of those in the room in these two teams did not 
contribute to discussion at all, or did so only very occasionally. This was in marked 
contrast to the smaller Haematology 1 team, and the Skin cancer team, where 
although there was not necessarily equal participation, most individuals contributed 
to discussion in some way or another most weeks. 
 
7.1.2 Attempts to change or challenge seating arrangements 
In both of the larger teams (Haematology 2 and Gynaecology), some time prior to 
the observation, there had been attempts to change the layout of the meeting in 
order to make it more inclusive: 
 
We did use to try sitting in a circle for our clinical MDT and nobody really 
liked that very much either, to try and encourage different people to 
contribute [laughs] for about two weeks. (CNS, Haematology 2, 
interview) 
 
However, as the quote implies this approach was not seen to be very successful. 
The Gynaecology team had also encountered practical difficulties in changing the 
meeting layout, partly because it meant moving the chairs at the start and the end 
of the meeting, and because of the need to display the imaging and pathology 
material. The size of the team was also cited as a factor: 
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I mean if you had smaller numbers and I’m not saying that we should be 
booting people out but you can kind of see how a circle or some kind of 
round discussion would be more effective. (CNS, Gynaecology, interview) 
 
Despite facing similar issues, and previously having tried the same solution, during 
the observation period there were differences between these two teams in how 
professionals responded to the lecture style seating arrangements. In Haematology 
2, there were no examples of lower status members challenging the established 
seating arrangements, and this was reflected in the view of one CNS: 
 
We all buy into it; we [the CNSs] all go and sit at the back and they [the 
consultants] go and sit at the front. And we don’t have to do it like that; 
we could mix it up a bit. (CNS, Haematology 2, interview)  
 
In contrast, the Lead CNS in Gynaecology often emulated the behaviour of the 
consultant gynaecologists and oncologists, and encouraged the other CNSs to do 
the same: 
 
I think we need to be sitting at the front to be visible and to have a 
presence and if you have to put yourself on the front row in between two 
clinicians to be part of the discussion well then that’s what we have to 
do…we always sit on the first or second row. No further back! [laughs] 
Or grab a chair and pull them forward. (CNS, Gynaecology, interview) 
 
Although these different approaches may to a certain extent reflect individual styles 
or personality traits, there were also differences in the structural arrangements of 
the CNS teams. In the Gynaecology team, the three Clinical Nurse Specialists 
worked closely with a psychologist. The interview data suggested that there was a 
conscious effort within this team to actively work together as a ‘psychosocial’ group 
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and to develop specific strategies to make sure they were able to participate during 
the meeting and to get their contributions heard: 
 
The idea was that we would have an hour at the beginning of the 
meeting where it would be pure…psychosocial, then we’d come together 
for our discussions [in the MDT meeting]...So the idea was that the 
nurses would sit on the front row, they wouldn’t sit at the back, get 
there on time, sit on the front row. (Psychologist, Gynaecology, 
interview) 
 
As illustrated in the quote above, the underpinning support of the psychologist 
appeared to be important in encouraging the CNSs to work together in a 
coordinated way: 
 
What I see my job is trying to get the, to get the psychosocial staff to 
translate their work into a way that is heard. (Psychologist, 
Gynaecology, interview) 
 
Having this additional source of support and leadership appeared to play a role in 
encouraging the CNSs in this team to challenge the seating arrangements. In 
contrast, there was no mention of an equivalent grouping of psychosocial staff in 
Haematology 2. In this team a psychologist did not attend the MDT meeting, and 
each CNS represented a different sub-specialty, responsible for specific groups of 
patients. There was therefore a less noticeable sense of a ‘team within a team’ 
within the Haematology 2 MDT meeting.  
 
In contrast to these teams, the seating arrangements in Haematology 1 and Skin 
were less contentious. This may have been as a result of the smaller size of the 
teams, because it meant there was less need to compete for space. The size of the 
rooms used by each of the teams were roughly similar, so in the smaller teams 
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there were often a number of empty seats, both at the front and the back of the 
room. This meant that lower status members of the team did not appear to 
‘displace’ higher status members of the team if they sat near the front of the room. 
For example, in the Skin team the CNS sat in the front row, alongside the MDT Lead. 
This arrangement allowed the CNS to regularly contribute bits of information to the 
MDT Lead (although this was often done quietly, and directly to the MDT Lead 
rather than to the group as a whole). The CNS did not view this as an attempt to 
challenge the status hierarchy and seemed unfazed by the seating arrangements:  
 
We all sit in the same place every time. I don’t think it makes…it’s just 
how it goes. (CNS, Skin, interview) 
 
Nonetheless, regardless of whether or not this was an explicit strategy, by 
emulating the behaviour of higher status members the CNS was able to create 
opportunities to contribute given her close proximity to the MDT Lead.  
  
7.1.3 Summary  
The seating arrangements in MDT meetings generally reflected the patterns of 
participation described in the previous chapter, with higher status members in all 
teams sitting towards the front of the room. There were some practical reasons for 
this. However, the seating arrangements appeared to have a particular impact on 
the contributions of lower status members in the larger teams, where there was 
more competition for space. In this context, when lower status members sat at the 
back of the room it was more difficult for them to contribute, either because they 
were not directly visible to others or because it was difficult for them to hear what 
was being discussed.  
 
Attempts to challenge the established seating arrangements were made by the 
CNSs in the Gynaecology team, who, with the support of a psychologist, used their 
physical placement in the room to increase their visibility. The CNS in Skin also 
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appeared to emulate the behaviour of higher status members of the team by sitting 
in the front row alongside the MDT Lead. This seemed to be important not only 
because it could help to create opportunities to contribute, but also because of the 
symbolic importance of being seen to be part of the ‘discussion’.  
 
7.2 The leadership style of the MDT Lead 
As discussed in my theoretical framework, leadership style can play a key role in 
moderating the effects of hierarchy on a group (Anderson and Brown, 2010). 
Inclusive leadership behaviour can overcome the effects of status hierarchy if 
leaders invite and appreciate contributions from lower status groups (Nembhard 
and Edmondson, 2006). However, those in positions of leadership can also 
exacerbate anxiety about speaking up in healthcare teams by inhibiting open 
discussion (Edmondson, 2003). Subtle body language signals and a lack of 
willingness to listen have both been identified as leadership behaviours that can 
make team members reluctant to contribute (Morrison, 2011).  
 
The previous chapter highlighted the influence of the MDT Lead over the decision 
making process. In this section I will use the observation and interview data in order 
to explore and contrast the different styles and leadership behaviours adopted by 
the MDT Leads in the four teams. The aim is to consider the role of leadership style 
on the participation of different professional groups during MDT discussion.  
 
7.2.1 Efficiency without structure: the Gynaecology MDT meeting 
The meeting atmosphere 
During observation, the decision making process in the Gynaecology MDT could 
appear hectic, with numerous things happening at the same time. This included 
separate conversations happening simultaneously between different groups, or 
people answering their mobile phones during meetings. It was notable that higher 
and lower status members of the team reported very different views from each 
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other when asked to describe the atmosphere, ranging from “nurturing”(Consultant 
Gynaecologist, interview) to “dysfunctional” (Oncology StR, interview). 
 
The role of the MDT Lead 
In the Gynaecology team the MDT Lead was a consultant gynaecologist, and was 
very obviously concerned with efficiency, and ensuring the meeting proceeded at a 
pace that would enable the team to cover the large number of patients that had to 
be discussed each week: 
 
When [MDT Lead, Consultant Gynaecologist] came in [to lead the MDT], 
she wanted efficient [sic].  She wanted to finish on time; get it done. And 
she made it very efficient. (Psychologist, Gynaecology, interview) 
 
During the meeting this style was apparent in the way that the MDT Lead moved 
rapidly between cases, and fitted in additional cases at every opportunity: “let's 
squeeze in a new one here rather than wait” or “next!” (MDT Lead, Consultant 
Gynaecologist, Gynaecology, observation field notes). The result was that the MDT 
meeting was very fast paced, and there were often several different things 
happening at the same time. One consequence of this was that it could be difficult 
to follow the thread of discussion: 
 
Sometimes when we get impassioned, everybody is speaking at once and 
some of the detail is lost in that…I suppose it has to do with chairing. 
(MDT Lead, Consultant Gynaecologist, Gynaecology, interview) 
 
As this quote illustrates, the drive for efficiency in this team was often coupled with 
a lack of structure. For example, the MDT Lead did not always clearly delineate the 
transition between patients, at times moving on to the next case while others 
continued discussing the previous patient. This made it difficult to keep track of 
which patient was being discussed. One implication of this was that it could limit 
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the ability of other members to contribute as they were either ‘too late’ to 
influence the decision that had already been recorded or they missed the beginning 
of the next discussion: 
 
Sometimes I feel that there’s a group of whoever still talking about a 
patient the chair has moved onto the next patient so…you wonder 
whether a decision has been made.  And that can be quite difficult at 
times because you’re trying to listen to two conversations or say so what 
is happening with Mrs X before we go on to Mrs Y. (CNS, Gynaecology, 
interview)  
 
Another consequence of this was that it made it easier for contributions from lower 
status members of the team to be ignored or marginalised from the discussion. This 
was recognised by both higher and lower status members of the team: 
 
The people who are at the meeting are generally very happy to discuss 
things and get involved in discussions but there are sometimes junior 
people who know the patient well, or the psychosocial members of the 
team who will know the patient very well and they don’t often get the 
opportunity to talk because it’s seen to be sort of leading off the point 
and not necessarily being a treatment decision, it’s a bit more touchy 
feely, sort of thing and the MDT is not so open to that, mainly because of 
time. (Consultant Gynaecologist, Gynaecology, interview) 
 
From a CNS perspective, this led to a feeling that their contributions were not 
valued by other members of the team: 
 
I think sometimes you feel that the discussion tends to move on when 
you’re still trying to get a point of view across.  So you, the importance of 
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what you’re trying to say is lost.  And there sometimes seems a, a 
disinterest in what you’re trying to say. (CNS, Gynaecology, interview) 
 
Overall then, the MDT Lead’s approach to chairing, which emphasised efficiency, 
coupled with a lack of structure, often appeared to accentuate the effects of the 
status hierarchy in this team. This in turn led to a sense of disengagement amongst 
some lower status members of the team:  
 
[CNS] said very clearly to me quite often: ‘what am I doing with two and 
a half hours sitting in there, to say two sentences which then aren’t 
listened to’? (Psychologist, Gynaecology, interview) 
 
This was compounded by the fact that in this team the MDT Lead was not only 
responsible for chairing the discussions each week, but also for recording the 
discussion and subsequent decision made for each patient. The Gynaecology team 
was the only team of the four I observed where the documentation of decisions was 
undertaken by the MDT Lead and not delegated to another member of the team. 
The rationale for this was to ensure the accuracy of the information recorded, 
particularly when pathology or radiology results had to be summarised in a brief 
way: “if you have a non-medic doing it, they quite often get it wrong” (Psychologist, 
Gynaecology, interview). However, it was also noted that this could result in a 
“trade-off between documentation and real discussion” (Psychologist, Gynaecology, 
interview). This view highlighted the tension between the chairing role, which could 
potentially encourage multidisciplinary discussion by facilitating contributions, and 
the documenting role, which focused on capturing and recording information.  
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7.2.2 Efficiency with structure: the Haematology 2 MDT meeting 
The meeting atmosphere 
During observation, the decision making process in the Haematology 2 meeting 
appeared to be markedly professional and purposeful. In part this reflected that fact 
that unlike the other MDTs I observed, nearly all meetings started on time or within 
a minute or two of the agreed start time. They also only ran over the allotted time 
on a handful of occasions. During case discussions, members took turns to speak 
(unlike in Skin and Gynaecology where there was often more than one discussion 
happening at the same time), and left the room to answer their mobile phones. 
However, there were occasional glimpses of humour. Members of this team 
described the meeting atmosphere as “lively” (StR, interview), “competitive” 
(Consultant Haematologist, interview) and “professional” (CNS, interview). 
 
The role of the MDT Lead 
The MDT Lead for Haematology 2, a consultant haematologist, also prioritised 
efficiency when chairing the MDT meeting. This was demonstrated by a clear 
commitment to start and end the meetings on time. However, the obvious drive to 
run the meeting efficiently did not manifest itself in the behaviours described in the 
Gynaecology team. Instead, efficiency was combined with a very structured 
approach, where cases were clearly introduced and decisions and key points of the 
discussion were often summarised before the team moved on to the next case. In 
addition, the mood in the meeting tended to be very focused. Although 
immediately prior to the meeting there would be lively conversation, as soon as the 
MDT Lead indicated that the meeting was to start, there was generally only a single 
discussion at any one time.  
 
In this way, the chairing style of the MDT Lead avoided some of the issues described 
above, and cases were generally clearly presented, with little or no overlapping talk 
and contributions were very rarely ignored. However, the emphasis on efficiency 
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was still very apparent, for example when the MDT Lead explicitly curtailed a 
discussion: 
 
Consultant Haematologist (MDT Lead): I wanted to record [patient] 
as a new follicular lymphoma going on rituximab maintenance but I 
don’t think we need to discuss that patient. (Haematology 2, 
observation transcript) 
 
As has been noted previously, in some instances it was argued that there was little 
need to discuss all cases in depth in the MDT meeting. In the example above, the 
MDT Lead curtailed discussion of a patient who was already scheduled to begin 
treatment. In this case, it is arguable that a further discussion in the MDT meeting 
would have been academic. Furthermore, in contrast to this, in other cases, the 
MDT Lead did make explicit requests for comments or disagreements. He also 
frequently checked if the rest of the team were content with the MDT’s proposed 
treatment plan before moving on to the next case. This was achieved by the use of 
question, such as: “is there anyone unhappy with the management plan?” or 
“Would anyone else like to record anything on the management plan for [patient]?” 
(MDT Lead, Consultant Haematologist, Haematology 2, observation field notes). 
This participative style was welcomed by two other consultants in the team during 
interviews, and was attributed with enabling a good balance to be achieved 
between efficiency and engaging the rest of the team.  
 
However, in addition to these positive views about the MDT Lead’s chairing style, it 
was apparent from the observation data that discussions in this meeting often had 
clear boundaries and focused on urgent medical or clinical issues. Phrases such as 
“is there a pressing clinical need to do that [discuss a patient]?” could therefore 
undermine the contributions from lower status groups with different types of 
information to share. As one CNS remarked: 
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You’re not invited to contribute and the pressure on time is such that 
sometimes you just think it’s not worth it because somebody’s going to 
say, “oh, they need a transplant or they’re dead.” (CNS, Haematology 2, 
interview) 
 
Verbal signals encouraging contributions were therefore not necessarily interpreted 
by all members of the team in the same way. This was particularly the case for 
those with psychosocial information to contribute:  
 
The meeting is…it’s medical…there are different disciplines of medicine 
who contribute but I don’t think it’s multi-professional…there isn’t much 
nursing input invited…we give it on the rare occasions that we may think 
it’s strongly required.  But I think…I would find it more satisfying if, when 
they’re known or when they’re relevant, the more social or the other bits 
of what that treatment would mean to a patient are included in the 
discussion.  I know times a factor but it’s very medical centric the 
meeting. (CNS, Haematology 2, interview) 
 
On one level therefore the MDT Lead was able to foster an environment which 
encouraged medical and diagnostic professionals to participate by using verbal cues 
and providing a clear structure to the meeting. However, the focus on medical 
issues and repeated reminders about efficiency had the potential to create a 
perception that there was a lack of willingness to incorporate certain contributions, 
notably psychosocial contributions, which were more likely to be made by CNSs. 
 
7.2.3 Structure without efficiency: the Haematology 1 MDT meeting 
The meeting atmosphere 
Based on the observation data, decision making happened in a relaxed and friendly 
atmosphere in Haematology 1, and members appeared to get on well with each 
other. Immediately before and after the meeting I often overheard conversations 
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about family, hobbies, holidays and so on. The sense of an open and cohesive team 
was echoed by the participants I interviewed, although one senior consultant 
haematologist described a sense of “us and them” between the consultants who 
made most of the decisions and the rest of the team. 
 
The role of the MDT Lead 
As in Haematology 2, in Haematology 1, the MDT Lead was a consultant 
haematologist who also brought a degree of structure to the meeting. Discussion 
followed the order of the patient list agreed in advance, and members of the team 
largely waited their turn to speak. As a result, there were very rarely separate and 
overlapping conversations – the focus during the meeting was on the patient being 
discussed at that point. Some members would on occasion quietly answer their 
mobile phones during the meeting, but this was done discretely and caused minimal 
disruption.  
 
In this team, the MDT Lead actively sought contributions from the rest of the team, 
demonstrating an inclusive style of chairing: “I said I'd bring it to see what everyone 
else thought” (MDT Lead, Consultant Haematologist, Haematology 1, observation 
field notes). In addition, he frequently provided openings for alternative viewpoints: 
“should we do that, [does] everybody agree?” (MDT Lead, Consultant 
Haematologist, Haematology 1, observation field notes). As a result, most members 
made a contribution during the meetings, even if only briefly. This was particularly 
noticeable in this team compared with the others because there were fewer 
members to contribute overall.  
 
In addition, the participative style of leadership created a sense that members of 
the team were receptive to the contributions of others. In contrast to the 
Haematology 2 and Gynaecology teams, this view was also shared specifically by a 
CNS during interview: “I think everybody is prepared to listen to everybody’s point of 
view” (CNS, Haematology 1, interview). In part, this seemed to reflect the MDT 
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Lead’s willingness to spend time on each case, and specifically the openness 
amongst the consultant haematologists to considering and including the CNSs and 
StRs during the meeting. This was a view the MDT Lead expressed during interview, 
but it was also apparent during the observation. As the example below illustrates, 
this was manifest in subtle behaviours, which provided direct openings for lower 
status members of the team to contribute. This included higher status members of 
the team directly referring to lower status members of the team either by name, or 
through the use of body language. For example, during discussion of a patient with 
a renal and haematological cancer, the MDT Lead engaged the CNS by turning to 
her and asking if she remembered another patient with a similar diagnosis. In this 
way, the MDT Lead used a more targeted approach to soliciting contributions, using 
both verbal and non-verbal cues to do so.  
 
In addition, a willingness to listen was also suggested by the time that was allowed 
for considering issues that were rarely discussed at length in Haematology 2 
meetings. In the case illustrated below, the Haematology 1 team spent a 
considerable period of time discussing the practicalities of the clinic appointment, 
to ensure that the patient in question had the appropriate support in place to give 
informed consent. It was very rare to hear this kind of discussion in Haematology 2 
(although it may have occurred outside of the meeting): 
 
Consultant Haematologist 4:  [Consultant Haematologist 3] do we 
need to see him with his family [StR] was saying… 
Consultant Haematologist 3:  I think it would be sensible to get a 
relative up because I’m not convinced that he entirely follows he 
says yes to lots of things and he really doesn’t seem to completely 
comprehend…so potentially I could go and see him on Thursday 
Consultant Haematologist 1:  yeh we could leave it at that if it’s all 
planned that his family are coming with him on that date 
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Consultant Haematologist 3: I didn’t know if they were but if they 
are 
StR: yeh they are 
Consultant Haematologist 1:  and then we’ll schedule for next 
Tuesday [CNS]? Just a CHOP [chemotherapy]  
Consultant Haematologist 3:  remind me [StR] and I’ll try and just 
pop down and see him next, on Thursday then 
StR: yeh he’s on the list so I’ll remind you yep 
(Haematology 1, observation transcript) 
 
Overall then, this style of participative leadership appeared to create an 
environment in which contributions from all professional groups were welcomed 
and valued. However, there were some drawbacks to this more open approach. At 
times the meeting could appear to be slow and inefficient. The MDT Lead rarely 
curtailed discussion even when it appeared to lose focus, or when discussion went 
“round in circles” (CNS, Haematology 1, interview). Long pauses and silences often 
created a sense of delay and a considerable amount of time was spent during the 
meeting searching for the information needed to make a decision. A number of the 
team mentioned during interviews that the meeting could be better organised, and 
argued that it was the MDT Lead’s role to move discussion on more quickly. Even 
the MDT Lead himself acknowledged that there was scope to run the meeting more 
efficiently: 
 
I think some of the very simple things could be hammered out quicker. 
On our busy days you can, it depends on who is presenting. Somebody 
has seen the patient and there is too much information for what is a very 
simple problem. And you could just say “this is the diagnosis, early stage 
CLL, watch and wait” and everybody says “absolutely fine” and you don’t 
need to know how they presented and what their comorbidities are 
because it is all irrelevant. (MDT Lead, Consultant Haematologist, 
Haematology 1, interview) 
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In addition, the inclusive approach adopted by the MDT Lead during the meeting 
was not always in itself sufficient to encourage lower status members of the team 
to contribute to discussion. Even in this team, the MDT Lead argued that there was 
scope for greater CNS involvement (although this view was not expressed by the 
CNS interviewed in this team): 
 
Sometimes there’s less input - the nursing input, whether they think 
patients are able to cope with the treatment. (Consultant 
Haematologist, MDT Lead, Haematology 1, interview) 
 
Although the emphasis on efficiency in the Haematology 2 and Gynaecology teams 
appeared at times to inhibit lower status contributions, analysis of the MDT Lead’s 
approach to chairing the Haematology 1 meetings suggests that there are also some 
benefits to keeping the meeting focused and purposeful. In addition, it has 
indicated that a willingness from the MDT Lead to incorporate the views of lower 
status members of the team is not necessarily in itself sufficient to ensure 
multidisciplinary discussion.  
 
7.2.4 Diffuse leadership: the Skin MDT meeting 
The meeting atmosphere 
Based on the observation data the Skin MDT meeting appeared to have a relaxed 
and friendly atmosphere. In part, this was because meetings regularly started late, 
and attendees tended to appear at different times throughout the meeting, with 
others leaving early. This reflected the view of the MDT Lead that people should not 
have to sit in on parts of the meeting that were not relevant to them.  
 
The observation data also demonstrated that there were good relationships 
between members of the team across the different specialities, and there was often 
a lot of humour during the meeting. It was notable that this was the only team 
where all the key words used by interviewees to describe the atmosphere in MDT 
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meetings had positive connotations, including “respectful” (CNS, interview), 
“friendly” (Consultant Medical Oncologist, interview), and “cordial” (Consultant 
Dermatologist, interview). 
 
The role of the MDT Lead 
The Skin MDT meetings were not easily categorised by assessments of ‘structure’ or 
‘efficiency’. In part, this was because there were distinct parts to the meeting and 
the style of leadership varied between these. While the MDT Lead, a consultant 
oncologist, was evidently in control during the discussion of patients with a 
diagnosis of melanoma, he visibly stepped back during the second half of the 
meeting when the team discussed squamous cell carcinoma and basal cell 
carcinoma cases. Although there was no dedicated chair during this period, in 
practice the position was often filled by one of the consultant dermatopathologist 
or pathologists, who each brought their own approach. This more informal 
arrangement meant that at times there was little central control over the meeting.  
 
As a result it was common for subgroups to form, and for these subgroups to be 
engaged in separate conversations while a patient was being discussed. In some 
cases a decision was made between two or three individuals rather than by the 
group as a whole. However, overall there tended to be a wide range of 
participation, and in general, all specialties contributed at one point or another 
during the meeting. This reflected the perception of the MDT Lead, who described 
decision making in the MDT meeting as a democratic process, which incorporated 
the views and opinions of different members of the team:  
 
The game plan that we come out with is one that generally speaking I 
think reflects what the opinions in the room are. (MDT Lead, Consultant 
Medical Oncologist, Skin, interview) 
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This view was also supported by the CNS, who acknowledged that while there were 
individuals who had a more influential role, there was scope for other members of 
the team to contribute as well: 
 
CNS: People seem to listen to each other. And I think it’s a fairly fair 
discussion. I think patients who are discussed there get a good hearing. 
Interviewer: ok, and does everyone get involved? 
CNS:  most people do….I suppose it depends who you’re discussing, no, I 
would say most people feel pretty comfortable at adding their… I mean 
it’s certainly dominated by certain people, [Consultant Medical 
Oncologist], [Consultant Plastic Surgeon], and [Consultant 
Dermatologist] I would say are the major people. But you know [they] 
probably carry out most of the major work as well to be honest. (CNS, 
Skin, interview) 
 
It was notable that the perception that there was a willingness within the team to 
listen to the views of others was echoed by CNSs in both Skin and Haematology 1, 
although not in Gynaecology or Haematology 2. As in Haematology 1, the MDT Lead 
in Skin adopted a number of specific behaviours that appeared to create an 
impression of willingness to listen. First, his physical positioning signalled a desire 
for engagement. Although he sat in the front row, he was very dynamic, swivelling 
round during discussions and maintaining eye contact with those behind him as well 
as the diagnostic consultants who sat at the front of the room. He verbalised his 
desire for an inclusive forum which incorporated the views of the whole team 
during interview: 
 
I think the things that work well for the Skin MDM in particular are that I 
think it’s quite a friendly meeting. So there’s a good, open atmosphere. 
So people can feel free to express their views. I think there’s good, how 
shall I put it, involvement by all parties so people do feel free to give 
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their opinions, ask questions. And I think that’s important. (MDT Lead, 
Consultant Medical Oncologist, Skin, interview) 
 
This more open approach to decision making was emphasised by the fact that in 
this team responsibility for recording the decision for each patient was devolved to 
the individual who had presented the case: 
 
Everyone has a responsibility to present their patient and the 
responsibility for taking down or for following up the management 
decisions. (Consultant Dermatologist, Skin, interview) 
 
A commitment to open decision making was also apparent in the MDT Lead’s 
approach to questioning, and he often explicitly sought consensus or alternative 
perspectives from other members of the team using phrases such as: “are you 
happy?”, “do you want me to…”, “alright is that agreed?” or “is that ok?” (MDT 
Lead, Consultant Medical Oncologist, Skin, observation field notes). While some of 
these behaviours were also evident in Haematology 2, a key difference was that in 
Skin, there were also specific prompts provided for the CNS in particular to 
contribute, either with verbal or non-verbal cues: 
 
Consultant Medical Oncologist (MDT Lead): [Patient] is a chap who 
we are tee-ing up for the Avast trial so this is a staging CT scan head 
chest abdo pelvis, past history of melanoma. Where was his 
primary? [physically turning to CNS] 
CNS: it was on his leg 
Consultant Medical Oncologist (MDT Lead): yeh on the leg 
CNS: he had a groin clearance and positive nodes 
(Skin, observation transcript) 
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As this example illustrates, contributions from the CNS were not restricted to 
psychosocial information, but also incorporated general information about a 
patient’s disease, or the treatment they had received to date. When prompted by 
the MDT Lead, the in-depth knowledge spanning both clinical and patient centred 
information held by the CNS enabled her to participate in discussion even where 
the focus was on clinical issues.  
 
The leadership style adopted by the MDT Lead could therefore be seen to create a 
sense of respect for the information provided by the CNS. These contributions were 
also followed up by the MDT Lead on a number of occasions with explicit 
agreement or support, adding to the impression that they were valued:  
 
CNS: I think they need a discussion at least about radiotherapy first 
because that’s what they are focused on at the moment  
Consultant Medical Oncologist (MDT Lead): ok so do that first ok 
(Skin, observation transcript) 
 
This tended only to happen for the melanoma cases however, and not for the large 
number of squamous cell carcinoma and basal cell carcinoma cancer cases 
discussed by this team in the second half of the meeting. As noted previously, the 
approach to these cases was different and often emphasised the diagnostic aspect 
of decision making, with limited input from lower status members of the team. This 
reflected the lower risk of these cancer cases, in comparison with melanoma cases: 
 
I mean some of them [basal cell carcinomas] are horrendous, but it’s 
rare…in the world of cancer they’re not massively, I mean it’s important 
that they are treated, but there are very few that are actually serious. 
(CNS, Skin, interview) 
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This meant that during the second half of the meeting when these cases were 
presented there was much less discussion, and there was more emphasis on 
efficiency: “come on, let’s crack on”, “come on!” and “ok, whatever” (Consultant 
Dermatopathologist, Skin, observation field note). In this context there was little 
time spent discussing how or why a specific decision had been made. This may have 
been a clinically appropriate and efficient approach to decision making for lower 
risk cases. However, what is interesting is the contrast between discussion of these 
cases and melanoma cases, which illustrates the importance of leadership 
behaviour on contributions from lower status members of the team. In Skin, this 
was particularly the case for the Plastic Surgery StRs, who were not necessarily 
familiar with the protocols used by the MDT, and had less experience of the 
decision making process: 
 
I think it’s quite tricky for the plastics registrars if they haven’t got 
consultant guidance. Because especially for the likes of me, who you 
know, attends 90% or whatever of the meetings. I’ve heard the 
discussion so many times I sort of know what they are going to say. 
(CNS, Skin, interview) 
 
One StR described how difficult it was to follow what was happening in the meeting, 
particularly when he was not familiar with the patient he was required to present. 
When decisions were made rapidly, without an explanation of the protocols or the 
rationale behind them, some of the StRs in the team visibly struggled to keep up 
with proceedings. This contrast is interesting because it highlights that it is possible 
to adopt a different approach - and encourage more or less participation amongst 
lower status groups - within the same meeting.  
 
7.2.5 Summary 
The importance of leadership behaviour as a moderating factor on the effects of 
status hierarchies was highlighted in my theoretical framework. The analysis above 
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builds on this by demonstrating the range of different leadership behaviours 
evident in the four teams I observed and considering their role in terms of 
multidisciplinary discussion.  
 
In the Gynaecology team where an average of 35 patients were discussed over a 
period of over two hours, the MDT Lead emphasised the importance of efficiency. 
However, when combined with a lack of structure in the meeting this meant that 
lower status groups could at times feel marginalised from discussion.  
 
In Haematology 2, although there were far fewer patients to discuss (and a 
correspondingly shorter meeting), the MDT Lead also prioritised efficiency in the 
meeting. Although a clear structure and focus during discussions meant that 
individuals were not ignored during the meeting, the priority given to clinical (as 
opposed to patient centred) information meant that verbal cues from the MDT Lead 
were not necessarily interpreted in the same way by different members of the 
team. The meeting was described by a CNS in this team as a clinical meeting, which 
provided little opportunity for nursing input. This suggests that a seemingly 
inclusive behaviour, in this case, general requests for contributions from the MDT 
Lead, was not necessarily sufficient on its own to encourage lower status groups to 
contribute.   
  
In contrast, in Haematology 1 and Skin, the MDT Leads adopted a more inclusive 
style of chairing. Specifically, this included directly referring to lower status 
members using both verbal and non-verbal cues as a way of soliciting contributions. 
However, in Haematology 1 when the MDT Lead did not curtail discussion even 
when it appeared to lose focus, or when time spent searching for information 
resulted in silences or pauses during the meeting, this led to perceptions of 
inefficiency. It is important to note that although the average number of patients 
discussed and the average length of meetings in Haematology 1 and 2 were similar, 
these average figures mask variation in individual discussions and between 
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meetings. This is reflected in the fact that the range of patients discussed by 
Haematology 1 was narrower than in Haematology 2, but the range of meeting 
duration was wider.  
 
The style of leadership displayed by the MDT Lead in Skin highlighted that it was 
possible to adopt different leadership styles within the same meeting. In Skin, the 
team discussed an average of 47 patients over a period of around an hour and a 
half. This meant prioritising efficiency at some points but facilitating contributions 
from lower status groups at others. However, a key difference between the Skin 
team and the others was the obvious clinical differences within the case mix, 
between melanoma cases and squamous cell carcinoma and basal cell carcinoma 
cases. This enabled a much clearer distinction to be made between the different 
disease types and subsequent time spent on discussion. 
 
7.3 Initial case presentations 
Building on this analysis it is useful to return to the different types of discussion in 
MDT meetings that were outlined in the previous chapter. As noted, there were 
cases where an extended multidisciplinary discussion was not felt to be necessary 
because it would not alter a decision. In these instances, behaviours that 
accentuated the effects of the status hierarchy could be seen as a way of using time 
in the MDT meeting more efficiently. However, on other occasions it was important 
for teams to moderate the effects of the status hierarchy in order to incorporate 
both higher and lower status contributions. One of the clearest ways in which 
members signalled a distinction between these different types of cases was through 
the initial case presentation.  
 
As mentioned in the previous chapter, the initial case presentation was the point at 
which a verbal summary of the patient to be discussed was presented to the rest of 
the team. It was one aspect of the meeting that was relatively open to all 
professional groups, higher and lower status. However, an initial case presentation 
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could either open up discussion, or it could serve as a means to close down or limit 
discussion to consultant medical, surgical and diagnostic professionals: 
 
I mean, you can talk can’t you and obviously encourage discussion by 
how you present the case, or you can talk and obviously discourage 
discussion…that’s quite important because you know people do respond 
to these things. (Consultant Gynaecologist, Gynaecology, interview) 
 
Although the presentation of clinical cases is a skill taught from an early stage of 
medical education (Olaitan et al., 2016), the way patients were presented in the 
MDT meeting varied between teams. It also varied within teams, depending on the 
individual presenting and the issue for discussion. Three categories were identified 
in the analysis:  
 
1) cases where there was no formal presentation  
2) case presentations where the emphasis was clearly on the clinical features 
of the disease or treatment, and  
3) case presentations which adopted a holistic perspective that incorporated 
information about both the patient as a person and their disease.  
 
To give an indication of the frequency of these different types of presentation, 
Table 15 provides a summary of presentation type based on the transcript of a 
single full meeting from each of the four teams. The analysis presented in the text 
below the table draws on these data, as well as data from the field notes of all 122 
MDT meetings observed, and the professional interviews.  
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Table 15: Frequency of case presentation type  
 Number of 
presentations 
No formal case 
presentation 
Clinically 
focused case 
presentation 
Holistically 
focused case 
presentation 
Gynae 31 7 (23%) 22 (71%) 2 (6%) 
Haem 1 13 2 (15%) 10 (77%) 1 (8%) 
Haem 2 11 1 (9%) 8 (73%) 2 (18%) 
Skin 39 9 (23%) 25 (64%) 5 (13%) 
 
7.3.1 No formal case presentation 
During the observation period, in a small proportion of cases in each team, patients 
were raised for discussion in the meeting without any sort of formal case 
presentation. This was more likely to happen in the Skin and Gynaecology teams 
than in either of the Haematology teams. Where there was no formal case 
presentation, this was often because a patient had previously been discussed by the 
team, or because no active treatment was required (or treatment had already been 
initiated). In the Skin cancer team for example, basal cell carcinoma cases were not 
always preceded by a formal case presentation, particularly when this involved the 
routine reporting of a complete excision (the removal of skin tissue with a margin 
that is clear of disease):  
 
Consultant Dermatopathologist: This was a curette defined excision 
she also had a fibro-epithelial polyp shaved off 
Consultant Dermatologist: this is the right nasal labial fold 
Consultant Dermatopathologist: …it says here right cheek 
Consultant Dermatologist: ok…any tumour in it? 
Consultant Dermatopathologist: no 
Consultant Dermatologist: ok so likely complete…there was no 
tumour in that 
Consultant Dermatopathologist: correct 
[the team move on to the next patient]  
(Skin, observation transcript) 
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As illustrated in this example, the patient’s name was not verbalised, although the 
dermatologist described the procedure undertaken. Following this it was 
established very quickly that there was no tumour in the specimen and the team 
immediately moved on to the next patient.  
 
In cases such as these the treatment protocol was for patients to be routinely 
followed up as a matter of course: they did not need further surgical treatment if 
the lesion had been successfully removed. In addition, as noted above, basal cell 
carcinoma cases were usually less serious than melanoma cancers, and were 
therefore dealt with much more quickly during the MDT meeting. 
 
In both Haematology teams the two full observation transcripts and field notes 
from all meetings indicated that the absence of a formal case presentation was the 
exception rather than the norm. For example in one case in Haematology 1, there 
was no initial presentation given as the team realised immediately that the scan due 
to be reviewed was not ready. Although a brief discussion subsequently took place 
about whether or not the patient in question should proceed with her scheduled 
chemotherapy, the formal presentation of the case and review of the scan was 
deferred until the following week.   
 
There were some exceptions to this in the Gynaecology team however. In this team 
the lack of a proper case presentation was specifically cited as a barrier to 
participation during the interviews, particularly in cases where other members of 
the team did not know the patient being discussed. In these cases, the lack of a 
presentation was seen to be problematic because it was then very difficult for other 
members of the team to contribute to the decision making process in a meaningful 
way: 
 
Findings II: Multidisciplinary discussion 
189 
 
 
The biggest problem from my point of view is that I often don’t know all 
of the patients…[and] unless you know the background to the case well 
it’s very difficult to disagree. (Oncology StR, Gynaecology, interview) 
 
This impacted on multidisciplinary discussion more generally, and was not limited 
solely to lower status professionals. However, as one consultant gynaecologist 
noted, if the team genuinely wanted to gather opinions from the full range of 
professionals in the team, it was essential to make an effort to include everyone, 
starting with a clear presentation of each case: 
 
They’re [consultant gynaecologists] not mindful of the fact that many 
people don’t know the patient at all, that if you want people to be 
involved you have to make an effort to involve them. (Consultant 
Gynaecologist, Gynaecology, interview) 
 
At times, this reflected the practical realities of a specialist MDT receiving referrals 
from other MDTs in the surrounding area. This was because in some cases no one in 
the team had met the patient when they were being discussed: 
 
Consultant Gynaecologist 1: oh this is this lady who oh god she’s got 
something to do with [a doctor at another Trust]…he’s been texting 
me asking me what’s happening I said I’m sure she’s got a plan so 
she’s having her surgery tomorrow so…I don’t know why they were 
all getting anxious about it  
Consultant Gynaecologist 2: a VIP or? 
Consultant Gynaecologist 1: I don’t know I didn’t meet her in 
clinic…I think we should we should meet these new patients, I feel. 
Just so we know what is going on 
Consultant Gynaecologist 2: yeh, absolutely 
(Gynaecology, observation transcript) 
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However, it is worth noting that in the other teams – including the other specialist 
MDTs in Skin and Haematology 2, which received external referrals from 
surrounding MDTs - if a patient was not known to anyone present, discussion was 
usually either deferred, or reference made to the patient’s clinical notes to provide 
some sort of context for a discussion.  
 
In the main then, lack of a case presentation could be seen as an attempt to 
minimise the time spent in the MDT on cases where there was little need for 
extended discussion, for example the routine reporting of pathology results or 
where there was no active treatment required. In the Gynaecology team however, 
there were also occasions where lack of a case presentation was seen as a barrier to 
multidisciplinary discussion because it excluded those who did not know a patient 
from contributing. 
 
7.3.2 Clinically focused case presentations 
It was much more common across all teams for cases to be introduced with a 
summary of the clinical aspects of the disease and the patient’s symptoms: 
 
Consultant Haematologist: this is a man who is 80 who presented 
with a CD5 negative lymphoproliferative disorder with 10-20% 
marrow involvement multiple small volume paraaortic and 
mesenteric adenopathy [swollen lymph nodes] and he had a spleen 
of 22cms he had a low platelet count which was his only cytopenia 
[reduction in number of blood cells] and he was given rituximab 
mono-therapy [chemotherapy] I think 2 years ago in May 2009 
which had little impact actually on the eh it improved it from about 
60 he was going to have an elective procedure to about under 100 
the main issue had been that he had new hepatomegaly [enlarged 
liver] and a scan was organised by the hepatobiliary surgeons. 
(Haematology 2, observation transcript) 
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As illustrated in this particular example, in contrast to the cases where there was no 
formal presentation, a clinically focused case presentation provided clarity about 
the disease and a focus for discussion. Cases presented in this way often clearly 
framed the issue for discussion as medical, surgical or diagnostic: “so this is just 
really reviewing her most recent MRI” (Consultant Medical Oncologist, Gynaecology, 
observation transcript).  
 
This type of case presentation was common for patients newly diagnosed with 
cancer, and who were being presented to the team for the first time or early in their 
treatment pathway. In this context, using the initial case presentation to focus 
discussion on key medical, diagnostic or surgical issues could help the team to 
maximise efficiency by prioritising input from those with the relevant expertise. This 
left little scope for those with patient centred information to contribute. However, 
this was not necessarily always seen to be problematic: 
 
There are some occasions when people bring genuine questions. “What 
should we do?”  “Where should we go next?” “I wondered if”.  But those 
are less common.  And that’s not necessarily a bad thing, I think you 
know, most of our treatment is relatively protocol driven. (Oncology StR, 
Gynaecology, interview) 
 
In the majority of cases presented in this way, therefore, there was little or no input 
from CNSs and StRs. However, although the majority of clinically focused case 
presentations did not lead to contributions from lower status members of the team, 
there were occasions in all teams where they did. There were a number of 
behaviours adopted by higher status members of the team which made this more 
likely. In some cases, a higher status member signalled the challenging nature of a 
case during the initial presentation, using words such as: “unusual” (Consultant 
Gynaecologist, Gynaecology, observation transcript), “complicated” (Consultant 
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Haematologist, Haematology 2, observation transcript), or “strange” (Consultant 
Medical Oncologist, Skin, observation transcript).  
 
This signalling appeared to provide an opening for multidisciplinary discussion, 
including an opportunity for lower status members of the team to contribute. In 
these cases, the information shared tended to relate to a patient’s disease or 
treatment pathway (rather than necessarily patient centred information per se). In 
contributing this type of information, lower status groups were able to act as a 
collective memory or knowledge source for the team. In doing so they could help to 
facilitate the decision making process: 
 
Consultant Gynaecologist: …she’s a little bit unusual we discussed 
her last week…it was all very complicated but she’d been to see 
[another doctor]…she said he said that she was normal so they 
came back here she said and so that’s so I’ve asked for the 
pathology actually to come down because it’s a little bit unusual and 
I think we should look at it here…I think we were hoping to have 
treatment done today 
CNS: she’s had her GFR [a test used to check how well the kidneys 
are working] she saw the oncologist today 
(Gynaecology, observation transcript) 
 
Another way in which higher status members of the team provided openings for 
lower status contributions following a clinically focused case presentation was 
through the use of questioning. Where there was no ‘signal’ in the initial case 
presentation, there were a number of examples of more specific and direct 
attempts to elicit contributions from other members of the team later in the 
discussion: 
 
Consultant Gynaecologist: so why is she an inpatient? 
Findings II: Multidisciplinary discussion 
193 
 
 
StR: so I think she was transferred from [another Trust] because she 
had a lot of ascites so I think they were just working her up  
(Gynaecology, observation transcript) 
 
This happened in all teams, and provided a tangible opening for those who knew 
the patient and were familiar with the treatment they had received, or were 
scheduled to receive. These examples illustrate that even in cases where the focus 
was on clinical aspects of the disease, lower status groups were able to use their 
knowledge to contribute to the discussion. This knowledge was not only restricted 
to psychosocial information. Instead, as a result of regular contact with a patient, 
CNSs and StRs also at times held information about a patient’s disease, symptoms 
and treatment and tests. They were often more familiar with these details than 
some of the consultant members of the team.  
 
7.3.3 Holistically focused case presentations 
On a small number of occasions in all four teams a case was presented to the MDT 
meeting holistically, providing an overview of both the patient and their disease to 
frame any subsequent discussion: 
 
Consultant Gynaecologist: she [is] rather a challenge to manage 
because she is very scared of hospitals and has gone away before 
finishing her test but she’s had a long history of just feeling vaguely 
unwell and then presented with shortness of breath…when I saw 
her in clinic last week she was very symptomatic and just 
uncomfortable in her abdomen it felt like she had large volume 
ascites [accumulation of fluid in the abdomen] so we admitted her 
for symptom control but actually the scans showed that she didn’t 
have a lot of ascites it was mainly omental cake [where the 
membrane lining the abdomen is abnormally thick] and we’ve done 
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the scans and I think we’ve done an omental biopsy as well so if we 
could look at her scans first. 
(Gynaecology, observation transcript)  
 
In this example, the consultant gynaecologist presented information about the 
patient’s psychosocial wellbeing, describing her fear of hospitals before going on to 
outline her current symptoms. It is worth noting that this was still a relatively brief 
presentation, lasting for just under a minute.  
 
Most holistic presentations led to multidisciplinary discussions: in this example, 
both the CNS and the psychologist were actively involved in the subsequent 
discussion. Contributions in these cases tended to be psychosocial in nature, for 
example relating to a patient’s state of mind, their preferences for treatment, or 
possible sources of support for those struggling.  
 
The smaller number of holistic case presentations is in line with the findings from 
the previous chapter, which suggested that full multidisciplinary discussion was not 
necessarily desirable, or feasible, for every patient on the MDT patient list. Instead, 
holistic discussion, which incorporated patient centred information, tended to be 
particularly important where patients had limited treatment options, or in cases 
where there were concerns about a patient’s ability to cope with treatment. The 
smaller number of holistic case presentations could therefore be seen to reflect 
attempts to prioritise certain cases for full multidisciplinary discussion.  
 
In these cases, a holistically focussed case presentation could frame the issue in a 
way that encouraged participation from lower status members of the team. In 
particular, a signal from a higher status member was one way of providing an 
opening for these contributions. This was evidenced when higher status members 
explicitly sought advice from others in the team: “now this is an interesting case I’d 
value your views” (Consultant Clinical Oncologist, Gynaecology, observation 
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transcript). This approach provided openings for lower status members to 
contribute: 
 
CNS: she just finds it extremely difficult I think she thinks by having 
treatment she’s doing something for herself   
(Gynaecology, observation transcript)  
 
There were some exceptions to this however. In two haematology cases (one from 
each team) information about the patient as a person was shared during the case 
presentation in order to emphasise the lack of other symptoms or problems: 
“previously very fit and well, active, went to the gym three times [a week]” (StR, 
Haematology 2, observation transcript), or “there was nothing in the history…he’s a 
mountain biker, does spinning classes” (Consultant Haematologist, Haematology 1, 
observation transcript). In these cases, the aim of sharing information about the 
patient appeared to be to emphasise their strengths in relation to treatment. It was 
therefore perhaps unsurprising that in these cases the initial case presentation did 
not lead to wider multidisciplinary discussion.  
 
The other exception where a holistic case presentation did not lead to input from 
lower status members of the team – even when there was an explicit prompt from 
a higher status member of the team – was when a lower status member of the 
team had not met the patient in question: 
 
Consultant Gynaecologist 1: it [a mass identified on the scan] needs 
out 
Clinical Oncologist: it’s very suspicious 
Consultant Gynaecologist 2: I’ve seen her again today but she’s 
really reluctant to have surgery  
Consultant Gynaecologist 3: is she? [sounds surprised] 
Consultant Gynaecologist 1: …is she symptomatic? 
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Consultant Gynaecologist 2: she is symptomatic she’s had long 
standing left sided pain and it was just getting worse 
Consultant Gynaecologist 1: …which, who’s she under which one of 
you has seen her [to the CNSs]? 
CNS: I’m not sure I haven’t seen her 
Consultant Gynaecologist 1: …does she need to see one of our 
psychology colleagues to help her with her decision making? 
Consultant Gynaecologist 2: no she’s signed a consent form today I 
had a chat with her 
(Gynaecology, observation transcript) 
 
In some cases therefore, a consultant was the only member of the team who had 
met the patient. In these cases, they provided the patient centred information both 
during the initial case presentation and then subsequently throughout the 
discussion. Overall however, it was more common for lower status members of the 
team to provide this kind of information in response to a holistic case presentation. 
 
7.3.4 Summary 
To summarise, there were different approaches to the initial case presentation and 
this appeared to have an impact on the extent to which lower status members of 
the team contributed to the subsequent discussion. In general, the lack of a clear 
case presentation made it more difficult for anyone in the meeting who had not 
met the patient to contribute constructively to the decision making process. This 
was not always necessarily problematic, for example, in cases that could be 
managed according to evidence-based protocols. However, in the Gynaecology 
team the failure to present a case properly was attributed with impairing 
multidisciplinary discussion, and making it more difficult for CNSs and StRs to 
contribute.  
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A clear clinical or holistic initial case presentation could ensure that everyone in the 
meeting was aware of key issues relating to the decision that needed to be made. It 
also seemed to enable teams to prioritise the contributions of particular groups by 
signalling the nature of the issue to be considered. In the examples observed, it was 
more likely that a holistic case presentation would draw in contributions from CNSs 
or StRs than a clinically focused presentation would. Nonetheless, a clinically 
focused presentation did not necessarily exclude contributions from lower status 
members of the team. Similarly, a holistic presentation did not guarantee their 
input. Specific behaviours from higher status members of the team, including the 
use of signalling during a presentation, and direct questioning, also made 
contributions from these groups more likely.  
 
7.4 Chapter Summary 
While the literature on cancer MDTs has highlighted the existence of inequalities in 
participation during MDT meetings (Lanceley et al., 2008, Kidger et al., 2009, Lamb 
et al., 2011b, Raine et al., 2014a), much less consideration has been given to the 
specific factors that inhibit or facilitate contributions from lower status groups. By 
exploring the decision making process in these four MDTs, this chapter has 
increased our understanding of the way that the physical layout of the meeting, the 
leadership style of the MDT Lead, and the initial case presentation can impact on 
multidisciplinary discussion. Table 16 (p. 199) summarises the factors that inhibited 
multidisciplinary discussion, and the contribution of lower status groups. Those that 
encouraged multidisciplinary discussion are summarised in Table 17 (p. 200).  
 
Of course, a key point already made is that for some discussions, input from lower 
status groups may not have made a difference to the outcome or final decision 
anyway. The factors described above that limited contributions from lower status 
groups are therefore not necessarily in and of themselves problematic.  
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Nonetheless, it is important to identify these factors because the literature suggests 
that behaviours that accentuate the effects of the status hierarchy are often 
unintentional. As a result, even leaders who want to encourage other team 
members to contribute may not behave in ways that demonstrate this (Morrison, 
2011). If MDTs are to incorporate the views of lower status groups when they are 
important therefore, they must be cognisant of the range of factors that can 
potentially inhibit them.  
 
Before concluding this chapter, it is also important to recognise that although status 
hierarchies clearly played an important role in the decision making process in these 
four cancer MDT meetings, regardless of the team environment or context, some 
individuals are more likely to speak up than others. This suggests that as well as 
status, factors such as gender, personality or disposition may also play a role in 
levels of participation in MDT meetings. For example, individuals who display high 
levels of extraversion have been shown to be more likely to speak up (Morrison, 
2011, Bienefeld and Grote, 2013). In addition, some of the differences described 
between the four MDTs may in part reflect differences in specialty and case load, 
although the fact that there were such marked differences between the two 
haematology teams suggests that this point should not be over-emphasised. 
Nonetheless, in the Skin team for example it was possible to clearly distinguish 
between different approaches based on disease type in a way that may not 
necessarily be possible in other specialities.
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Table 16: Summary of factors that inhibited multidisciplinary discussion  
Factor Reason for impact Influenced by Team 
1. Hierarchical seating 
arrangements 
Competition for space can exclude 
lower status groups sitting at the back 
of the room 
Size of team  
 
 
Haematology 2 
Gynaecology 
(but challenged) 
2. MDT Lead prioritises 
efficiency during discussion 
Verbal cues suggesting a lack of 
willingness to listen can create a sense 
of futility about value of contributing 
Accentuated by a lack of structure 
during discussion 
Gynaecology 
Haematology 2 
3. MDT Lead does not 
provide clear structure 
during discussion 
Can marginalise lower status 
contributions  
Accentuated by focus on efficiency 
during discussion 
Gynaecology 
Skin (SCC and 
BCC cases only) 
4. MDT Lead combines 
chairing role and 
documenting of decisions 
Can prioritise recording information 
over discussion  
The need to ensure accuracy of 
information recorded 
Gynaecology 
5. No formal case 
presentation given when 
introducing patient for 
discussion 
Difficult to contribute for those who 
have not met the patient being 
discussed 
Reason for discussion  
 
Which professionals have met the 
patient being discussed 
All 
6. Clinically focused case 
presentation used to 
introduce patient for 
discussion 
Framing issue as medical, surgical or 
diagnostic can exclude patient centred 
information  
Reason for discussion  
 
Signalling or questioning by higher 
status individual  
All 
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Table 17: Summary of factors that facilitated multidisciplinary discussion 
Factor  Reason for impact Influenced by Team 
1. Non-hierarchical seating 
arrangements 
Symbolic importance 
Creates opportunities to contribute 
Size of team  
 
 
Skin 
Gynaecology 
Haematology 1 
2. Support for lower status 
groups from a third party  
Can encourage lower status to work 
together to contribute 
Role of third party (in this case 
Psychologist) 
Gynaecology 
3. MDT Lead solicits 
contributions directly from 
lower status individuals with 
verbal and non-verbal cues 
Can indicate that contributions are 
welcomed and valued 
Needs to be directed specifically at 
lower status groups 
Skin (CNS) 
Haematology 1 
(CNS and StR) 
4. Holistically focused case 
presentation used to 
introduce a patient for 
discussion 
Framing issue in order to encourage 
sharing of patient centred information  
Which professionals have met the 
patient being discussed 
All 
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Chapter 8. Lower status contributions: successful 
approaches   
 
The previous two chapters have explored the way that status hierarchies unfold in 
MDT meetings, as well as the factors that facilitate or inhibit multidisciplinary 
discussion. The focus of this chapter will be on the contributions made by those 
who participated least in the MDT meeting. The aim is to address research question 
three: what approaches are used by lower status groups in order to contribute 
during MDT meetings?  
 
In order to address this aim, this chapter presents the results of Thematic Analysis 
II, which was based on data from 88 case discussions where lower status groups 
contributed during the observation period5. It describes five approaches used by 
lower status groups to contribute: sharing information, asking questions, providing 
practical suggestions, framing, and using humour. It also considers their impact on 
three key intermediary processes identified during the analysis: prompting 
discussion, influencing a treatment plan, and facilitating team working. As 
demonstrated in my theoretical framework these processes are important because 
robust discussion, consideration of alternative or diverse viewpoints, and good 
team work, are associated with high quality decision making (Larson et al., 1998, 
Lanceley et al., 2008, Lamb et al., 2013b, Raine et al., 2014b).  
 
The frequency with which these approaches were used, and their impact on 
decision making processes across the four teams, are summarised in Table 18. A 
note on the use of frequencies is provided in Box 5. This chapter will consider each 
of the five approaches in turn, exploring when and how they were used, and 
considering why they were successful.  
                                                     
5
 The figure of 88 case discussions refers to unique sections of discussion, each relating to a single 
patient, selectively transcribed from the audio of a full MDT meeting  
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Table 18: Summary of approaches used and outcomes for lower status 
contributions 
 
 
APPROACH 
 
OUTCOME 
Prompts 
discussion 
Influences 
treatment plan 
Facilitates 
team work 
Total 
Sharing information 65 23 19 107 
Asking questions 21 12 0 33 
Practical suggestions 5 18 0 23 
Framing  14 9 0 23 
Using humour  0 8 12 20 
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Box 5: A note on frequencies  
Given the lower rates of participation amongst CNSs and StRs, the analysis for this 
chapter draws on a much smaller dataset than the previous two chapters. To 
ensure transparency, I use figures to illustrate the frequency with which I 
observed each of the five approaches being used. This enables me to demonstrate 
the patterns observed, and provide readers with a sense of scale.  
However, there are limitations to using numerical data in qualitative research. The 
concept of frequency generally holds less importance in this context, when a 
single example is potentially as useful as multiple examples when the goal is to 
understand an underlying process (Mason, 2010). Also, the frequencies presented 
here are based on coded examples theoretically sampled from a larger purposive 
sample. In practice therefore a code assigned more frequently in one team could 
simply reflect differences in the amount of data collected.  
 
Nonetheless, the differences in data collected between Skin, Haematology 1 and 
Haematology 2 were minimal. The exception to this was Gynaecology, where the 
observation period was shorter, and fewer patients were discussed overall. It is 
possible that lower frequencies of lower status contributions in Gynaecology could 
reflect the shorter observation period, albeit offset by the longer weekly meeting 
duration (Table 19, p. 204). 
 
However, the shorter observation period in Gynaecology does not fully explain 
differences in the patterns of participation observed between the teams. While StRs 
in Gynaecology contributed successfully on fewer occasions than in any other team, 
the same was not true of CNSs. Despite the shorter observation period, CNSs 
contributed successfully on more occasions in Gynaecology than they did in 
Haematology 1 and Haematology 2 (Table 19, p. 204). This suggests that the length 
of the observation period, and the total number of cases discussed, were not the 
defining influence on the patterns of participation identified.  
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Table 19: Summary of observation data by team and frequency of contributions 
Team Meetings 
observed 
(weeks) 
Patients 
discussed 
(number) 
Meeting 
duration 
(hours) 
Case 
discussions* 
Successful 
contributions** 
StR CNS Total 
Gynae 18 324 2.5 17 5 33 38 
Haem1 38 390 1 20 30 28 58 
Haem2 35 371 1 20 35 10 45 
Skin 31 384 1.5 31 6 59 65 
* The number of case discussions selectively transcribed for Thematic Analysis II.  
**Successful contributions coded within the selective transcripts only.  
 
8.1 Sharing information 
The approach used most frequently by lower status groups to contribute across the 
four teams was sharing information. Chapter 6 demonstrated clear differences in 
levels of participation between higher and lower status groups. However, lower 
status groups did share information during the MDT meeting, albeit less frequently 
than other members of the team. From the sample of 88 case discussions where 
lower status groups contributed, there were 107 occasions across the four teams 
when CNSs and StRs shared information as a way of contributing to the decision 
making process6 (Table 18, p. 202).  
 
This included contributions based on clinical information about a patient’s disease, 
symptoms or treatment, and contributions based on information predominantly 
about the person diagnosed with cancer, including their preferences for treatment, 
psychosocial wellbeing, or information about their family or social circumstances. I 
discuss both of these approaches in relation to their impact on the decision making 
process in more detail below. 
 
                                                     
6
 The number of occasions on which a specific approach was coded can be greater than the 88 
discussions transcribed because one or more individual(s) could contribute on more than one 
occasion during each discussion, i.e. during the course of a discussion a CNS could ask questions on 
three occasions and an StR could ask one, giving four occasions of ‘asking questions’ in one 
discussion.  
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8.1.1 Sharing clinical information about a patient’s disease or treatment 
As the most commonly used approach to contribute in all four teams, sharing 
clinical information about a patient’s disease, symptoms or treatment impacted on 
the decision making process in three ways. It prompted further discussion in all four 
teams, and facilitated teamwork and influenced treatment plans in Haematology 1, 
Haematology 2 and Skin (Table 20).  
 
Table 20: Frequency of sharing clinical information by team and outcome 
Sharing clinical 
information 
Case 
discussions* 
Prompts 
discussion 
Influences 
treatment plan 
Facilitates 
teamwork 
Total 
Gynae  17 6 0 0 6 
Haem1  20 13 5 5 23 
Haem2  20 15 2 7 24 
Skin  31 14 4 3 21 
Total 88 48 11 15 74 
* The number of case discussions selectively transcribed for Thematic Analysis II 
 
Prompting discussion 
Information sharing could prompt discussion in the MDT meeting by highlighting 
that a lower status member of the team held unique information. This provided an 
opportunity for higher status individuals to seek out further information about a 
patient’s disease or prior treatment before making a decision. To illustrate, the 
excerpt below follows on from a presentation by the MDT Lead of a patient with 
relapsed disease. The StR spoke up following this presentation to tell the team that 
the patient had been admitted as an inpatient earlier that day: 
 
StR: she’s actually an inpatient today she came in this morning 
Consultant Haematologist 1: because? 
StR: she’s got a temperature…she got a call last night telling her to 
come in… 
Consultant Haematologist 1: so she’s not neutropenic? 
StR: no 
Consultant Haematologist 1: has she got PICC [peripherally inserted 
central catheter]? 
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StR: yeh that’s come out I told them to take that out 
(Haematology 1, observation transcript) 
 
Sharing clinical information that was not necessarily known to other members of 
the team was therefore a way of prompting discussion as new information was fed 
into the decision making process. Although it was more common for StRs to share 
clinical information in this way, CNSs in all four teams also used this approach on 20 
occasions: 
 
Consultant Radiologist: if you look at the amount of oedema around 
this deposit on the right there’s been an increase compared with 
the baseline CT of November 
CNS: that’s on steroids as well isn’t it 
Med-Onc: yeh…clinically he’s deteriorating quite quickly…so I think 
it’s really palliation  
(Skin, observation transcript) 
 
In this example, the CNS’s reminder that the patient in question was on steroids 
emphasised the significance of the finding that the scan showed disease 
progression, prompting the medical oncologist to contribute information about the 
role of palliation. A potential explanation for the success of this type of contribution 
was that it provided a means for lower status individuals to act as a ‘collective 
memory’ for the team, by sharing their detailed knowledge of a patient: 
  
I mean obviously I can’t know every single patient, because there’s 50 of 
them on the list. But…certainly the melanoma patients I meet them at 
diagnosis and I see them through… I generally know what’s going on 
with them. From diagnosis through surgery, and then into oncology, 
possibly palliative care. Generally…I know where patients are. So I can, I 
can give information to discussions. (CNS, Skin, interview) 
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Influencing a treatment plan 
In addition to prompting discussion, on 11 occasions across the 88 case discussions, 
information shared by a CNS or an StR resulted in a change to the treatment 
proposed for a patient. Some changes were relatively minor - for example a 
decision not to prescribe a patient a laxative alongside their chemotherapy after the 
team were informed by an StR that these had previously made the patient vomit. 
However, others were more fundamental, including decisions about whether a 
patient should be admitted to hospital, or whether or not to proceed with a 
particular course of treatment:  
 
Consultant Haematologist: is she going to be fit to go down for her 
radiotherapy do you think? 
StR: not the way she was today, no… she’s on HDU [high 
dependency unit] 
Consultant Haematologist: …so if we cancel her [StR] could we say 
to [the Clinical Oncologist] we might discuss re-planning her to have 
to have radiotherapy to her kidney plus her thigh 
(Haematology 1, observation transcript) 
 
Sharing this type of clinical information was a way of raising awareness amongst 
other team members about a patient’s ability to tolerate treatment, reflecting their 
physical fitness or comorbidities. This ensured that teams had up to date 
information when making treatment plans.  
 
Facilitating team work 
Not all information sharing contributions influenced a treatment decision or 
prompted further discussion. There were also 15 instances where information was 
shared in a way that facilitated team work. 
 
Sharing clinical information could facilitate team work because it provided a 
mechanism for supporting a decision made by a higher status member of the team, 
Findings III: Lower status contributions 
208 
 
and helped to create a sense of a shared team purpose. This is illustrated in the 
example below, where both the StR and the CNS contributed in a way that 
supported the decision proposed by a consultant haematologist:   
 
Consultant Haematologist 2: Did he have pamidronate [a type of 
drug called a bisphosphonate] when he came in? 
SpR: he had pamidronate when he came in   
Consultant Haematologist 1:  …right. We should probably continue 
him on IV bisphosphonate through his treatment 
Consultant Haematologist 7: when would he be potentially 
harvestable? 
Consultant Haematologist 2: so on the back of his fourth course 
CNS: if he comes in next week there is a potential slot  
Consultant Haematologist 7: I could see him on Monday 
Consultant Haematologist 2: that’s great 
(Haematology 1, observation transcript) 
 
8.1.2 When was sharing clinical information successful? 
The circumstances in which sharing clinical information was a successful approach 
were shaped by both patient and team factors.  
 
Patient factors 
As illustrated in the examples above, and echoing findings from the previous two 
chapters, lower status groups were far less likely to share clinical information about 
patients newly diagnosed, and where they had not met the patient being discussed. 
Instead, StRs and CNSs were more likely to share clinical information about patients 
who were mid- or post-treatment, because at this stage they had often seen the 
patient more recently than other members of the team: 
 
StR: so Prof she’s coming to see you today at 11 o clock…but she’s 
still on she’s been on steroids for about 10 days now  
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Consultant Pathologist: she’s on steroids? 
StR: this biopsy…was done after a week of steroids 
Consultant Pathologist: ok well that could account for part of the 
problem 
(Haematology 2, observation transcript) 
 
Lower status groups were also more likely to share information during discussion of 
patients who had relapsed disease, those who were described as elderly, and those 
with comorbidities or psychosocial issues that would potentially impact on the 
treatment decision, such as an inability to give consent: 
 
This lady's on lithium. She's not brilliant. She's very difficult to get 
information from. She's got very strange affect…If it wasn't for her 
mental state she'd be very eligible for trials, but you just can't 
consent her for them. (CNS, Skin, observation field note) 
 
In order to do this however it was essential that lower status groups had unique 
knowledge to share. As a result, this was not an approach that could be used 
successfully in all cases.  
 
Team factors 
The frequency of sharing clinical information was relatively consistent across teams, 
with the exception of Gynaecology. In this team there were noticeably fewer 
instances than in the other three teams (Table 20, p. 205). As discussed previously, 
it is possible that this reflects the shorter observation period. Alternatively, it may 
reflect the presence of factors that inhibit multidisciplinary discussion, which were 
highlighted in the previous two chapters. It is possible that the hierarchical seating 
arrangements, prioritisation of efficiency by the MDT Lead and lack of structure, 
which characterised discussions in Gynaecology, made it more difficult for lower 
status groups to share information in this team than in others.  
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8.1.3 Sharing information about the patient as a person  
In all teams, information primarily about the person, including a patient’s 
preferences for treatment, and their psychosocial wellbeing, was shared less often 
than clinical information about the disease or treatment. Nonetheless, there were 
circumstances in which this type of information was shared, predominantly by 
CNSs, but also on a small number of occasions by StRs. This impacted on the 
decision making process in three ways: it prompted further discussion, influenced 
treatment plans, and less frequently, facilitated team work (Table 21). 
 
Table 21: Frequency of sharing patient centred information by team and outcome  
Sharing 
information about 
patient as person 
Case 
discussions 
Prompts 
discussion 
Influences 
treatment plan 
Facilitates 
teamwork 
Total 
Gynae  17 8 3 1 12 
Haem1  20 6 4 0 10 
Haem2  20 1 1 0 2 
Skin  31 5 7 3 15 
Total 88 20 15 4 39 
 
Prompting discussion 
As with clinical information, sharing information about the patient as a person 
signalled that a lower status member of the team held potentially relevant 
information. This was a way for lower status groups to establish their credibility. For 
example, by sharing information in a way that emphasised her experience of 
supporting a patient with mental health issues through a previous round of 
chemotherapy, a CNS in Haematology 1 was able to successfully prompt discussion 
about whether or not the team should proceed with further treatment: 
 
Consultant Haematologist 1: I think the question is whether he 
would cope [with chemotherapy]…my recollection is he probably, 
he wouldn’t 
CNS: …well, it’s difficult because we saw him regularly throughout 
his [previous treatment]…and he did personality wise he improved 
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so much on treatment and once he was familiar with us and coming 
every time  
Consultant Haematologist 1: because of the regular, it was probably 
the regular interaction 
CNS: and I had a good rapport with him 
Consultant Haematologist 1: …is he ok with needles and things? 
CNS: well we managed every week to get a needle in him and the 
first few weeks we had to keep explaining why we were doing it and 
he sometimes would say he didn’t and then a bit of convincing he 
was ok but generally he was fine 
(Haematology 1, observation transcript) 
 
Sharing information based on previous experience of supporting a patient through 
treatment, or as a result of explicitly discussing an issue with a patient prior to the 
MDT meeting, was a concrete way to present a different perspective to that put 
forward by other members of the team. This was a key mechanism for prompting 
further discussion. 
 
Similarly, although they did so less frequently than CNSs, StRs also on occasion 
shared patient centred information in the MDT meeting. This was another way to 
prompt discussion when the information being shared was likely to impact in some 
way on the ability of the team to deliver treatment:   
 
Consultant Haematologist: and why does she need transport? 
StR: because she lives alone and doesn’t have anyone to get her 
places 
Consultant Haematologist: hmm quite complicated 
StR1: yes [laughs] 
(Haematology 1, observation transcript) 
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Influencing a treatment plan 
In addition to prompting discussion, CNSs and StRs were also able to influence the 
decision making process on 15 occasions by sharing information about a patient’s 
preferences or psychosocial wellbeing:  
 
Consultant Medical Oncologist: well if the situation was a little bit 
more favourable we could offer her the Nicam study in January…the 
problem is that…it’s the Asian population who are more likely to 
have acral melanomas but it’s also the population who also tend to 
have language problems as well  
CNS: she speaks Cantonese, that could be helpful 
Consultant Medical Oncologist: yeah  
Oncology StR: I’ll ring the interpreters 
Consultant Medical Oncologist: yeah I think to consent her for the 
study we will have to have an interpreter…yeah ok that’s going to 
be challenging and then actually getting her up and down to clinic 
regularly is going to be challenging as well 
CNS: as long as she is told when to come and she’s not informed by 
letter she’s ok 
Consultant Medical Oncologist: ok [pause] when are you planning to 
see her again in terms of recovery from surgery? 
CNS: [her next appointment is on the] 30th 
Oncology StR: I remember she was on the ward about two months 
ago she recovered very well… 
Medical Oncologist: ok…Nicam’s not going to be open until January 
so…can we just make a note…I’ll arrange to see her [then] 
(Skin, observation transcript) 
 
In this example, the information shared by the CNS and StR enabled the MDT Lead 
to conclude that the proposed treatment option of enrolling the patient in a clinical 
trial was feasible, despite the fact that the patient did not speak English. This 
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example also shows how it was possible for lower status groups to ensure that a 
decision reflected the needs and circumstances of an individual patient by providing 
essential context: 
 
I’ve met them [the patients], I know if they live on their own, if they can’t 
get about…I think it’s more background information that helps you make 
a decision: would a patient be able to get in, is this treatment 
appropriate? How well is this patient? Should this patient be considered 
for such and such. I have an opinion then. (CNS, Skin, interview) 
 
Facilitating teamwork 
Finally, on four occasions a CNS (three times in Skin, and once in Gynaecology) 
provided information in a way that facilitated team work. This is illustrated in the 
example below where the team were engaged in a lengthy discussion about how to 
respond to a patient who was described as deeply confused and anxious. In this 
situation, the CNS used her knowledge of the patient to support the proposal made 
by a higher status member of the team and to provide reassurance that the patient 
was likely to be accepting of the proposed treatment plan: 
 
Consultant Surgeon: so we’re probably going to have to decide for 
her in a way even if that’s in as much as pushing her towards 
[having further surgery] 
CNS: I think she’d be happy with that though 
(Skin, observation transcript) 
 
8.1.4 When was sharing information about the patient as a person 
successful? 
Patient factors 
Lower status individuals shared information about a patient in order to prompt 
further discussion amongst the team in cases when patients had limited treatment 
options, or where there were concerns about a patient’s ability to cope with 
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treatment. Sharing information also influenced decisions in cases where a patient 
was unlikely or unable to comply with recommended treatment, or to attend their 
scheduled appointments – essentially, where there were potential barriers to the 
team implementing their proposed treatment plan.  
 
This type of information was also used successfully to influence treatment planning 
in cases where there was more than one option available for a patient. In these 
circumstances, knowledge of a patient’s preferences could be instrumental in 
helping the team to choose between alternative treatments. As illustrated in the 
example below, the CNS’s awareness of the patient’s preference shaped the choice 
between surgery or radiotherapy: 
 
Consultant Medical Oncologist: this is a guy with multiple cutaneous 
metastases…so in terms of quality of life what we’ve been debating 
is whether surgery would be a better option or whether we should 
be thinking about radiotherapy… 
CNS: …the patient’s definitely keen on surgery if that’s any if 
somebody can see him just to 
Consultant Surgeon: …we’ll see him we can probably resect it 
Consultant Medical Oncologist: …ok so to see to see [Consultant 
Surgeon] 
(Skin, observation transcript) 
 
Team factors 
The frequency of examples where lower status groups shared information about 
the patient as a person was similar across three of the four teams (Table 21, p. 210). 
The exception in this case was Haematology 2, where there were just two examples 
of StRs sharing information about the patient as a person, and no examples of a CNS 
doing so. The low frequency of this approach in this team is perhaps unexpected, 
given that there were up to ten StRs and five CNSs in Haematology 2, more than in 
any other team. It does however resonate with the view of the CNS interviewed in 
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this team, who felt that there was little time in the meeting for her contributions: “I 
just think you wouldn’t get very far in that meeting” (CNS, Haematology 2, 
interview).  
 
However, data presented in Chapter 6 also showed that information about patient 
preferences was not any less likely to be mentioned in Haematology 2 than in other 
teams (in 7% of cases, within the range of 5-8% observed across the teams). This 
was also the case for information about psychosocial factors, which were 
mentioned in 11% of cases in Haematology 2, again within the range of 4-12% 
observed across the four teams (see Table 14, p. 144). This suggests that lower 
frequencies of CNS and StR information sharing contributions did not necessarily in 
themselves mean discussions were less patient centred. Instead, it appears that the 
mechanism for sharing this type of information was different in Haematology 2 than 
in other teams, with a greater role for higher status than lower status members of 
the team. 
 
8.2 Asking questions  
The second most frequent approach used by lower status groups to contribute was 
asking questions. This was most likely to prompt discussion, but on a smaller 
number of occasions it also influenced a treatment plan (Table 22). 
 
Table 22: Frequency of asking questions by team and outcome 
Asking questions Case 
discussions 
Prompts 
discussion 
Influences 
treatment plan 
Total 
Gynae  17 4 3 7 
Haem1  20 5 8 13 
Haem2  20 4 0 4 
Skin  31 8 1 9 
Total 88 21 12 33 
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Prompting discussion  
Asking questions prompted discussion in two different ways. First, it could stimulate 
others to share expertise or opinions. Secondly, it could raise awareness of an issue 
not previously mentioned in the MDT, by highlighting specific patient needs. 
 
Using questions in order to stimulate others to share information capitalised on the 
MDT meeting as a forum for bringing together individuals with diverse knowledge 
and expertise. For StRs in particular, questions were an opportunity to prompt 
higher status members to explicitly verbalise their expertise: “sorry…what made her 
a stage IV?” or “is he for autograft?” (StR, Haematology 2, observation transcript). 
This in turn could prompt discussion before a decision was made: 
 
StR: what dose are we talking [about]?  
Consultant Haematologist 2:  …50mg of pred[nisolone] 
Consultant Haematologist 1:  …if you look at…some of the Italian 
studies they were planned to escalate up to 200 but when you look 
at the median tolerated dose it was always somewhere between 50 
and 100 
Consultant Haematologist 2:  …and then you wean it down so 
they’re not actually on high dose steroids long term  
Consultant Haematologist 1:  yep 
Consultant Haematologist 3:  ok we’ll give that a go thanks 
(Haematology 1, observation transcript) 
 
In addition to stimulating others to share expertise or opinions, asking questions 
was also an approach used by CNSs to raise awareness of an issue amongst the 
team that had the potential to impact on the treatment plan agreed. This could 
prompt further discussion and information sharing in advance of a decision being 
made: 
 
CNS: how many [doses] of radiotherapy is she going to need? 
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Consultant Haematologist 1: [Clinical Oncologist] was going to give 
her five, five big doses 
CNS: …is that five fractions daily or over a course of [a longer period 
of time]? 
Consultant Haematologist 1: one day for five days  
Consultant Haematologist 4: I think she was going to have two this 
week and three the next week  
CNS: …because she relapses really quick, doesn’t she? 
Consultant Haematologist 2: …well that thigh [lesion] doesn’t go 
does it…within six weeks of stopping she just sprouts it somewhere 
else 
(Haematology 1, observation transcript) 
 
Influencing a treatment plan  
Asking questions also enabled lower status groups to influence a treatment plan, 
although this happened less frequently than prompting discussion. In total, this 
approach was used on 12 occasions across the 88 case discussions, predominantly 
by CNSs in Gynaecology and Haematology 1.   
 
Questioning was a way to challenge a higher status member of the team, without 
directly disagreeing: “is she going to tolerate R-CHOP [chemotherapy]?” or “do we 
need to admit patients just for documentation purposes?” (CNS, Haematology 1, 
observation transcripts). 
 
It was also an approach adopted by CNSs as a way of advocating on behalf of a 
patient, to ensure that the decision took their needs and specific circumstances into 
account. For example, during discussion of a patient with relapsed disease, the MDT 
Lead in Haematology 1 indicated that the patient was unlikely to be suitable for 
transplant. However, it became clear that the patient had not yet been made aware 
of this. In response, the CNS used questions as a means of challenging the team to 
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raise the issue with the patient, in order to avoid creating unrealistic expectations 
about further treatment: 
 
CNS: Why are we doing all this then?...I just think that as much as 
they might not be psychologically prepared you are also giving them 
false hope 
(Haematology 1, observation transcript) 
 
This intervention from the CNS prompted a change in the proposed treatment plan, 
and led to a commitment from the MDT Lead to discuss the issue with the patient in 
order to: “make sure they start preparing…as best they can.” (Consultant 
Haematologist, Haematology 1, observation transcript). 
 
Although overall CNSs were more likely to influence a treatment plan as a result of 
asking questions, there were three occasions when an StR did so. In two of the 
three cases, the MDT Lead was absent, and the StR in question knew the patient 
well. In this context, asking questions was a way of shaping the practicalities of a 
treatment plan to ensure it was appropriate for a specific patient’s needs: “Should 
we delay her clinic appointment if she’s not [had her scan in time]?” (StR, 
Haematology 1, observation transcript). 
 
8.2.1 When was asking questions a successful approach? 
Patient factors 
StRs were more likely to ask questions in clinically complex cases, for example when 
a patient was unable to tolerate what would be standard treatment, had complex 
comorbidities, or relapsed disease. In these cases, decisions were often less 
straightforward and questions were a mechanism for eliciting the expertise of other 
team members by prompting them to share their experience where treatment 
would not follow existing evidence based protocols: 
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Consultant Haematologist 5: I’m not sure that the PET is a useful 
intermediary because we could just biopsy the lesion  
StR: and if the biopsy shows follicular lymphoma? 
Consultant Haematologist 5: yeh I still don’t know…if the biopsy 
shows follicular lymphoma what will we do…I actually personally 
think this is more of a clinical decision  
Consultant Haematologist 2: …you know you want to try and get as 
much of a clear answer rather than likeliness for this lady  
Consultant Haematologist 3: I think she needs a biopsy…the reason 
I’m saying that is if she’s got transformed disease in that shoulder 
that’s progressive then a transplant would be futile if she’s got 
follicular lymphoma  
Consultant Haematologist 5: ok 
(Haematology 2, observation transcript) 
 
Reflecting their patient advocacy role, CNSs asked questions in cases where there 
was a difficult decision made during the meeting, or where there was disagreement 
between different members of the team as to the most appropriate treatment. 
Disagreements stemmed from clinical complexity, or because a patient was likely to 
need additional support from psychosocial members of the team as part of the 
treatment plan:  
 
Consultant Gynaecologist: she should have a breast assessment 
given the abnormalities  
CNS: how are we going to work it? …She is really anti having the 
mammogram…you know it’s going to be extremely difficult to get 
any sort of diagnosis because she is just adamant…she doesn’t want 
…anything done breast wise 
(Gynaecology, observation transcript) 
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Team factors 
Asking questions was an approach used by lower status groups in all four MDTs, 
with little variation. Although it was used successfully most frequently in 
Haematology 1 (on 13 occasions across the 20 case discussions), it was also used on 
multiple occasions in Skin, Gynaecology and Haematology (Table 22, p. 215). 
 
8.3 Providing practical suggestions or alternatives  
A third approach adopted by lower status groups was to present contributions as 
practical solutions or suggestions. This included suggestions that aimed to address a 
challenge faced by the team, as well as solutions presented as an alternative to a 
proposed course of action.  
 
In contrast with the approaches described previously, making practical suggestions 
was more likely to influence a treatment plan than it was to prompt discussion, and 
there were no examples of this approach being used to facilitate teamwork (Table 
23).  
 
Table 23: Frequency of making practical suggestions by team and outcome  
Practical suggestions Case 
discussions 
Prompts 
discussion 
Influences 
treatment plan 
Total 
Gynae  17 2 3 5 
Haem1  20 3 10 13 
Haem2  20 0 0 0 
Skin  31 0 5 5 
Total 88 5 18 23 
 
Influencing a treatment plan 
Overall, of the 23 contributions framed as practical solutions or suggestions, 18 
were successful in influencing a treatment plan (Table 23). Practical suggestions or 
alternatives were a way for lower status groups to influence a treatment plan in a 
non-confrontational manner. This approach was a way of ensuring that the 
treatment decision made reflected the needs of a patient without directly 
challenging or disagreeing with other team members. As illustrated in the exchange 
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below, a CNS led the Haematology 1 team towards an alternative solution in 
response to a suggestion from the MDT Lead that a patient be admitted to an 
inpatient ward for the next stage of his treatment:  
 
Consultant Haematologist 1: I mean if we feel that actually getting 
him up [to clinic] with his family’s going to be a struggle and it may 
be easier just to admit him and do it all as an inpatient  
CNS: …are they [the patient’s family] coming on Thursday when he 
comes to the day unit do you think? 
Haematology StR 1: yes  
CNS: they are his family? 
Haematology StR 1: yep 
CNS: …so can somebody see him on the day unit and do it all like 
that if they can’t come up tomorrow?  
Haematology StR 2: somebody [consultant haematologist 3] or 
whoever could dictate a letter from the MDT for the GP… 
Consultant Haematologist 3:  …I mean I can do a letter 
Consultant Haematologist 1:  …yeh we could leave it at that if it’s all 
planned that his family are coming with him on that date 
Consultant Haematologist 3:  I didn’t know if they were but if they 
are 
Haematology StR 1: yeh they are… 
Consultant Haematologist 1:  …ok excellent 
(Haematology 1, observation transcript) 
 
Key to the success of this approach was the knowledge held by an StR in the team 
who was able to confirm details about the patient’s next appointment. The CNS was 
able to solicit and build on this information in order to lead the team towards an 
alternative solution. This led the team to agree to see the patient with his family at 
his next scheduled outpatient clinic, rather than admit him as an inpatient.  
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Prompting discussion 
In five cases, providing practical alternatives or suggestions did not result in a 
change to the treatment plan, but it did prompt further discussion (Table 23, p. 
220). 
 
Providing an alternative suggestion was a way of raising awareness of an issue that 
had the potential to impact on the team’s ability to deliver treatment:  
 
Consultant Gynaecologist 1: [name of patient]  
Consultant Gynaecologist 2: minor dysplasia deaf dumb…crikey  
CNS: …her nephew was there today and was signing and obviously I 
think there’s limited capacity to actually understand that she’s got 
cancer but she’s been in hospital before and she coped extremely 
well she’s got fantastic family support…but I was just thinking I 
know we’ve used visual aids before…so maybe we can do that 
Consultant Gynaecologist 1: …oh yes sorry I was just wondering why 
it sounded familiar I saw a letter from her this morning 
CNS: I just thought so she was prepared sort of post operatively and 
things 
Psychologist: yeh yeh yeh so we can look at those and we can add to 
them if necessary  
(Gynaecology, observation transcript) 
 
This type of contribution appeared to be successful because it enabled teams to 
resolve or overcome a challenging or complex situation. A common thread 
underpinning the five examples was the knowledge held by CNSs or StRs of the 
patient and their needs or circumstances. This information appeared to be critical in 
developing an appropriate solution or alternative course of action to enable the 
team to incorporate these needs into the final treatment plan.   
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8.3.1 When was providing practical suggestions a successful approach?  
Patient factors 
Practical suggestions were used most commonly when there were factors that were 
likely to impact on the ability of the team to implement their proposed treatment 
plan, including situations where family or carers had expressed strong preferences 
on behalf of a patient, or when there were potential communication difficulties. To 
illustrate, in one example from the Gynaecology team, a consultant gynaecologist 
had initially stated his intention to see a patient in clinic to discharge her from his 
care. However, the patient did not have cancer, and there were concerns amongst 
the team that she was being over-medicalised. Building on these concerns, the CNS 
made the practical suggestion ultimately adopted by the team that the consultant 
write to the patient instead of seeing her in clinic: 
 
Psychologist: I think the main thing I would say is we just do not 
want to keep medicalising her…to bring her down from [another 
Trust] to here is yet another medical appointment… 
CNS: …can we write to her to tell her? 
Psychologist: …yeh exactly 
(Gynaecology, observation transcript) 
 
Team factors 
Making practical suggestions was an approach used successfully most frequently in 
Haematology 1 (on 13 occasions across 20 case discussions). This was followed by 
Gynaecology (5 occasions across 17 case discussions), and Skin (5 occasions across 
31 case discussions). There were no examples across the 20 case discussions in 
Haematology 2 (Table 23, p. 220). 
 
8.4 Framing contributions in medical or surgical terms 
The fourth most frequently used approach to contribute in the MDT meeting was 
for lower status groups to frame a contribution in medical or surgical terms. This 
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approach was used on 23 occasions across the 88 case discussions. For StRs, as 
medical or surgical trainees, it was not surprising that the majority of their 
contributions were framed in medical or surgical terms, and that they successfully 
prompted discussion amongst higher status members of the team by explicitly 
tapping into their areas of expertise.  
 
However, the focus of this section is explicitly on two sets of cases. First, those 
cases where CNSs used a medical (rather than a psychosocial) rationale in order to 
engage other members of the team in a discussion or to influence a treatment plan. 
These examples were notable because CNSs were much less likely than other 
members of the MDT to present their contributions in this way. Secondly, cases 
where an StR framed their contribution in medical or surgical terms specifically in 
order to ensure that a decision was made for a patient and not deferred to a later 
meeting. This was notable because it involved a lower status member actively 
challenging a decision to defer made by the MDT Lead.  
 
8.4.1 CNSs using a biomedical rationale to frame a contribution 
On eight occasions CNSs were able to prompt discussion amongst other members of 
the team by framing their contribution in biomedical terms. This approach was used 
by CNSs in all four teams, although predominantly in Gynaecology (Table 24). 
 
Table 24: Frequency of framing among CNSs by team and outcome  
Framing Case 
discussions 
CNS prompts 
discussion 
CNS influences 
treatment plan 
Total 
Gynae  17 5 1 6 
Haem1  20 1 0 1 
Haem2  20 1 1 2 
Skin  31 1 3 4 
Total 88 8 5 13 
 
As mentioned above, contributions from CNSs that were framed in biomedical 
terms were notable because CNS were much less likely than other members of the 
MDT to present their contributions in this way. This reflects differences in their 
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training and expertise, and their role as psychosocial members of the team. As such, 
in these cases, CNSs were not only sharing information that was more typically 
shared by medical or surgical members of the team, but they were also adopting a 
distinctly medical frame in order to do so: 
 
Consultant Radiologist: we’ve got recent imaging from here for the 
cervical spine which merely shows degenerative disease…there’s an 
extensive spinal canal component in the current study which wasn’t 
seen previously  
CNS: …she has had spinal radiation since Friday she’s had five 
fractions and she’s having the fifth fraction today. She 
had…fractures in T9, 10 and 11 last Monday. We were planning an 
autograft 
(Haematology 2, observation transcript) 
 
On five occasions, CNSs were also able to successfully influence a treatment plan by 
framing a contribution in medical or surgical terms. In these cases, CNSs combined 
their knowledge of the medical features of the case with knowledge of the patient 
(and their family’s) wishes. For example, the CNS in Skin was able to persuade the 
team to make a referral for radiotherapy, in spite of the surgeon’s initial reluctance 
to consider further treatment:  
 
Consultant Medical Oncologist: why [is this patient on the list]? 
CNS: well the reason I asked him to be put back on is… 
Consultant Surgeon: …I did his axillary clearance [surgery] in 
December…and you can’t get any more out you’re not going to get 
everything 
CNS: no he had like 24 positive nodes didn’t he with extra capsular 
spread…anyway his son has gone into orbit and wants him to have 
some radiotherapy yesterday and he’s talking about going down to 
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pay for it somewhere…his son’s just very adamant that he wants 
him seen immediately 
(Skin, observation transcript) 
 
These examples illustrate how framing contributions in medical or surgical terms 
enabled CNSs to both stimulate discussion amongst the team, and to successfully 
challenge other members of the MDT. This reflects findings from the literature, 
which suggest that the way that a contribution is framed can be essential to its 
success, particularly where there is a lack of consensus within a team about the 
legitimacy, importance or relevance of the issue being raised (Piderit and Ashford, 
2003). The interview data suggested that in the Gynaecology team at least there 
was an intentional strategy to improve engagement by considering how best to 
share information in a way that captured the attention of other professionals: 
 
The nurses often give a lot of verbatim stuff, I mean “she’s got three 
small children and she doesn’t get on with her mother in law,”…and 
basically, the doctors stop listening…so the idea was when we talked 
about the patients [before the MDT meeting], I would say “okay, and 
what are you going to say in the MDM, how are you going to introduce 
this?  You’ve got one sentence, what are you going to do?”  And they’d 
prepare that and say that. (Psychologist, Gynaecology, interview) 
 
Framing issues from a medical perspective in order to align with the priorities of 
higher status members of the team could therefore be seen as an attempt by lower 
status individuals to capture the attention of higher status members in a fast paced 
environment.  
 
8.4.2 Framing: the role of StRs in ensuring a decision was made 
It was relatively common for MDT Leads in all four teams to defer discussion of one 
or two patients each week, for example where there was information missing. 
However, on 10 occasions StRs challenged a higher status call to defer a decision:  
Findings III: Lower status contributions 
227 
 
I put two patients on the MDT and the last one almost didn’t get 
discussed until I kicked up a fuss.  You know, she was on the list [and] 
wasn’t going to be discussed because of time issues and then I put my 
foot down and said we needed a decision. (StR, Gynaecology, interview) 
 
The observation data illustrate the importance of the way this type of challenge was 
framed to its success. In the example below from the Haematology 2 team, two 
consultant haematologists initially attempted to delay discussion of a patient in the 
absence of another consultant member of the team. However, the StR was able to 
ensure that the discussion was not postponed by framing the issue in a way that 
emphasised the clinical urgency of the need to make a treatment decision: 
 
Consultant Haematologist 1: I think given the complexity of the case 
we probably should wait or defer the case 
Consultant Haematologist 2: do we have to make a decision this 
week? It’s just he’s really, she’s very well known to him [the absent 
consultant] 
Haematology StR: well we need to review her material today…we’ve 
got histology to look at haven’t we? 
Consultant Haematologist 1: …I personally think it’d be better to do 
everything together but if there is a clinical pressing need I can show 
what I’ve got… 
Haematology StR: well she’s got rapidly enlarging lymphadenopathy 
and started on steroids so we need to make some treatment 
decision[s]  
(Haematology 2, observation transcript) 
 
As illustrated in the example above, the StR initially attempted to ensure the case 
was discussed by making the point that there was histology material to review. 
However, this was less successful than the second attempt, which emphasised the 
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medical rationale for making a decision immediately and prompted the team to go 
on and discuss the case.  
 
Interestingly, the use of framing as an approach by StRs to contribute successfully 
was not distributed evenly across the teams. As illustrated in Table 25 it was most 
common in Haematology 2. It is possible that this links back to the point made in 
the previous chapter about the emphasis on efficiency that was evident in this 
team. It is perhaps not surprising that in this context, there were occasions when 
lower status members had to make an explicit case for a patient to be discussed 
rather than deferred to a subsequent meeting. Emphasising a medical rationale for 
doing so could be seen as a way to legitimately challenge a higher status member if 
they initially attempted to move the discussion on.  
 
Table 25:  Frequency of framing among StRs by team and outcome 
Framing Case 
discussions 
StR prompts 
discussion 
StR influences 
treatment plan 
Total 
Gynae  17 0 0 0 
Haem1 20 0 0 0 
Haem2  20 4 4 8 
Skin  31 2 0 2 
Total 88 6 4 10 
  
8.5 Using humour 
The fifth, and least frequently adopted approach used by lower status groups to 
contribute successfully during the MDT meeting was humour. Although humour 
was used frequently in the four MDTs overall, higher status members of the team 
were more likely than lower status members of the team to contribute in this way. 
Nonetheless, on 20 occasions across the four teams humour was also used by a 
CNS: 
 
Consultant Medical Oncologist: well in that case ok I’ll see her I’ll try 
and explain it as best I can…and say that on balance we feel that we 
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should be trying to define the limit of her surgery because only then 
can we really tell her how bad the surgery’s going to be 
Consultant Surgeon: well don’t use the word bad 
[CNS laughs] 
Consultant Surgeon 2: surgery is never bad it can go 
CNS: extensive 
Consultant Medical Oncologist: oh extensive ok [laughter] alright is 
that agreed? 
(Skin, observation transcript) 
 
The use of humour during the MDT meeting was described by one CNS as “helpful” 
(CNS, Skin, interview). In particular, it provided a means of facilitating team work, 
but it was also used as a means of influencing a treatment decision (Table 26).  
 
Table 26: Frequency of using humour by team and outcome  
Humour Case 
discussions 
Influences 
treatment plan 
Facilitates team 
work 
Total 
Gynae  17 0 3 3 
Haem1  20 2 1 3 
Haem2  20 4 1 5 
Skin 31 2 7 9 
Total 88 8 12 20 
 
Facilitating team work 
On 12 occasions, CNSs facilitated team work by using humour. This could promote 
social cohesion by diffusing tensions, or by enabling the team to unite against a 
shared challenge. Humour in these circumstances promoted integration within the 
team, as higher and lower status individuals bonded over a shared outlet of 
laughter: 
 
Consultant Gynaecologist 1: you owe me big time because who did I 
see this morning [patient name] 
Findings III: Lower status contributions 
230 
 
Consultant Gynaecologist 2: now I did say [loud laughter in the 
background] I waited and I did say she’s never late I actually decided 
that I would see her myself 
Consultant Gynaecologist 1: she [the patient] said she [Consultant 
Gynaecologist 2] has left! She’s gone without seeing me, you’ll have 
to see me [instead] doctor 
CNS: funnily enough…on the cervical cancer training day weekend 
she was there and she ignored me for two days! [laughter] 
Consultant Gynaecologist: doesn’t she want to go to [another Trust] 
for her treatment? Shall we sell that to her? 
CNS: we could sell it 
Consultant Gynaecologist 2: well done for seeing her I do think she 
needs to see a dose of everybody 
(Gynaecology, observation transcript) 
 
In this example, the CNS extended the joke made initially by a consultant 
gynaecologist. This created an opportunity for the team to acknowledge the shared 
challenges they faced in managing a patient well known to the team.  
 
Influencing a treatment plan 
Humour was also used on eight occasions by CNSs when challenging another 
member of the team or as a way of softening a difficult message. For example, 
during a discussion in Haematology 1 the CNS suggested that careful consideration 
be given to which member of the team discussed the treatment plan with a patient 
following a decision not to go ahead with a transplant. The CNS laughed while 
conveying the message, whilst also verbally distancing herself from the criticisms by 
referring to the patient as being ‘sensitive’ and pointing out that they had 
‘misinterpreted’ information they had been sent:  
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CNS: I don’t know if this is right or wrong to say but they are 
pernickety about who they like talking to about certain things and 
I’m wondering if somebody specific needs to speak with them  
Consultant Haematologist: …who were you thinking? 
CNS: …well no I just on speaking with them I know she’s had issues 
with certain people nothing derogatory about anybody…[the 
patient] picks up on things sometimes a bit too sensitively and gets 
annoyed, because I know she had some issues with [another 
consultant haematologist] at the beginning and [the consultant 
haematologist] came to me and said I didn’t mean to say what I said 
[CNS is laughing at this point]  
Consultant Haematologist: …she also had some issues about…she 
doesn’t like the copy letters 
CNS: she misinterpreted it 
(Haematology 1, observation transcript) 
 
Using this approach, the CNS was able to prompt the MDT Lead to agree to speak to 
the patient himself: “I’m happy to do it if you want” (Consultant Haematologist, 
Haematology 1, observation transcript). In two other examples humour appeared to 
be used to challenge the team to think differently about a case. These examples 
both came from Haematology 2. As was noted in Chapter 6 decisions about 
whether a patient was suitable for transplant were often complex and could lead to 
differences of opinion within the team. On two of these occasions, CNSs used 
humour while contributing to the discussion:   
 
Consultant Haematologist 1: there might be disagreement in the 
room about that but the issue is that he is able to get to 
appointments with great difficulty but he does come and although 
sometimes he’s difficult to contact by phone generally we can track 
him down if we try hard enough [laughter] 
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CNS: well he’s got better he has got better he’s just very 
independent and quite stubborn 
Consultant Haematologist 2: I can relate to that 
CNS: I thought you would [loud laughter from the team] 
(Haematology 2, observation transcript) 
 
This was also reflected in the second example: 
 
Consultant Haematologist: these patients need to comply with 
therapy…is he able to do that?... 
CNS: …he messes around but he understands 
Consultant Haematologist 2: yeh he messes around but generally he 
has been compliant 
Consultant Haematologist 3: he still goes to the pub from the ward 
though every day 
Consultant Haematologist 2: he goes to the pub every day from the 
ward, yes [laughter] 
CNS: I don’t think he drinks that excessively when he goes he does 
go but  
Consultant Haematologist 2: as his sister said he’s only been 
paralytic two or three times since he presented in January 
CNS: like most of the people in this room [this is said quite quietly 
but it results in loud laughter]  
(Haematology 2, observation transcript) 
 
The use of humour in both of these examples fits with the findings from other 
studies which suggest that humour is a mechanism that enables individuals to raise 
concerns or issues that they may not be able to do otherwise (Rowe and Regehr, 
2010). Humour can be seen as a way of masking an underlying message, which 
although presented in a light hearted way, may contain a more serious point (Dean 
and Major, 2008). From this perspective, the CNSs’ comments in these examples 
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could be seen as an attempt to minimise the significance of the issues that were 
being presented as barriers to treatment. The contributions in both examples 
emphasised the fact that these patients were ‘like other members of the team’ and 
could be seen as an attempt to normalise the negative descriptions of these 
patients’ behaviours.  
 
8.5.1 When was using humour a successful approach?  
In general, humour was used by CNSs in cases where there were particular 
challenges facing the MDT. For example, frustrations with IT equipment or patients 
that the team perceived as being difficult to manage. However, as the examples 
above illustrate, humour was also used in circumstances where a complex decision 
was being made and where there were potential differences of opinion between 
team members. In these cases humour provided a way of expressing a different 
perspective without directly challenging another member of the team. This enabled 
CNSs to deliver a potentially difficult message in a non-confrontational manner. 
 
Across the 88 selective transcripts from the 122 meetings I observed, it was notable 
that there were no examples of humour being used by StRs in the MDT meeting 
setting. It is not possible to use the observation data to determine the reason for 
this, but the literature suggests that there are implicit group norms that surround 
the use of humour, including the circumstances in which it can be used and by 
whom (Rowe and Regehr, 2010). Given their status as doctors in training it may be 
that StR did not think it would be appropriate to use humour when contributing 
during the MDT meeting - although it could also reflect differences in individual 
personalities.  
 
8.6 Chapter Summary 
This chapter has illustrated the key role that can be played by lower status groups in 
the MDT meeting, by focusing specifically on 88 cases where lower status groups 
contributed to the decision making process.  In doing so it has identified and 
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described the approaches used, and considered why, and when, they were 
successful in influencing key processes in the MDT meeting. 
 
Approaches used by lower status groups to contribute 
Five approaches were used by CNSs or StRs to prompt discussion, influence a 
treatment plan or promote team work (Table 27, page 237). The most frequently 
used approach, sharing information, was the only approach that influenced all three 
of these team processes. Asking questions and framing contributions in medical or 
surgical terms were more likely to prompt discussion than to influence a treatment 
plan (and neither approach was observed facilitating teamwork). However, as a 
somewhat more direct approach, making practical suggestions was more likely to 
influence a treatment plan than it was to prompt discussion. In turn, using humour 
as a means of fostering social cohesion was more likely to promote teamwork, 
although it also influenced treatment planning on a smaller number of occasions.  
 
Table 27 (page 237) also illustrates that StRs used a narrower range of approaches 
to contribute than CNSs did across the teams. It was notable for example that 
humour was not used by StRs, even though it was an approach adopted by CNSs in 
all four teams. In addition, approaches that were used by both groups were often 
used with different effect. For example, while it was common for StRs to ask 
questions as a means of facilitating discussion by prompting higher status 
individuals to share their expertise, CNSs were more likely to use questions as a 
means of influencing a treatment plan, for example by advocating on behalf of a 
patient. 
 
Understanding when lower status contributions were successful  
This chapter builds on the findings presented in Chapter 6, by providing a more 
detailed analysis of the context in which lower status contributions were successful.  
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Patient factors 
As well as being more likely to contribute when patients had limited treatment 
options, or when there were concerns about a patient’s ability to cope with 
treatment, a series of medical and non-medical factors were common when lower 
status groups contributed using the five approaches identified in this chapter.  
 
Non-medical factors related to patients who had expressed a strong preference 
prior to the MDT meeting, and to patients who were deemed to be socially or 
psychologically vulnerable. This was also the case for patients unlikely to ‘comply’ 
with the treatment recommended by the team, as well as cases where there were 
likely to be difficulties in communication between the patient (and/or their family) 
and the wider team.  
 
Medical factors related to patients who were brought for discussion mid- or post 
treatment, those with relapsed disease, or complex comorbidities that meant they 
were not physically well enough to tolerate standard treatment. In addition, these 
approaches were used by lower status groups when a clinically pressing issue 
necessitated a change in treatment plan or in cases where there was more than one 
treatment option, and there were differences of opinion between members of the 
team as to which was most appropriate. 
 
Team factors 
It also became apparent that there were differences between teams. To better 
understand these differences, the next chapter will integrate the findings from this 
chapter with those from Thematic Analysis I. This will enable a more nuanced 
understanding to be developed about potential explanations for the differences 
observed between teams and lower status groups.  
 
Understanding why lower status contributions were successful 
A key factor underpinning many of the successful contributions from both CNSs and 
StRs in all four teams was that when contributions were successful it was often 
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because lower status groups held unique knowledge about a patient. This 
knowledge was gained as a result of being the person who had seen the patient 
most recently, or as a result of having developed a relationship with them over 
time. When lower status groups were in possession of this unique knowledge they 
could use it to establish credibility and create opportunities to contribute by 
complementing the knowledge and expertise held by others.  
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Table 27: Summary of approaches used by lower status groups and impact of contributions 
 
 
 
 
APPROACH USED 
OUTCOME 
Prompts discussion Influences treatment plan Promotes team work 
CNS StR CNS StR CNS StR 
Sharing information       
Asking questions       
Providing practical 
suggestions or alternatives 
      
Framing        
Using humour        
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Chapter 9. Understanding lower status contributions in 
the MDT context  
 
The previous chapter presented the findings from Thematic Analysis II, exploring 
the approaches used by CNSs and StRs to contribute during MDT meetings and their 
impact on the decision making process. In this chapter I go on to integrate these 
findings with those from Thematic Analysis I (presented in Chapters 5, 6 and 7). 
Thematic Analysis I explored the decision making process, the effects of status 
hierarchies and the factors that influenced multidisciplinary discussion in the four 
MDTs. Integrating these analyses by considering the patterns of CNS and StR 
participation in light of key MDT features provides a richer context in which to 
explore the contributions of lower status groups.  
 
Table 28 maps out the team features identified in Thematic Analysis I. This chapter 
will explore patterns of CNS and StR contributions in relation to each of these. 
 
Table 28: Summary of MDT features identified in Thematic Analysis I  
Team feature Key components Location in text 
Specialty Haematology Chapter 5 described the research 
setting, including the specialties 
under study, the size of the teams 
and membership 
Gynaecology 
Skin 
Team structure Team size 
Seating arrangements Chapter 7 described the role of 
seating arrangements on 
multidisciplinary discussion 
Decision 
making 
processes 
Power and prestige order Chapter 6 reviewed the decision 
making process in the four MDTs 
against the key components of 
Berger’s power and prestige order 
Initial case presentation Chapter 7 explored the use of three 
approaches to introduce cases for 
discussion in the MDT meeting 
Leadership Prioritising efficiency Chapter 7 identified key aspects of 
leadership behaviour that played a 
role in facilitating or inhibiting 
multidisciplinary discussion 
Inclusive leadership  
Lack of structure  
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9.1 Specialty and lower status contributions 
The four teams encompassed three different specialties: haematology cancers, 
gynaecology cancers and skin cancers. There were a number of similarities between 
the two Haematology teams, which enables them to be grouped together and 
compared with Skin and Gynaecology. First, both Haematology teams had a similar 
case mix, and discussed a similar number of patients each week (an average of 14 
and 15). Secondly, in both teams leadership was provided by a consultant 
haematologist, who brought a clear structure to the meeting, and it was unusual for 
patients to be discussed without being formally presented first to the team. A third 
team characteristic related to specialty which distinguished the Haematology teams 
from Skin and Gynaecology was the composition of membership, notably the 
presence of multiple Consultant Haematologists and the absence of surgical 
professionals (reflecting the nature of haematology cancers as diseases of the 
blood). 
 
The following section will consider the role of specialty on the contributions of StRs 
and CNSs across the teams. 
 
Specialty and StR contributions 
Reflecting their shared specialty, there were similarities in the patterns of successful 
contributions from StRs in the two Haematology teams. In particular, StRs in both 
Haematology teams contributed proportionately much more frequently than those 
in Gynaecology or Skin (Table 29, p. 240).  
 
In addition, Table 29 illustrates that StRs in the Haematology teams influenced a 
wider range of decision making processes than StRs in the other two teams. 
Haematology StRs successfully prompted discussion, influenced treatment plans, 
and promoted team work. In contrast, StRs in Gynaecology and Skin were only 
successful in prompting discussion, with the exception of one example in Skin 
where an StR influenced a treatment plan.  
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Table 29: StR contributions by team and outcome 
Team Case 
discussions* 
Number 
of StRs 
Prompts 
discussion 
Influences 
decision 
Facilitates 
teamwork 
Total  
Gynae  17 4-6 5 0 0 5 
Haem1  20 2-3 16 10 4 30 
Haem2  20 Up to 10 22 7 6 35 
Skin  31 2-4 5 1 0 6 
* The number of case discussions selectively transcribed for Thematic Analysis II 
 
Given the similarities in disease type and caseload between the two haematology 
teams, it is possible that the higher frequency of StR contributions reflects the 
nature of the specialties involved. This fits with the profile of haematology patients, 
and their relationship with members of the MDT. Haematology patients are often 
well known to members of the team given the nature of their illness, which can 
extend over long periods of time, and which often involves ongoing monitoring, 
treatment and support (O’Connor and Townsend, 2009). For example, in 
Haematology 1, it was the responsibility of the StRs to review patients regularly, 
and in advance of every cycle of treatment.  
 
In contrast, the surgical input that forms a core part of gynaecology and skin cancer 
treatment is much more likely to involve a discrete intervention at a fixed point in 
time during one part of a patient’s cancer pathway. As a result, StRs in Skin and 
Gynaecology described having little knowledge of the individual patients being 
discussed during the meeting. This was further compounded by the high caseload of 
patients in the two surgical specialties. There were an average of 47 cases discussed 
in the Skin team each week and 35 in Gynaecology, in comparison with 14 and 15 
cases in the two Haematology teams. This suggests that StRs in Haematology were 
more likely to hold unique information. In this context it is perhaps unsurprising 
that they contributed more frequently than StRs in other specialties.  
 
Specialty and CNS contributions 
However, while specialty might help to explain patterns of StR participation, it does 
not appear to account for differences in participation between CNSs. As Table 30 
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shows, there were marked differences in the frequency of CNS contributions 
between the four teams. The CNS in Skin contributed more frequently than CNSs in 
any of the other three teams. It is also notable that there were clear differences 
between teams in the same specialty. CNSs in Haematology 1 contributed much 
more frequently than CNSs in Haematology 2. CNSs in Haematology 1 also used a 
wider range of strategies to contribute than CNSs in Haematology 2. These 
differences suggest that factors other than specialty played a role in influencing 
successful CNS contributions.  
 
Table 30: CNS contributions by team and outcome 
Team Case 
discussions 
Number 
of CNSs 
Prompts 
discussion 
Influences 
decision 
Facilitates 
teamwork 
Total  
Gynae  17 3 19 10 4 33 
Haem1  20 2 10 16 2 28 
Haem2  20 5 3 5 2 10 
Skin  31 1 25 21 13 59 
 
To understand differences in CNS contributions, it is necessary to consider what 
factors other than specialty differentiated the four teams. A key difference between 
the two haematology teams was that Haematology 2 was a specialist MDT providing 
transplant services, while Haematology 1 provided a less specialist level of care. In 
practice this meant that Haematology 1 had to refer patients on to another centre if 
a transplant was required. Although this happened relatively infrequently, it is 
possible that the lower frequency of successful CNS contributions in Haematology 2 
reflected a need for greater medical input in more complex cases. However, there 
were other differences between the four MDTs that may better explain these 
patterns of CNS participation. These include the size of the team, the seating 
arrangements and the leadership style of the MDT Lead. Each of these factors will 
be considered in the sections that follow.   
 
9.1.1 Summary of the impact of specialty on lower status contributions 
The influence of specialty in terms of the nature of patients being discussed, 
including their diseases and the treatment required, appeared to be reflected in the 
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patterns of participation amongst StRs across the four teams. Specifically, StRs 
contributed successfully more frequently in the two Haematology teams, where 
they were more likely to have regular interaction with patients, than they did in 
Gynaecology or Skin. However, this pattern was not evident amongst CNSs, 
suggesting that specialty did not necessarily influence the contributions of CNS and 
StR in the same way. To understand these differences it is necessary to consider 
other factors that differentiated the four teams.  
 
9.2 Team structure and lower status contributions 
In addition to differences in specialty, there were structural differences between 
the four teams in their size, as well as in their physical seating arrangements. In the 
following section I will explore the interaction between these structural features 
and the contributions made by lower status groups in the four MDTs.  
 
9.2.1 Team size 
Of the four teams Haematology 2 was by far the largest, followed by Gynaecology. 
Both of these teams were noticeably larger than Haematology 1 and Skin. This was 
also reflected in team composition: Haematology 1 and Skin were not only smaller 
overall, but they also had fewer lower status individuals in attendance at MDT 
meetings (Table 31).  
 
Table 31: Summary of contributions by team size and composition  
 
It might be expected that a greater number of CNSs and StRs would provide 
increased opportunities for lower status professionals to contribute, and that teams 
with more CNSs and StRs would therefore have a higher frequency of lower status 
Team Case 
discussions 
Size Number 
of CNSs  
Number 
of StRs 
Successful contributions 
StR CNS Total 
Gynae  17 28 3 4-6  5 33 38 
Haem1  20 17 2 2-3  30 28 58 
Haem2  20 40 5 Up to 10 35 10 45 
Skin  31 21 1 2-4  6 59 65 
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contributions. This would reflect both a greater critical mass of lower status 
individuals in the meeting, and an increase in the likelihood that at least one lower 
status member had met a patient being discussed.  
 
However, the range and frequency of approaches used by lower status groups 
across the teams suggest that this was not the case. As illustrated in Table 31 (p. 
242), overall, lower status groups contributed more frequently in the two smaller 
teams (Skin and Haematology 1) than they did in the two larger teams (Gynaecology 
and Haematology 2) – in spite of having fewer StRs and CNSs in attendance. This 
suggests that smaller teams, with fewer members, provided greater opportunities 
for lower status groups to contribute.  
 
Nonetheless, although this pattern was evident at the level of the team, there was a 
more nuanced pattern of participation evident when considering CNS and StR 
contributions separately.  
 
Team size and StR contributions 
There was in fact little consistency in patterns of participation according to team 
size when considering StR contributions in isolation. Thus, StRs in the smallest team 
(Haematology 1) did contribute successfully more frequently than StRs in 
Gynaecology, which was much larger and had more StRs. However, both 
Haematology teams had similar levels of successful StR participation, despite 
striking differences in team size. Furthermore, Gynaecology and Skin, as a large and 
a small team respectively, both had relatively low frequencies of successful StR 
participation. In this context, team size did not appear to be central to the patterns 
of participation observed.  
 
Instead, and as outlined in the discussion above, it appeared that the common 
factor underpinning patterns of StR contributions was specialty, with the most 
pronounced similarity being between the two haematology teams. This suggests 
that the features distinctive to haematology as a cancer specialty – particularly the 
Integration of Findings 
244 
 
smaller case size and more frequent contact with patients that define the 
haematology StR role – may provide greater opportunities for StRs to contribute in 
the MDT meeting setting.  
 
Team size and CNS contributions 
In contrast, the pattern of higher frequencies of successful contributions amongst 
smaller teams with fewer CNSs was more distinct. This was evident in three of the 
four teams. To illustrate, Table 31 (p. 242) shows that the sole CNS in Skin, the 
second smallest team, contributed successfully more frequently than CNSs in any of 
the other teams, and more frequently than the five CNSs in Haematology 2 
combined.  
 
The exception to this pattern was Gynaecology. This was a large team, with the 
second highest number of CNSs. Nonetheless, this team had the second highest 
frequency of successful CNS contributions, despite having a shorter observation 
period than any of the other three teams and a correspondingly smaller dataset to 
theoretically sample from. This suggests that in this team there were other factors 
mitigating the effects of team size, which enabled CNSs to contribute successfully 
more frequently.  
 
To explore this further, the next section considers one of the key factors that 
differentiated the two largest teams. As described in Chapter 7, the Haematology 2 
and Gynaecology teams had different approaches to seating arrangements in the 
MDT meeting. 
  
9.2.2 Seating arrangements 
Chapter 7 concluded that hierarchical seating arrangements, where higher status 
individuals sat at the front of the room and lower status sat at the back, had the 
potential to inhibit multidisciplinary discussion. This was identified as a barrier to 
lower status contributions in Haematology 2, and in Gynaecology, which were both 
large teams where the meeting room was often at full capacity. In contrast, the 
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seating arrangements in Haematology 1 and Skin were less obviously hierarchical 
and as smaller teams there was less competition for space (Table 32). 
 
Table 32: Summary of contributions by team and seating arrangements  
Team Case 
discussions 
Hierarchical seating 
arrangements 
Successful contributions 
StR CNS Total 
Gynae  17 Yes (but challenged by CNSs) 5 33 38 
Haem1  20 No 30 28 58 
Haem2  20 Yes 35 10 45 
Skin   31 No 6 59 65 
 
Seating arrangements and StR contributions 
Chapter 7 also highlighted the importance of visibility in creating opportunities to 
contribute. This factor appeared to be less important for StRs than CNSs, as StRs did 
not sit in the front row in any of the four teams (except on fewer than a handful of 
very rare occasions, for example if they were representing a consultant member of 
the team who was absent). In general however, while StRs in Skin and Gynaecology 
sat towards the back of the room, in Haematology 1 and Haematology 2 StRs 
tended to sit in the middle. These differences appeared to align with the differences 
described above in relation to specialty, with similarities in the seating 
arrangements of StRs in both Haematology teams, and correspondingly higher 
frequencies of successful contributions than in the other two teams. In Skin and 
Gynaecology, where StRs often sat towards the back of the room, there were lower 
frequencies of successful contributions. This suggests a pattern where those sitting 
at the back were less likely to contribute than those sitting closer to the front. The 
observation and interview data described in Chapter 7 provided an insight into why 
this might be the case by illustrating that it could be harder to hear and be heard in 
the back rows.   
 
Seating arrangements and CNS contributions  
Given the importance of visibility in creating opportunities to contribute, it might be 
expected that in teams where CNSs sat alongside consultant members of the team, 
they would have higher frequencies of successful contributions. Table 32 provides 
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support for this view, with the CNS in Skin – who sat next to the MDT Lead in the 
front row each week – having the highest frequency of successful contributions 
across the four teams. In contrast, CNSs in Haematology 2, who sat clustered 
together at the back of the room, had a much lower frequency of successful 
contributions than any of the other three teams.  
 
This potential explanation is further strengthened when considering the similarities 
and differences between Haematology 2 and Gynaecology. As described previously, 
both teams were large, and higher status individuals tended to cluster in the front 
two rows of seats. This created a well-established hierarchical seating arrangement.  
 
However, the evidence presented in Chapter 7 showed that CNSs in the 
Gynaecology team challenged these hierarchical seating arrangements, by actively 
positioning themselves in the front rows, even if this meant ‘pulling a chair 
forward’. There was no evidence of this amongst CNSs in Haematology 2. In this 
context, and in spite of a shorter observation period, CNSs in Gynaecology 
contributed successfully markedly more frequently than CNSs in Haematology 2 
(Table 32, p. 245). This meant that overall, CNSs in Gynaecology were more likely 
than CNSs in Haematology 2 to prompt discussion, to influence a treatment plan, 
and to promote teamwork. This suggests that challenging the hierarchical seating 
arrangements was a key mechanism for CNSs in Gynaecology to overcome some of 
the barriers to multidisciplinary discussion.  
 
9.2.3 Summary of impact of team structure on lower status contributions 
It was possible to differentiate between the four teams based on their size, with 
Haematology 2 and Gynaecology being notably larger than Skin and Haematology 1. 
Similarly, hierarchical seating arrangements were more evident in the two largest 
teams, although these were challenged in Gynaecology but not in Haematology 2. 
By considering lower status contributions in the context of these structural 
differences, it has been possible to identify some tentative explanations for the 
patterns of participation observed.  
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First, it is clear that structural factors do not necessarily influence CNS and StR 
patterns of participation in the same way. Team size, for example, appeared to be 
of particular importance to CNS contributions, with smaller teams with less 
hierarchical seating arrangements providing greater opportunities for CNS 
contributions. This is in keeping with previous research that has shown that 
individuals are likely to contribute more in smaller groups (Morrison, 2011). 
However, this was less evident in relation to StR contributions, and it was also 
notable that in Gynaecology (which was a large team) where CNSs challenged the 
hierarchical seating arrangements they contributed more frequently than CNSs in 
Haematology 2 where they did not. This highlights the potential for lower status 
groups to mitigate the effects of a large team, for example by considering their 
physical placement.  
 
9.3 MDT processes and lower status contributions 
In addition to the structural differences described above, teams also differed in 
relation to some aspects of the decision making process. Chapter 6 described the 
power and prestige order in the four teams, and Chapter 7 described different 
approaches to the way that cases were initially presented for discussion in MDT 
meetings. The following section considers the interaction between these processes 
and lower status contributions in the four MDTs. 
 
9.3.1 The power and prestige order  
Chapter 6 described significant similarities across the teams in relation to the power 
and prestige order, with lower status groups being less likely to initiate participation 
and receiving fewer opportunities to participate than higher status members. Lower 
status individuals also had less influence than surgical, medical and diagnostic 
consultants in all four teams. Within this framework however, there were two key 
differences between the teams in terms of opportunities to participate. The first 
difference related to perceptions amongst members of the Gynaecology team 
about the amount of time spent reviewing imaging and pathology, at the expense of 
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professionals with other types of information to contribute. The second related to 
differences in perceptions amongst lower status groups in the four teams about the 
extent to which they were able to speak freely during MDT meetings.   
 
Differences in time spent reviewing imaging and pathology 
The first difference related to the proportion of time spent reviewing imaging and 
pathology in Gynaecology in comparison with the other three teams. Although time 
spent reviewing scans was essential in enabling surgical members of the team to 
plan a patient’s surgical treatment, the proportion of time that this took up during 
the meeting was raised as an issue of concern by five of the seven team members 
interviewed. Given the fixed period of time available each week for the MDT 
meeting, time spent discussing imaging and pathology impacted on the time 
available for other types of information. Interview data from the Gynaecology team 
indicated that this could exclude less experienced junior doctors and those from a 
psychosocial background from discussion. These views appear to be supported by 
the data showing that the overall frequency of lower status contributions in 
Gynaecology was the lowest of the four teams observed (Table 31, p. 242).  
 
However, the shorter observation period in this team makes it difficult to draw firm 
conclusions about this. In addition, although the frequency of successful StR 
contributions in this team was low, the relatively high frequency of successful CNS 
contributions has already been noted. Table 31 (p. 242) indicates that CNSs were no 
less likely to contribute in this context than in other teams where less time was 
spent reviewing imaging or discussing pathology. This was the case despite the 
perception of team members that extended periods of time spent reviewing 
imaging during the meeting was problematic.  
 
Differences in perceptions amongst lower status groups 
The second difference between the teams in the power and prestige order related 
to reported perceptions of lower status groups, about the extent to which they felt 
able to speak freely in the MDT meeting. In Haematology 2, the view of the CNS 
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interviewed - that the meeting was a place for doctor to doctor communication - 
fits with the low frequency of successful CNS contributions in this team. In contrast, 
perceptions about the extent to which lower status groups felt able to speak up 
were more positive in Haematology 1 and Skin, the two teams with the highest 
frequency of lower status contributions. These perceptions are in keeping with 
some of the other characteristics that differentiated the teams, for example, seating 
arrangements and leadership style, which also appeared to influence levels of 
participation. 
 
Again, however, the exception to this was in Gynaecology. The view was expressed 
by the CNS and StR interviewed in the Gynaecology team that there were limited 
opportunities for their contributions during the MDT meeting. This was also 
evidenced in the observation data when on a small number of occasions lower 
status individuals were ignored or talked over. In this context, the relatively high 
frequency of CNS contributions is unexpected. Again, this highlights that CNSs were 
contributing successfully in spite of the barriers documented. Notably however, this 
was not the case for StRs.  
 
9.3.2 Initial case presentations 
Chapter 7 identified three approaches to introducing a case for discussion in the 
MDT: those where there was no formal case presentation, clinically focused case 
presentations and holistically focused presentations. However, these approaches 
were used in all four teams. As a result, it is difficult to identify discernible patterns 
in the data at the level of the team, which may have shaped the patterns of 
participation observed amongst lower status groups.  
 
Interview data from the Gynaecology team did suggest that the lack of a case 
presentation was a barrier to multidisciplinary discussion. This was because it could 
exclude those who did not know a patient well from contributing. It is possible that 
this is reflected in the low frequency of StR contributions in this team, although, 
again, it does not explain the relatively high frequency of CNS contributions. While 
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in Skin there were also cases discussed without a formal case presentation, this was 
attributed more to the specific case mix in the team, and the difference between 
melanoma and SCC and BCC cases. In common with the findings above, there were 
marked similarities between the two Haematology teams.  
 
9.3.3 Summary of the impact of MDT processes on lower status 
contributions 
At a high level, all four teams followed similar decision making processes, and used 
a mix of approaches to present cases for discussion. Differences in team processes 
were therefore less marked than structural differences. However, the perceptions 
of lower status individuals about the extent to which they were able to speak freely 
largely aligned with patterns in the frequency of lower status contributions. Thus, in 
Skin and Haematology 1, where lower status individuals interviewed provided a 
positive assessment of their ability to speak up freely during the MDT, there were 
higher frequencies of lower status contributions. Conversely, in Haematology 2, a 
less positive assessment from the CNS interviewed appeared to be reflected in the 
low frequency of successful CNS contributions. These findings are supported by 
literature that suggests that a key explanation for a failure to contribute in a team 
environment is a sense of futility about the value of speaking up (Morrison, 2011). 
The exception to this pattern was amongst CNSs in Gynaecology, who contributed 
comparatively more frequently than CNSs in Haematology 1 and 2, despite more 
frequent reports (from a wide range of professionals) of barriers that limited 
opportunities for multidisciplinary discussion.  
 
9.4 Leadership style and lower status contributions 
Chapter 7 described the leadership styles observed in each of the four teams, 
identifying three factors that could inhibit multidisciplinary discussion: the MDT 
Lead prioritising efficiency during discussion, a lack of structure, and the MDT Lead 
combining chairing and documenting of decisions. In contrast, when an MDT Lead 
demonstrated inclusive leadership behaviours, such as directly soliciting 
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contributions from lower status individuals using verbal and non-verbal cues, this 
could facilitate multidisciplinary discussion. The following section will consider these 
factors in relation to the contributions made by lower status groups in each team. 
 
9.4.1 Prioritising efficiency 
The MDT Leads in Gynaecology and Haematology 2 both clearly prioritised 
efficiency during MDT discussions. This was in contrast to Haematology 1, and 
partly in contrast to the Skin team, where efficiency was prioritised in lower risk SCC 
and BCC cases, although less so for melanoma cases (Table 33).  
 
The overall frequency of successful contributions from lower status individuals 
provides some support for the view that an emphasis on efficiency could inhibit 
multidisciplinary discussion. As illustrated in Table 33, there were proportionately 
fewer lower status contributions in Gynaecology and Haematology 2 than there 
were in Skin or Haematology 1. Again, however, the pattern is more nuanced when 
considering StR and CNS contributions separately. 
 
Table 33: Summary of contributions by team and MDT leadership style  
Team Case 
discussions 
MDT Lead prioritises 
efficiency 
Successful contributions 
StR CNS Total 
Gynae  17 Yes 5 33 38 
Haem1   20 No 30 28 58 
Haem2  20 Yes 35 10 45 
Skin  31 SCC and BCC cases only 6 59 65 
 
Prioritising efficiency and StR contributions 
Frequencies of successful contributions amongst StRs in Gynaecology, Skin and 
Haematology 1 provide further evidence that an emphasis on efficiency could 
inhibit multidisciplinary discussion (Table 33). In Gynaecology, where efficiency was 
a defining feature of the MDT Lead’s style, there were correspondingly low 
frequencies of successful contributions from StRs. In Skin, a team with 
proportionately low StR contributions, some StRs visibly struggled to keep up with 
the discussion and recording of decisions when the team prioritised efficiency in 
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order to progress quickly through a long list of SCC and BCC cases. In contrast, in 
Haematology 1, where efficiency was not prioritised by the MDT Lead, StRs had 
comparatively higher rates of successful contributions. 
 
The exception to this pattern was in Haematology 2. In this team StRs had similar 
(and slightly higher) rates of successful contributions to StRs Haematology 1, in spite 
of differences in the approach of the respective MDT Leads to efficiency. It is 
possible therefore that efficiency was less of a barrier to StR contributions - which 
were predominantly information sharing contributions - in certain circumstances. 
For example, aside from the knowledge of patients more typically held by StRs, 
another factor that was common to both Haematology teams (and distinct from 
Gynaecology and partially in Skin) was the role of the MDT Lead in providing a clear 
structure during discussion. It may be the case that in this environment it was easier 
for StRs to share information, even when efficiency was prioritised.  
 
However, it is also possible that StRs in Haematology 2 were adapting to the 
leadership style in order to ensure the success of their contributions. Table 34 and 
Table 35 (p. 253) illustrate the approaches used and outcomes achieved by StRs in 
Haematology 2 and Haematology 1. The most notable difference between the 
teams is that StRs in Haematology 2 were more likely to use framing as an approach 
to contribute successfully, than StRs in Haematology 1 (who were more likely to 
make practical suggestions). It is possible therefore that StRs in Haematology 2 
were actively responding to the time pressured environment by framing their 
contributions in a way that resonated with higher status members of the team.  
 
Table 34: Summary of StR contributions and approaches used in Haematology 2  
Haem 2 (n=20) StR prompts 
discussion 
StR influences 
decision 
StR promotes 
teamwork 
Total  
Sharing information 14 3 6 23 
Asking questions 4 0 0 4 
Practical suggestions 0 0 0 0 
Framing 4 4 0 8 
Using humour - - - - 
Total 22 7 6 35 
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Table 35: Summary of StR contributions and approaches used in Haematology 1 
Haem 1 (n=20) StR prompts 
discussion 
StR influences 
decision 
StR promotes 
teamwork 
Total  
Sharing information 12 4 4 20 
Asking questions 2 3 0 5 
Practical suggestions 2 3 0 5 
Framing 0 0 0 0 
Using humour - - - - 
Total 16 10 4 30 
 
Prioritising efficiency and CNS contributions 
Turning to consider CNS contributions, there is no clear pattern to suggest an 
association between an emphasis on efficiency and less frequent CNS contributions. 
Although the CNS interviewed in Haematology 2 directly attributed her reluctance 
to contribute to a perception that there was limited time during the meeting for 
CNS contributions, the higher frequencies of successful contributions amongst CNSs 
in Gynaecology and in Skin suggest that factors other than efficiency were 
important. This is particularly salient given that in the Gynaecology team CNSs were 
also contributing in an environment where there was often a lack of structure 
during discussion, and where the MDT Lead was responsible for chairing the 
meeting and documenting the agreed treatment plan. All three of these factors 
were identified as potential barriers to multidisciplinary discussion in Chapter 7. 
 
To explore this further I will go on to consider the factors identified that facilitated 
multidisciplinary discussion. It is possible that inclusive leadership behaviours 
enabled lower status individuals to minimise the effects of these barriers. 
 
9.4.2 Inclusive leadership behaviour 
Chapter 7 identified inclusive leadership behaviours that facilitated multidisciplinary 
discussion, in particular when MDT Leads solicited contributions directly from lower 
status members of the team using verbal or non-verbal cues. This was observed in 
Haematology 1, and in Skin. Although the MDT Lead in Haematology 2 also sought 
opinions and consensus within the team, this was not targeted at, or capitalised on 
by, lower status groups specifically.   
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As illustrated in Table 36 in teams where inclusive leadership behaviours were 
demonstrated during the observation period there were higher levels of successful 
contributions from lower status groups. There was also a clear pattern between the 
target of verbal or non-verbal cues, and the frequency of successful contributions. 
This is reflected most clearly in the relatively evenly-balanced contributions of CNSs 
and StRs in Haematology 1, where the MDT Lead directed cues at both StRs and 
CNSs, but also in the higher frequencies of CNS contributions in Skin.  
 
The relatively high frequency of CNS contributions in the Gynaecology team is again 
notable, given the absence of inclusive leadership behaviours evidenced by the 
MDT Lead. However, another important factor identified in Chapter 7, which was 
specific to the Gynaecology team, related to the support provided for CNSs by a 
Consultant Psychologist in the team. Although the Consultant Psychologist was not 
responsible for chairing the meeting, as a senior member of the psychosocial team, 
this provided an additional source of leadership support for clinical nurse 
specialists. In seven of the 10 selective transcripts where a CNS successfully 
contributed in Gynaecology7, the psychologist contributed too. It is possible that 
this alternative source of support and leadership is another factor that helps to 
explain the relatively high frequency of CNS contributions in this team. 
 
Table 36: Summary of contributions by team and inclusive leadership behaviours 
Team Case 
discussions 
MDT Lead solicits contributions 
directly 
Successful contributions 
StR CNS Total 
Gynae  17 No 5 33 38 
Haem1   20 Yes – CNS and StR 30 28 58 
Haem2  20 No 35 10 45 
Skin  31 Yes – directed at CNS 6 59 65 
                                                     
7
 As described in Chapter Four, of the 17 case discussions selectively transcribed from the 
Gynaecology team, 10 contained input from CNSs only, five from StRs only and two with input from 
CNSs and StRs. 
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9.4.3 Summary of the impact of leadership on lower status contributions 
This analysis has highlighted that the role of leadership on lower status 
contributions was complex. In part, this reflects the fact that leadership behaviours 
that facilitated, and those that inhibited lower status contributions, were often 
present within the same team. It was also evident that inclusive leadership 
behaviours did not necessarily benefit all professional groups in the MDT context 
simultaneously. Thus, apparently inclusive leadership behaviours could be directed 
towards specific professional groups, without necessarily extending to others. This 
would explain the fact that in some teams, notably Skin and Gynaecology, there 
were considerable imbalances in the frequency of participation between CNSs and 
StRs. Finally, the examples from Gynaecology also illustrate that other members of 
the team (aside from the MDT Lead) could play a role in countering the effects of 
leadership behaviours that might otherwise inhibit lower status contributions.  
 
9.5 Team summaries 
Having considered the role of team features on StR and CNS contributions across 
the four teams, this chapter will conclude by briefly summarising their influence 
within each team. It will also incorporate findings from Chapter 8 to consider the 
role of lower status groups in facilitating multidisciplinary discussion. 
 
9.5.1 Gynaecology 
In Gynaecology, there was a range of factors that had the potential to inhibit 
multidisciplinary discussion, including large team size, a high caseload (which meant 
that patients were not always well known), hierarchical seating arrangements, 
negative perceptions amongst lower status groups about speaking up in the MDT 
meeting, and an MDT Lead who prioritised efficiency during discussion. This was 
reflected in the low frequency of StR contributions. However, it was much less 
evident in relation to CNS contributions. This suggests that there were important 
factors mitigating barriers to CNS contributions in this team, which did not impact 
on StRs in the same way. 
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The analysis provided a number of potential explanations. First, CNSs in this team 
adopted a wide range of approaches in order to contribute (drawing on all five 
approaches identified in Chapter 8, in comparison with StRs who adopted three). 
Secondly, in this team CNSs also challenged the hierarchical seating arrangements, 
by positioning themselves alongside consultant members of the team. In addition, 
an important source of leadership and support for the CNS team was provided by a 
psychologist who attended these meetings. There was no equivalent to this role 
observed in any of the other three teams under study. 
 
9.5.2 Haematology 2 
CNSs in Haematology 2 faced many of the same barriers to those in Gynaecology, 
including a large team size, hierarchical seating arrangements, negative perceptions 
of the ability of lower status groups to speak up in the MDT meeting, and an MDT 
Lead who prioritised efficiency. However, there appeared to be less in the way of 
factors to counteract these. In particular, the MDT Lead rarely directly invited 
contributions from psychosocial members of the team. In addition, CNSs 
themselves appeared less likely to challenge barriers to their participation. This was 
reflected in the comparatively low frequency of CNS contributions in this team, and 
in the narrower range of approaches used by CNSs when they did contribute (only 
three out of the five approaches that were evident in the Gynaecology team for 
example).  
 
In contrast, for StRs, it appeared that specialty was a key influence, reflecting 
differences in caseload and the amount of time spent with the patients being 
discussed by the team as a result of the nature of their disease. There was also 
some evidence that StRs in Haematology 2 responded directly to cues in the 
environment. This included framing their contributions in medical or surgical terms 
as an approach to capture the attention of higher status members of the team in 
response to the emphasis on efficiency. 
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9.5.3 Haematology 1 
In turn, Haematology 1 had fewer of the features identified as potential barriers to 
multidisciplinary discussion. It was a small team, the MDT Lead adopted inclusive 
leadership behaviours, and both StR and CNS reported in interview that they felt 
comfortable contributing and that they would be listened to. However, it was 
acknowledged that most communication was doctor to doctor and Chapter 6 
described how the MDT Lead expressed the view that there was scope for more 
contributions from other members of the team. In this context, the overall 
frequency of contributions in this team was not noticeably higher than in others (it 
was the second highest overall). It is possible that this reflects findings from the 
literature, which suggest that decisions about whether to speak up in a team can be 
influenced by implicit assumptions about whether a contribution is likely to be 
effective based on factors such as previous experience of team working, 
professional socialisation and learning (Detert and Edmondson, 2011).  
 
Nonetheless, a key feature of lower status contributions in this team was the 
relatively even pattern of participation between CNSs and StRs. This was in contrast 
to the other teams, where there were marked differences in frequency between 
CNS and StR participation. As a result, it could be argued that the approach in 
Haematology 1 reflected a more open forum for discussion for both CNSs and StRs – 
one where multidisciplinary discussion was not necessarily more frequent, but 
where when it did take place, it did so in a way that engaged all team members in 
discussion. 
 
9.5.4 Skin 
Of all the teams, it is most difficult to disentangle the potential role of structural, 
process and leadership factors on lower status contributions in the Skin team. There 
are two main reasons for this. First, in this team, there were variations in processes 
and leadership style depending on the type of case being discussed (melanoma 
cases versus SCC and BCC cases). Secondly, there was only one CNS, and it is 
possible that the higher frequency of contributions could be a reflection of a 
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specific style or personality. Nonetheless, it remains the case that supportive factors 
such as the smaller size of the team, the non-hierarchical seating arrangements, and 
inclusive leadership behaviors, were evident in this team. In the context of the data 
from the three other teams, this suggests that these factors were also likely to have 
played a role in the higher frequency of CNS contributions in Skin.   
 
9.6 Chapter Summary 
This chapter integrated the findings from Thematic Analysis I and II in order to 
deepen our understanding of the role of specialty, team structure, decision making 
process and leadership factors on the contributions of lower status groups in the 
MDT setting. In doing so, it has demonstrated that there was no single factor that, 
in isolation, could fully explain the patterns of participation amongst lower status 
groups.  
 
Instead, different combinations of team and individual factors appeared to be 
important. Team factors such as size and specialty (and corresponding differences 
in the nature of cases being discussed) presented challenges to and opportunities 
for multidisciplinary discussion. At the same time, both higher and lower status 
individuals played a role. Higher status individuals could provide support for lower 
status contributions by demonstrating inclusive leadership behaviours. In turn, 
lower status individuals were observed adopting different strategies to contribute 
as well as challenging hierarchical seating arrangements.
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Chapter 10. Discussion and Conclusions 
 
This thesis set out to explore the role of status hierarchies in the decision making 
process in cancer MDT meetings. Following an introductory chapter, Chapter 2 
described the policy context that MDTs operate in, noting proposals in the most 
recent national cancer strategy to adopt a more streamlined approach to discussing 
cases in the MDT meeting. Chapter 2 also reviewed the literature on cancer MDTs, 
highlighting inequalities in participation between different professional groups, with 
limited contributions from CNSs in particular. This was identified as being 
potentially problematic, given their role in contributing patient centred information 
to the decision making process. It also became apparent that little consideration 
had been given to the role of junior doctors in the MDT meeting.   
 
Chapter 3 then presented the theoretical framework underpinning the study, 
examining evidence of the effects of status hierarchies on efficiency, information 
sharing and discussion within teams. However, it was clear that existing solutions 
designed to encourage the participation of lower status groups, drawn from the 
theoretical and empirical literature on status hierarchies, would not necessarily be 
transferrable to the MDT setting. This was because it was unlikely to be practical or 
desirable to involve all professionals in every discussion. 
 
Building on the existing policy and research literature, this thesis addressed three 
research questions, which were set out in Chapter 4. Chapter 5 described the 
methodological approach taken to address these questions. Chapters 6 and 7 used 
observation and interview data from four cancer MDTs to consider the way that 
status hierarchies unfolded during the decision making process, and to explore the 
factors that facilitated or inhibited multidisciplinary discussion. Chapter 8 then 
sought to identify approaches used by lower status groups to contribute in MDT 
meetings using data from 88 cases across the four cancer MDTs.  
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Chapter 9 considered these approaches in light of the key team features presented 
in earlier chapters in order to deepen understanding of the structural, process and 
leadership features of MDTs on the contributions of lower status groups. 
 
This chapter summarises the key findings as they relate to each of the three 
research questions posed, and considers them in light of the existing literature. It 
also explores the implications of the findings for my original theoretical framework, 
before reviewing the main limitations of the study and my approach to the 
research. The chapter concludes by considering the implications for policy and 
practice and suggests possible areas for further research.  
 
10.1 Summary of key findings 
A summary of the main findings are provided in Box 6. 
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Box 6: Summary of key findings 
How do status hierarchies unfold during the decision making process in cancer 
MDT meetings? 
1) Higher status medical and surgical consultants played a dominant role at 
each stage of the decision making process in Haematology, Gynaecology and 
Skin cancer MDTs. In many cases this promoted efficient decision making, by 
aligning expertise with influence. However, some CNSs and StRs reported 
being reluctant to speak up, and their contributions were not always taken 
on board by other team members. 
2) CNSs and StRs were more likely than other members of the MDT to hold 
information about patient preferences, psychosocial factors, and physical 
wellbeing, although they only contributed in a subset of cases.  
What factors facilitate or inhibit multidisciplinary discussion? 
3) Multidisciplinary discussion was influenced by team factors, as well as 
behaviours adopted by higher and lower status individuals. 
4) Specifically, factors that inhibited multidisciplinary discussion included large 
team size, hierarchical seating arrangements, a focus on efficiency and a 
lack of structure in discussions. Where the MDT Lead chaired the meeting 
and documented agreed treatment plans, this could also limit 
multidisciplinary discussion. In addition, the lack of a formal case 
presentation or a disease focused case presentation often limited discussion 
to consultant team members.  
5) Factors that facilitated multidisciplinary discussion included non-
hierarchical seating arrangements, support from other team members, and 
direct invitations to contribute, particularly from the MDT Lead. Holistically 
focused case presentations also encouraged participation from lower status 
groups with patient centred information to share. 
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What approaches are used by lower status groups to contribute to MDT 
decision making? 
6) Lower status groups contributed successfully by sharing information, asking 
questions, providing practical suggestions or alternatives to a proposed 
course of action, framing contributions in medical or surgical terms, and by 
using humour. These approaches prompted discussion, influenced 
treatment plans and facilitated teamwork. 
7) CNSs and StRs contributed successfully in cases where medical factors (such 
as relapsed disease or presence of complex comorbidities) or non-medical 
factors (such as strong patient preference or psychosocial needs), had the 
potential to impact on the ability of teams to deliver treatment. 
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10.2 Review of main findings and contributions  
In the section below, I address each of the three research questions in turn, 
reviewing the findings in light of the existing literature, and highlighting my 
independent contribution.  
 
10.2.1 How do status hierarchies unfold during the decision making process 
in cancer MDT meetings? 
Status characteristics theory provided me with a framework to explore the role of 
status hierarchies at each stage of the decision making process in MDT meetings in 
four cancer MDTs. Chapter 6 demonstrated that across all four teams there were 
striking differences in levels of participation and influence between professional 
groups. In particular, medical and surgical consultants were shown to play a central 
role in the decision making process. This finding is consistent with previous research 
on cancer MDTs which has highlighted lower rates of participation in MDT meetings 
amongst CNSs (Lanceley et al., 2008, Kidger et al., 2009, Lamb et al., 2011b), and 
junior doctors (Dew et al., 2014). 
 
Much of this previous research has emphasised the negative implications of these 
patterns of participation (Lamb et al., 2011c, Lamb et al., 2011d, Taylor et al., 
2012a). This has led to suggestions that input from specialist nurses, and 
consideration of patient preferences, should be included more systematically in 
MDT discussions, for example through the use of checklists (Kidger et al., 2009, 
Lamb et al., 2011b, Lamb et al., 2012b). From this perspective, challenging medical 
dominance equates to working towards more equal participation of all 
professionals in MDT meetings (Atwal and Caldwell, 2006). However, in view of the 
pressure on MDT caseloads, there has also been increasing interest in how MDTs 
can balance the need for detailed multidisciplinary discussion of some patients 
against the requirement to discuss large numbers of comparatively straightforward 
cases (Lanceley et al., 2008, Lamb et al., 2014a).  
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My findings add a new perspective to this debate. By drawing on a functionalist 
view of hierarchy I was able to show how capitalising on the status hierarchy 
enabled MDTs to make decisions quickly and efficiently, and in line with their peer 
review obligations. The observation and interview data also enabled me to show 
the ways in which teams streamlined discussion. In the four teams studied, this was 
largely done implicitly during the MDT meeting itself, for example when discussion 
was curtailed by the MDT Lead in straightforward cases, but encouraged in others 
that were more complex. Previous research into the views of urology professionals 
suggests that there is some support for this type of approach, particularly for 
patients with low risk prostate, bladder and renal cancers (Lamb et al., 2014a).  
 
There is also tentative evidence from three focus groups that patients too, with 
prostate, breast, upper gastrointestinal and sarcoma cancers, also recognise the 
need for efficiency in the MDT meeting (Lamb et al., 2014b). This reflects the view 
that extensive discussion of straightforward cases is not necessarily an effective use 
of an expensive, and limited, resource (Chinai et al., 2013, De Ieso et al., 2013, Ryan 
and Faragher, 2014, Sarkar et al., 2014).  
 
At the same time however, the hierarchical patterns of participation that promoted 
efficiency in the MDT meeting also had implications for multidisciplinary 
engagement in the decision making process. Notably, although there was wide 
recognition that lower status groups had a key role to play in sharing patient 
centred information in the four MDTs under study, some CNSs and StRs reported 
feeling excluded from MDT discussion. This echoes findings from previous studies, 
which have shown that embedded patterns of participation along hierarchical lines 
in healthcare teams can make it challenging for lower status groups to share 
information or to contribute - even when this could benefit the decision making 
process (Lichtenstein et al., 2004, Lanceley et al., 2008).  
 
As noted previously, for some MDT discussions, information about a patient’s 
preferences or psychosocial wellbeing can be fundamental to making a decision 
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that reflects their needs and circumstances (Jalil et al., 2013). More generally, there 
are also benefits for teams in encouraging holistic, multidisciplinary discussion even 
if this discussion does not ultimately change a proposed treatment plan. For 
example, sharing information about psychosocial factors can foster empathy 
amongst members of a team and encourage a more holistic approach to care 
overall (Davis et al., 2014).   
 
The literature suggests that there are a number of potential explanations for not 
contributing within a team environment. Although team members may refrain from 
participating because they do not have an opinion to offer, or information to share 
(Dyne et al., 2003), other explanations include fear of negative consequences, such 
as damaging interpersonal relationships, a sense of futility, or implicit, taken for 
granted beliefs about behavioural norms within a group setting (Morrison and 
Milliken, 2003, Detert and Edmondson, 2011).  
 
The impact of time constraints is also important, as evidence suggests that 
knowledge and information sharing decline when teams are working under 
pressure (Campbell and Stasser, 2006). In the MDT setting, longer case discussion 
has been associated with higher quality of information and team contribution 
(Lamb et al., 2013b), and a perceived lack of time has been reported as a barrier to 
the participation of CNSs and allied health professionals (Lanceley et al., 2008, 
Kidger et al., 2009, Devitt et al., 2010).  
 
If, therefore, efficiency is prioritised above all else, there is a risk that cancer MDT 
meetings become little more than ‘tick box exercises’ (De Ieso et al., 2013). In these 
circumstances it is possible that other important elements of the decision making 
process, such as the judgement of other healthcare professionals, and the 
preferences and circumstances of individual patients themselves, will be overlooked 
or diminished (Blumenthal, 2004).  
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In light of these factors, striking a balance between efficient decision making and 
incorporating the patient centred contributions of lower status professionals, is 
likely to be an ongoing challenge for MDTs. My findings from the observation and 
interview data are instructive in this regard because they illustrate the specific 
circumstances in which lower status contributions were integrated into the decision 
making process in the four teams under study. In line with the findings from a 
previous observational study of a gynaecology cancer MDT meeting, I found that 
patient preferences, circumstances and support needs were more likely to be 
mentioned when they potentially impacted on a treatment plan, when patients had 
expressed a strong opinion, or when there was more than one possible treatment 
option (Kidger et al., 2009). In addition, my findings also suggested that these 
factors were more likely to be incorporated in an MDT discussion when patients had 
limited treatment options, or where there were concerns about a patient’s ability to 
cope with treatment, due to age or frailty, vulnerability, or the intensity of the 
required treatment.  
 
These findings add to the emerging literature which has only recently begun to 
consider the factors that may influence whether a case will benefit from MDT 
discussion or not. A handful of studies have recently been undertaken of MDTs in 
colorectal, urology and upper gastro intestinal cancers to identify which patients 
benefit most from MDT discussion. These studies identify factors common across 
tumour type, which challenge the current convention of discussing all new patients 
in an MDT meeting. In particular, it has been shown that patients with recurrent or 
metastatic disease are likely to benefit from a multidisciplinary discussion, either 
because this is more likely to change the proposed treatment plan (Rao et al., 2014, 
Ryan and Faragher, 2014), or because patients are likely to have a higher symptom 
burden and may have more complex support needs (Strong et al., 2012).  
 
Furthermore, a study of colorectal cancer patients in Scotland demonstrates an 
association between improved survival (after more than 6 weeks) and discussion of 
patients with advanced disease in an MDT meeting, which was not evident for 
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patients with operable or early stage disease (Munro et al., 2015). Incorporating my 
findings alongside those from these previous studies, it is possible to begin 
identifying a series of cases that are potentially likely to benefit from MDT 
discussion, based on both medical and non-medical complexity. I discuss the 
implications of these findings for policy, practice and further research in more detail 
below [Section 10.5, p. 283].  
 
10.2.2 What factors facilitate or inhibit multidisciplinary discussion? 
Chapter 7 addressed research question two, by exploring the factors that facilitated 
or inhibited multidisciplinary discussion in MDT meetings. Drawing on observation 
and interview data from four MDTs it considered the physical layout of the 
meetings, the leadership style of the MDT Lead, and the way that a case was 
presented to the team.  
 
The physical environment of the MDT meeting  
The importance of the physical environment of the MDT meeting was a key theme 
to emerge in responses from over 2,000 MDT members to a survey in early 2009, 
about MDT working (National Cancer Action Team, 2010a). My findings suggest that 
this remains a relevant issue for MDTs, by illustrating how hierarchical seating 
arrangements had the potential to exclude some individuals from discussion. This 
was more obvious in the two largest teams (Haematology 2 and Gynaecology), 
suggesting that the size of the team was also important. This finding is consistent 
with previous research, which suggests that individuals are likely to contribute more 
in smaller groups (Morrison, 2011). Previous research has also shown that 
excessively large teams may discourage some members from participating (West 
and Lyubovnikova, 2013), and that large teams are associated with poorer 
information sharing and difficulties in communication (Borrill et al., 2000).  
 
Other researchers have studied the optimal size of healthcare teams. This literature 
suggests that around 12 to 15 members is optimal for healthcare team performance 
(measured in terms of efficiency, quality of technical innovations, adherence to 
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schedules and ability to resolve conflict). Performance has been shown to decline in 
teams that are larger than this (Barrasa et al., 2007). It was notable that all of the 
team meetings I observed were larger than this, with the smallest (Haematology 1) 
having an average of 17 members, and the largest (Haematology 2) on occasion 
having up to 40 individuals present during the MDT meeting.  Nonetheless, while it 
is unusual for teams to be this large outside of healthcare, it is not uncommon in 
either primary or secondary healthcare teams, or MDTs specifically (Borrill et al., 
2000, Harris et al., 2014).  
 
It is perhaps unsurprising then that my analysis suggests that issues relating to the 
physical environment of MDTs have still not been fully resolved. While all four of 
the MDTs I studied used a lecture style seating arrangement, in the National Cancer 
Action Team survey of MDT members carried out in 2009, only a minority of 
respondents (23%) agreed that this was the best approach. In contrast, 62% 
reported that a boardroom or horseshoe layout was better suited to facilitate 
effective team working (Taylor and Ramirez, 2009). However, as the examples from 
Haematology 2 and Gynaecology indicate, changing the physical layout of meetings 
is not necessarily an easy solution, and it is to a certain extent dependent on the 
physical space available, as well as commitment from all team members if change is 
to be successfully embedded.  
 
The role of the MDT Lead 
The NIHR-funded MDT Study which preceded this PhD highlighted the importance 
of the role of the MDT Lead for MDT meeting effectiveness. In particular, MDTs with 
focused and directive chairing tended to have higher rates of decision 
implementation than teams where the position of chairperson was rotated 
between team members (Raine et al., 2014a). Further analysis of the observation 
and interview data from these four cancer MDTs has enabled me to extend this 
finding by specifically identifying ways in which leadership behaviours could foster - 
or conversely, limit - discussion, in the context of the MDT meeting. In particular, I 
found that a focus on efficiency and a lack of structure in discussions could 
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discourage lower status groups from contributing. In contrast, leadership 
behaviours were most successful in encouraging lower status contributions when 
they were directly targeted at lower status groups.  
 
Inclusive leadership behaviours have been observed previously in cancer MDTs. An 
observation study of ten gynaecology MDT meetings in England demonstrated how 
the use of a ‘round the table’ process at the end of each MDT meeting was used by 
the MDT Lead to provide opportunities for all team members to participate. This 
time was often used by nurses within the team to speak up and ask questions or to 
provide feedback on cases that had not already been presented (Kidger et al., 
2009). My findings also highlighted examples, in both the Haematology 1 and Skin 
MDTs, where the MDT Leads adopted inclusive leadership behaviours. 
Correspondingly the interviews with CNSs in these teams suggested that lower 
status groups believed that there was a willingness to listen to their contributions. 
This was in contrast to interviews with CNSs in Haematology 2 and Gynaecology, 
where lower status groups reported that they struggled to make a contribution or 
felt marginalised from discussion. This supports previous research which has 
suggested that inviting and acknowledging the contributions of lower status 
individuals in discussion when their voices would not otherwise be heard, can help 
to create an atmosphere where individuals feel able to contribute freely (Nembhard 
and Edmondson, 2006). 
 
Initial case presentation 
The finding that there was variation both between and within MDTs in relation to 
the way in which cases were presented is supported by research into cancer MDT 
decision making in both the UK and in New Zealand. This includes differences in the 
extent to which an explicit reason was given for discussing the case (Dew et al., 
2014), and in the extent to which a case presentation limited multidisciplinary 
discussion (Lanceley et al., 2008). In Lanceley’s (2008) qualitative study of a 
gynaecology MDT meeting in England, the way a case was framed in the initial 
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presentation set limits on the content of subsequent discussion. This made it 
difficult for non-medical members to contribute. 
 
However, while the way in which a case presentation is framed has been identified 
as a barrier to contributions in the MDT meeting (for CNSs in particular) in previous 
literature, my findings also suggest that the initial case presentation can provide 
positive opportunities for multidisciplinary discussion. In the four teams studied, it 
was shown that a holistic case presentation could be used to facilitate 
multidisciplinary discussion and encourage participation from lower status 
members of the team with patient centred information to share. These findings 
highlight the importance of the way discussion is framed in the MDT meeting on 
both the levels of participation and the extent to which discussion incorporated the 
physical, social and psychological needs of each patient.  
 
10.2.3 What approaches are used by lower status groups to contribute in 
MDT meetings? 
As noted above, lower rates of participation amongst CNSs in particular are well 
documented in existing research. However, in spite of calls for increased 
participation of CNSs in MDT meetings, there has as yet been little in the way of 
specific suggestions about how teams can enhance multidisciplinary engagement 
(Rowlands and Callen, 2013). The findings presented in Chapter 8 begin to address 
this gap in knowledge by exploring a subset of cases from four cancer MDTs, where 
lower status groups did contribute. This has enabled me to extend our 
understanding of the role of lower status groups in the MDT meeting in two ways.  
 
First, it demonstrates the potential value of lower status contributions, by 
highlighting their role in key processes previously associated with high quality 
decision making (Larson et al., 1998, Lanceley et al., 2008, Lamb et al., 2013b, Raine 
et al., 2014b). Secondly, by identifying five approaches used by lower status groups 
in these four MDTs, it provides an insight into how those with lower status 
contributed successfully, within the context of an environment with well-
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established status hierarchies. This extends the findings of a small number of earlier 
studies, which have explored the role of individual strategies, used by nurses in 
particular, in order to exert influence over higher status members of the team. This 
includes the use of humour in community mental health (Griffiths, 1998), and 
breast cancer MDT meetings (Amir et al., 2004), as well as the use of questions in 
palliative care MDT meetings (Arber, 2008). While these earlier studies provide a 
valuable insight into the use of a single, specific approach to participate in the MDT 
context, the findings of this study suggest that CNSs, and indeed other lower status 
members of the MDT, use a range of different techniques in order to contribute in 
the context of the weekly meeting. Taken together these approaches provide a 
useful set of practical approaches that can be used to enhance the ability of lower 
status groups to contribute in the MDT meeting context.  
 
The literature provides potential explanations for the success of these approaches. 
The first of these relates to the use of tactical communication. Tactical 
communication has been described as a way of maintaining working relationships 
within a team by avoiding direct confrontation, particularly where established 
status hierarchies exist (Hewitt et al., 2015). A number of the approaches identified 
in the four cancer teams in this study can be interpreted in this way, for example 
the use of questions or alternative suggestions to challenge other team members 
without being confrontational. Similarly, humour was used by lower status 
individuals when making a potentially ‘difficult’ point.  
 
It is also possible that some lower status individuals possess particular 
characteristics that help to explain the success of their contributions. Previous 
research has concluded that CNSs who advocate successfully in the MDT meetings 
possess characteristics of confidence, a sense of being ‘right’, experience, and good 
communication skills. In addition, they also need to hold relevant information that 
enables them to contribute (McGrath et al., 2006).  
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This last point, about holding the relevant information, was a key theme 
underpinning many of the successful contributions I observed. The insight gained by 
nurses as a result of their greater contact with patients is well documented 
(McGrath et al., 2006). However, the observation data shed light on the way in 
which this knowledge was used by CNSs, and also by StRs, in order to influence 
decisions made in the MDT setting. This extends the concept of ‘encountered 
authority’ previously described in a study of cancer MDT decision making in New 
Zealand (Dew et al., 2014). In this previous study encountered authority was 
described as authority that was granted to higher status team members who had 
met the patient, as an additional source of authority over and above their medical 
or surgical expertise. My findings suggest that this encountered authority may also 
extend to other members of the MDT as well. This was apparent for example when 
lower status groups held unique information they were able to use in order to 
influence a treatment plan. It was also apparent in situations where more than one 
team member had met the patient and higher and lower status individuals had 
different views about whether they would be able to cope with additional 
treatment.  
 
This is important in the context of a wider point that emerged in all three findings 
chapters: that CNSs and StRs had not always met a patient being discussed at the 
time of the MDT meeting. Reflecting the waiting time targets for cancer diagnosis 
and treatment, for many new patients, a consultant member of the team may often 
be the only person to have met them when they are first being discussed in the 
MDT meeting. This has practical implications for which cases are discussed in depth 
in the MDT meeting, and how much time is spent on those cases where only one 
member of the team has seen the patient - versus those where other team 
members have also had the opportunity to do so. I discuss these practical 
implications below in Section 10.5 (p. 283).  
 
For those cases where patient centred information is instrumental to the decision 
making process, integrated findings from Chapters 6, 7 and 8 demonstrated that 
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encouraging multidisciplinary discussion in the MDT meeting was a multifaceted 
challenge. It relied on aligning team features with the behaviours of higher and 
lower status groups. No single factor fully explained patterns of participation 
amongst lower status groups in the MDT meeting, but it was clear that specialty, 
team size, seating arrangements and the process of decision making were 
important. For higher status groups, inclusive leadership behaviours and support for 
contributions made by lower status individuals were also key. In turn, lower status 
groups could use a range of different approaches to contribute successfully, and 
could capitalise on the openings provided by other team members or work together 
to challenge established barriers. Genuine multidisciplinary discussion was more 
likely when these factors were combined.    
 
10.3 Theoretical contribution 
Chapter 3 presented the theoretical framework underpinning my thesis, drawing on 
literature from the field of micro organisational behaviour. It considered the role of 
status hierarchies within teams and explored the way these hierarchies could 
explain patterns of participation within MDT meetings. Developing this theoretical 
framework was a key stage in the research process, informing the development of 
my research questions and the choice of data I selected from the NIHR-funded MDT 
Study to address these (as described in Chapter 1 and Chapter 5). It also facilitated 
my exploration of the patterns of participation and information sharing in MDT 
meetings at each stage of the decision making process, and enabled me to make 
sense of the data during my analysis and interpretation (Maxwell, 2005, Leshem 
and Trafford, 2007).  
 
While the theoretical framework helped to provide coherence to this research 
study, any theoretical framework risks narrowing a researcher’s field of vision by 
excluding alternative ways of framing the issue being studied (Maxwell, 2005). 
Three factors minimise the risk of this in relation to this study. First, the issue of 
status had already been identified as a meta-theme during the analysis conducted 
for the NIHR-funded MDT Study. The rigorous process of developing these themes, 
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as part of a multidisciplinary research team, with oversight from an expert steering 
group, and peer review of the study outputs, provided me with a strong foundation 
for selecting this as an area of further study. Secondly, it was clear from review of 
the literature that issues of status were particularly salient within healthcare teams, 
reflecting the strong and well-established professional identities involved. Thirdly, I 
also spent a considerable period of time while developing my research questions 
exploring a range of possible theoretical perspectives, of which status was only one. 
Carrying out a series of ‘thought experiments’ in the form of weekly assignments 
during a ten week course on micro organisational behaviour at London Business 
School challenged me to come up with a range of plausible explanations for my 
observations during data collection (Maxwell, 2005). It was only at the end of this 
process, and in light of the first two factors, that I came to my decision that there 
was particular value in exploring the decision making process through the lens of 
status.  
  
As demonstrated in the discussion above, using status as a lens to explore the 
decision making process in MDT meetings enabled me to contribute to the 
literature on cancer MDT meetings. At the same time, applying status 
characteristics theory in a naturalistic setting enabled me to contribute to the 
theoretical literature as well. Chapter 3 highlighted that the literature within the 
field of micro organisational behaviour challenged a key assumption underpinning 
policy on MDT meetings, that teams would optimally share and integrate the 
diverse knowledge of all team members. However, the existing solutions proposed 
in this body of literature did not reflect the specific characteristics of MDTs as a 
team setting.  
 
As a result, exploring status in the MDT setting enabled me to deepen 
understanding of the role of status in the decision making process in two specific 
ways. First, by identifying the behaviours adopted by leaders to facilitate or inhibit 
contributions from lower status members of the team, I was able to extend 
knowledge of leadership behaviours in the context of a dynamic team model. 
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Secondly, my findings provide an insight into the role of lower status members in 
teams with well-established status hierarchies, where it was not possible to 
overcome the effects of the hierarchy at a group level. In the section below I 
consider the MDT as a setting for enhancing our understanding of dynamic teams, 
before considering these two specific theoretical contributions in turn.  
 
10.3.1 The MDT as a setting for enhancing our understanding of dynamic 
teams 
It was demonstrated in Chapter 3 that MDTs fulfilled the key criteria of a team, with 
defined membership, a clear task that required interdependence between 
members, and a wider organisational structure. However it was also recognised that 
the MDT model was in some respect more dynamic than the traditional type of 
team described in much of the published literature (Cohen and Bailey, 1997, 
Wageman et al., 2012). The dynamic nature of MDTs became even more apparent 
following exploration of the decision making process using the observation and 
interview data. In particular it was notable that membership of MDTs was in 
practice relatively fluid, with changes in attendance at meetings from week to week 
and over longer periods of time. In all teams, junior doctors rotated between 
specialties every six to twelve months. This meant that they were only members of 
a specific team for a relatively short period of time, before being replaced by a new 
group of their peers. In this more dynamic model, these individuals faced the 
double challenge of being ‘new’ to the team, and being lower status than fully 
qualified medical or surgical consultants. In some cases this appeared to impact on 
the willingness of junior doctors to speak up or to share information in the MDT 
meeting. This added an extra dimension of complexity to the decision making 
process and emphasised the status differences between team members. 
 
Another key feature that defines MDTs in healthcare is the limited extent to which 
collaborative work takes place outside of the weekly MDT meeting. Although the 
weekly MDT meeting brought individuals together with the joint task of making 
decisions about patient care, it was shown in Chapter 6 that this was often the only 
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point at which team members came together. Although interdependence is seen as 
essential to any definition of a team, interdependence in these teams was 
essentially restricted to the weekly MDT meeting (Wageman et al., 2012). In this 
context, it is possible that the strong professional identities brought into the team 
environment are reinforced if - outside of the weekly meeting - team members 
essentially continue to operate in parallel (Mickan and Rodger, 2000). This has the 
potential to impact on the ability of members to exchange and integrate 
information from different sources (Mickan and Rodger, 2000, Oborn and Dawson, 
2010). 
 
Nonetheless, although these features mean that MDTs are in some respects 
different to ‘traditional’ types of team, the teams landscape has already changed 
rapidly in recent years (Wageman et al., 2012). In particular, stable and well defined 
membership is becoming increasingly rare, and the nature of interdependence has 
changed for many teams in response to globalisation and advances in technology 
(Wageman et al., 2012). In this context, and as a model which brings together 
diverse groups of professionals within an environment with well-established status 
hierarchies, MDTs are not unique. Dynamic team models embedded in hierarchical 
settings are common throughout healthcare, as well as in other fields, such as 
aviation and emergency response teams (Edmondson, 2003, Bienefeld and Grote, 
2013).  
 
From this perspective, MDTs provide an opportunity to enhance our understanding 
of teams by exploring how they cope in a more dynamic setting (Wageman et al., 
2012). By exploring the decision making process in MDT meetings through 
observation and interviews, I was able to identify the way in which teams worked 
within an environment where it was not possible, nor desirable, to flatten status 
hierarchies. Instead, in this setting, teams had to capitalise on the status hierarchy 
in order to promote efficiency, while also facilitating and integrating contributions 
from lower status individuals on specific occasions, even though these individuals 
were less likely to contribute overall. This suggests that status hierarchies cannot be 
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characterised in exclusively ‘positive’ or ‘negative’ terms. Instead, they need to be 
interpreted in relation to the specific context in which they operate, recognising 
that this can vary within teams as well as between teams. This means that it is 
crucial to better understand the role of higher and lower status individuals in these 
dynamic team settings which are characteristic of MDT meetings. 
 
9.3.2 Leadership behaviour in dynamic teams 
The literature on status already demonstrates the role of leadership behaviours on 
the willingness of team members to participate in discussion or share information 
(Nembhard and Edmondson, 2006, Anderson and Brown, 2010, Mitchell et al., 
2015). In line with these findings, it was shown in Chapter 7 that within the MDT 
setting, leadership played a key role in facilitating or inhibiting lower status 
contributions. However, while previous literature has relied on high level 
quantitative measures of team members’ perceptions of leader inclusiveness, there 
has been little research to demonstrate exactly what leadership behaviours shape 
perceptions of openness (Morrison, 2011).  
 
Using observation and interview data from the four cancer MDTs to identify specific 
leadership behaviours that facilitated or inhibited contributions enabled me to 
extend this literature.  Exploring the different leadership styles of the MDT Leads in 
these four MDTs showed that when team leaders emphasised efficiency and failed 
to provide a clear structure during discussions, lower status groups could be 
discouraged from contributing. In addition, when the MDT Lead adopted a dual role 
of chairing the meeting, whilst at the same time documenting agreed treatment 
plans, this could also limit contributions by prioritising recording of information over 
integration of contributions. This finding reflects the theory of dual task 
interference, which has previously been identified as an issue in MDT meetings 
when professionals are required both to chair and participate in discussion at the 
same time (Soukup et al., 2016b). It was also notable that general requests for 
contributions were not necessarily sufficient on their own to encourage lower 
status groups to contribute. Instead, support from other team members and 
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signalling and direct invitations to lower status members of the team using both 
verbal and non-verbal cues were key approaches that succeeded in soliciting lower 
status contributions.   
 
10.3.3 The role of lower status individuals in dynamic teams  
Although the role of higher status leaders is a key area of interest within the 
literature on status hierarchies, much less attention has been given to the way in 
which lower status individuals themselves can contribute where status hierarchies 
are a feature of the team setting. A focus to date has been on identifying the factors 
that are likely to impede contributions, but there is little empirical evidence to 
demonstrate the nuanced behaviours required - depending on the nature of the 
contribution being made – to ensure effective lower status participation (Morrison, 
2014). This is perhaps not surprising. As lower status members typically have less 
influence, it is likely to be particularly challenging for these individuals to be able to 
overcome the effects of the hierarchy, particularly because higher status members 
may behave in ways that preserve the status quo (Owens and Sutton, 2001). 
However, by identifying a subset of cases in MDT meetings where lower status 
groups did participate I was able to highlight specific approaches adopted by lower 
status groups in order to make a contribution.  
 
These findings extend the theoretical framework that underpins this study by 
illustrating the way in which teams can capitalise on the knowledge and expertise of 
all members in situations where it is not possible or desirable to flatten the status 
hierarchy.  Although the literature on status demonstrates that status hierarchies 
can impact negatively on the decision making process by disrupting information 
sharing and integration of contributions (Cohen and Zhou, 1991, Bunderson and 
Reagans, 2011, Bendersky and Hays, 2012), in reality, for some teams it will not be 
possible or desirable to moderate or flatten the hierarchy (Filc, 2004, Bienefeld and 
Grote, 2013). In recognition of this, by focusing specifically on cases where lower 
status members did contribute, I showed that adopting a wide range of approaches, 
including asking questions, using humour and sharing information, enabled lower 
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status individuals to work within this context. These approaches enabled lower 
status groups to contribute to the decision making process without challenging the 
established status hierarchy. 
 
10.4 Strengths and limitations 
10.4.1 Conducting the study as part of the NIHR-funded MDT study 
There were a number of advantages and disadvantages inherent in conducting my 
research as part of the larger NIHR-funded MDT Study. Working as part of a 
research team in the Department of Applied Health Research at University College 
London meant that I was able to benefit from a wide range of constructive input 
and expertise from clinicians, academics and patient representatives. This gave me 
first-hand experience of the process of designing and managing a large and complex 
applied health research study, and as such provided an invaluable starting point for 
launching my own independent study for the PhD. The data collection and initial 
qualitative analysis for the NIHR-funded MDT Study was also a very reflective 
process, and regular analytical conferences with other researchers and advisory 
group members prompted debate, discussion and challenge which were all 
essential in ensuring rigour and developing and strengthening my research skills.    
 
However, there are also limitations that reflect some of the constraints of 
conducting my study in this way. While Haematology, Gynaecology, and Skin cancer 
teams were recruited in order to maximise diversity, there are a wide range of 
cancer specialities not represented in this study. Furthermore, for practical reasons 
(to enable observation of multiple sites) all the teams were based in a single 
geographical area (London), which means that they may be unrepresentative of 
cancer MDT meetings more generally. As discussed in Chapter 5, this limits the 
ability to generalise the findings from this study. Nonetheless, the four teams 
provided a diverse context in which to study decision making. In addition, the 
themes identified in the analysis were largely common across the four teams and 
different specialities, which included both local and specialist MDTs. This suggests 
that the findings are likely to have broad relevance to cancer MDT meetings more 
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widely. They are however unlikely to be transferrable to settings where status 
hierarchies are not based on characteristics associated with expertise, as this was a 
key feature of these teams.  
 
A further limitation relates to the number of interviews I conducted, reflecting the 
tight timescales that were a feature of the NIHR-funded study. In particular, given 
the focus of my PhD on the role of lower status groups, it may have been beneficial 
to purposively sample a greater proportion of CNSs and StRs from the four teams 
being studied. This was not possible due to resource constraints. Nonetheless, the 
purposive sampling process was designed to capture the diversity of professional 
groups attending cancer MDTs, and as such ensured a breadth of coverage. The 
extensive observation period across the four teams also gave me an exceptionally 
rich dataset to drawn on in order to explore what actually happened in MDT 
meetings. This meant that I was not solely reliant on the reports of members 
themselves, but could compare and contrast these accounts with my own 
observations.   
 
In addition to the limitations described above which apply to the whole thesis, there 
are also limitations specific to the findings presented in Chapter 8. The analysis for 
this chapter was predominantly based on observation data. This was because the 
topic guide for the NIHR-funded MDT Study did not focus specifically on the 
approaches used by lower status groups to get their voices heard. This meant that I 
was not able to triangulate between observation and interviews in the same way as 
I did in the first two findings chapters. As well as this, the analysis was based on a 
subset of 88 cases theoretically sampled from the main dataset. This meant that 
there were fewer examples to draw on when developing my themes. This reflects a 
broader challenge inherent in studying individuals who have limited participation 
within a group, because it is far easier to focus on those who express ideas and 
share information verbally, than on those who are largely silent (Dyne et al., 2003).  
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However, a key benefit of the extended period of observation I undertook was that 
it enabled me to identify recurring patterns in the data even amongst those who 
participated the least. Conducting this type of analysis with a more limited 
observation dataset would have been particularly challenging. It also remains the 
case that the approaches identified are important because they provide an insight 
into what is possible in these teams. Even if some approaches were only used on a 
relatively small number of occasions, this does not undermine their legitimacy 
(O’Reilly and Parker, 2013). Further research into the approaches used by CNSs and 
StRs in a wider range of cancer MDT meetings, which more extensively incorporates 
the perspectives of these individuals themselves, would provide further 
opportunities to fully explore this issue.  
 
10.4.2 Using observation as a data collection method 
One of the key limitations of MDT observation is that it can alter the behaviour of 
those being studied (Harris et al., 2014). However, I sought to minimise this risk by 
carrying out two weeks of pilot observation in each team to enable the MDTs to 
become accustomed to my presence. In addition, the size of the four teams and the 
fact that there were often other visiting researchers, and medical students who did 
not participate but were in attendance, meant that I was less conspicuous and there 
was nothing to indicate that my presence disrupted the team dynamics. The fact 
that I observed the teams for such a long period of time was also likely to be 
beneficial in minimising any observer effect.  
 
Observation of a clinical decision making forum as a non-clinician also presented 
challenges for me as a researcher. Particularly in the early stages of data collection, 
the rapid pace of discussions and complex medical terminology meant it was 
sometimes difficult to keep up. However, the two weeks of pilot observation were 
helpful in this respect, and provided an opportunity for me to learn the names and 
roles of key members in advance of data collection, as well as giving me an 
overview of the way meetings worked. In addition, I was also able to refer to the 
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audio files following each meeting, throughout the period of data collection, and 
subsequently, which provided me with an opportunity to re-immerse myself in each 
meeting as necessary.   
 
10.4.3 Focusing on processes versus outcomes 
Outcomes play a central role in health services research, given that the ultimate 
goal is to improve patient care (Rubin et al., 2001). However, as described 
previously, there is a wide range of factors that might potentially impact on clinical 
outcomes, over and above what happens in the MDT meeting, with no possibility (in 
the UK at least) to set up a randomised control trial that may help to disentangle 
the effects of MDT processes on outcomes (Sevdalis and Green, 2014). Instead, I 
have focused explicitly on the process of decision making, without considering the 
impact on the quality of decisions made or their influence on clinical outcomes. This 
is nonetheless important because developing a better understanding of processes is 
in itself valuable as a pre-requisite for improvement, in particular because decisions 
themselves are influenced by the way in which they are made (Lamb et al., 2011c, 
Dew et al., 2014). 
 
10.4.4 Measuring status 
Another key limitation of this work relates to the measure of status I adopted. Using 
professional group as an objective measure of status is an approach well-
established in the literature. However, status differences also exist within as well as 
between professional groups, which means it is possible that this categorisation was 
overly simplistic. Nonetheless, it was clear from early on during the observation 
period that the ‘between group’ status differences (e.g. doctor versus nurse) were 
more salient than the ‘within group’ status differences, reflecting the conclusions of 
other researchers  (Nembhard and Edmondson, 2006). In addition, a key benefit of 
this approach was that it enabled me to compare teams across three different 
specialities, allowing me to explore the decision making process in a wider range of 
contexts. 
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10.5 Implications for policy, practice and future research  
Although the small, purposively selected sample for this study limits generalisability, 
the findings discussed above illustrate processes that have a number of implications 
for policy, for practice in cancer MDT meetings, and for future research. These are 
summarised in Box 7 and discussed in more detail below. 
 
Box 7: Implications for policy and practice identified by the study 
Summary of recommendations for cancer MDTs 
 There is a need for national guidance to provide clarity for teams about 
which cases to discuss in depth in MDT meetings 
 MDTs should agree local triage processes to identify cases for detailed 
discussion in advance of MDT meetings 
 MDTs should consider appointing an MDT Lead primarily on the basis of 
their leadership skills, rather than their professional skills 
 MDTs should separate chairing and documenting roles so that the MDT 
Lead is not responsible for both 
 MDTs should review the layout and seating arrangements in team 
meetings 
 MDTs should review their approach to presenting cases for discussion in 
MDT meetings 
 Surgical and medical consultants in particular should use both verbal 
and non-verbal cues in order to explicitly seek input from other team 
members 
 CNSs and StRs should adopt a wide range of strategies to contribute 
during MDT meetings 
 
10.5.1 Implications for policy  
By illustrating the way that the four MDTs under study were able to promote 
efficient decision making by aligning expertise with influence, the findings from my 
study appear to provide support for the direction set in the most recent cancer 
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strategy:  Achieving world-class cancer outcomes: a strategy for England 2015 – 
2020. This strategy proposes that MDT processes should be streamlined, with less 
time spent on cases that can be managed according to evidence based treatment 
guidelines (Independent Cancer Taskforce, 2015).  
 
However, my findings also indicate that there may be a need for more detailed 
national guidance, to provide clarity for teams about which cases are likely to 
benefit from being discussed in depth, and which can be streamlined. Based on the 
evidence from the four cancer MDTs studied, this could incorporate guidance on 
both medical and non-medical factors that are likely to increase the complexity of 
treatment planning. My findings suggest that the medical factors that may indicate 
the need for multidisciplinary discussion include patients being re-discussed mid or 
post treatment, those with relapsed disease, or those with complex comorbidities 
which mean they are not physically well enough to tolerate standard treatment. 
The findings also suggest that patients may benefit from discussion if there is more 
than one treatment option available but clinical uncertainty or disagreement about 
which is most appropriate, and where a treatment plan needs to change once 
treatment has started.  
 
In addition, guidance on the non-medical factors that may indicate the need for 
multidisciplinary discussion could include patients with strong preferences 
(particularly where these are likely to run counter to standard treatment), socially 
or psychologically vulnerable patients, or those unlikely to ‘comply’ with the 
treatment recommended by the team, as well as cases where there are likely to be 
difficulties in communication between the patient (and/or their family) and the 
wider team. The practical implications for teams in terms of identifying these 
patients in advance of an MDT meeting are discussed in more detail below. 
 
Any national guidance would benefit from incorporating the views of a wider range 
of cancer professionals and patients than it was possible to include in this study. 
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Further research to test these findings across a broader range of specialties is also 
essential, given that they are based on study of only four teams.  
 
10.5.2 Implications for practice in cancer MDT meetings 
1) ‘Triaging’ cases for discussion in advance of the MDT meeting  
My findings also indicate that individual MDTs may benefit from explicitly agreeing 
which cases should be discussed in depth at an MDT meeting, and establishing a 
process to triage cases accordingly in advance of the MDT meeting. Local 
agreement at an MDT level is likely to be particularly important in light of the 
different views expressed by MDT members in this study about the right balance 
between ‘efficiency’ and holistic discussion in the MDT meeting. Once teams have 
agreed on criteria for triaging cases the MDT Lead could use these in advance of the 
weekly meeting to filter cases, maintaining an audit trail of any decisions that are 
agreed not to require a full discussion, and freeing up time for more detailed 
consideration of complex cases. 
 
The process of agreeing criteria for triage could also provide an opportunity for 
teams to formally discuss and acknowledge the different perspectives within the 
team about the role of psychosocial information and patient preferences in 
particular. This could be part of a process of team reflexivity. Reflexivity has been 
shown to improve healthcare team effectiveness by creating an environment in 
which teams can explicitly review their practice and processes in light of their 
overall purpose, and make changes accordingly (West et al., 2012). Open discussion 
and reflection on these decision making processes may therefore enable teams to 
reach agreement about the most appropriate way to allocate time in the MDT 
meeting.  
 
Over time, these discussions are likely to help teams to improve their triage process 
as they become better able to identify cases that would benefit from discussion in 
advance. Importantly however, existing research suggests that for the triage 
process to be successful, those cases selected for discussion would need to be 
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properly prepared, with all the necessary information available during the meeting 
(Lamb et al., 2013b). This means that teams may also have to consider practical 
issues such as who in the team has met the patient when triaging cases for 
discussion, if they are to ensure that a wide range of information is incorporated 
into the decision making process where it has been agreed that this is most 
valuable. 
 
2) Leadership in the MDT meeting 
My findings also suggest that teams should be aware of the factors that are likely to 
facilitate or inhibit contributions from lower status team members in particular. The 
MDT Lead could play a key role in providing leadership in this regard, by ensuring 
that lower status contributions are incorporated during those discussions where it 
has been agreed that this is most valuable. If teams are to achieve this they may 
benefit from considering who in their team is best equipped to provide inclusive 
leadership, irrespective of professional group, and ensuring they receive 
appropriate training. Medical members bring clinical expertise that others do not, 
and retain ultimate responsibility for a patient’s treatment. Nonetheless, other 
team members may also be able to provide strong leadership skills that could 
successfully integrate the perspectives of the wide range of professionals in 
attendance.  
 
Teams may also benefit from considering the scope of the role of the MDT Lead. In 
one of the teams I observed, this role extended to documenting treatment plans (as 
well as chairing the meeting). However, this had implications for multidisciplinary 
discussion. Teams that currently combine these roles could therefore consider 
alternative options for documenting treatment plans. Based on the different 
approaches used by the four teams in this study, it is possible that other consultant 
members, StRs, or the MDT coordinator could take on this role. Key to this would be 
a team member’s ability to understand and process complex clinical information 
(for example about scan results). At the same time, as teams rely more on 
technology to facilitate their MDT meetings, IT skills will also be important if the 
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person recording the decisions is to keep up with the rapid pace of decision making 
(for example, where this involves recording treatment plans directly into electronic 
patient records during the meeting).  
 
3) Seating arrangements in the MDT meeting 
Given my findings illustrating the potential for seating arrangements to impact on 
the participation of certain groups in the MDT meeting, teams may benefit from 
explicitly reviewing the layout and seating arrangements of their team meetings, 
and considering and testing alternatives that take into account local circumstances, 
such as the size of the team, the equipment needed (e.g. screens to present 
imaging) and the facilities available.  
 
4) Case presentations 
Given the range of issues that the four MDTs in this study addressed in their weekly 
meetings, it would appear unlikely that there is one standard approach that can be 
used to introduce all cases, in all teams. However, at a local level teams should be 
cognisant of the potential impact of the way a case is presented on subsequent 
discussion. In particular, my findings suggest that there should be enough 
information presented for those who have not met the patient to be able to 
contribute constructively. For cases where it is agreed to be useful to facilitate 
multidisciplinary discussion, teams may benefit from encouraging holistic case 
presentations in order to provide opportunities for those with psychosocial 
information to contribute.  
 
5) Encouraging lower status contributions during multidisciplinary discussion 
My findings suggest that directed efforts from both higher and lower status 
individuals within the MDT are likely to be important if teams are to successfully 
encourage contributions from those least likely to participate. This may require 
training for both higher and lower status groups. In particular, higher status groups 
may benefit from knowledge of approaches that can be used to encourage lower 
status contributions, for example using both verbal and non-verbal cues to explicitly 
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seek input from lower status groups within the team. In turn, my findings also 
suggest a series of practical strategies that could be used by CNSs and StRs in order 
to contribute to MDT meetings. Fundamentally however, teams also need to be 
cognisant of the impact of discussing patients who have not yet met key members 
of the team. In these circumstances, even if opportunities are provided for lower 
status individuals to contribute, they are unlikely to be able to do so.  
 
10.5.3 Areas for further research 
My findings have provided suggestive evidence for the types of cases that may 
benefit from multidisciplinary discussion in an MDT meeting. However, if MDTs are 
to streamline other discussions it is important that this does not disadvantage 
patients whose treatment plans are ‘approved’ rather than discussed in detail in the 
MDT meeting. Further research that examines the effects on patient or clinical 
outcomes of a triage process would therefore be of great value. However, given the 
challenges inherent in doing this, notably the fact that the MDT meeting is just one 
part of a complex patient pathway, an intermediary step may be to assess the 
quality of decisions that are ‘approved’ versus those that are ‘discussed’. This could 
be done by assessing treatment plans against best practice guidelines. Equally, the 
views of patients themselves are likely to be important and there is also a need to 
explore these perspectives to determine what is acceptable to patients. 
 
Further study is also needed of the approaches used by lower status groups to 
contribute during MDT meetings. A wider sample of cases, or a more diverse range 
of teams and specialities may highlight additional approaches used by lower status 
groups to contribute. There is also a need to explore the views of lower status 
groups themselves about when, how and why they adopt different approaches, 
recognising that this may not always be done consciously. As such, observation will 
remain an important source of data.  
 
Another area that I did not fully explore in this thesis was the role of psychologists 
in the MDT meeting. This group is very rarely mentioned in the literature, possibly 
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in part because they are not core members of all cancer MDTs. During the 
observation period for this study for example the Gynaecology team was the only 
team where a psychologist regularly attended weekly MDT meetings. However, this 
role was identified as a factor in helping those in the team with psychosocial 
information to share to work together cohesively. Given that it was not possible to 
explore the scope of this role in detail in my study it would be useful if further 
research were to consider the ways in which lower status groups can be supported 
by a ‘third party’ in the meeting. The consultant clinical psychology role is 
interesting because it is distinctive in combining consultant status with a 
psychosocial role. It is possible therefore that these professionals have the potential 
to bridge the gap between higher and lower status members of the team. This could 
potentially provide another mechanism for encouraging multidisciplinary 
discussion, and would therefore be a valuable field of further study.   
 
10.6 Conclusion 
If cancer MDT meetings are to achieve their full potential, they must be able to 
identify and incorporate the relevant knowledge of team members during the 
decision making process. At the same time, MDTs are also tasked with making 
decisions in a highly time-constrained environment. The findings from this study 
suggest that status hierarchies can both support and challenge teams in achieving 
these potentially conflicting goals.  
 
Promoting efficient decision making by capitalising on the expertise of higher status 
members of the team would appear to be a pragmatic approach to capitalise on an 
expensive and finite resource. However, efficiency should not come at the expense 
of holistic treatment planning for those patients most likely to benefit from 
multidisciplinary discussion. In these cases, this study has highlighted approaches 
that can be used by MDTs to capitalise on the relevant knowledge and skills of all 
team members when making decisions in the MDT meeting.  
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Appendix 1: MDT Study publications and presentations 
Peer reviewed publications 
 
 Raine, R, Nic A' Bhaird, C, Xanthopoulou, P, Wallace, I, Ardron, D, Harris, M, 
Barber, J, Prentice, A, Gibbs, S, King, M, Blazeby, J, Michie, S, Lanceley, A, Clarke, 
A & Livingston, G (2015) Use of a formal consensus development technique to 
produce recommendations for improving the effectiveness of adult mental 
health multidisciplinary team meetings, BMC Psychiatry 15:143 doi: 
10.1186/s12888-015-0534-6 
 
 Raine, R, Wallace, I, Nic a’ Bháird, C, Xanthopoulou, P, Lanceley, A, Clarke, A, 
Prentice, A, Ardron, D, Harris, M, Gibbs, S, Ferlie, E, King, M, Blazeby, JM, 
Michie, S, Livingston, G, Barber, J (2014) Improving the effectiveness of 
multidisciplinary team meetings for patients with chronic diseases: a 
prospective observational study, Health Services and Delivery Research, 2(37) 
doi: 10.3310/hsdr02370 
 
 Raine, R, Xanthopoulou, P, Wallace, I, Nic a’ Bháird, C, Lanceley, A, Clarke, A, 
Livingston G, Prentice A, Ardron D, Harris M, King M, Michie S, Blazeby JM, 
Austin-Parsons N, Gibbs S, Barber, J (2014) Determinants of treatment plan 
implementation in multidisciplinary team meetings for patients with chronic 
diseases: a mixed-methods study, BMJ Quality & Safety. doi: 10.1136/bmjqs-
2014-002818   
 
 O'Driscoll, W, Livingston, G, Lanceley, A, Nic a Bháird, C, Xanthopoulou, P, 
Wallace, I, Manoharan, M, Raine, R (2014) Patient experience of MDT care and 
decision-making, Mental Health Review Journal, 19(4) doi: 10.1108/MHRJ-07-
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Conference Presentations 
 
 Wallace, I, Nic a Bhaird, C, Xanthopoulou, P, Raine, R (2014) Improving the 
effectiveness of multidisciplinary team meetings: assessing the predictors of 
decision implementation. Paper presented at the Health Services Research 
Network Symposium, Nottingham  
 
 Wallace, I, Nic a Bhaird, C, Xanthopoulou, P (2013) Improving the effectiveness 
of multidisciplinary team meetings for patients with chronic diseases. Paper 
presented at a Training Day for Specialty Registrars in Geriatric Medicine, 
London Chest Hospital
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Appendix 2: Use of secondary sources in this thesis 
Chapters 2 and 3 of this thesis are based on reviews of policy and literature on cancer 
MDTs within the field of applied health research, and research and theory from the 
micro organisational behaviour literature. I used slightly different approaches to search 
these diverse bodies of literature, although all searches were underpinned by a 
structured and methodical approach. I briefly describe the search strategies and 
review processes below.  
 
Search strategy for policy and grey literature on cancer MDTs 
My starting point for this search was my existing knowledge of key policy documents, 
gained during a previous role as an NHS Service Improvement Manager, and 
supplemented by extensive literature reviews conducted as part of the NIHR-funded 
MDT Study. I also drew on three published reviews of the development of cancer 
policy in England (Griffith and Turner, 2004, Haward, 2006, Richards, 2010). From this 
starting point, I used a process of snowball sampling to identify other relevant policy 
and guidance documents (Mathew et al., 2003). In addition, I searched the following 
sources for grey literature comprising policy, guidance, or commentary relating to 
cancer multidisciplinary teams: 
 
 Cancer Quality Improvement Network System (CQuINS) http://www.cquins.nhs.uk/ 
 Cancer Research UK: http://www.cancerresearchuk.org/about-us/cancer-taskforce  
 Commissioning Support for London1 
 Department of Health: www.gov.uk/government/organisations/department-of-
health  
 London Cancer: www.londoncancer.org/  
 London Cancer Alliance: www.londoncanceralliance.nhs.uk/ 
 Macmillan Cancer Support: http://www.macmillan.org.uk/  
 My Cancer Treatment: http://www.mycancertreatment.nhs.uk/  
                                                     
1
 This website is no longer operational – CSL was shut down in 2011 
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 National Cancer Intelligence Network: www.ncin.org.uk/home  
 National Institute for Health and Care Excellence: www.nice.org.uk/ 
 NHS England: http://www.england.nhs.uk/  
 NHS Improving Quality: http://www.nhsiq.nhs.uk/ 
 Public Health England (Cancer Commissioning Toolkit): 
https://www.cancertoolkit.co.uk/Home/PublicUsers  
 The King’s Fund: www.kingsfund.org.uk/  
 The National Cancer Action Team (NCAT)2: 
webarchive.nationalarchives.gov.uk/20130513211237/http:/www.ncat.nhs.uk/ 
 The National Peer Review Programme: www.nationalpeerreview.nhs.uk/  
 The Royal College of Physicians: www.rcplondon.ac.uk/  
 The Royal College of Surgeons: www.rcseng.ac.uk/  
 The Royal College of Pathologists: www.rcpath.org/  
 The Royal College of Nursing: www.rcn.org.uk/  
 The Royal College of Radiologists: www.rcr.ac.uk/  
 
These websites were searched before and after the implementation of the NHS 
restructure in April 2013, because a number of organisations and their associated 
websites were closed or rebranded following this. A further update of this search was 
conducted in May 2015 following the General Election on 7 May. No documents were 
identified beyond July 2016. 
 
In addition, I searched: 
 
 PubMed using the terms: ‘cancer’ AND ‘policy’ AND ‘england’ (title and abstract, all 
documents up to October 2016)  
 HMIC using the terms: ‘cancer’ AND ‘policy’ AND ‘england’  (title, all documents up 
to October 2016) 
                                                     
2
 The NCAT website was archived following the NHS restructure in 2013. Responsibility for this website 
has transferred to NHS Improving Quality (NHS IQ). 
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 CINAHL using the terms: ‘cancer’ AND ‘policy’ AND ‘england’ (title, all documents 
up to October 2016). 
 
Review of policy and grey literature 
In order to focus my review, I only included policy and guidance relating to the English 
NHS. Whilst a number of other countries across Europe (Prades and Borras, 2011), 
Australia (Cancer Australia and The Royal Australian College of Obstetricians and 
Gynaecologists, 2011), New Zealand (Ministry of Health, 2012), and America (American 
College of Surgeons and Commission on Cancer, 2012) have also introduced models of 
multidisciplinary team working, the relevance of these policy documents was limited 
due to underlying differences in the healthcare systems.   
 
Initially, to determine which articles were relevant I reviewed titles and executive 
summaries of publications identified in the search, and searched the content of all 
policy or guidance documents for reference to ‘multidisciplinary teams’ or 
‘multidisciplinary team meetings’. I retrieved all documents that made reference to 
multidisciplinary team meetings in cancer. I marked up the relevant excerpts in the 
text to allow me to move back and forth between key points. Following this I adopted 
a narrative approach to write up the results of this analysis in order to set the scene for 
this study (Buse et al., 2010). 
 
Search strategy for research literature on cancer MDTs  
I searched for literature on cancer MDTs in a number of different phases. Initially, 
papers related to measuring or improving the effectiveness of cancer MDTs were 
identified in a search of key databases (including Web of Science, MEDLINE and OVID) 
as part of the NIHR-funded MDT Study. Key words included ‘multidisciplinary’, ‘cancer’, 
‘team’ and ‘effectiveness’. This early search incorporated papers published between 
2005 and 2010. Reference lists of key articles were reviewed to identify further, 
relevant documents, and references were also sought from experts in the field. 
 
I updated this search periodically throughout the NIHR-funded MDT Study in order to 
Appendices 
314 
 
keep abreast of emerging research. I also made use of four systematic reviews relating 
to MDT meetings: one on the impact of MDTs on patient outcomes (Prades et al., 
2014); one on cost-effectiveness (Ke et al., 2013); one on the quality of decisions made 
by cancer MDTs (Lamb et al., 2011b); and one on the effectiveness of MDT meetings 
for lung cancer (Coory et al., 2008). I also drew on a literature review of the impact of 
cancer MDTs on clinical practice and patient outcomes (Croke and El-Sayed, 2012).  
 
In addition, I conducted a review of PubMed, Embase (via OVID SP), CINAHL and NHS 
Health Management Information Consortium databases in June 2015. This was to 
ensure that no key research papers had been missed, and to focus the search 
specifically on issues of status and participation in MDT meetings. I used combinations 
of the search terms ‘multidisciplinary’; ‘cancer’; ‘team’; and ‘status’ or ‘hierarchy’ or 
‘information sharing’ or ‘decision making’. I repeated this search periodically during my 
thesis write up to keep abreast of emerging research.  
 
Search strategy for research and theory in the micro-organisational literature 
My starting point in the micro-organisational literature was the review of key texts. In 
the early stages, my secondary supervisor helped me to identify a number of 
important papers and literature reviews on teams (Levine and Moreland, 1990), 
diversity within teams (van Knippenberg and Schippers, 2007), and status 
characteristics theory (Bunderson, 2003) amongst others. I also attended a ten week 
introductory course on micro organisational behaviour at London Business School and 
used the weekly reading lists and seminars as a starting point for exploring the vast 
literature. When I had selected status as a theoretical perspective for my thesis (the 
rationale for this is explained in Chapter 5), I built on this starting point by reviewing 
reference lists of key articles and PhD theses, identifying significant authors in the field 
(e.g. Berger, Edmondson, and Nembhard) and conducting searches of the JSTOR 
database using key words related to ‘status’ and ‘teams’. As I reviewed this literature I 
extended my search to include the concepts of ‘voice’ and ‘silence’ as these emerged 
as key ideas when considering the role of lower status groups.  
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When searching for literature for my theoretical framework I did not exclude any 
papers based on date of publication alone. This reflected the fact that some of the 
initial papers on status characteristics theory were published in the 1970s.  
 
Reviewing the literature on cancer MDT meetings and status 
I used a similar approach to reviewing the literature in both fields. Initially, I reviewed 
titles and abstracts from the papers I had identified in my search. This enabled me to 
determine which articles were most relevant to my research questions. I then read 
selected articles in full, before summarising the findings and developing key themes. I 
created a series of mindmaps to display these themes and to determine the structure 
of my write up, as illustrated in Figure 6 overleaf. 
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Figure 6: Mindmap of key themes from literature review on cancer MDTs
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Appendix 3: MDT participant information sheet 
[Trust logo] 
VERSION 2 (SMH) 3 AUGUST 2010 
PARTICIPANT information leaflet 
 
Improving the effectiveness of Multi-Disciplinary Team Meetings (MDMs) for 
patients with chronic diseases 
 
We would like to invite you to take part in a research study.  Please read this leaflet 
which tells you about the study and what it involves and ask one of our team if 
there is anything that is not clear. Take time to decide whether or not you wish to 
take part. 
 
What is the purpose of the study? 
Multi-Disciplinary Team Meetings (MDMs) are widely used across the NHS for 
managing chronic diseases. We want to find out more about the factors that 
influence clinical decision making at MDMs.  The findings will be used to improve 
treatment decisions in your MDM and in other MDMs across the NHS by 
recommending possible improvements in the way that MDMs work.   
 
Why have I been chosen? 
We wish to examine a number of MDMs covering a wide range of clinical conditions 
affecting a diverse range of patients. All members of your multi-disciplinary team 
have been provided with this information sheet because we wish to observe your 
MDM and to invite some MDM members to participate in an interview.  We will 
invite MDM members from each core professional group represented on the MDM, 
including both regular and infrequent attenders, to be interviewed.   
 
What does the research involve? 
If all multi-disciplinary team members consent, a researcher – Ms Isla Wallace - will 
attend and observe a number of consecutive MDMs. She will not be an active 
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participant in these meetings, but will both audiotape the meeting and take notes, 
using a structured form. She will collect information on the structure of the meeting 
(including the number of patients discussed, the professional mix of members 
attending); processes (including the roles of each of the members); patient related 
factors that are discussed and the clinical decision made. We expect to attend and 
observe between 22 and 41 meetings, depending on the number of patients 
discussed. In this part of the study, you will not be required to do anything outside 
of, or in addition to your normal day to day activities. 
 
Following this, the researcher will conduct face-to-face interviews with a selection 
of multi-disciplinary team members. The purpose of these interviews is to explore 
members’ perceptions of MDM strengths and weaknesses; factors influencing MDM 
decisions; their professional role and value to the MDM. The questions will be 
flexible and open-ended, to allow you the chance to raise the issues that you feel 
are important.  If you are approached to be interviewed, we will ask you to sign a 
further consent form. All information given during these interviews will be kept 
strictly confidential and no names will be attached to the information provided. The 
interview will be conducted at a convenient time and place of your choosing. The 
interview will last between 30 minutes and one hour and may be ended by you at 
any time. It will be tape-recorded, if you consent, but the tapes will be destroyed 
after analysis has been completed.   
 
Do I have to take part? 
It will be entirely up to you to decide whether or not to take part in the study and 
you can withdraw from the study at any time without having to give a reason. If you 
decide to participate, you will be asked to sign a consent form, and given a copy to 
keep.  A decision not to take part or a decision to withdraw from the study will not 
affect your work in any way.  
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What are the possible disadvantages of being interviewed? 
It is expected that this study does not have any disadvantages, but the interview will 
take between thirty and sixty minutes of your time.   
 
What are the possible benefits of being interviewed? 
The information we get from this study will improve the MDM decision-making 
process by highlighting areas of excellence and possible weaknesses.  If you take 
part in an interview, your anonymised views will contribute to our findings and any 
resulting recommendations for change. 
 
Will what I say be confidential? 
Yes.  We will follow ethical and legal practice and all information about you will be 
handled in confidence. If you are interviewed, this will take place in private, and the 
recording will not contain your name or any personal information, only a study 
identification number.  Recordings will be encrypted and held in a computer in the 
Department of Epidemiology and Public Health, UCL.  Only those members of the 
research team who are directly involved in analysing the information will have 
access to the recordings.  In publications and reports, the identity of participating 
MDMs will not be revealed, only basic descriptive information on the conditions 
covered and regional location of the MDM will be given. Professor Rosalind Raine is 
the Chief Investigator and she has overall responsibility for confidentiality and data 
security.  
 
What will happen to the results of the study? 
Once the study has finished the results will be analysed and conclusions drawn 
about how treatment decisions are reached, and how this process might be 
improved.  Findings will be published in scientific journals, but the MDM and all 
individuals will be referred to in anonymised form.  Quotes from the interviews may 
be used, but again will be anonymised.  Any quotes where the individual concerned 
could be identified by another team member, or anyone else, will not be used.  We 
will also visit your MDM and provide a summary of our findings.  Again, interview 
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quotes will only be used as long as the speaker’s anonymity can be preserved.  
MDM members will have the opportunity to discuss the findings and give their 
views on the recommendations. 
 
Who is organising and funding the research 
Professor Rosalind Raine is the Chief Investigator and the study is funded by the 
National Institute of Health Research. No payments are made to the researchers 
conducting this study. 
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given a favourable opinion by East London Research Ethics Committee. 
 
What do I do if I wish to make a complaint about the research? 
If you wish to complain about any aspect of the research, you should contact the 
Chief Investigator, Professor Rosalind Raine or the researcher. If you feel you do not 
receive a satisfactory response and you wish to take the matter further you should 
contact the Complaints Manager (see below) giving the project title and the 
Principal Investigator’s contact details.   
 
Contact details 
Please contact [researcher] if you would like to ask questions about the study or for 
any other reason: 
By [telephone]: or by email: [email address] or post: [post]   
  
You can also contact: Professor Rosalind Raine on [telephone] or by email [address]  
Contact details for the Complaints Manager are: [local service address and 
telephone] 
 
Thank you very much for taking the time to read this information about the study. 
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Appendix 4: MDT participant consent form 
[Hospital logo] 
UCL Project ID number: 10/071             
Participant ID number for this study:        
 
Title of study: Improving the effectiveness of Multi-Disciplinary Team Meetings (MDMs) 
for patients with chronic diseases: Non-participant observation 
 
Chief investigator: Professor Rosalind Raine   Principal Investigator at [Hospital]:  
Researchers: Isla Wallace, Caoimhe Nic a’ Bhaird, Dr Penny Xanthopoulou 
 
INFORMED CONSENT FORM 
                                                                                                                                                                          Please initial box 
1. I confirm that I have read and understand the participant information sheet 
dated 03/08/10 (version 2) for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered satisfactorily.      
 
   
2.  I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason and without my medical care or legal rights being 
affected.      
 
   
3.  I understand that all the information I provide for the purposes of this study will be kept 
strictly confidential.  
 
   
4.  I consent to the multidisciplinary meetings being taped and understand that these 
recordings will be stored securely and destroyed after analysis is complete.  
 
   
5.  I agree to being quoted anonymously in the results. 
 
 
   
6.  I agree to take part in this study.  
 
____________________ ________________ ____________________ 
Name of Participant (PRINT) Date Signature 
________________________ ________________ ____________________ 
Name of person taking consent Date Signature   
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Appendix 5: Qualitative observation coding sheet 
Meeting date:  
Team ID:  
 
INPUTS - Systems, organisational 
 
1. Mention of national policy directives or guidelines: 
 
2. Mention of local guidelines/rules/regulations: 
 
3. Mention of resource issues (staff, time, money)? How do these factors impact 
on decision-making: 
 
4. Mention of other individuals/services/teams within organisation that impact on 
options/decision made: 
 
5. Other broader contextual factors influencing decision-making: 
 
INPUTS - Team and task 
 
6. What information is shared in advance? How does this influence decision-
making? 
 
7. Meeting environment (Size of room / seating arrangement / light / acoustics): 
 
8. What use is made of technology? e.g. access to test results, patient notes, 
virtual team. How does this influence decision-making? 
 
9. How structured is the meeting process? (e.g. following agenda, protocol): 
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10. Who presents cases? How?  Use of structured proforma? Framing of decisions 
to be made:   
 
11. Patient factors: who mentions patient preferences? Who, if anyone, mentions 
carer or family preferences? How do attendees react? Any variation by patient 
characteristics: 
 Socio-demographic (age, gender) 
 Socioeconomic (education, poverty) 
 Social (marital status, employment, family) 
 Health literacy (understanding of condition and navigation of healthcare 
services) 
 
12. Mention of missing information? (test results, attendees) Impact on decision-
making: 
 
13. Other team, task and patient inputs influencing decision-making: 
 
MEDIATORS - Team processes, emergent states 
 
14. Participation / Communication: who dominates? Who has least involvement? Is 
there a hierarchical pattern of participation or a relatively even distribution? 
 
15.  Any misunderstandings/lack of clarity - between whom? Who asks questions? 
To whom? Is there dissent or conflict? Who disagrees? How is it dealt with? 
 
16. Leadership style: clear role or several competing leaders?  Does the leader 
dominate discussion or decision-making, or take a back seat? Do they encourage 
involvement or limit contributions (e.g. because of time)?  Do they checking 
understanding or proceed at their own pace? 
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17. Cohesion: Any social conversation immediately pre/post meeting? Is everyone 
focused on the task - anyone chatting/disinterested? Mood/affect - Relaxed? 
Pressured? Formal? Focused on task? 
  
18. Decision mechanisms: Is consensus sought? How? (Verbal, eye contact) Are 
decisions made in the absence of consensus? 
 
19. Other mediators, processes influencing decision-making: 
 
OUTCOMES 
 
20. Clarity of recommendations; Who records the decision? Is there a verbal 
summary and rationale? Is responsibility for implementation discussed? 
 
Other:  
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Appendix 6: Quantitative observation data collection tool 
 
 
Patient Data Proforma: Haematological cancer (1)  
 
 
A.  PATIENT AND SOCIAL CHARACTERISTICS  
Information shared explicitly during MDM (written/verbal): 
 
1. Descriptors of age  Elderly   Young   No mention 
2. English proficiency  Poor   Good/native  
 No mention 
 
3. Ethnicity 
 
White 
 
 Mixed 
  Black   Asian   No mention 
 
Nationality           
                    _______________________________ 
 
4. Marital Status: 
  Single   Widowed  
 Married/ 
cohabiting 
  Divorced  Separated  No mention 
5. Relationship with services  Obstructive   Non-adherent      Positive   No mention 
6. Caring roles 
 
Yes   No 
  No mention 
7. In residential care  Yes   No   No mention 
8. Disability  Yes   No   No mention 
9. 
Difficult socioeconomic 
circumstances 
 
Yes   No  
 No mention 
 
 
10a. Social support 
 
Good 
 
 Ambiguous    Poor    No mention 
  
 10b. Free text detailing social needs discussed: 
 
 
 
 
Health behaviours 
11. Smoking 
 
Yes   No    Prev. history   No mention 
  
12. Heavy drinking 
 
Yes   No   Prev. history   No mention 
  
13.  Physical activity 
 
 Inactive 
 
 Regular exercise   No mention 
 
14.  Patient knowledge of managing condition    Poor    Good      No mention 
  
15.  Patient/carer prefs mentioned  Patient     Carer    Both     No mention 
Study ID       
 
MDT Date: 
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B.   DIAGNOSIS/SEVERITY 
Information shared explicitly during MDM (written or verbal):  
Diagnosis Confirmed Suspected Ruled Out  
1.  Leukaemia (CLL/CML) 
       
No mention 
2.  Lymphoma – Non-hodgkin’s  
       
No mention 
3.  Lymphoma – Hodgkin’s 
       
No mention 
4.  Myeloma (MM) 
       
No mention 
 
5. WHO diagnosis 
 
new diag. 
 relapse  refractory  Other  No mention 
 
6. WHO perf. status  0 
 1
  2
  3
  4
  
No mention 
 
7. Ann Arbor stage 
 
I 
 II  III  IV
   No mention 
 
 
 
        
8.  Stage modifiers 
 
A 
 B  E  S   No mention 
 
 
FLIPI 1 = prognostic 
index for follicular 
lymphoma () 
 FLIPI 2 = new prognostic 
index for follicular 
lymphoma () 
 Raised LDH 
Age >60 
Stage III/IV 
Raised Hb 
Nodal aval >3 
 
 
 B2M >N 
Age >60 
Node size >6cm 
Hb <N 
BM involvement 
 
    
    
    
    
    
9. FLIPI1  score    0-5  10. FLIPI2 score   0-5  
 No mention/unclear   No mention/unclear  
 
 
IPI – non-Hodgkin 
lymphoma () 
 IPS – prognostic score for 
advanced Hodgkins () 
 Rai Stage 
(for chronic lymphocytic leukaemia) 
 Age >60 
LDH >N 
WHO PS >2 
F/N areas >2 
Stage ¾ 
 
 Hb <N 
Age >45 
Male 
Albumin <N 
Stage IV 
Lymphocytosis 
Leukocytosis  
 
 0= low risk, lymphocytosis 
1= intermediate risk, + 
lymphadenopathy 
3= int risk, hepatomegaly/ 
splenomegaly 
4 = high risk, +low rbc 
5 = high risk, lymphocytosis plus 
thrombocytopenia 
 
 
      
      
      
      
       
       
11. IPI score /5  12. IPS score /7  13. Rai Stage (0-5)  
 No mention/unclear   No mention/unclear   No mention/unclear  
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C.  COMORBIDITIES 
Information shared explicitly during MDT (written or verbal):  
 
Comorbidities Yes  No Suspected  
1. HIV         No mention 
2. HIV post-transplant         No mention 
3. Other immunosupp         No mention 
4. Hepatitis B/C         No mention 
5. Other infection        No mention 
6. Pregnancy        No mention 
7. Cardiac               No mention 
8. Renal         No mention 
9. Respiratory         No mention 
10. Depression/anxiety         No mention 
11. Obesity         No mention 
  
 
 
 
 
  
C. Free text detailing additional co-morbidities 
 
 
 
D.  ACTIONS AND DECISIONS  
Information shared explicitly during MDM (written/verbal): 
 
1. Rational for patient being discussed here 
 
a New Referral 
b Feedback  
c Specific query 
d Unknown to MDM members 
 
2. Missing info  Yes   No 
3. Presenter questioned before decision made?  Yes   No   No mention 
4. Is the intent curative or palliative?  Curative   Palliative   No mention 
 
 
 
Decision 
Code 
5. Actions discussed 
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6a. How is decision recorded? 
 
Written    Verbal   Both   Neither 
 Unclear to 
researcher 
6b. Named decision owner?  Yes   No 
6c. Is decision conditional?   Yes   No   No mention 
7a. How is decision recorded?  Written    Verbal     Both   Neither   Unclear to researcher  
7b. Named decision owner?  Yes   No 
7c. Is decision conditional?   Yes   No   No mention 
6. Decision 1 
 
 
 
 
 
8. Factors impacting on team ability to make a decision (free text): 
 
 
 
9. Any disagreements/challenges? 
 
Yes 
 
 No 
 
 
9a. Cause/content of disagreement:  
7. Decision 2  
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Appendix 7: Professional interview topic guide 
 
 
 
 
 
 
 
 
MDT STUDY: Participant interview topic guide 
 
Version 1, 28.3.12 
 
INTRODUCTION FOR PARTICIPANTS 
 
The purpose of this interview is to explore your views on the multidisciplinary team 
meetings that you attend for [team name], and to discuss some of the factors 
influencing MDM decision-making.   
 
The questions will be flexible and open-ended, to allow you the chance to raise the 
issues that you feel are important. Your responses will be confidential, and 
anonymised in any findings we publish. They will not be shared with your team. 
There are no ‘right’ or ‘wrong’ answers and I stress that this is not about individuals, 
but about the system. There is conflicting evidence in the literature about whether 
MDTs are effective or not, and this is what we would like to explore. 
 
Interviewer will then talk through information sheet if needed and answer any 
questions. 
 
 
Department of Applied Health Research 
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Warm Up  
1.  This interview is about your experience of the MDT meeting, in general, how do you 
find working in this way? 
 What do you think works well about your MDT meeting? 
 Is there anything you would change about your MDT meeting?  
 If there was no MDT meeting, what difference would it make? 
 Is the MDT a good use of your time? What is most/least valuable? 
 What would you describe as the primary role of the MDM?  Does it have any 
other functions?  
 
2. What factors are most important to the success of an MDT meeting? 
 
Team Processes – I’d like to focus now on the wider team 
3. What is the atmosphere like in the team meetings? What do you think creates this 
atmosphere? 
 What would make it better? 
 Do you think people are able to speak freely during the meetings? Why? 
 How do different professional groups interact in the team? 
 Are some professions more or less relevant to the meeting than others? 
 What do you see as your role in the meeting?  
 What kind of issues do you bring to the meeting? Do you think the MDM is 
the best way to do this? 
 
4. What happens when people disagree?  
 Can you give example of time you disagreed? 
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Decision-making - can I get you to think about decision-making in the MDM? 
5. How does the team come to a decision about a case/patient? 
 What information do you need to make a decision? 
 Probe re barriers to accessing information. 
 Are there times when the team doesn’t come to a decision? Why is this? 
 
6. Can you talk a bit about patient preferences in relation to decision-making? 
 How much do you tend to know about patient’s preferences? To what extent 
do they influence decision-making?  
 How could patient preferences be incorporated into decision-making? 
 What about other factors, for example, other illnesses or conditions: how do 
these influence decision-making? 
 
7. Is there anything you think doesn’t get discussed enough during the meeting? 
 Is there anything you think less time should be spent on? 
 Can changes happen (realistically) to improve it? How (how can x or y 
happen)? 
 
8. How do MDT meetings affect the quality of clinical decisions? 
 Do you think MDT meetings lead to better clinical decisions for patients?  
 Prompt for a specific example 
 Are there times when poor/sub-optimal decisions are made? Why do you 
think this happens? Prompt for a specific example 
 
9.  Can you describe a time when a decision made at the meeting was changed? Why 
did this happen? 
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10. How much of decision-making happens outside the meeting? How does the quality 
of these decisions compare?  
 
 
11. To conclude this section, could you reflect on what could be improved about the 
way decisions are made? 
 
 
External influences  
 
12. How is decision-making influenced by resourcing issues (e.g. time-constraints, 
funding, staff shortages)? 
 
 
13. Thinking about the physical environment, are there any aspects of the room or 
layout that influence the way the team interacts? 
 
14. At the moment, there are a lot of changes going on in the NHS… 
 How would you describe the impact of this on your organisation?  
 And do you think this has impacted on the team?  
 
15. Finally, is there anything else you think is relevant? 
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Appendix 8: Patient interview topic guide 
 
 
 
 
UCL Department of Applied Health Research 
 
 
MDT STUDY: Patient interview topic guide 
 
Version 1, 28.3.12 
 
INTRODUCTION FOR PATIENTS 
 
This research aims to understand clinical decision-making processes through the 
eyes of the patient. There will be three sections to the interview. First, we’d like to 
hear about your experience of your care so far. Then we’ll move on to how you and 
your healthcare team make decisions about your care. Finally, we’ll discuss more 
generally how you feel patients should be involved in these kinds of decisions. 
 
We would like to emphasise that the study is being conducted by UCL and we are 
not employed by your Trust or the NHS. 
   
We wish to reassure you that you do not have to answer any question you feel 
uncomfortable with and you can stop the interview at any time. This will in no way 
affect your care.  
 
This is about getting your views across.  Your responses will be confidential: they 
will not be shared with your healthcare team. Quotes from the interviews may be 
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used in our findings, but it will not be possible to identify you or your healthcare 
team from these. 
 
Interviewer will then talk through patient information sheet if patient/carer wishes 
 
Warm up - I’d like to start by asking you about your condition and your care  
 
1.  Could you briefly tell me about your [condition] and the most important ways that it 
affects you? 
Encourage focus on main condition (focus of MDM) & impact on quality of 
life  
 
2.  What types of care do you currently have for your [condition]? 
 
Encourage brevity & focus on major health (+/- social care) interventions 
 
3.  Can you describe how decisions were/ are made about your care?  
 Who are the main people involved in making decisions about your care? i.e. 
are respondents aware of multidisciplinary team (MDM) vs. individual 
consultant making decision? 
 What involvement did you have in making decisions / planning care? 
 What were your preferences/wishes regarding your care? 
 Can you describe any times when you were invited to discuss or choose any 
aspects of your care? 
 Did you want to make choices? Does it depend on the type of decision? 
 
4.  Please can we talk in more detail about a particularly important decision that was 
made about your care? This may include a treatment, diagnostic procedure, 
something about the timing, setting (inpatient/outpatient) or anything else such as 
a 2nd opinion.  
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5.  Can you describe how you made your decision to / not to receive this care? Can you 
tell us the factors that influenced the decision? 
 Any perceived concerns / benefits e.g. side effects; time in hospital; 
convalescence time; enormity of procedure; quality of life etc.  
 Where they received information from (e.g. family, friends, reading, clinical 
staff)  
 Which of these factors made a difference to the decision made? Why? 
 Extent to which their choice / decision was influenced by personal 
characteristics e.g. belief systems (fatalism, faith, ‘willing to try anything’, 
autonomy [want to retain personal control], delegation [want their Dr to 
make important decisions] etc.)  
 Extent to which personal characteristics interacted / were mediated by 
context e.g. their relationship with key health professionals / the importance 
of the decision / uncertainty surrounding management options etc. 
 
6.  Is there anything about your care that you know now, that you would like to have 
known before? 
 Side effects, time in hospital, recuperation issues, specified risks etc. 
 How might this information have changed your care preferences / decision? 
 
MDT meetings - increasingly in the NHS, patient care is managed by a team of 
professionals with different skills, rather than one person. For example, [insert 
relevant mix of professionals] may meet together once a week to discuss different 
cases. Patient care decisions are often made in these in ‘multidisciplinary team 
meetings’, by the whole (multidisciplinary) team.  
 
7.  What do you know about these meetings? 
 Do you know that your care is discussed?  
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 Were decisions fed back to you?  
 What do you think about this way of working? 
 How do you feel about your care being discussed in these meetings? 
 
8.  What were /are the important things about you that you would want the 
multidisciplinary team to consider when they meet to discuss your care/ 
management? 
 Priority (quality versus quantity of life etc.); attitude to risk; personal trade- 
off between benefits & risk; family support / commitments; work 
commitments; age; specific comorbidities etc. 
 
9.  What were / are the important things about your care that you would want the 
multidisciplinary team to consider when they meet to discuss your care/ 
management? 
 Defined benefits & concerns e.g. side effects; time in hospital; convalescence 
time; enormity of procedure; quality of life etc.; importance of short versus 
long term effects   
 Timing; setting etc. 
 
10. When is the most appropriate time to discuss this information with you?  
 How should it be done & how often? e.g. before or after the MDT 
 Who would you want to represent your views at a multidisciplinary meeting 
(key health professional; patient advocate; patient/carer) 
 
11. Are there issues that you would wish to remain confidential (not to be shared) 
when the team is discussing management options for you? 
As appropriate, probe, with sensitivity:  
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 Comorbidities; risky behaviours; personal circumstances (do NOT press to 
define these if the patient does not volunteer the information). 
 
In this final section, I’d like to talk more generally about how you think 
multidisciplinary teams should work 
 
12. Do you think it is important for multidisciplinary teams to always consider patients’ 
views when making a decision about care? 
As appropriate, probe the influence of:  
 Context e.g. major decisions (to have a major intervention or not etc.) versus 
decisions about process (scheduling, setting etc.); 
 Intervention specific issues e.g. where there is clinical uncertainty about 
options; quality of life (pain, impact on mobility / independence etc.) 
 
13. What information should be fed back to patients about the multidisciplinary team 
meeting decision-making process about their care? 
As appropriate, probe:  
 How the MDT decided what to recommend e.g. whether it was protocol / 
evidence based; the specialties involved in making the decision; options 
discussed; factors which influenced the decision etc. 
 
14. Do you have any suggestions for ways for patients’ views to be represented at the 
multidisciplinary team meeting?  
As appropriate, probe:  
 Some suggestions include: staff known to patient attend; patient advocate 
attends; preparatory meeting with patient; patient preferences written down 
in advance; patient submits a written statement; patient/carer attends 
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meeting; formalised feedback after the meeting; decision options discussed 
with patient after meeting etc. 
 How would this work in practice? e.g. would they find it upsetting, would 
they understand the discussion, would it be intimidating; is it feasible (work 
& family commitments)? 
 What about for patients who feel unable to express their view / ask 
questions? 
 
Finally, is there anything else about how patients are involved in decisions about 
their healthcare that you would like to add? 
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Appendix 9: Patient information leaflet 
[Trust logo] 
VERSION 3,  28 February 2012 
 
Patient information leaflet  
Improving the effectiveness of multidisciplinary team meetings in healthcare 
 
We would like to invite you to take part in a research study.  Please read this leaflet 
which tells you about the study and what it involves and ask one of our team if 
there is anything that is not clear. Take time to decide whether or not you wish to 
take part. 
 
What is the purpose of the study? 
Multidisciplinary Team Meetings (MDMs) are widely used across the NHS for 
managing patient care. We want to find out more about the factors that influence 
clinical decision making at MDMs.  The findings will be used to improve care 
decisions in your MDM and in other MDMs across the NHS, by recommending 
possible improvements in the way that MDMs work.   
 
Why have I been chosen? 
As part of our research we wish to explore methods for taking patients’ wishes 
about their care into account during MDM decision making. We are therefore 
inviting a diverse range of patients to be interviewed. 
  
What does the study involve? 
A researcher will contact you to see if you are willing to be interviewed.  If you are, 
they will arrange a time and day that suits you. You will be interviewed in private at 
a place of your choice. This may be at your home or at this clinic, when you next 
have an appointment.  During the interview, the researcher will ask you questions 
about your health care wishes and expectations and the extent to which these were 
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met by the decisions made about your care at the MDM.  They will also be 
interested to hear any suggestions you may have to improve patients’ involvement 
in health care decision making. The questions will be flexible and open-ended, to 
allow you the chance to raise any issues that you feel are important.  The interview 
will last between 30 minutes and one hour and may be ended by you at any time. It 
will be tape-recorded, if you consent, but the tapes will be destroyed after analysis 
has been completed.  You will also be asked to allow the researcher to collect 
medical information about your condition and hospital care from your medical 
records.  
 
Do I have to take part? 
It will be entirely up to you to decide whether or not to take part in the study and 
you can withdraw from the study at any time without having to give a reason. A 
decision not to take part or a decision to withdraw from the study will not affect 
your care in any way. 
 
If you are interested in taking part then the health care professional who has given 
you this sheet will give us your contact details. The researcher will then contact you 
by phone. If you prefer to be contacted by another method, then please tell the 
person who gave you this sheet and we will email or write to you instead. The 
researcher will then arrange to meet you. You can contact the researcher or other 
members of the research team at any other time using the contact details below.  
 
If you decide to be interviewed, you will be asked to sign a consent form to say that 
you are happy to take part and that you agree to the researcher having access to 
your hospital records. You will be given a copy of the consent form to keep.  You will 
still be free to withdraw from the interview at any time, and without giving a 
reason.   
 
What are the possible disadvantages of being interviewed? 
It is expected that this study does not have any disadvantages, but the interview will 
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take up your time.   
 
What are the possible benefits of being interviewed? 
The information we get from this study will improve the MDM decision-making 
process by highlighting areas of excellence and possible weaknesses.  If you take 
part in an interview, your views will contribute to our findings and any resulting 
recommendations for change. However the identities of participants will not be 
revealed in any publication or report relating to this research. 
 
Will what I say be confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. If you are interviewed, this will take place in private, and the 
recording will not contain your name or any personal information, only a study 
identification number.  Recordings will be encrypted and held, together with 
information from your medical records in a password protected computer in the 
Department of Applied Health Research, UCL.  Only those members of the research 
team who are directly involved in analysing the information will have access to the 
files on the computer.  Professor Rosalind Raine is the Chief Investigator and she 
has overall responsibility for confidentiality and data security. 
 
Involvement of your doctor 
The health care professional in charge of your care here is aware that you have 
been invited to participate in this study. If you decide to participate, a copy of your 
signed consent form will be kept in your notes.  However s/he will not see any study 
information with your name on it. In all publications and reports, the identity of 
participants will not be revealed. 
 
What will happen to the results of the study? 
Once the study has finished the results will be analysed and conclusions drawn 
about how care decisions are reached, and how this process might be improved.  
Findings will be published in a scientific journal, but it will not be possible to identify 
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you or your healthcare team.  Quotes from the interviews may be used, but again, 
these will be anonymised.  We will also produce a summary of our findings which 
we will send to you. 
 
Who is organising and funding the research 
Professor Rosalind Raine is the Chief Investigator and the study is funded by the 
National Institute of Health Research. No payments are made to the researchers 
conducting this study. 
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given a favourable opinion by East London Research Ethics Committee. 
 
What happens if I become upset by any aspect of the study? 
In the unlikely event that you become distressed by any aspect of the study, the 
researcher will offer support and can contact a person suggested by you if that is 
your wish. This may be your partner or carer. If you ask, they will also provide 
feedback (the content of which will be agreed with you) to the healthcare 
professional who is primarily responsible for you care.  In the event of illness, the 
researcher will contact the healthcare professional most readily available to offer 
help. 
 
What do I do if I wish to make a complaint about the research? 
If you wish to complain about any aspect of the research, you should contact the 
Principal Investigator [name], the Chief Investigator, Professor Rosalind Raine or the 
researcher. If you feel you do not receive a satisfactory response and you wish to 
take the matter further you should contact the Complaints Manager (see below) 
giving the project title and the Chief Investigator’s contact details.   
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Contact details 
Please contact the researcher, Isla Wallace, if you would like to ask questions about 
the study or for any other reason: 
 
By telephone : 020 7679 1860  
    
By email:  i.wallace@ucl.ac.uk 
 
By post:  Isla Wallace 
Department of Applied Health Research  
University College London 
1-19 Torrington Place  
London WC1E 7HB 
 
You can also contact: 
Professor Raine on 0207 679 1713 or by email (r.raine@ucl.ac.uk). 
 
Contact details for the Complaints Manager are: 
[Local contact details] 
 
More general information about taking part in medical research is available from 
the Patient Advice and Liaison Service (PALS), either online at www.pals.nhs.uk or 
via your local PALS office at: 
[contact details for local service] 
 
Thank you very much for taking the time to read this information about the study.  
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Appendix 10: Patient consent form for interviews 
[TRUST LOGO] 
 
VERSION 3,     28 MARCH 2012 
 
UCL Project ID number: 10/071                  
Patient ID number for this study:  
 
Title of study: Improving the effectiveness of multidisciplinary team meetings in 
healthcare 
 
Chief investigator: Professor Rosalind Raine 
Principal Investigator at [Trust]: [Name]  
Researcher: Isla Wallace 
 
INFORMED CONSENT FORM 
                                                 Please initial 
box 
1. I confirm that I have read and understand the patient information sheet 
dated 28/03/12 (version 3) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily.      
 
 
   2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason and without my medical 
care or legal rights being affected.      
 
 
   3.  I understand that all the information I provide for the purposes of this study 
will be kept strictly confidential.  
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   4.  I understand that the researchers will need to know my name, address and 
contact details. These will be used only to contact me about the study. I give 
permission for the researchers to have this information.  
 
 
   5.  I understand that the researchers will have access to my medical records. The 
researchers will use these: 
 to collect medical information about my condition and care  
 to update my contact details if these change during the study 
I give permission for these individuals to have access to my records. 
 
 
   6.  I consent to the interview being taped and understand that these tapes will 
be stored securely and destroyed after analysis is completed. 
 
 
   7. I agree to being quoted anonymously in the results.  
 
 
   8.  I agree to take part in this study 
 
 
 
 
____________________ ___________           ________________ 
Name of Participant (PRINT) Date                          Signature 
 
_________________________ ____________         ________________ 
Name of person taking consent Date                         Signature 
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Appendix 11: Thematic framework I  
Theme Sub-theme Code (sub-codes in italics) 
I. THE DECISION MAKING  
PROCESS  
Meeting Function decision making 
peer to peer learning 
teaching 
Initiating Participation initial case presentation 
Opportunities to Participate reflections on imaging input 
reflections on pathology input 
clinical information provided to support interpretation of 
imaging or pathology 
high participation 
low participation 
multidisciplinary discussion 
asks questions 
responds to question 
gives advice 
Evaluation of Contributions contribution not invited 
lower status contribution not incorporated 
- lower status contribution ignored 
lower status interrupted 
willingness to contribute  
Influence defers decision 
steers discussion  
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Theme Sub-theme Code (sub-codes in italics) 
issues directive or request 
makes decision 
Explanations for patterns of 
participation and influence 
importance of higher status knowledge 
limits of lower status knowledge 
time pressure specifically as a barrier to participation 
willingness to speak up 
II. EFFECTS OF STATUS 
HIERARCHIES  
Efficiency time pressures 
minority of patients where MDT makes a difference 
tension between discussing all patients and discussing in 
depth 
Benefits of MDT Meetings access to a range of opinions 
ensures consistent approach to treatment 
improves coordination and speed of care 
improves patient care 
increases recruitment to clinical trials 
opportunity for cohesion and communication 
provides holistic view of the patient 
provides reassurance for patient and clinician 
Information Sharing reflections on levels of information shared 
content of discussion 
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Theme Sub-theme Code (sub-codes in italics) 
patient contact with MDT members 
- medical or surgical consultants 
- other doctor 
- StR 
- CNS 
Role of patient centred information 
- patient preferences 
- psychosocial factors 
- physical wellbeing and comorbidities 
Multidisciplinary Discussion 
(circumstances where it occurs) 
Patients with limited treatment options 
- palliative care 
- relapse 
Inability to cope with treatment 
- Elderly of physically frail patients 
- Vulnerable patients 
III. FACTORS INFLUENCING 
MULTIDISCIPLINARY DISCUSSION 
Meeting Atmosphere provides support for lower status contribution 
seeks consensus 
member descriptions of atmosphere 
disengagement 
humour 
Physical Environment seating arrangements 
attempts to change or challenge seating arrangements 
quiet talk and acoustics 
personalities 
Leadership Style attempt to limit discussion  
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Theme Sub-theme Code (sub-codes in italics) 
clear structure 
decision making is an open process 
does not curtail discussion 
invites contributions 
lack of structure 
About the Teams gynae meeting context 
haem1 meeting context 
haem2 meeting context 
influence of peer review 
skin meeting context 
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Appendix 12: Thematic framework II 
Theme Strategies Outcomes 
 
Asking questions  Asks questions  Prompts discussion 
 Influences decision 
 
Framing contributions in medical or 
surgical terms 
 Psychosocial frames contribution from a medical perspective 
 StR provides a clinical rationale for discussion 
 Prompts discussion 
 Influences decision 
 
Providing a practical alternative or 
solution 
 Proposes an alternative solution (specifically challenging 
another suggestion) 
 Proposes solution to a problem facing the team 
 Prompts discussion 
 Influences decision 
 
Sharing information  Provides clinical information 
 Provides information about patient as a person 
 Prompts discussion 
 Influences decision 
 Facilitates teamwork 
 
Using humour  Uses humour  Influences decision 
 Facilitates teamwork 
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Appendix 13: ‘Questioning’ node by professional group 
Professional group Nvivo node 
frequency 
Illustrative quote 
 
Surgeon 
 
100* Is she symptomatic at the moment? (Consultant Gynaecologist, Gynaecology, observation transcript) 
Haematologist 
 
73 Can I just ask, his stage of disease previously was more than stage one, is that right? (Consultant 
Haematologist, Haematology 2, observation transcript) 
Oncologist 
 
42 This woman is eligible for Nicam [a clinical trial]. The question is, is she fit enough for Nicam?  
(Consultant Medical Oncologist, Skin, observation field note)  
Dermatologist 
 
15 In a patient like this do you think there’s a higher risk…of getting radiotherapy induced tumour at the 
edges of the areas or is that not something you see really? (Consultant Dermatologist, Skin, 
observation transcript) 
Radiologist or 
imaging specialist 
 
16 So can somebody tell me a bit what’s going on? Because there have been long standing 
abnormalities, haven’t there? (Consultant Radiologist, Gynaecology, observation transcript) 
Pathologist or 
histopathologist 
18 Does he [the patient] want radiotherapy? (Consultant Dermatopathologist, Skin, observation 
transcript) 
CNS 14 So do we follow her with ultrasound? (CNS, Skin, observation transcript) 
StR 10 Ok, does anyone have any strong feeling whether we need to take this porto-cath out then? 
(Haematology StR, Haematology 2, observation transcript) 
Psychologist 3 Does her son come with her regularly? (Psychologist, Skin, observation transcript) 
* These numbers should not be interpreted as meaningful in themselves. Some differences will simply reflect composition of the teams and the length of their meetings, for 
example only one team had dermatology input, while all four had radiology input. However, I used the node frequencies during analysis as a starting point to explore patterns 
in the data, comparing these with data from my field notes, looking for similarities and discrepancies. 
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Appendix 14: ‘Responds to question’ node by professional group 
Professional 
group 
Nvivo node 
frequency 
Illustrative quote 
Surgeon 
 
67 Gynaecologist 2: has she got somebody that comes with her? 
Gynaecologist: her daughter’s got lupus so was at [another hospital] at the time that she was seeing 
me in the clinic  
(Gynaecology, observation meeting transcript) 
Haematologist 
 
66 MDT coordinator: is he an in-patient still at the moment? 
Consultant Haematologist: no it [the patient’s discharge summary] said he was discharged, his most 
recent one  
(Haematology 1, observation meeting transcript) 
Oncologist 
 
46 Gynaecologist: how old is she? Born in [year]. She’s fit and well? 
Consultant Medical Oncologist 2: yeh she’s fit and well she’s had a laparoscopy in [country 
abroad]…that’s when they picked up the nodules 
(Gynaecology, observation meeting transcript) 
Dermatologist 
 
14 Dermatopathologist: who’s he coming to see? 
Consultant Dermatologist 2: I don’t know it says on the MDT sheet it just says [name of surgeon] 
(Skin, observation meeting transcript) 
Radiologist or 
imaging specialist 
64 Consultant Haematologist: can I just check what was the response, what magnitude of response has 
he had [to chemotherapy]? 
Radiologist: ….it’s [the tumour] 3.8 to 3.3 centimetres so by RECIST [response evaluation criteria in 
solid tumours] criteria it would be stable 
(Haematology 2, observation meeting transcript) 
Pathologist or 
histopathologist 
45 Gynaecologist: what are the dimensions of the tumour [pathologist]? 
Pathologist: …it was described as 45 but it looked as if it was lining the whole endometrial cyst so it 
was only 5mm of thickness…and quite diffuse so you know it was difficult to see a mass 
(Gynaecology, observation meeting transcript) 
CNS 31 Clinical Oncologist: remind me the background, so he’s got axillary disease and what other disease? 
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 CNS: none everything else was clear the CT was clear 
Clinical Oncologist: there’s no mets? [metastatic disease: the spread of cancer to other parts of the 
body] 
CNS: no 
(Skin, observation meeting transcript) 
StR 
 
24 Consultant Haematologist 2: was it a definite diagnosis? 
StR: they are pretty sure, the antibodies were negative…but they say that doesn’t discount the 
diagnosis but she has been started on steroids… 
Consultant Haematologist 2: ok but the diagnosis was based on a clinical diagnosis 
StR: correct 
(Haematology 2, observation transcript) 
Psychologist 0 - 
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Appendix 15: ‘Giving advice’ node by professional group 
Professional 
group 
Nvivo node 
frequency 
Illustrative quote 
Surgeon 
 
3 Consultant Gynaecologist 2: so if it’s endometriod [cancer] is it worth trying some provera [medication 
for treating hormone dependent cancers] 
Consultant Medical Oncologist 2: have we not done that?...we’d need to check…but it’s a good point 
(Gynaecology, observation transcript) 
Haematologist 
 
11 Consultant Haematologist 5: ok so the decision is between further salvage using chemotherapy…or 
radiation…so what’s the general 
Consultant Haematologist 2: …I wouldn’t want to give somebody radiotherapy in this situation without 
a PET [scan] to confirm [if he has progressive disease elsewhere] 
(Haematology 2, observation transcript) 
Oncologist 
 
9 Consultant Clinical Oncologist: I didn’t offer her treatment the last time there wasn’t any evidence to 
really support it I suppose what she’s really concerned about is the next time it comes back it’s going 
to be more widespread and she’s got this fixation in her mind that if she’d had some treatment it 
would have prevented that from happening 
Consultant Medical Oncologist: …well…there’s nothing to target with radiotherapy here is there in an 
adjuvant sense so I think she should have nothing, but that’s not helpful to you  
(Gynaecology, observation transcript) 
Dermatologist 
 
2 Consultant Medical Oncologist: ok but what I don’t want to do I don’t want to add to her confusion 
that’s the [issue] 
Consultant Dermatologist 1: …what about…explaining it in terms that [surgeon 1] just did…saying if it 
were, if you were my sister [I’d be advising]…  
(Skin, observation transcript) 
Radiologist or 
imaging specialist 
8 The skeletal deposits don’t look like the sort that would give him a pathological fracture so they 
probably can be ignored 
(Consultant Radiologist, Skin, observation transcript) 
Pathologist or 6 He may need further biopsies  
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histopathologist (Consultant Dermatopathologist, Skin, observation transcript)  
CNS 
 
3 I think as well we need to try and avoid telling people like that to go to their GPs. I think we need to see 
them (CNS, Haematology 1, observation transcript) 
StR 
 
0 - 
Psychologist 
 
3 I think the fact that she’s seeing lots of people isn’t helping her is it I think you’ve got to have one 
person who is the driver here (Psychologist, Skin, observation transcript) 
 
